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ABSTRACT 
The second lactate threshold (LT2) has long been associated with endurance performance 
in trained endurance athletes. In Australia, the state institutes and academies of sport 
utilise the modified maximum deviation (D-max) method to determine LT2 in endurance 
athletes for the purpose of establishing training intensities and indicating whether athletes 
are appropriately adapting to training loads. For LT2 methods to be considered valid, it had 
been suggested that strong associations with simulated endurance performance and the 
maximal lactate steady-state (MLSS) are required. Although research has established a 
strong relationship between the modified D-max and endurance performance, there are 
gaps in the literature which this thesis aims to investigate. Firstly, research is yet to 
examine the capacity of the modified D-max to: (a) elicit a workload sustainable for 30 min 
with a steady-state blood lactate concentration ([La-]; an indicator of MLSS), and; (b) a 
maximum workload during endurance events, in endurance-trained athletes.  
 
The first study within this thesis examined the capacity of the modified D-max LT2 to 
correlate with 40 km cycling time trial performance, reflect a cycling power output that was 
sustainable for 30 min whilst eliciting a steady-state [La-], and elicit mechanical and 
physiological responses similar to the second ventilator threshold (VT2) and mean values 
achieved during a 40 km cycling time trial. It was found that the power output and V̇O2 at 
LT2 were significantly correlated with 40 km cycling performance, but the strongest 
combination of variables included both maximal and fractional utilisation variables. 
Furthermore, LT2 was not significantly different to VT2, and elicited similar physiological 
responses to mean values achieved during a 40 km cycling time trial. However, only 50% 
of the 10 participants successfully maintained exercise at their LT2 power output with a 
concomitant steady-state [La-], suggesting the modified D-max LT2 is not a strong indicator 
of MLSS. 
 
Despite physiological differences between men and women, few studies have exclusively 
explored female responses or have compared these effects between sexes in exercise 
science research. Of those that have, the concentrations of ovarian hormones are rarely 
considered, despite their potential to influence [La-], LT2 and endurance performance. A 
small number of studies have found significant relationships between the modified D-max 
LT2 and endurance cycling performance in women, albeit without consideration, control or 
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appropriate measurement of ovarian hormones. Therefore, the second study extended 
study one, to explore the same experimental aims, in endurance-trained women (n = 12) 
whilst controlling for ovarian hormone concentrations through the use of hormonal 
contraceptives. When comparing to the men’s results from study one, power output and 
V̇O2 at LT2 were also found to be significantly correlated with 40 km cycling performance in 
endurance-trained women. Additionally, combining maximal (peak power output and 
V̇O2max) and fractional utilisation (V̇O2 and power output at LT2) variables produced the 
strongest prediction of performance in women (r2 = 0.87) and men (r2 = 0.95). In women, 
VT2 was significantly higher than LT2 for all variables measured, despite no differences 
observed for the men. More women (73%) than men (50%) completed 30 min of cycling 
and elicited a steady-state [La-] at their LT2 power output, despite LT2 being significantly 
higher than the self-selected power output during a 40 km cycling time trial in women. 
 
The final study examined the sensitivity of the modified D-max LT2 to adapt to a brief high-
intensity interval training (HIIT) intervention in already-endurance trained men (n = 9) and 
women (n = 8). Although not significant, women (but not men) showed a trend towards LT2 
power output improvement (2.2%; p = 0.08) post-HIIT. Mean 40 km time trial performance 
significantly improved in both men (-1.7%) and women (-2.6%), with no difference in the 
magnitude of change between sexes. Furthermore, although LT2 power output explained 
77% of the improvement in 40 km cycling performance in women, none of the measured 
variables explained the performance improvement in men, suggesting that mechanisms 
other than those responsible for the LT2 were involved. The LT2-performance relationship 
was intensity-dependent in both men and women, shown by significant correlations at 
post-HIIT but not baseline. Some of the sex-related differences may, at least in part, be 
explained by the influence of oestradiol, perhaps by the exacerbation of the sex-based 
differences in substrate metabolism and subsequent effects on [La-] and fatigue, and/or 
greater cardiovascular stress in men than women. 
 
Collectively, these studies improve understanding of the modified D-max method of LT2 
determination in endurance-trained men and women. The findings suggest that whilst the 
modified D-max LT2 is a good correlate of 40 km cycling performance in both men and 
women, combining it with maximal variables provided stronger predictions of cycling 
performance. Furthermore, LT2 was not a strong indicator of MLSS in men or women; its 
greater capacity to explain training-related performance improvements in women than men 
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illustrates inconsistency between sexes, and thus, limited generalisability. Therefore, 
although it is recommended that sports scientists continue to use the modified D-max 
method of LT2 determination to predict 40 km cycling performance in both men and 
women (preferentially in conjunction with other laboratory-derived measures for stronger 
prediction capacity), it is suggested for use in women only when evaluating cycling 
performance improvements in response to a short HIIT program. 
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s: seconds 
V̇CO2: volume of carbon dioxide expired 
V̇E: ventilation 
V̇O2: volume of oxygen inspired 
V̇O2max: maximal oxygen uptake 
V̇O2peak: peak oxygen uptake 
VT1: first ventilatory threshold 
VT2: second ventilatory threshold 
W: Watts 
W·kg-0.32: allometrically scaled Watts 
W·kg-1: Watts relative to body mass 
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CHAPTER ONE 
 
Introduction 
 
1.1 Introduction to the research problem 
It has been well-established that maximal oxygen uptake (V̇O2max) is an important 
physiological variable given it sets the upper limit for aerobic metabolism [1] and 
predicts endurance performance amongst untrained groups [2, 3]. However, in a 
highly-trained population (i.e. those possessing physiological variables and/or a 
training/race status of a high level, as previously classified [4]), it appears that 
changes in performance may be equally or more strongly correlated with other 
variables such as the fractional utilisation of V̇O2max (as determined through the 
assessment of lactate or ventilatory data) [5, 6]. The second lactate threshold (LT2) is 
described as the exercise intensity indicating the upper limit of equilibrium between 
lactate production and clearance, i.e. the maximal lactate steady-state (MLSS) [7, 8]. 
The LT2 is commonly used to establish endurance performance status [9-11], 
prescribe training zones [12, 13] and monitor changes in response to training [12-14].  
 
In Australia, the state institutes and academies of sport utilise the modified maximum 
deviation (D-max) method to determine LT2 in triathletes, and it is embedded in the 
National Protocol [15] to establish guidelines for quantifying training and racing. As 
determined by the modified D-max method, LT2 is identified as the point on the 
polynomial regression curve that yields the maximal perpendicular distance to the 
straight line formed by LT1 (the lowest intensity at which there is a sustained 
increased in blood lactate concentration ([La-]) above resting values [16]) and the final 
blood lactate concentration [10] collected in a passive state 3-4 min post-test [15]. The 
modified D-max LT2 has been shown to correlate with 1 h cycling performance in 
trained female cyclists and triathletes (n = 12 - 24) [10, 17] and 30 min cycling 
performance in well-trained veteran cyclists (men, n = 8; women, n = 1). 
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Furthermore, these researchers showed that power output [10, 18] and heart rate [18] at 
LT2 approximated power outputs and heart rates elicited during their respective 
performance trials. However, for LT2 methods to be considered valid, Faude et al. 
suggested that strong associations are also required with the maximal lactate 
steady-state (MLSS), because metabolically, endurance capacity can be regarded 
as the highest steady-state by energy supply from oxidative phosphorylation [19]. 
Therefore, the capacity of the modified D-max LT2 to determine the MLSS (i.e. the 
capacity to exercise for 30 min with a steady-state [La-]) warrants investigation. 
Furthermore, considering LT2 is also used to monitor changes in response to 
training, investigation into its sensitivity to training adaptations is justified. 
 
A sex bias in sport and exercise medicine research has recently been highlighted, 
with female participants shown to represent only 39% of the literature, with 4-13% 
incorporating females only across three leading journals from 2011 to 2013 [20]. This 
is likely explained, at least in part, by the challenges surrounding control of ovarian 
hormone levels. In women of reproductive age, oestrogen and progesterone 
fluctuate with phases of the menstrual cycle, whilst male physiology remains 
relatively consistent from day to day [21]. This fluctuation has the potential to influence 
physiological variables at rest and during exercise. For example, [La-] has been 
shown to be significantly higher at rest [22] and in response to exercise at 25% 
V̇O2max [23] in the follicular phase (FP) compared to the luteal phase (LP) of the 
menstrual cycle. Since the modified D-max method can be prone to artificial changes 
to LT2 if the initial 0.4 mmol·L-1 rise in [La-] occurs at a different stage during an 
incremental test [24], the modified D-max curve and subsequent LT2 may be 
influenced by fluctuations in ovarian hormone concentrations. However, none of the 
three studies that investigated the relationship between the modified D-max LT2 and 
endurance performance in women [10, 17], and a group combining men and women 
[18], controlled for or verified ovarian hormone concentrations. According to Elliott-
Sale et al. [25], research that attempts to control for ovarian hormone concentrations 
is weakened by factors such as inconsistencies in the definition and measurement of 
reproductive hormone status, methodological inconsistencies, and high intra- and 
inter-individual variability in oestrogen and progesterone concentrations. Therefore, 
methods that minimise the fluctuations in endogenous concentrations of sex 
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hormones, such as hormonal contraceptives, may assist in providing more accurate 
results in female-specific and sex-based comparative research. 
 
Research is yet to examine changes in the modified D-max LT2 in response to 
training. In endurance-trained athletes, small improvements in performance are 
critical to success; therefore, establishing the sensitivity of laboratory-derived 
variables such as peak power output and LT2 to detect these performance changes 
is important. High-intensity interval training (HIIT), defined as repeated short-to-long 
bouts of rather high-intensity (80-100% peak heart rate [26]) exercise interspersed 
with recovery periods [27], has been shown to improve running (3-10 km) [28-30], 
treadmill roller skiing (12 km) [31] and cycling (15-40 km) [32-40] time trial performances 
in trained athletes, although the majority of these studies involved men only [28, 30, 32-
40], with only one study combining men and women [31] and another not stating the 
sex of participants [29]. In response to HIIT, LT2 adaptations in endurance-trained 
athletes have only been reported in response to training interventions over one year 
[40], five months [41], and in one short-term study where seven HIIT sessions were 
completed in seven days [39]. Although significant performance improvements were 
reported [15 km cycling time trial (~15%) [40], 20 min running time trial (~4%) [41] and 
20 km cycling time trial (8-10%) [39], respectively], the capacity of LT2 to predict these 
performance changes was not reported in any study.  
 
1.2 Aims and objectives 
The aim of this thesis was to examine the efficacy of the modified D-max method of 
LT2 determination to establish performance outcomes, reflect competition intensities, 
and adapt to training in endurance-trained men and women. Specifically, the 
objectives of the thesis were: 
1. To investigate the relationships between the modified D-max LT2 and other 
laboratory-measured variables [including different expressions of power 
output and maximal oxygen uptake (V̇O2max)], and 40 km cycling time trial 
performance in trained male and female cyclists and triathletes, controlling for 
ovarian hormone concentrations;  
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2. To investigate the validity of the modified D-max LT2 by:  
a. comparing it to VT2, and; 
b. investigating whether 30 min of exercise at LT2 power output 
i. was sustainable; 
ii. corresponded to a steady state [La-]; and  
iii. elicited similar physiological responses to those produced during 
a 40 km cycle time trial; 
3. To compare the findings of men and women as assessed via objectives 1 and 
2; 
4. To examine the sensitivity of the modified D-max LT2 to adapt to a brief HIIT 
intervention in already-endurance trained men and women. 
 
1.3 Organisation of the thesis 
To address these objectives, a review of the literature was initially conducted to 
explore the available evidence regarding: (1) the laboratory measures most strongly 
associated with endurance performance and how these differ between untrained and 
trained individuals; (2) the most commonly reported methods of LT2 determination 
(including the maximal lactate steady-state (MLSS), onset of blood lactate 
accumulation (OBLA), the individual lactate threshold (IAT), the maximum deviation 
(D-max), and modified maximum deviation (D-max) methods, and their respective 
strengths and weaknesses; (3) the considerations required for participation of female 
athletes in sports science research; (4) physiological differences between men and 
women, and the potential influences of these differences on endurance exercise 
training and performance; and (5) the optimal training stimulus to improve 
physiological and performance outcomes in trained endurance athletes over a 
relatively short duration (i.e. HIIT). The review of the literature comprises Chapter 2 
of this thesis.  
 
An experimental study was then conducted to investigate the capacity of the 
modified D-max LT2 to: (1) correlate with 40 km cycling performance; (2) reflect a 
power output that is sustainable for 30 min whilst eliciting a steady-state [La-]; and 
(3) reflect a power output, heart rate, V̇O2 and [La-] that are similar to those produced 
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during a 40 km cycling performance trial in trained male cyclists and triathletes. 
Experimental study one comprises Chapter 3 of this thesis. 
 
A second experimental study assessing the same research questions in trained 
women was then conducted. Ovarian hormone concentrations were controlled 
through the use of hormonal contraceptives. Experimental study two comprises 
Chapter 4 of this thesis. The outcomes of the first and second experimental studies 
in men and women were then compared and contrasted in Chapter 5 of this thesis.  
 
Finally, the influence of a brief 10-session HIIT intervention was conducted in trained 
male and female cyclists and triathletes to: (1) examine the sensitivity of LT2 to 
training adaptations; (2) examine the sensitivity of the LT2-performance relationship 
to training adaptations; and (3) compare these adaptations between men and 
women. Experimental study three comprises Chapter 6 of this thesis. 
 
Additional research that was completed as part of the overall thesis is included in the 
appendices. Appendix one reports the agreement between and reliability of two 
metabolic systems to provide support for the use of different equipment used in 
experimental studies one and two. Appendix two compares four different methods of 
blood [La-] determination to provide support for the different methods used in 
experimental studies one, two and three. 
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CHAPTER TWO 
 
Literature Review 
 
2.1 Introduction 
Laboratory testing has been used extensively for many years to assess various 
physiological [42] and biomechanical [43] factors associated with exercise 
performance. The aims of such testing include better understanding of how athletes 
perform in the field, to monitor changes in response to training programs and to 
establish losses in exercise capacity following injury or de-training [44]. One of the 
most extensively used laboratory tests conducted for endurance athletes is 
measurement of their V̇O2max. The current review evaluates some of the most 
widely-used measures to assess endurance performance; V̇O2max and various 
threshold indices which are often expressed as fractional utilisation of V̇O2max will 
be examined. Of these thresholds, most emphasis will be placed on LT2 with less 
analysis of VT2 because of the extensive use of LT2 in Australia by the national and 
state institutes and academies of sport. This review will define what these measures 
are, why they are measured, their relationships with endurance performance and 
their responses to endurance and also high-intensity exercise training. Examining 
the correlations of these lab-based measures with performance is imperative if 
accurate and efficient monitoring of athletes is to occur. Determining the most 
sensitive measure – that is, one that responds to training in the same direction and 
of a similar proportional magnitude as performance does, will minimise the need to 
complete performance time trials which are both physically- and time-demanding. It 
will also ensure precise monitoring of athletes before and after a block of training, 
leading into a phase of competition or after a period of de-training, and will provide 
valuable feedback to coaches and sport scientists.  
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2.2 Endurance Performance Prediction 
2.2.1 Maximal Oxygen Uptake 
V̇O2max has been defined as the highest rate at which oxygen can be taken up and 
utilised by the body during exercise [1]. It reflects an individual’s maximal rate of 
aerobic energy expenditure [45] and is one of the most reported measures in exercise 
physiology [45-47]. The effectiveness of using V̇O2max to predict endurance 
performance and its sensitivity to detect changes as a result of training have been 
examined in many studies, over many years. These studies have produced a range 
of differing findings, which is likely to be related, at least in part, to the differing levels 
of training of the participants. Given the extensive use of laboratory-based testing in 
athletes, it is important to consider the relevance of measures including V̇O2max and 
the role they play in determining an individual’s endurance capacity, their capacity to 
determine those most likely to be successful in endurance exercise and those 
individuals likely to adapt the most in response to training. 
 
2.2.1.1 V̇O2max in homogeneous vs. heterogeneous groups 
A.V. Hill et al. first defined V̇O2max in 1922 following a study in which Hill as the 
subject had his oxygen consumption (V̇O2) determined using Douglas bags during 
discontinuous incremental running [48]. Today, the accepted method of establishing 
V̇O2max is by assessing V̇O2 during incremental exercise to fatigue, whereby oxygen 
uptake (V̇O2) reaches a maximum beyond which no further increase is seen, despite 
an increase in intensity [1]. However, some individuals do not reach a plateau in their 
V̇O2 response to incremental exercise, and therefore other methods of V̇O2max 
achievement have been proposed, including a respiratory exchange ratio > 1.15 and 
blood [La-] > 8-9 mmolL-1 [1]. Thoden [49] recommended that a verification phase be 
performed following the incremental phase of a V̇O2max test, beginning with a 
5-15 min recovery, followed by a constant speed run/cycle to exhaustion at a speed 
that was one stage higher than the last completed stage of the incremental phase. 
Achieving a peak V̇O2 in the verification phase that was similar to or lower than the 
V̇O2max achieved in the incremental phase then confirmed a “true” V̇O2max. Whilst 
the verification phase has been shown to be similarly reliable (CV = 3.9%) to the 
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plateau method (CV = 3.5%), the duration of the verification phase has been 
reported as a potential limitation; when < 3 min, V̇O2 may not have had sufficient time 
to reach maximum before volitional exhaustion [50]. Subsequently, differences remain 
in the literature surrounding specific criteria for V̇O2max attainment.  
 
Bassett [51] stated that in 1923, Hill and Lupton stressed the importance of V̇O2max in 
athletic performance and noted that a low V̇O2, as well as a low maximum oxygen 
debt or a high oxygen requirement would limit endurance performance. Many studies 
have established a significant relationship between V̇O2max and various measures 
of endurance performance. For example, Butts et al. [2] showed that in recreational 
triathletes (n = 23) performance times during each leg of the triathlon were 
significantly correlated to their corresponding V̇O2max values in absolute terms for 
swimming (r = -0.49; p < 0.01) and cycling (r = -0.57; p < 0.01) and relative terms for 
cycling (r = -0.78; p < 0.01) and running (r = -0.84; p < 0.01). These findings are 
consistent with those of others, such as those reported for a mixed group of junior 
athletes and ex-athletes (n = 11), in which V̇O2max was significantly related to 800 
m, 1500 m and 5000 m mean running speeds (r = -0.73- -0.77; all p < 0.01; n = 11) 
[52], and for male (n = 111) and female master athletes (n = 57) where V̇O2max was 
significantly correlated with 5 km (r = -0.64 and r = -0.66; both p < 0.01), 10 km 
(r = -0.66 and r = -0.68; both p < 0.01) and 42.2 km (r = -0.59 and r = -0.67; both 
p < 0.01), respectively [3].  
 
While researchers have generally found significant relationships between V̇O2max 
and endurance performance with heterogeneous groups, the association is weaker 
in homogeneous groups, particularly already well-trained endurance athletes of 
comparable ability and similar V̇O2max [53-56]. For example, relationships between 
V̇O2max and endurance running performance (10-42.2 km: r = -0.55- -0.81; all 
p < 0.01) were weaker than other variables such as peak treadmill velocity 
(r = -0.91- -0.94; all p < 0.01) in trained distance runners (n = 43; mean ± SD 
V̇O2max: 66.2 ± 8.0 mLkg-1min-1) [54]. Furthermore, since the distance being 
covered determines the rate of possible energy utilisation, it also determines how 
much V̇O2max contributes to performance [57]. This is shown by events lasting 
beyond 10-15 min, where the mean exercise intensity did not induce V̇O2max; mean 
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marathon intensity in trained runners is reportedly 75-85% V̇O2max and during 
10 km it is 90-100% V̇O2max, compared to a 5 km run which is performed at 
approximately V̇O2max [1]. Therefore, the V̇O2max required by athletes competing in 
different event distances will differ, depending on the required upper limit for energy 
production. However, regardless of competition distance, well-trained endurance 
athletes typically all possess high V̇O2max values, as a likely consequence of years 
of endurance training, and having reached their upper limits. For example, 
well-trained 5000 m runners have reported V̇O2max values of 
81.4 ± 4.1 mLkg-1min-1 (men) and 66.7 ± 9.7 mLkg-1min-1  (women), which are 
similar to those reported by well-trained marathon runners of 79.6 ± 7.3 mLkg-1min-1  
(men) and 72.9 ± 3.8 mLkg-1min-1 (women) [58]. Despite similar V̇O2max values, a 
progressive increase in strength of the V̇O2max-performance relationship has been 
reported when running distance increased (3.2 km: r = 0.83; 9.7 km: r = 0.86; 15 km: 
r = 0.89; 19.3 km: r = 0.91 and 42.2 km: r = 0.91; all p < 0.05) in trained male 
distance runners (n = 18) [59], which provides evidence that exercise 
distance/duration is a confounder in the association between V̇O2max and 
endurance performance. 
  
2.2.1.2 V̇O2max and exercise training in previously untrained populations 
The influence of training on changes in V̇O2max has been investigated by a number 
of researchers. V̇O2max has consistently been shown to increase in response to 
endurance training and, more recently, with high intensity interval training (HIIT) in 
previously untrained subjects. These improvements in V̇O2max have been reported 
after as few as six training sessions over 12 days in previously untrained males, in 
response to both continuous, endurance training (+5%; p < 0.05; n = 8) and HIIT 
(+9%; p < 0.05; n = 8) [60]. Increases in V̇O2max appear independent to exercise 
mode, with improvements elicited in running V̇O2max (9.3 ± 1.3%; p < 0.05; n = 16) 
and inline-skating V̇O2max (8.6 ± 1.8%; p < 0.05; n = 19) after 27 sessions of 20 - 40 
min of combined continuous and interval training in their respective modes [61], as 
well as cycling V̇O2max (9%; p < 0.05 after 24 sessions of 20 - 35 min continuous 
cycling training and 15%; p < 0.01 after 24 sessions of cycling HIIT including 5 min 
bouts, matched to continuous training for energy expenditure and duration; n = 11 
30 
 
[62]). Additionally, a 10-week, mixed training program of cycling (6 x 5 min intervals, 
three days per week) and running (30 - 40 min continuous training, three days per 
week) in participants (n = 8) who ranged from very sedentary to moderately-active, 
increased mean cycle V̇O2max significantly after the first week (+5%; p < 0.05), with 
a continuous linear improvement until week 10 (mean improvement: +44%; p value 
not reported) [63]. This study also highlights the influence of training program length 
on magnitude of V̇O2max improvement, and reported a very strong relationship 
between V̇O2max and number of training weeks (r = 0.99; p < 0.01) [63].  
 
These findings were extended by time-course results showing progressive overload 
is necessary if further improvements in V̇O2max are to occur [64-66]. For example, 
Hickson et al. [64] reported a mean increase in V̇O2max of 14% after the first three 
weeks of combined cycling HIIT (6 x 5 min intervals at 90 - 100% V̇O2max, three 
days per week) and continuous running or cycling (40 min at highest sustainable 
intensity, three days per week; n = 9), with no further increase after week four. When 
training intensity was increased for an additional five weeks (90 - 100% of new 
V̇O2max for HIIT and new highest sustainable intensity for continuous training), a 
further 8% improvement in V̇O2max was seen after three weeks, with no change in 
the final two weeks. Collectively, the available research shows that in healthy, 
previously untrained individuals, V̇O2max can increase in response to continuous, 
endurance training and HIIT, regardless of the exercise mode. However, certain 
limits may exist where further increases are not possible without the implementation 
of progressive overload, for example by increasing the absolute, not necessarily the 
relative, exercise intensity. 
 
Whether improvements in V̇O2max translate to improvements in endurance 
performance has also been investigated. Lambert and Noakes [67] examined the 
effect of 12 weeks of continuous training (5-120 min per day) in rats (n = 7) and 
found that the improvement in V̇O2max did not coincide with improvements in 
maximum incremental running time to exhaustion at either four weeks (performance: 
+34%; p < 0.01; V̇O2max: +0%); 8 weeks (performance and V̇O2max unchanged 
compared to 4 weeks) or 12 weeks (performance: +14%; p < 0.01; V̇O2max: +9%; p 
< 0.01 compared to 4 weeks). Furthermore, Daniels et al. [65] reported that although 
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there was a similar magnitude of improvement in running performance (805 m and 
3218 m; 8%; p < 0.01) as V̇O2max (9%; p < 0.01) during the first four weeks of 
training (continuous running for 3.2-6.4 km, 5 days per week) in previously untrained 
participants (n = 12), performance improvements continued over the next four weeks 
(3%; p < 0.01) without a concomitant improvement in V̇O2max (0%). Similarly, 
Vollaard et al. [47] found that although V̇O2max and 15 min cycling performance were 
related at baseline (r = 0.89; p < 0.01) and post-training (24 sessions of 45 min 
cycling at 70% pre-training V̇O2max; r = 0.86, p < 0.01) in previously sedentary 
males (n = 24), no relationship existed between the change in V̇O2max and the 
change in time trial performance as a result of endurance training (r = 0.2; p > 0.05). 
These studies show that training-induced improvements in endurance exercise 
performance are not consistently matched with improvements in V̇O2max, 
suggesting that V̇O2max and endurance performance are not causally related. 
Although improvements in V̇O2max have been reported in initial stages of training, 
endurance performance continues to improve with no further changes in V̇O2max, 
suggesting that other mechanisms are more closely related with endurance 
performance. 
 
2.2.1.3 V̇O2max and exercise training in trained athletes 
The capacity for improvement in V̇O2max and endurance performance in already 
well-trained endurance athletes has also been examined. Since the smallest change 
in performance can be of utmost importance for athletes, it is crucial to understand 
which laboratory-based variable/s provide/s the closest association with these 
potentially small performance changes. Despite improvements in both V̇O2max and 
endurance performance in response to continuous, endurance training in previously 
untrained individuals (discussed above), it has been consistently shown that 
changes do not occur when already highly-trained athletes increase the volume of 
their submaximal training [68]. Specifically, it has been reported that once a V̇O2max 
of > 60 mL·kg-1·min-1 has been achieved, endurance performance is not improved 
with an additional increase in submaximal training volume [69]. Therefore, the 
prescription of HIIT to compliment the ‘aerobic base’ established by submaximal 
training is common for well-trained endurance athletes to further improve their 
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endurance performance [70], with conflicting evidence surrounding the capacity for 
V̇O2max to improve in response to HIIT [34-36, 39, 40, 71]. For example, Laursen et al. [71] 
showed no change in V̇O2peak despite improvements in peak power output (4.3%; p 
< 0.05) and time to fatigue (~92%; p < 0.05) in highly-trained male cyclists (n = 7) 
after a HIIT intervention (four sessions of 20 x 60 sec intervals at peak power output, 
120 s recovery).  
 
Conversely, a subsequent study by Laursen et al. [34] showed that changes in 
V̇O2peak (+3-8%; p < 0.05) paralleled changes in 40 km cycle time trial speed 
(+4-6%; p < 0.05-0.01) after three different HIIT programs (8 sessions of: 8 x 
~2.5 min at peak power output, 1:2 work: recovery ratio; n = 8 (group 1); 8 x ~2.5 min 
at peak power output, recovery at 65% heart rate max; n = 9 (group 2) and; 12 x 30 s 
at 175% peak power output, 4.5 min recovery; n = 10 (group 3)). However, the 
authors subsequently reported that the change in V̇O2peak was only modestly 
related to the change in 40 km cycling performance (r = 0.41; p < 0.05) [36]. 
Furthermore, whilst two blocks of periodised HIIT over one year (14-15 sessions of 4 
x 4 min at 90-95% heart rate max, 3 min recovery at 70% heart rate max, performed 
in each of November and January) successfully improved V̇O2max (10.5%) and 
15 km cycle time trial performance (14.9%) in a case-study trained male cyclist [40], 
shorter-term HIIT interventions of seven sessions in seven days (group 1: 25 x 
5-20 s at highest possible intensity, work: recovery ratio of 1:5 at 30-40% peak 
power output; n = 9 and group 2: 10 x 15 - 45 s, at highest possible intensity, work: 
recovery ratio of 1:5 at 30-40% peak power output; n = 10) [39] and eight sessions in 
four weeks (group 1: 8 x 4 min at heart rate eliciting 80% peak power output, 90 s 
self-paced recovery; n = 6 and group 2: 8 x 4 min at 80% peak power output, 90 s 
self-paced recovery; n = 6) [35], showed no changes in V̇O2max, despite 
improvements in 40 km (group 1: 2.1%; group 2: 2.3%; both p < 0.01) [35] and 20 km 
(group 1: 4.6%; group 2: 6.8%) [39] cycling time trial performances. 
 
Physiological mechanisms reported to underpin changes in V̇O2max in trained 
endurance athletes are myocardial morphological adaptations that increase maximal 
stroke volume, increased capillarisation of skeletal muscle and increased oxidative 
capacity of type II skeletal muscle fibres [72]. All stimuli appear to be intensity 
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dependent up to V̇O2max, indicating that HIIT performed at or near V̇O2max may be 
most effective when aiming to increase V̇O2max in endurance-trained athletes [72]. 
However, a physiological mechanism relating to improvements in endurance 
performance has been reported as improved skeletal muscle buffering capacity [33, 
38], which may explain why changes in endurance performance in response to HIIT 
are rarely paralleled by changes in V̇O2max in trained endurance athletes. 
 
It is likely that the inconsistencies in V̇O2max adaptations in response to HIIT may be 
explained, at least in part, by the duration of the intervention and/or the duration and 
intensity of the work and relief intervals. All of these variables have the capacity to 
influence the total time spent exercising above 90% V̇O2max; one of the key 
physiological variables most strongly suggested to influence the adaptations to HIIT 
[27]. Therefore, the aforementioned studies showing no improvement in V̇O2max [35, 39, 
71] may have been of insufficient duration (4-8 sessions) and/or insufficient work and 
relief interval durations and intensities (5-60 s at maximum intensity with a work: 
recovery ratio of 1:5, and 4 min at 80% peak power output with a self-selected work: 
recovery ratio of 3:1) to create adequate time exercising above 90% V̇O2max. 
However, the importance of V̇O2max as a valid measure for assessing performance 
improvements after HIIT remains in question, due to findings reporting only a modest 
association between V̇O2max improvements and performance improvements [36] and 
since numerous HIIT studies involving well-trained endurance athletes did not even 
report changes in V̇O2max after training [32, 33, 37, 38].  
 
The weight of evidence suggests that since V̇O2max sets the upper limit for aerobic 
metabolism, it has value in establishing endurance performance status in a relatively 
untrained population or within a heterogeneous group. In those previously untrained, 
V̇O2max appears to increase over time as a result of training, however, the change 
in V̇O2max does not always correlate with changes in performance, suggesting that 
V̇O2max and endurance performance are not causally related and that other 
physiological measures may be responsible for performance adaptations. For 
homogeneous groups such as those who are highly-trained, endurance performance 
is not significantly related to V̇O2max. Moreover, although HIIT interventions in well-
trained athletes have generally shown improvements in endurance performance, the 
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adaptations of V̇O2max are less consistent, with those reporting no change likely 
exercising for an insufficient time above 90% V̇O2max. Nevertheless, V̇O2max may 
not be the most sensitive measure to detect performance changes throughout an 
athlete’s season and subsequently, may not require frequent testing. In a highly-
trained population it appears that changes in performance may be equally or more 
strongly correlated with other variables such as running economy [73], the velocity [74, 
75] and power output [5, 10] at V̇O2max and the fractional utilisation of V̇O2max (as 
determined through the assessment of lactate or ventilatory data) [5, 6]. These 
findings will be discussed in subsequent sections of this review. 
 
2.2.2 Fractional utilisation of V̇O2max 
Blood lactate and ventilatory parameters have, over many years, been used to 
establish the highest percentage of V̇O2max an athlete is able to sustain for up to 
~60 min during endurance exercise. These measures are commonly expressed as a 
fractional utilisation (%) of V̇O2max; such as the power output, speed, heart rate or 
V̇O2 occurring at this lactate or ventilatory ‘breakpoint’. As alluded to earlier in this 
review, the importance of these measures relates to the findings that they are more 
strongly correlated with endurance performance in homogeneous groups such as 
well-trained endurance athletes than measures originally believed to be the most 
indicative of performance, such as V̇O2max. 
 
2.2.2.1 Blood [La-] measures 
In 1927, Douglas et al. observed an increase in blood lactate concentrations ([La-]) 
above certain sub-maximal work rates [76, 77]. The term ‘lactate threshold’ has gained 
acceptance by many to describe the work rate above which this increase in blood 
[La-] occurs during incremental exercise [14, 76]. This process is related to an increase 
in lactate appearance in the blood that is not accompanied by a concomitant rise in 
lactate disposal [78]. This decline in metabolic clearance rate, a measure of efficiency 
for lactate disposal [79], produces a continuous rise in blood [La-] at exercise 
intensities approaching those that elicit LT2 [78]. For these reasons, it is generally 
accepted that exercise above the intensity eliciting LT2 is not able to be sustained 
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beyond ~60 min [78]. Even though lactate production is essential to support continued 
adenosine triphosphate (ATP) regeneration from glycolysis [80], exercise above LT2 
has been associated with more rapid fatigue through the disturbance of the internal 
physic-chemical environment due to metabolic acidosis [81, 82], an increase in 
adenosine diphosphate (ADP) [82], or an accelerated glycogenolysis as a result of 
increased sympathoadrenal activity [14, 83]. Furthermore, this rapid fatigue above LT2 
intensity may also be due to ineffective pathways for transferring the reducing 
equivalents to the mitochondria [84]. Specifically, it has been proposed that 
redistribution of shuttle-associated metabolites across the mitochondrial membrane 
is the mechanism responsible for a decrease in the malate-aspartate shuttle flux, 
impairing transport of cytosolic NADH, leading to a progressive NADH accumulation 
and lactate production [85]. 
 
The frequent use of measuring LT2 in athletic populations has emerged from 
evidence showing that it is a good indicator of endurance performance in 
homogeneous groups of athletes [9, 10, 86-88]. Indeed, ‘LT2 testing’ is a central 
measurement tool used by institutes and academies of sport throughout Australia 
and around the world to gauge the ‘fitness’ of their endurance athletes at a particular 
point in time. It is also used to establish endurance performance status [9-11], to 
prescribe training zones [12, 13] to enable athletes to improve their endurance capacity 
and to monitor changes in response to training [12-14].  
 
Moreover, the relationship between LT2 and endurance performance appears to be 
stronger than the V̇O2max-endurance performance relationship in trained endurance 
athletes. For example, an early study by Farrell et al. [59] reported stronger 
relationships (r ≥ 0.91; all p < 0.05) between the treadmill velocity corresponding to 
the onset of plasma lactate accumulation (defined as the velocity just prior to the 
exponential increase in plasma [La-]) and running performances over 3.2 - 42.2 km in 
experienced male distance runners, than between V̇O2max and performance 
(r = 0.83-0.91; all p < 0.05; n = 18) [59]. Subsequent investigations have provided 
support for these findings and although LT2 determination methods are now quite 
diverse, research has consistently shown that LT2 parameters are stronger 
correlates of endurance performance than V̇O2max is [5, 10, 17, 74].  
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Bishop et al. [10, 17] reported in two separate studies that 1 h cycle time trial 
performance correlated more strongly with LT2 measured via six different methods 
(r = 0.61-0.84; all p < 0.01 [10] and r = 0.71 - 0.89; all p < 0.05 [17]) than with V̇O2peak 
(r = 0.55; p < 0.01 [10] and r = 0.65; p < 0.05 [17]) in trained female cyclists and 
triathletes (n = 24 [10] and n = 12 [17]). Further support for these relationships were 
provided by Bentley et al. [5] who reported significant relationships between 90 min 
cycling time trial performance and LT2 determined via log (r = 0.91; p < 0.01) and D-
max methods (r = 0.77; p < 0.05) but not V̇O2max (r = 0.11; p > 0.05) in trained, male 
cyclists and triathletes (n = 9). In addition to measures of LT2, peak workload 
achieved during maximal incremental tests to fatigue have also produced stronger 
relationships with endurance cycling performance than V̇O2max in these 
aforementioned studies (r = 0.81; p < 0.01 [10], (r = 0.91; p < 0.01 [5]. However, cross-
sectional studies reporting strong correlations between peak workload and LT2 with 
endurance performance do not provide information on whether the relationships are 
causal, just simply that they are associated. Training interventions aimed at 
examining the effect of exercise training on peak workload achieved during a 
maximal incremental test, LT2 and/or V̇O2max, as well as the changes in endurance 
performance, provide an opportunity to establish potential cause and effect between 
these variables and endurance performance.    
 
With an endurance training intervention over six weeks (3 x 20 min run per week at 
75% V̇O2max), Stratton et al. [75] reported maximum velocity achieved during an 
incremental test was the single best laboratory predictor of 5000 m running 
performance at both pre- and post-training (r = 0.89; p < 0.01 and r = 0.83; p < 0.01, 
respectively) in previously untrained participants (n = 39). Furthermore, the 
relationship between velocity at LT2 and performance strengthened from pre- 
(r = 0.73; p < 0.01) to post- (r = 0.76; p < 0.01) training, while the relationship 
between V̇O2max and performance weakened (r = 0.55; p < 0.01 and r = 0.51; 
p < 0.01 for pre- and post-training, respectively). In addition to supporting others [5, 10, 
17] by confirming that maximal workload achieved during an incremental trial and LT2 
produce stronger correlations with endurance performance than V̇O2max for those 
with an endurance-training base, the findings also suggests that maximal workload 
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and workload at LT2, but not V̇O2max, may be causally related to endurance 
performance. However, less is known about the relationship between laboratory 
measures and endurance performance before and after a bout of training in already 
well-trained athletes, or whether the changes in laboratory measures could explain 
the performance changes. To date, relationships have been reported between 
improvements in 40 km cycling performance and increases in skeletal muscle 
buffering capacity (n = 6; r = -0.74; exact p value not reported) [38], anaerobic 
capacity (r = 0.40; p < 0.05; n = 41) [36], the second ventilatory threshold (r = 0.42; p 
< 0.01; n = 41) [36], and peak power output during an incremental trial (r = -0.92; p < 
0.01; n = 20) [33] in response to HIIT, however to the best of our knowledge, changes 
in LT2 and their association with performance changes have not been assessed. 
 
The weight of evidence suggests that LT2, often expressed as velocity (km) or power 
output (Watts), and maximum workload achieved during a maximal incremental trial 
are strong correlates of endurance performance amongst well-trained, homogeneous 
groups of individuals, producing reliably stronger relationships with performance than 
V̇O2max. Furthermore, improvements in laboratory variables, including maximal 
power output and skeletal muscle buffering capacity in response to training have 
produced significant correlations with performance improvements, suggesting a 
causal relationship between these variables and endurance performance. From 
these findings, it could be interpreted that maximum workload achieved during an 
incremental trial is the most attractive measure for assessing performing status and 
the effectiveness of a training intervention, without the need for invasive blood 
sampling, compared to LT2 determination. However, LT2 has the potential to provide 
additional information including appropriate intensities for training and competition 
and this will be discussed in subsequent sections of this review. Therefore, further 
investigation into its capacity to adapt to training and into the nature of its 
relationship with endurance performance, is warranted. 
 
2.2.2.2 Ventilatory measures 
As an alternative, and sometimes in addition to blood [La-] measures, ventilatory 
measures have also been used by a number of researchers to establish the highest 
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fraction of V̇O2max that endurance athletes can maintain during prolonged exercise. 
The VT2 has been defined as the exercise intensity above which the increase in 
ventilation becomes disproportional to the increase in power output or speed 
produced during an incremental exercise test [14]. The primary stimulus responsible 
for the increase in ventilation at the VT2 are central chemoreceptors, mainly 
influenced by an increase in the partial pressure of CO2 [89] and peripheral 
chemoreceptors, influenced by [H+], [K+], catecholamines and an increased body 
temperature [90, 91]. Some have used VT2 in preference to LT2, primarily because it is 
non-invasive in nature. 
 
As with other laboratory-based measures such as V̇O2max and LT2, the relationship 
between VT2 and endurance performance has also been examined. With the 
recruitment of elite male cyclists (n = 14), Hoogeveen and Hoogsteen [92] assessed 
the validity of four different methods of VT2 determination as indicators of 40 km 
cycling time trial performance; (1) a steeper increase in V̇CO2 as compared to V̇O2 
(V-slope method); (2) a respiratory exchange ratio (RER) of 0.95; (3) an RER of 1.00 
and; (4) an increase in V̇E/V̇O2 without a concomitant increase in V̇E/V̇CO2 (V̇E/V̇O2 
method). Results indicated that the V-slope and V̇E/V̇O2 methods were significantly 
correlated with time trial performance (r = -0.82; p < 0.01 and r = -0.81; p < 0.01 
respectively), however other variables such as V̇O2max or LT2 were not reported, so 
comparisons cannot be made.  
 
Amann et al. [91, 93] expanded on these findings and examined the predictive validity 
of five different VT2 methods (1: V̇E/V̇O2; 2: breakpoint of ventilatory equivalent of 
carbon dioxide (V̇E/V̇CO2); 3: V-slope; 4: RER = 1 and; 5: RER = 0.95) in relation to 
40 km cycling performance at the beginning (February; n = 15) and end (September; 
n = 15) of a competitive cycling season in male road cyclists [91], and in comparison 
with five different LT2 methods (1: Stegmann’s individual anaerobic threshold; 2: 
Baldari method (the stage preceding the second 0.5 mmol·L-1 increase in [La-]; 3: 
4 mmol·L-1; 4: 1 mmol·L-1 increase in 3 min and; 5: the stage preceding the first 
1 mmol·L-1 increase in [La-]) [93] at a single point during their season (n = 15). Results 
showed strong, significant relationships between each of the VT2 methods (except 
for V̇E/V̇CO2) and mean time trial power output in both February (r = 0.73-0.81; 
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p < 0.01-0.05) and September (r = 0.76-0.92; p < 0.01-0.05) [91]. However, only the 
V̇E/V̇O2 method produced an average power output that was not significantly 
different from the average time trial power output at both time points and thus were 
deemed the superior choice for VT2 determination [91]. Although LT2 (excluding 
Stegmann method) produced significantly strong relationships with 40 km cycling 
performance (r = 0.58-0.72; p < 0.01-0.05) the correlation was stronger for some VT2 
methods including V-slope (r = 0.79; p < 0.01) and V̇E/V̇O2 (r = 0.80; p < 0.01) [93]. 
Additionally, two VT2 methods (V̇E/V̇O2 and RER = 0.95) and one LT2 method 
(4 mmol·L-1) produced a mean power output that was not significantly different from 
mean time trial power output. Together, these two studies highlight that VT2, 
determined via the V̇E/V̇O2 method is most consistently related to 40 km cycling 
performance and capable of eliciting a power output similar to mean time trial power 
output. However, whether this method produces consistently stronger relationships 
with endurance performance than methods of LT2, is unknown. 
 
Furthermore, in trained marathon runners (n = 18) VT2 (expressed as %V̇O2max) 
produced a stronger relationship with endurance performance (measured as an 
endurance index; computed based on marathon time; r = 0.85 p < 0.01) than 
between V̇O2max and performance (r = 0.11; p > 0.05), with VT2 explaining 73% of 
the variance in endurance index [94]. Others have also provided evidence for this 
strong relationship between VT2 and endurance performance in various modes of 
exercise; ultra-endurance triathlon (r = 0.87; p < 0.05; n = 11 [95] and r = 0.76 and 
0.66 for the cycle and run phases, respectively; both p < 0.01; n = 21 [96]), short-
course triathlon (r = -0.78; p < 0.05; n = 18 [97], road cycling (r = -0.81; p < 0.01; n = 
8) [98] and off-road cycling (r = -0.66; p < 0.05; n = 12) [99]. In addition to LT2, studies 
assessing ventilatory measures consistently provide evidence for the fractional 
utilisation of V̇O2max being more closely related to endurance performance than 
other measures more traditionally sought after, such as V̇O2max [94, 97-100].  
 
2.2.2.3 Fractional utilisation methods and training 
Both the LT2 and VT2 have been shown to improve as a result of various training 
techniques in trained endurance athletes. An early study by Sjodin et al. [101] 
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demonstrated that adding a continuous 20 min run at the velocity eliciting LT2 
(equivalent to 4 mmol·L-1) to the usual program of well-trained middle and long-
distance male runners (n = 8) once a week for 14 weeks increased running velocity 
at LT2 (+4%; p < 0.01), without a concomitant increase in V̇O2max. Guellich and 
Seiler [102] expanded on this and examined differences in training durations and 
intensities during the basic preparation period (15 weeks) in junior elite male cyclists 
(n = 51) who were labelled as either responders (n = 17) or non-responders (n = 17) 
in terms of their improvement in LT2 (power output·kg-1 body mass eliciting a [La-] of 
4 mmol·L-1). It was found that the responders, who improved their LT2 by +11 ± 4% 
completed significantly more training at intensities eliciting a low [La-] (i.e. 
< 2 mmol·L-1; p < 0.01), than non-responders, who completed more training at 
intensities eliciting a high [La-] (3 - 6 mmol·L-1) did not improve their LT2 (-7 ± 6%). 
However, large individual training responses were reported (and the mean LT2 
improvement was only 3%), likely due to previously reported inter-individual 
differences in [La-] independent of training status [103-106]. Furthermore, end-of-
season performance outcomes were not different between responders and non-
responders (six international medals each), highlighting that differences in this 
method of LT2 determination were not causally related to performance differences. 
 
More consistently, research has shown that increasing the intensity of endurance 
training has the capacity to improve LT2 in trained endurance athletes. For example, 
Evertsen et al. [41] found that in response to five months of “mixed training” in junior 
elite cross-country skiers (11 males and 9 females) consisting of either mainly 
moderate (86%) or high (83%) intensities, running velocity at LT2 improved in the 
high-intensity group only (+3.2 ± 0.9%; p < 0.05). This was significantly greater 
(p = 0.03) than the decrement observed in the moderate-intensity group 
(-1.1 ± 1.6%; p = 0.50). Furthermore, these LT2 improvements were accompanied by 
significantly greater improvements in running performance in the high-intensity group 
(3.8% vs. 1.9%; p < 0.05). Similar responses have been reported for VT2, with 
significantly greater improvements (15 vs. -1%; p < 0.05) reported in response to 
HIIT (20 x 60 s at peak power output with 120 s recovery), than to moderate-intensity 
training following only four sessions in well-trained male cyclists (n = 14) [71]. 
Moreover, improvements in VT2 were not accompanied by improvements in V̇O2max, 
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suggesting that VT2 is more sensitive than V̇O2max in detecting changes in response 
to training in already well-trained endurance athletes. A more comprehensive review 
of the adaptations of these threshold measures, specifically LT2, in response to HIIT 
will be reviewed in section 4 of this chapter. 
 
Mechanistically, an improvement in the LT2 in response to training is characterised 
by a rightward shift of the velocity-time curve, thereby allowing an athlete to exercise 
for longer at the same exercise intensity or to sustain a higher speed for a given 
exercise duration. Hurley et al. [107] have provided evidence for the latter in previously 
untrained participants (n = 8) and reported a lower [La-] for the same relative 
intensity during 10 min running at 55 - 75% V̇O2max (p < 0.05) after 12 weeks of 
training consisting of three days per week of HIIT and three days per week of 
continuous training. As outlined earlier, the same mechanism appears to hold true in 
trained endurance athletes [108]. In regards to lactate kinetics, this improvement in 
LT2 with training status could be explained by a delayed increase in lactate 
production in the fast-twitch muscle fibres (-28-50%) as previously shown in trained 
versus untrained rats (p < 0.05) [109]. Alternatively, others suggest that metabolic 
clearance rates are enhanced with training [78]. For example, for a comparable blood 
[La-] elicited as a result of the same relative exercise intensity, trained participants (n 
= 6) yielded 65% higher lactate appearance and disposal rates compared to those 
who were untrained (n = 6) [78], indicating that improved metabolic efficiency, rather 
than increased lactate tolerance may explain the improvement in LT2 with training. 
  
Blood lactate and ventilatory parameters are consistently used as indicators of 
fractional utilisation of V̇O2max; the highest percentage of V̇O2max able to be 
sustained for ~60 min during endurance exercise. Both measures appear to be more 
consistently related to endurance performance in well-trained endurance athletes 
and more sensitive to detect changes as a result of training, than more traditional 
measures such as V̇O2max. Furthermore, the intensity of training appears to be a 
crucial variable, with LT2 and VT2 shown to increase significantly more in response to 
HIIT than to moderate-intensity training. Despite the popularity of using blood lactate 
and ventilatory parameters for the purpose of assessing performance status, a 
number of different methods of LT2/ VT2 detection have been developed over the 
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years, resulting in considerable variation. Since the LT2 is the focus of this thesis due 
to its extensive use in Australia by the national and state institutes and academies of 
sport, the most commonly-used methods for determining LT2 will be discussed in 
greater detail in subsequent sections of this review. This will include a review of their 
capacities to establish performance status and respond to training in already well-
trained endurance athletes. Additionally, the strengths and weaknesses of different 
methods and areas for future research will be discussed. 
 
2.3 Methods Of Lactate Threshold Determination 
2.3.1 Maximal Lactate Steady-State (MLSS) 
 
2.3.1.1 Introduction 
The importance of establishing a steady-state exercise intensity was initially reported 
when maximal steady-state V̇O2 was shown to be higher (as a percentage of 
V̇O2max) in highly-conditioned runners, than those who were of a lower training 
status [110]. Since then, research has consistently shown that the maximal fraction of 
V̇O2max an individual can sustain during exercise is a stronger determinant of 
endurance performance than the individual’s V̇O2max [17, 59, 98]. Thus, focus has 
shifted to establishing the most valid, reliable and efficient method of determining this 
fraction, which scientists have examined through the measurement of lactate and 
ventilatory threshold points during both maximal incremental exercise and 
submaximal, continuous exercise. These thresholds are broadly considered to 
coincide with the exercise intensity above which lactic acid production in the 
exercising muscles exceeds the maximal rate at which it can be removed [76], or the 
exercise intensity where the maximal rate of lactate clearance is surpassed [78].  
 
A criteria for determining maximal steady-state exercise intensity was first 
established in 1975, where the heart rate response during 10 min of steady-state 
exercise eliciting a [La-] of 2.2 mmol·L-1 was shown to be the best predictor of 
conditioning level (r = 0.90; p < 0.01) amongst participants of low (n = 4), moderate 
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(n = 6) and high (n = 3) fitness [111].  Since then, the highest sustainable exercise 
intensity has been thought to coincide with and also represent the MLSS. 
Establishing an individual’s MLSS has generally involved the use of several discrete 
constant load tests of around 30 min duration, with increasing or decreasing 
workloads performed on subsequent days until the highest steady state [La-] is found 
[105, 112, 113]. An increase in [La-] of no more than 1 mmol·L-1 between 10 and 30 min 
during these constant load exercise trials has been commonly reported as the 
criteria for determining MLSS [8], although 0.05 mmol·L-1 has also been used [114-116]. 
The mean blood [La-] eliciting MLSS has been reported as 4 mmol·L-1 but with large 
inter-individual variation [117, 118]. The MLSS has been associated with the highest 
sustainable rate of aerobic metabolism (known as critical power) [119, 120] and a 
predictor of endurance performance [19, 121, 122]. While [La-] and V̇O2 appear to remain 
stable at MLSS [113], heart rate seems to increase over time, although it does not 
attain maximum values [113, 123], thus it may not be valid to use heart rate as an 
indicator of steady-state intensity. This increase in heart rate over time, known as 
cardiovascular drift, is reportedly due to thermal stress, a reduced blood volume and 
a large volume of active muscle mass [124]. Once the exercise intensity exceeds 
MLSS, there is an increase in [La-] and V̇O2 together with a corresponding reduction 
in exercise tolerance [14]. 
 
Baron et al. [113] provided support for the accuracy and validity of MLSS in 
establishing the highest steady-state (or “constant load”) exercise intensity. When 
endurance-trained men (n = 11) cycled at the intensity corresponding to their MLSS 
until fatigue (55.0 ± 8.5 min), results showed a steady-state was achieved for a 
number of physiological measures in addition to [La-], including concentrations of 
pyruvate, haematocrit, haemoglobin, bicarbonate and NH4; redox state 
(lactate/pyruvate); arterial pressures of O2 (PO2) and CO2 (PCO2); arterial O2 
saturation; pH and base excess [113]. Furthermore, although [La-] was stable 
(increase in [La-] of < 1 mmol·L-1) between 10 and 30 min, there was a decrease in 
[La-] between 20 (6.79 ± 2.49 mmol·L-1) and 30 (6.18 ± 2.58 mmol·L-1; p < 0.05) min, 
which may be explained by either reduced production or increased peripheral 
utilisation of lactate [113]. These results suggest that MLSS was successful in 
establishing an exercise intensity that maintained physiological homeostasis for ~55 
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min, with mechanisms other than those related to the peripheral system causing 
fatigue.  
 
2.3.1.2 Relationship between MLSS and endurance performance 
Despite this support for the accuracy and validity of MLSS, research appears 
equivocal as to whether the MLSS is capable of (1) producing a strong correlation 
with endurance performance and (2) producing a workload matching that of the 
workload sustained by athletes during endurance events. With short- to moderate-
duration endurance events, significant relationships between MLSS and 
performance in trained athletes have been found. For example, running velocity at 
MLSS has been shown to correlate strongly with 8 km running performance 
(r = 0.92; p < 0.05) in well-trained men (n = 13) [125], and with sprint triathlon 
performance time (750 m swim, 20 km cycle, 5 km run; r = 0.83; p < 0.05) in 
moderately-trained male triathletes (n = 10) [126]. Furthermore, cycling velocity at 
MLSS correlated with 40 km cycling time trial velocity (r = 0.84; p < 0.05) in 
competitive cyclists (n = 3 women and 6 men) [127]. Additionally, an agreement 
between MLSS intensity and the intensity sustained during performance trials has 
been reported whereby there was no significant difference between mean 8 km 
running velocity (16.01 ± 0.32 km·h-1) and running velocity at MLSS (15.7 ± 0.3 km·h-
1; p > 0.05) [125], nor between the velocity (36.8 ± 1.0 km·h-1), [La-] (6.7 ± 0.7 
mmol·L-1) and heart rate (174.7 ± 2.6 beatsmin-1) at MLSS and those elicited during 
40 km cycling performance (36.6 ± 0.9 km·h-1, 6.1 ± 0.7 mmol·L-1 and 174.1 ± 2.6 
beatsmin-1, respectively; all p > 0.05) [127]. These findings suggest that MLSS is 
capable of establishing performance status as well as an exercise intensity that is 
not different from the intensity sustained during performance trials of at least ~30-65 
min. 
 
In addition to timed performance trials, some have examined MLSS workload in 
relation to exercise time to fatigue. In previous studies, exercise time to fatigue at 
MLSS workload has been reported as 55 ± 8.5 min in trained male cyclists (n = 11) 
[113] and 37.7 ± 8.9 min for cycling and 34.4 ± 5.4 min for running in recreationally-
active men (n = 15) [128]. In both studies however, fatigue was not accompanied by 
any physiological limitation such as reaching maximum V̇O2 or heart rate. However, 
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there were large inter-individual differences in time to fatigue during cycling (30.0 to 
65.2 min) and running (30.0 to 50.3 min) [128] in the lesser-trained participants, 
although the range of [La-] was not reported. In the trained participants, mean [La-] at 
MLSS was 5.5 ± 1.5 mmol·L-1 with a large range of 3.6 - 7.9 mmol·L-1 [113]. Both of 
these studies demonstrate that (1) exercise to fatigue at MLSS workload produces 
high levels of inter-individual variability; and (2) utilising MLSS workload as a 
sustainable workload during an endurance event will be individually- and duration-
dependent.  
 
2.3.1.3 Methodological inconsistencies 
Inconsistencies in the available literature with regard to the relationship between 
MLSS and endurance performance may be due, at least in part, to the different 
methods used by various researchers to determine MLSS. Table 2.1 provides a 
summary of all the studies found that have examined the relationship between MLSS 
and various measures of endurance performance in already well-trained endurance 
athletes, excluding training studies. The criteria for MLSS determination and what is 
considered a [La-] ‘steady state’ and the many different variables analysed and 
reported may also contribute to differences in findings between investigative groups. 
For example, variables such as [La-] at MLSS, workload at MLSS (expressed as 
either power output or speed), relative intensity at MLSS (% V̇O2max) and V̇O2 at 
MLSS have all been used to examine the relationship between MLSS and 
endurance performance. Furthermore, differences in performance distances, modes 
of exercise and training status of participants all have the potential to influence 
results. In addition, most researchers used a fixed duration for MLSS trials, rather 
than a ‘time to fatigue’ test which may potentially be less sensitive to detect inter- 
and intra-individual differences in MLSS. Finally, the duration of the MLSS trials used 
by many of the research groups has often been markedly different to the exercise 
durations in the performance time trials, reducing the specificity between testing and 
competition.  
 
As acknowledged by researchers, there are a number of limitations associated with 
using multiple tests to establish MLSS. Firstly, there is lack of consistency in the 
protocol used, with the number of constant load tests performed ranging from one to 
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ten and with differing percentage increases and/or decreases in workload for 
subsequent tests. This has the potential to produce marked differences in MLSS 
determination from protocol alone. Furthermore, the use of several constant load 
tests is time consuming [125], labour intensive and requires a high number of 
sampling time-points for the collection of blood [103, 129]. In addition, most tests are 
terminated after 30 min so it is not clear whether the determined MLSS is indeed the 
highest [La-] above which no further increase occurred [116]. It has also been 
suggested that the MLSS does not actually represent a true physiological steady 
state [113, 130]. For example, even though parameters such as [La-], V̇O2, V̇CO2, RER 
and bicarbonate concentration have been found to remain reasonably stable 
between 10 and 30 min at the MLSS (p > 0.05), other variables such as respiratory 
rate, heart rate (both increased) and pH (decreased) have all been shown to vary 
significantly (p < 0.05) within a constant load exercise trial [113, 130]. Based on these 
criticisms, a need for MLSS to be reliably estimated from a single incremental 
exercise test [125] or other more efficient tests is evident, and clearly warranted. 
 
2.3.1.4 Alternative methodology 
In an attempt to address limitations such as being invasive and time-consuming, 
researchers have sought alternative methodologies for determining MLSS. Hauser et 
al. [115] showed strong correlations between power output determined by three 
different LT2 methods and MLSS in men varying in training status (n = 57). The LT2 
methods used were (1) onset of blood lactate accumulation (OBLA; r = 0.89; 
p < 0.05), (2) individual anaerobic threshold (IAT; r = 0.83; p < 0.05) and (3) + 1.5 
mmol·L-1 lactate model (determined by adding 1.5 mmol·L-1 on the value of the 
lowest lactate/performance ratio [131]; r = 0.88; p < 0.05). Furthermore, although 
power output determined by OBLA and IAT were not significantly different from 
MLSS power output, the + 1.5 mmol·L-1 model significantly under-estimated MLSS 
(~20%; p < 0.01). However, mean differences between OBLA and IAT in comparison 
to MLSS were high (-7.4 ± 25.1 and 12.4 ± 24.6, respectively) and thus all LT2 
methods were deemed invalid for individual MLSS determination. More recently, the 
+ 1.5 mmol·L-1 lactate model correlated strongly with MLSS power output (r = 0.94; 
p < 0.05) and showed good agreement with MLSS (71% of participants achieved an 
anaerobic threshold within ± 5 % of MLSS and mean power output (248 ± 35 W), 
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V̇O2 (44.9 ± 7.5 mL·kg-1·min-1), heart rate (164 ± 12 beats·min-1) and [La-] 
(3.1 ± 0.6 mmol·L-1) reflective of the + 1.5 mmol·L-1 method were not significantly 
different from those reflective of MLSS (247 ± 33 W, 47.3 ± 7.0 mL·kg-1·min-1, 
169 ± 11 beats·min-1 and 3.5 ± 0.6 mmol·L-1, respectively) in trained male cyclists 
(n = 14) [132]. Therefore, it appears that training status influences the relationship and 
agreement between LT2 methods and MLSS, and despite its weak validity for MLSS 
determination in a group of men with differing training status’, the + 1.5 mmol·L-1 
lactate model appears to be appropriate for establishing a mean power output, V̇O2, 
heart rate and [La-] reflective of MLSS in trained male cyclists.  
 
Additionally, a test determining the blood lactate minimum (defined as the velocity at 
which a curve fitted to the "U-shaped" blood lactate data derived from the 
incremental test reached a nadir) which involved participants performing a short 
period of supramaximal exercise to induce hyperlactemia before commencing a 
standard incremental treadmill test, exhibited a mean heart rate (173 ± 3 beats·min-1) 
and [La-] (4.5 ± 0.3 mmol·L-1) similar to those produced at MLSS 
(176 ± 4 beatsmin-1 and 4.4 ± 0.4 mmol·L-1, respectively; both p > 0.05) in trained 
male runners (n = 13) [125]. However, mean velocity determined by the blood lactate 
minimum (14.9 ± 0.2 km·h-1) was significantly lower than the velocity eliciting MLSS 
(15.7 ± 0.3 km·h-1; p < 0.05). Furthermore, it produced a weaker correlation with 
MLSS (r = 0.61; significance not reported) and a weaker estimate of MLSS 
(SEE = 0.75 km·h-1) than LT2 (determined as the velocity immediately preceding a 
sudden and sustained increase in [La-]; r = 0.94; SEE = 0.33 km·h-1), VT (determined 
as the velocity immediately preceding the first loss of linearity in plots of V̇CO2 
against V̇O2; r = 0.77; SEE = 0.61) and OBLA (determined by interpolation; r = 0.93; 
SEE not reported) [125].  Additionally, a predicted MLSS from a two-part protocol 
consisting of two constant-speed treadmill runs of 20-min duration at approximately 
65 and 90% V̇O2peak separated by 40 min of rest, showed a poor correlation with 
MLSS speed (r = 0.29; p = 0.49) and it significantly underestimated MLSS speed 
(p < 0.05), heart rate (p < 0.01), [La-] (p = 0.01) and % V̇O2peak utilised (p < 0.05) in 
trained male runners [103]. 
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More recently, the lactate minimum has been considered valid to estimate MLSS in 
moderate- to highly-trained men (n = 63) [133]. However, despite a significant 
correlation between power output at lactate minimum and cycling power output at 
MLSS (r = 0.97; p < 0.01), mean power output, heart rate, V̇O2, ventilation and RPE 
were all significantly higher at MLSS compared to those at lactate minimum (all 
p < 0.01). This is supported by others who have shown that power output at MLSS 
correlated with power output produced during the final 30 sec of a three min all-out 
cycle test (r = 0.93; p < 0.01), but the power output was significantly lower at MLSS 
(p < 0.01) in trained male cyclists [134]. Although others have shown no difference 
between mean lactate minimum cycling speed and mean MLSS cycling speed on 
average (p > 0.90) [135], individual responses revealed that the lactate minimum did 
not provide a good estimate of MLSS in 21% of participants. Additionally, a mixed 
sample of men and women (n = 14; male vs. female ratio not specified) with a 
combination of recreational and elite cycling experience showed a lack of specificity 
and reduced capacity to draw meaningful conclusions from these findings. 
Therefore, despite producing weaker relationships with MLSS than other methods of 
LT2 determination, it appears that LT2 determined by the ‘lactate minimum’ criteria 
could be used to establish a mean heart rate and [La-] (but not velocity) at MLSS in 
trained runners. However, to the contrary for trained cyclists, despite physiological 
responses reflective of the lactate minimum and MLSS being different, a relationship 
existed when expressed relative to power output. Therefore, if the purpose is to 
establish physiological responses that are equal to those elicited at MLSS, the 
1.5 mmol·L-1 lactate model (as mentioned in earlier paragraph) appears to be more 
appropriate for trained male cyclists. Collectively, these findings demonstrate that 
researchers have acknowledged the flaws associated with traditional MLSS testing 
and are seeking to determine more effective and efficient methods - Table 2.1 below 
summarises some of these attempts, whilst Table 2.2 summaries the identified pros 
and cons of the MLSS method.  
 
2.3.1.5 Changes in MLSS with training 
The effectiveness of MLSS as a method to accurately predict endurance 
performance can also be determined by its adaptability to training. In untrained 
participants, power output at MLSS has been shown to improve by 14.7% (p < 0.01), 
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in conjunction with a V̇O2max improvement of 11.2% (p < 0.01) after six weeks of 
aerobic training (three sessions per week for six weeks at MLSS power output and 
training duration progressing from 24 to 39 min) [136]. However, no change in time to 
fatigue (p > 0.05) or [La-] at MLSS (p > 0.05) were observed. Additionally, similar 
heart rate, %V̇O2max and RPE responses (p > 0.05) were also elicited post-training, 
with heart rate maintenance possibly reflecting similar demands on both the 
cardiorespiratory system and adrenergic activity [136]. Others also support this finding 
of an increase in MLSS workload (4.5%; p < 0.05) without a concomitant increase in 
heart rate after six weeks of endurance running training in previously untrained 
participants [137]. Furthermore, there were no significant differences in [La-] at MLSS 
between untrained men and trained endurance cyclists,  (p > 0.05) despite the 
trained athletes producing higher MLSS power outputs when expressed in absolute 
terms and relative to body weight (p ≤ 0.05) [122]. This consistent finding that MLSS 
workload/power output increased in response to training independent of changes in 
other physiological systems, likely reflects a change in lactate kinetics whereby an 
increased metabolic clearance rate was achieved post-training to accommodate the 
maintenance of a higher power output, as previously found by Messonnier et al. [78].  
 
Although it is likely that endurance performance would improve when MLSS 
workload improves in response to training, and this is evidenced indirectly by those 
showing that a significantly higher power output was maintained despite no change 
in exercise time during a time to fatigue trial post-training [136], a distance-specific 
performance test would provide direct evidence for this and should be included in 
future research. Additionally, comparing the correlations between MLSS and 
endurance performance pre- and post-training will provide additional information on 
the sensitivity of MLSS to adapt in the same way as performance and warrants 
investigation. 
 
Conversely, there is some evidence to suggest that running duration (43%; p < 0.01) 
and distance (51%; p < 0.01) at MLSS velocity improved significantly after 12 training 
sessions at MLSS intensity in male, master endurance runners [138]. However, 
similarly to the findings of others, there was a significant increase in workload 
(running velocity) at MLSS post-training (4.2%; p < 0.01), despite no changes in 
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other physiological responses, such as [La-] at MLSS (p = 0.9) or the fractional 
utilisation of V̇O2max (p = 0.9). The authors explained these changes as a result of 
an improved endurance capacity, i.e. an improved capacity to sustain the same 
fraction of V̇O2max for a longer period after training. This is further justified by the 
finding that despite an increased running velocity at MLSS, no change in [La-] at 
MLSS was seen, suggesting that improved lactate kinetics contributed to this 
improved endurance capacity. 
 
Although a number of research groups have attempted to reduce the number of tests 
used to establish MLSS [103, 125, 129, 139-141], further questions relating to the MLSS 
remain. While it is reasonable, certainly on theoretical grounds, to consider that 
strong relationships exist between various threshold measures (as determined from 
an incremental exercise test), MLSS and endurance performance, consistent 
evidence in support of this association is not strong. Moreover, it is not clear whether 
the MLSS intensity calculated from laboratory testing (whether by inference from 
submaximal lactate data or from several constant load tests) is higher, lower or 
essentially the same as the intensity that an endurance-trained athlete could 
maintain during an endurance performance trial, since this appears individually- and 
duration-specific. Finally, it remains to be shown whether, as a result of endurance 
training, potential increases in threshold parameters are also reflected with 
concomitant increases in MLSS. Methodological issues aside, MLSS is generally 
accepted as representative of an individual’s highest sustainable exercise intensity, 
although numerous inconsistencies exist in the optimal duration of this sustainable 
intensity. It is the relationship between MLSS and other threshold parameters 
coupled with their functional significance in terms of endurance performance 
outcomes that warrants further investigation.  
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Table 2.1. A summary of studies correlating MLSS to performance in trained endurance athletes. 
MLSS: maximal lactate steady state; V̇O2max: maximal oxygen uptake; V̇O2peak: peak oxygen uptake; [La-]: lactate concentration; mmol·L-1: millimoles per 
litre; HR: heart rate. 
Study Participants Training status MLSS determination method Performance 
measure 
Findings 
Jones and Doust 
[125] 
Male runners (n = 
13) 
Trained (V̇O2max 
53 - 67 mL·kg-
1·min-1) 
Highest velocity at which [La-] did 
not increase by more than 1.0 
mmol·L-1 between min 10 and 30 of 
the constant velocity runs. 
8 km running 
performance 
Velocity at MLSS correlated with performance 
velocity (r = 0.92; p value not provided); 
MLSS and 8 km velocities not significantly 
different. 
Beneke, Hutler and 
Leithauser [105] 
Male participants 
(n = 33) 
Endurance 
cyclists (n = 10), 
untrained (n = 
23); V̇O2max not 
reported 
Highest [La-] that increased by no 
more than 1.0 mmol·L-1 during the 
final 20 min of constant workload 
(calculated as average [La-] at min 
15, 20, 25 and 30 of MLSS 
workload). 
Peak workload 
determined from 
incremental test 
Workload at MLSS correlated with peak 
workload (r = 0.82; p < 0.01); 
[La-] and intensity at MLSS not correlated with 
performance. 
Harnish, Swensen 
and Pate [127] 
Female (n = 3) 
and male (n = 6) 
cyclists 
Competitive 
(V̇O2peak 4.42 
L·min-1) 
≤ 1.0 mmol·L-1 change in [La-] 
during the final 20 min of a MLSS 
trial. 
HR at MLSS = mean HR during the 
last 20 min of the MLSS trial. 
5 km time trial (90% 
average speed); 
40 km time trial 
Speed at MLSS correlated with 90% 5 km time 
trial speed (r = 0.85; p < 0.05); 
Speed at MLSS correlated with 40 km time trial 
(r = 0.84; p < 0.05); 
Speed, [La-] and HR at MLSS were similar to 
corresponding 40 km time trial values. 
Van 
Schuylenbergh, 
Vanden Eynde and 
Hespel [126] 
Male triathletes 
(n = 10) 
Moderately 
trained (V̇O2peak: 
cycling 5.0 ± 0.2; 
running 5.1 ± 0.2) 
Highest [La-] that increased no 
more than 1.0 mmol·L-1 during the 
final 20 min of the 30 min constant 
workload test. 
National University 
Triathlon 
Championship (500 
m swim, 20 km 
cycle, 5 km run) 
Run and swim speed at MLSS and [La-] at 
MLSS run = strongest set of correlates of 
triathlon finish time (r = 0.99; p < 0.05); 
Run speed at MLSS strongest correlate of 
triathlon performance (r = 0.83; p < 0.05); 
[La-] at MLSS correlated with triathlon 
performance (r = -0.73; p < 0.05). 
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Table 2.2. A summary table outlining the pros and cons of the MLSS method. 
 
PROS CONS 
Avoids subjective data interpretation and lack of  
methodological standardisation [135] 
Minimum of two (but often requires 3-4) testing sessions performed on 
different days [135] 
Continuous training at MLSS intensity appears to be an effective tool for 
improving MLSS intensity [136] 
Labour intensive and requires a high number of sampling time-points for 
the collection of blood [103, 129] 
Numerous viable options available to predict MLSS in single test [115, 125, 
127, 132, 133, 135, 142] 
Not a complete physiological steady state [130] 
No effect of exercise mode on MLSS workload as % of maximum [121, 143] Large inter-individual differences in time to fatigue and [La-] at MLSS [113, 
128], making it hard to use it to set maintainable workloads for endurance 
events 
 MLSS defined in different ways by different authors and measured using 
different numbers and/or different durations of constant-load exercise 
bouts [125] 
MLSS: maximal lactate steady state. 
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2.3.2 Onset of Blood Lactate Accumulation (OBLA) 
 
2.3.2.1 Introduction 
Due to the various difficulties associated with MLSS testing previously reported in 
section 2.2.1, researchers have focused heavily on not only creating and validating 
new methods to predict MLSS, but also on validating different LT2 parameters, such 
as OBLA, IAT, D-max and most recently, the modified D-max. According to Faude et 
al., it is desirable for LT2 to achieve a high linear correlation with endurance 
performance and a close relationship with MLSS for validity as a performance 
indicator and for training intensity prescription, respectively [19]. Few studies have 
investigated the relationship between various LT2 parameters and MLSS, and 
despite most showing a high correlation between power output/ velocity at LT2 and 
MLSS, a low number of participants were often reported (n = 8-22) [115]. Furthermore, 
few studies have reported the absolute differences between LT2 power outputs/ 
velocities and those occurring at MLSS and thus, the agreement between these 
variables is not well known.  
 
As a method of LT2 determination, OBLA is well-established and is calculated as the 
workload eliciting a blood [La-] response of 4 mmol·L-1 by linear interpolation [144]. 
Others have used a fixed blood [La-] of 3.5 mmol·L-1 instead of 4 mmol·L-1 when 
incremental tests with 3 min stages were utilised [16, 104, 145]. Additionally, plasma [La-] 
(as opposed to whole blood [La-]) has also been utilised, using the same fixed 
concentration of 4 mmol·L-1 [17]. It is known that with the onset of exercise, lactate 
diffuses first into the plasma compartment resulting in a rise in plasma [La-]. There is 
however, a delay until this lactate is diffused into the erythrocytes. For this reason, a 
sample of whole blood reflects a concentration that has been diluted by lower 
erythrocyte lactate levels and has been suggested to be less sensitive than true 
plasma [La-] [146]. These findings suggest that there is likely some discrepancy when 
fixed concentrations of lactate are used to indicate a reflection point. As a result of 
these differences between whole blood and plasma [La-], a method titled ‘onset of 
plasma lactate accumulation’ (OPLA) has been developed differently to the fixed 
blood lactate concept. The OPLA method has been determined a number of different 
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ways via visual inspection of graphs relating [La-], workload intensities and V̇O2 [59], 
however will not be a focus in this review. 
 
 
2.3.2.2 Relationship and agreement of OBLA with endurance performance/ 
MLSS 
Research investigating the relationship and agreement between OBLA and MLSS 
(and/or endurance performance) is inconsistent (Table 2.3). For example in male 
(n = 7), but not female (n = 9) junior elite cross country skiers, OBLA produced a 
stronger relationship with performance than all other methods studied (anaerobic 
threshold, threshold of decompensated metabolic acidosis, the exercise intensity 
where respiratory exchange ratio reaches 1.0 and V̇O2peak) [147]. However, 
performance distances completed by the men (5-30 km) were twice the distance 
completed by the women (2.5-15 km). This may have contributed to the difference 
since it has been reported that exercise lasting ~1 h was performed at an intensity 
reflective of OBLA [93], suggesting that for durations significantly less than 1 h (such 
as for the female distances of 2.5-15km), the intensity would be higher than OBLA, 
and therefore there would be no relationship between OBLA and performance. 
Furthermore, different mechanisms contribute to fatigue over different distances and 
intensities, whereby exercise in the ‘severe’ domain (above LT2 and critical power, 
i.e. non-steady-state and maintainable for less than ~40 min) results in fatigue due to 
the kinetics of the V̇O2 slow component, resulting in a fall in muscle phosphocreatine 
concentration, pH and an increase in inorganic phosphate [148]. Conversely, fatigue 
whilst exercising in the ‘heavy’ domain (between LT2 and critical power; lasting 
between ~40 min and 3 h) is a consequence of muscle glycogen depletion. These 
differences may explain why including different competition distances for males and 
females may have confounded the relationship between OBLA and performance. 
Alternatively, according to the authors it may have been related to the narrower 
range of the performance ranking scale in the female participants, compared to the 
males which may have mathematically resulted in a weaker correlation [147]. 
Furthermore, in experienced male cyclists (n = 15), OBLA was significantly 
correlated with 40 km cycling performance (r = 0.60; p < 0.05), but this relationship 
was not as strong as those produced between 40 km performance and peak power 
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output (r = 0.71; p < 0.01), the Baldari LT, described as the stage preceding the 
second 0.5 mmol·L-1 increase in [La-] (r = 0.72; p < 0.01), or five methods of VT2 
determination (r = 0.73-0.81; p < 0.01) [93]. Although OBLA was one of only three 
LT2/VT2 methods (the others being the V̇E/ V̇O2 method of VT2 determination and 
RER of 0.95 method of VT2 determination) that elicited a power output not 
significantly different from mean 40 km time trial power output, VT2 was considered 
superior to OBLA and the other LT2 methods since they produced stronger 
correlations with performance and reflected 40 km performance intensities [93]. 
Consistently, despite significant relationships between power output at OBLA and 30 
min cycling time trial performance in moderate to well-trained male cyclists (n = 11) 
when derived from graded exercise tests with 3-min (r = 0.82; p < 0.01) and 5-min 
(r = 0.90; p < 0.01) stages, other variables produced stronger relationships (3 min: 
peak power output, D-max LT2 and LTlog determined as the power output at which 
[La-] increased exponentially when the log [La-] is plotted against the log power 
output; 5 min: peak power output and LTlog) [149].  
 
In a group of men with different endurance levels (n = 57), the comparison of power 
output at different threshold parameters (OBLA, IAT and +1.5 mmol·L-1 model) 
revealed that despite significant correlations between MLSS and each of OBLA 
(r = 0.89; p < 0.05), IAT (r = 0.83; p < 0.05) and +1.5 mmol·L-1 model (r = 0.88; 
p < 0.01), and no significant differences between mean MLSS power output and the 
mean power output at OBLA and IAT, large individual differences resulted in all 
methods being invalid for MLSS power output determination. Finally, in 
recreationally-active men (n = 11), the relationships between exercise workrate 
(velocity for running and power output for cycling) at OBLA and MLSS were 
significant for both cycling (r = 0.81; p < 0.01) and running (r = 0.94; p < 0.01), 
although absolute workrates were similar between OBLA and MLSS in running but 
not cycling (typical error of estimate for running = 5.5 % and cycling = 20.7 %) [150].  
 
Collectively, previous research suggests that OBLA is not a valid measure of MLSS 
or endurance performance since its capacity to: (1) correlate with MLSS and 
measures of endurance performance were consistently weaker than other threshold 
measures; (2) reflect performance intensities was good on average, but lacks 
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individual specificity which is likely explained by the nature of using a fixed 
4 mmol·L-1 detection method. Therefore, OBLA appears unable to fulfil the criteria for 
establishing a meaningful individual exercise intensity recommendation, for training 
or competition, and this is supported by others [115, 151]. 
 
2.3.2.3 Reasons for inconsistencies  
One criticism of using OBLA as an indicator of performance is related to the 
heterogeneity in [La-] between individuals. For example, during 60 min of cycling at 
60 and 75% V̇O2max in men (n = 21) of “low” (V̇O2max < 55 mL·kg-1·min-1), 
“medium” (55-65 mL·kg-1·min-1) and “high” (> 65 mL·kg-1·min-1) aerobic capacity, the 
coefficients of variation in [La-] were large (52.4 and 41.3% during the 60 and 75% 
V̇O2max trials, respectively), with no difference between “low”, “moderate” and “high” 
groups (p ≥ 0.08) [152]. Moreover, the [La-] at MLSS was shown to exceed 4 mmol·L-1 
in swimming (range: 5.8-11.0 mmol·L-1), cycling (range: 3.6 - 9.5 mmol·L-1) and 
running (range: 3.7-6.9 mmol·L-1) in recreational triathletes [126]. Similarly, Kilding and 
Jones [103] reported a [La-] range of 2.1-4.9 mmol·L-1 at MLSS in endurance-trained 
male runners, and this supports the earlier findings of others [104-106].  
  
Another potential confounder in the capacity of OBLA to correlate with MLSS and 
endurance performance is the stage duration of the incremental test used to 
determine OBLA. Heck et al. [16] showed strong correlations between running speed 
at OBLA and running speed at MLSS with 3 min (r = 0.979; p value not reported) and 
5 min (r = 0.975; p value not reported) stage durations. However, the workload 
duration was shown to significantly influence the corresponding blood [La-] with 
mean values of 3.50 and 4.05 mmol·L-1 (p < 0.01) for the three and five min stages, 
respectively. According to the authors, this reflects an over-estimation of the 
workload at MLSS if the prediction is made using three min workloads [16]. This 
inconsistency may be accounted for by the use of the different fixed [La-] for different 
stage durations [16, 144]. Van Schuylenbergh et al. [112] presented similar findings 
whereby the relationship between OBLA and MLSS was weak when small workload 
increments (5% body mass) were employed every 30 sec (r = -0.31; p > 0.05) and 
strengthened with larger workload increments (60% body mass) every 6 min 
(r = 0.71; p < 0.05) in elite cyclists (n = 21; sex not specified). Although workloads at 
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OBLA and MLSS were similar regardless of the stage duration (321 ± 14, 314 ± 
12 and 311 ± 9 W at short duration OBLA, long duration OBLA and MLSS, 
respectively), OBLA could not explain as much variance in MLSS as the D-max 
method could (50% vs. 72%, respectively). 
 
Additionally, it appears that exercise mode has the potential to impact the capacity of 
OBLA to relate to MLSS and endurance performance. It has been shown that power 
output relative to active muscle mass and [La-] are both lower if the volume of active 
muscle increases. This is supported by studies showing lower [La-] at MLSS in 
rowing than cycling (67-74%; p < 0.01-0.05) in junior male rowers (n = 6) [143] and 
when comparing trained male rowers (n = 11) and trained male cyclists and 
triathletes (n = 16) [121]. However, this difference was eliminated when expressed 
relative to the volume of active muscle recruited [121, 143]. Although OBLA was not 
directly measured in these studies, the findings suggest that exercise mode may 
influence its validity to predict MLSS, and this supports those who have assessed 
this directly [115, 125, 150]. For example, Figueira et al. showed that although MLSS 
workload was correlated with OBLA workload in both cycling (r = 0.81; p < 0.01) and 
running (r = 0.94; p < 0.01), running speed, but not cycling power output (p < 0.01), 
was similar between OBLA and MLSS [150].  
 
Collectively, these confounders provide evidence to suggest that OBLA has the 
potential to be influenced by a range of factors including inter-individual differences 
in [La-], incremental test stage duration and exercise mode – all of which indicate 
that it is not a measure sensitive to reflect MLSS or endurance performance. 
 
2.3.2.4 OBLA and training 
Research has shown that [La-] at MLSS and OBLA (determined as the power output 
eliciting a [La-] of 3.5 mmol·L-1) were not different and significantly correlated in both 
trained male cyclists (r = 0.77; n = 9) and untrained men (r = 0.81; n = 10), despite a 
significantly higher power output at MLSS and OBLA in the trained cyclists, 
suggesting that the validity of OBLA to estimate MLSS cycling power output was 
independent to aerobic capacity [122]. Therefore, it could be speculated that OBLA 
would occur at a higher absolute workrate after a period of training due to the 
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resulting increase in metabolic clearance rate. However, after a 14 week period of 
increased training volume in young swimmers (n = 7; age: 13.3 ± 1.3 years), 
Toubekis et al. [153] showed that although there was a significant increase in 200 m 
swimming performance (1.88%; 95% CI = 0.74-3.01) from baseline to 14 weeks, 
OBLA improved from week six to 14 only, and the improvement in OBLA was not 
related to the performance improvement over this period (r = 0.21; p > 0.05). These 
findings suggest that OBLA was not sensitive to detect changes in performance in 
response to training. Furthermore, although improvements in the power output at 
OBLA were seen in junior elite male cyclists (n = 51) after 15 weeks of training in the 
basic preparation period [102], the variability in the change in OBLA was large and the 
authors classified some cyclists as ‘responders’ (11 ± 4% improvement in OBLA) 
and others ‘non-responders’ (7 ± 6% decrement in OBLA; p < 0.01 between groups), 
despite no difference in performance improvements between the ‘responders’ and 
‘non-responders’. However, performance was not statistically analysed and simply 
assessed by medal success 5-6 months after the determination of post-training 
OBLA. Therefore, these results should be interpreted with caution. Finally, the 
influence of training intensity on the change in OBLA has produced conflicting 
results. For example, results have shown that cyclists (n = 17 men) who significantly 
improved OBLA spent less time training at moderate to high intensities (3-6 mmol·L-1 
[La-]) and more time at low intensities (< 2 mmol·L-1 [La-]) compared to those who 
showed no improvement in OBLA (p < 0.01; n = 17 men) [102]. However, changes in 
OBLA had no influence on performance, since there were no differences 
(determined by medal success) between groups [102]. Conversely, others have shown 
a significantly greater increase in running speed at OBLA (p = 0.03) and 
performance improvements (increase in distance covered during 20 min running; 
p = 0.05) in elite cross country skiers (n = 11 men and 9 women) in response to five 
months of HIIT (80-90% V̇O2max continuously for 10 min to 2 h or as intervals of 
40 s to 7 min, 2-3 times per week) compared to moderate-intensity training (60-70% 
V̇O2max for 40 min to 3 h, 7 days per week) [41], highlighting that higher training 
intensities were necessary to improve OBLA. 
 
In summary, although OBLA was originally introduced as a simple method of 
determining LT2, previous research suggests that it is not a valid measure of MLSS 
59 
 
or endurance performance and is therefore unable to fulfil the criteria for assessing 
endurance performance or establishing a meaningful individual exercise intensity 
recommendation, for training or competition. Furthermore, OBLA has shown to be 
confounded by a range of external factors such as inter-individual differences in [La-], 
incremental test stage duration, exercise mode and training intensity, suggesting it is 
not a sensitive measure to detect true changes in MLSS or endurance performance, 
or to compare between individuals. A summary of the positive and negative research 
findings discussed in this thesis section is presented in Table 2.4. 
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Table 2.3. A summary of studies correlating OBLA to MLSS or endurance performance. 
 
Study Participants Training status Methods Findings 
Tanaka and 
Matsuura [154] 
Male distance and/ 
or marathon runners 
(n = 12) 
Highly trained (V̇O2max 
73.1 ± 5.2 mL·kg-1·min-1) 
Marathon run (42.2 km) Velocity at OBLA correlated with velocity during 
marathon (r = 0.68; p < 0.05); 
Velocity at OBLA (5.30 m·s-1) significantly faster than 
velocity during marathon (4.49 m·s-1; p < 0.05) 
Heck et al. [16] Healthy men (n = 16) Varying endurance 
capacities 
Running MLSS (highest speed 
maintainable with an increase 
in [La-] ≤ 1.0 mmol·L-1 in final 
20 min) 
Running speed at OBLA correlated with MLSS with 
three (r = 0.98; p < 0.05) and five min (r = 0.98; 
p < 0.05) stage durations 
Jones and 
Doust [125] 
Male runners (n = 
13) 
Trained (V̇O2max range 
53 – 67 mL·kg-1·min-1)  
8 km running performance 
Running MLSS (highest speed 
maintainable with an increase 
in [La-] ≤ 1.0 mmol·L-1 in final 
20 min) 
Velocity at OBLA correlated with 8 km run 
performance (r = 0.81; p < 0.05) and velocity at MLSS 
(r = 0.93; p < 0.05); 
Velocity at OBLA (16.1 ± 0.2 km·h-1) not different from 
velocity at MLSS (15.7 ± 0.3; p > 0.05) 
Larsson at al. 
[147] 
Junior cross country 
skiers (men = 7; 
women = 9) 
Elite (Run V̇O2peak: men; 
71.1 ± 7.4 mL·kg-1·min-1, 
women; 59.8 ± 3.2 mL·kg-
1·min-1) 
Ranking scale from the results 
of 4 competitions (men: 5 – 30 
km, women: 2.5 – 15 km) 
OBLA correlated with performance in men (r = -0.95; p 
< 0.01); 
No significant relationship in women 
McNaughton et 
al. [149] 
Male cyclists (n = 11) Trained (V̇O2max 62 ± 8 
mL·kg-1·min-1) 
30 min cycle time trial PO at OBLA (3 min stage) correlated with PO during 
30 min cycling time trial (r = 0.82; p < 0.01); 
PO at OBLA (5 min stage) correlated with PO during 
30 min cycling time trial and (r = 0.90; p < 0.01); 
No difference between PO at OBLA for 3 (295.8 ± 
40.0 W) and 5 min (289.4 ± 35.4 W) stages (p > 0.05) 
Amann et al. [93] Male road cyclists (n 
= 15) 
Highly trained (V̇O2max 
68.6 ± 4.2 mL·kg-1·min-1) 
40 km cycle time trial PO at OBLA correlated with 40 km cycling time trial 
performance (r = 0.60; p < 0.05); 
No difference between PO at OBLA and PO during 
time trial (p = 0.39) 
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Figueira et al. 
[150] 
Men (n = 11) Recreationally active Running and cycling MLSS 
(highest workload maintainable 
with an increase in [La-] ≤ 1.0 
mmol·L-1 in final 20 min) 
Workload at OBLA correlated with workload at MLSS 
in cycling (r = 0.81; p < 0.01); 
Workload at OBLA correlated with workload at MLSS 
in running and (r = 0.94; p < 0.01); 
Workload at OBLA was lower than workload at MLSS 
in cycling (156.2 ± 41.3 vs. 179.6 ± 26.4 W; p < 0.05); 
No difference between workload at OBLA and 
workload at MLSS in running (3.2 ± 0.6 vs. 3.1 ± 0.4 
m.min-1; p > 0.05) 
Hauser et al. 
[115] 
Men (n = 57)  Varied (training volume: n 
= 20 between 10 and 14 
h·week-1, n = 19 between 
2 and 8 h·week-1, n = 18 
no sport) 
Cycling MLSS (several 
constant load tests; highest 
workload maintainable with an 
increase in [La-] ≤ 0.05 mmol·L-
1 in final 20 min) 
OBLA correlated with MLSS (r = 0.89; p < 0.05); 
PO at OBLA was lower than PO at MLSS (3.3 %; p < 
0.05) 
Tanaka et al. 
[155] 
Men (n = 11) Non-endurance athletes 
and/or very active 
1500 m running performance OBLA velocity correlated with MLSS velocity (r = -
0.71; p < 0.05) 
 
OBLA: onset of blood lactate accumulation; MLSS: maximal lactate steady-state; PO: power output; V̇O2peak: peak oxygen uptake; V̇O2max: maximal 
oxygen uptake; mL·kg-1·min-1: millilitres, per kilogram, per minute; [La-]: lactate concentration; mmol·L-1: millimoles per litre; km: kilometres. 
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Table 2.4. A summary table outlining the pros and cons of the OBLA method. 
 
PROS CONS 
Determined by the use of a single visit incremental test [7, 16, 104] to 
determine MLSS or performance indirectly, so it is less time expensive 
[150] 
May be sensitive to conditions of glycogen depletion and super-
compensation, and they do not reflect inter-individual differences in the 
kinetics of blood lactate accumulation [156, 157] 
Strong relationships between OBLA and MLSS/ performance [16, 93, 115, 154], 
showing good predictive ability 
Workload at OBLA different to workload at MLSS/ workload during 
performance [115, 150, 154] 
Aerobic fitness level does not affect the validity of OBLA [122] OBLA is not sensitive to detect changes in aerobic training status [153] 
No difference between workload at OBLA for 3 or 5 min stages [149] Differences in protocol are likely to influence the workload corresponding to OBLA [16] 
 Different exercise modes may produce different levels of [La
-] [121, 143] and 
have inconsistent agreements with MLSS [150] 
 Inter-individual differences in [La-] independent of training status [103-106] 
MLSS: maximal lactate steady-state; OBLA: onset of blood lactate accumulation; [La-]: lactate concentration. 
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2.3.3 Individual Anaerobic Threshold (IAT) 
 
2.3.3.1 Introduction 
The IAT was first defined by Stegmann et al. [158] as the maximal metabolic rate at 
which the elimination of blood lactate is equal to the rate of diffusion into the blood 
during exercise. As with the previously described methods of LT2 determination, the 
theoretical basis behind the IAT is that it represents the highest metabolic rate 
associated with a steady-state blood lactate response during submaximal exercise of 
30 - 45 min [158]. In contrast to methods of LT2 determination that are based on a 
fixed [La-], or fixed inclinations of [La-], the IAT takes into account individual lactate 
kinetics in the blood during, and immediately after, incremental exercise to 
exhaustion. This is completed by examining the lactate diffusion along gradients and 
its simultaneous elimination [159].  
 
2.3.3.2 Reliability, reproducibility, validity and objectivity 
The reliability, reproducibility, and validity of the IAT was first assessed in male 
cyclists with a range of aerobic capacities (n = 11) [160]. Reliability and reproducibility 
were assessed by an incremental test-retest design, whilst validity was assessed by 
a 45 min constant load trial at the power output reflective of IAT, with subsequent 
trials completed at IAT ± 5%, IAT ± 2.5% or IAT ± 7.5%. IAT was considered valid 
when: (1) exercise was sustained for ≥ 30 min; (2) [La-] changed by < 0.5 mmol·L-1 
(3) pH changed by < 0.005 pH units; and (4) PCO2 changed by < 0.3 kPa, during the 
last 15 min of at least 30 min exercise. It was found that the IAT produced a high 
test-retest reliability (r = 0.98; SE 8W) and the power output reflective of IAT was 
reproducible (test 1: 240.3 ± 41.7 W; test 2: 236.6 ± 42.9). However, only four 
participants confirmed validity of the IAT by meeting the criteria described above, 
with the IAT shown to over-estimate a sustainable, steady-state cycling power output 
in 64% of participants. Nonetheless, steady-state was observed for the majority of 
participants at power outputs within 2.5% of the estimated IAT and was therefore 
considered valid in ~73% of participants in the study. It is important to note, however, 
that the authors’ criteria for steady-state was different to the criteria generally 
accepted for detecting MLSS (see Chapter 2.2.1 of the present thesis) and may have 
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influenced the results. Additionally, the recovery periods used were inconsistent with 
the original protocol of Stegmann and Kindermann [158] and therefore the reliability 
and reproducibility should not be considered transferable to the original protocol. 
 
The findings of Urhausen et al. [161] also supported the validity of IAT during their 
investigation examining the responses of adrenalin, noradrenalin, [La-] and heart rate 
in male endurance-trained runners and triathletes (n = 14) during four randomised 
running protocols of 45 min duration at 85%, 95%, 100% and 105% IAT. Results 
showed an over-proportional increase in adrenalin (p < 0.05-0.06) and noradrenaline 
(p < 0.01) at 105% IAT compared to 85 - 100% IAT, as well as an increase in [La-] at 
105% IAT (p value not reported) compared to a steady-state [La-] during trials 
performed at 85 - 100% IAT (main effect for [La-] p < 0.01). These findings confirmed 
that the IAT was indicative of a true physiological break point which corresponded to 
the aerobic-anaerobic transition. However, one methodological difference between 
this study and others was identified in relation to the determination of a [La-] steady-
state. Urhausen et al. [161] identified a [La-] steady-state as an increase in [La-] of 
< 1 mmol·L-1 between 15 and 45 min or < 0.5 mmol·L-1 during the final 15 min, which 
is similar, although not identical, to the more commonly reported criteria for MLSS 
detection (see Chapter 2.2.1 of the present thesis). As discussed for the study above 
by McLellan and Jacobs [160], these methodological inconsistencies may have 
impacted the results. 
 
The findings of Coen et al. [162] support the objectivity and reliability of IAT in relation 
to running velocity when reported in trained male (n = 87) and female (n = 24) 
runners and triathletes. Inter-observer-variability was investigated by comparing the 
graphic determination of IAT by four differently skilled examiners, and reliability was 
assessed by a test-retest design. Furthermore, the influence of a reduced exhaustion 
(protocol reduced by 180 s), preliminary exercise (competition warm-up), step 
duration (5 min compared to the original protocol of 3 min) and speed increment 
(1 km·h-1 compared to the original protocol of 2 km·h-1) was also investigated by 
comparing to the original protocol in a test-retest design. Results showed that 
graphical determination of IAT produced a low inter-observer-variability with no 
significant differences between four independent examiners (p > 0.05). Although [La-] 
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(p = 0.07) and heart rate (p < 0.05) reflective of IAT were different between the test 
and re-test, running velocity was identical, and there were no differences between 
the test and retest for other protocol manipulations (reduced exhaustion, preliminary 
exercise, step duration or speed increment; all p > 0.05). The only protocol 
manipulation to affect IAT determination was the reduction in speed increment which 
significantly increased the IAT velocity (~6%; p < 0.05). Nevertheless, the authors 
concluded that the IAT was highly objective, reliable and insensitive to changes in 
the protocol with the only possible influence being that of a change in speed 
increment [162].  
 
Therefore, despite methodological differences, the literature generally supports the 
IAT as a reliable, reproducible, valid and objective measure of LT2 determination. 
However, the generalisability of research findings should not be applied across all 
exercise modes or maximal exercise protocols that differ in speed increments 
between stages.  
 
2.3.3.3 Relationship and agreement with MLSS and performance 
Very few studies have directly compared the IAT with MLSS or directly with 
endurance performance (Table 2.5). Original research showed that the workload at 
IAT was lower than the workload at OBLA in the majority of their trained participants, 
and since exercise was maintained for 50 min at the workload corresponding to the 
IAT but not OBLA, it was suggested that the IAT must be reflective of MLSS [159], 
although multiple constant load tests were not performed. However, subsequent 
research showed that power output and blood [La-] reflective of IAT were significantly 
higher (12% and 68%, respectively; both p < 0.01) than MLSS power output and 
blood [La-] in trained male rowers (n = 9), despite there being a strong relationship 
between IAT power output and MLSS power output (r = 0.81; p < 0.01) [7]. This 
overestimation of IAT power output in relation to MLSS power output; 7%; p = 0.04) 
was confirmed by Hauser et al. [115], despite a significant correlation between the two 
thresholds (r = 0.83; p < 0.05) in males of varying endurance levels (n = 57). 
Furthermore, findings from this study contributed to the knowledge of IAT further by 
showing that in comparison to MLSS, IAT power output produced large individual 
differences and therefore did not fulfil the criteria for establishing a meaningful 
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individual training intensity [115]. However, the authors concluded that IAT was 
sufficiently valid when determining mean but not individual MLSS, and this confirms 
earlier findings of Bourgois and Vrijens [163] who stated that the IAT demonstrated a 
reliable point of reference of the range of steady-state [La-] in young, trained male 
rowers (n = 10), despite only 60% of participants eliciting a steady-state [La-] during 
30 min of constant load exercise at IAT power output. 
 
In order to investigate findings that the traditional IAT protocol (3 min stages during a 
maximal incremental test) did not elicit an IAT exercise intensity equivalent to MLSS 
in all individual cases (due to concerns that the stage duration was not 
representative of [La-] in response to prolonged exercise at the same stage [164], 
Baldari and Guidetti [165] compared this traditional protocol with one where each [La-] 
value was assigned to the workload immediately before that of its measurement. 
Results showed that the new protocol elicited an IAT running speed that all 
participants (n = 21 men and 20 women of mixed training backgrounds) sustained for 
30 min, and all elicited a steady-state [La-], whereas the traditional protocol was 
either not sustainable for 30 min (n = 6 men and n = 9 women), or did not elicit a 
steady-state [La-]. Although these results suggest that this alternative protocol may 
be recommended for establishing the highest sustainable exercise intensity for at 
least 30 min, there were some notable weaknesses. For example, the IAT was 
detected via a simplified visual inspection method, in comparison to the graphic 
determination method reported in the original protocol which was shown to have low 
inter-observer-variability [162]. Additionally, [La-] steady-state was assessed during 
only one constant load trial performed at the intensity reflective of IAT determined 
from each of the new and traditional protocols, so it is unknown whether MLSS was 
achieved. Therefore, it is unknown whether this new protocol established an exercise 
intensity that under-estimated MLSS. Finally, although moderately-high V̇O2max 
values were reported for the participants (from 47.5 ± 3.0 mL·kg-1·min-1 for dancers 
to 59.2 ± 3.5 mL·kg-1·min-1), it is unknown whether the findings would transfer to a 
group of homogeneous, endurance-trained athletes. 
 
The capacity of the IAT to correlate with endurance performance has been 
investigated to a lesser extent than its capacity to correlate/agree with MLSS. Amann 
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et al. [93] investigated the IAT determined via two methods; the traditional Stegmann 
and Kindermann method [159] and the modified version described above by Baldari 
and Guidetti [165]. It was found that the Baldari and Guidetti method (r = 0.72; p < 
0.01) [165] but not the traditional Stegmann and Kindermann method (r = 0.52; p > 
0.05) [159] was significantly correlated with 40 km cycling time trial performance in 
trained male cyclists (n = 15). However, power output determined by the Baldari and 
Guidetti method [165] significantly underestimated 40 km time trial power output (14%; 
p value not stated) and therefore its capacity to establish a performance intensity 
cannot be confirmed.  
 
Collectively, the research that has investigated the IAT in comparison with MLSS 
and endurance performance suggests that the IAT may be sufficiently valid when 
determining mean or reference range MLSS, but lacks the sensitivity for 
individualised MLSS detection for training intensity establishment, and competition 
intensity determination. However, a lack of research in endurance-trained 
participants does not allow for strong evidence-based conclusions to be made on its 
strengths and weaknesses for this population. 
 
2.3.3.4 IAT and training 
Few studies have sought to determine whether changes to the IAT occur with 
endurance training and hence, whether the IAT is sensitive to detect changes in 
training status and/ or endurance capacity. McLellan and Jacobs [166] compared the 
IAT as determined by two protocols; (1) an incremental test followed by complete 
rest (passive recovery) and; (2) an incremental test followed by low-intensity 
exercise at 35% V̇O2max (active recovery), before and after eight weeks (29 
sessions) of endurance training (30 min cycling at 75-85% maximum heart rate) in 
previously untrained men (n = 6) and women (n = 3). Although IAT power output was 
significantly higher when detected by the active recovery than the passive recovery 
protocol before (14%; p < 0.05) but not after (3%; p > 0.05) training, similar 
improvements in IAT power output (33% for passive, and 22% for active; both 
p < 0.05) occurred post-training regardless of the protocol adopted. Therefore, it was 
concluded that although the IAT occurred at a higher metabolic rate when an active 
rather than passive recovery protocol was adopted, the influence of the recovery 
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phase on IAT determination did not influence the sensitivity of IAT to respond to 
training. However, since one possible explanation for the difference between 
protocols at baseline but not post-training was related to training status (i.e. it was 
suggested that the active recovery intensity was optimal for [La-] removal at baseline 
but not post-training since LT2 is commonly higher post-training), it could be 
suggested that the active recovery protocol may not be sensitive to training in 
endurance-trained populations.  
 
Recent findings confirmed the sensitivity of the traditional IAT protocol (passive 
recovery) in response to endurance training (50 weeks of jogging or walking for 45 
min, three days per week at either 60% heart rate reserve or heart rate at lactate 
threshold) in previously untrained middle-aged men (n = 7) and women (n = 11) [167]. 
In comparison to other measurements (V̇O2max, resting heart rate and exercising 
heart rate), the IAT was determined the most sensitive tool to detect changes in 
response to endurance training with the lowest intra-individual coefficient of variation 
(1.9%) and the lowest number of non-responders (n = 1). Furthermore, 14 out of 18 
participants increased their IAT by ≥ 5.6% and in three participants the IAT was 
unable to be determined. However, neither of the training studies discussed [166] [167] 
examined performance trials, so it is unknown whether the relationship between IAT 
and performance is affected by training, and whether these training adaptations differ 
in endurance-trained individuals. 
 
Keith, Jacobs and McLellan [168] also investigated the sensitivity of the IAT in 
response to training in recreationally-active men (n = 21), by comparing two training 
groups; one cycled continuously for 30 min at IAT power output, and the other cycled 
for 7.5 min at 30% below the IAT- V̇O2max difference, and then for 7.5 min at 30% 
above the IAT- V̇O2max difference for a total of 30 min, for eight weeks (29 
sessions). Results showed that mean power output at IAT significantly improved in 
both the continuous (17%; p < 0.05) and intermittent training groups (21%; p < 0.05), 
with no difference between groups (p > 0.05), suggesting that IAT adaptations may 
be related to mean training intensity, rather than the continuous or intermittent nature 
of training.ed 30 min. session- 
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The value of individualising exercise thresholds should not be underestimated and 
the weight of evidence suggests that the IAT is a reliable, reproducible, valid and 
objective measure of LT2 determination. However, it appears to lack the sensitivity 
for individualised MLSS detection and therefore, its use in training and competition is 
not supported. The IAT appears to improve in response to endurance training, 
although this statement is without substantial scientific research. Furthermore, 
additional research is required to establish whether the IAT improves concomitantly 
with endurance performance improvements after training; this will establish its 
sensitivity to detect meaningful changes. A summary of the pros and cons related to 
the IAT as discussed in this thesis section is presented in Table 2.6. 
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Table 2.5. A summary of studies correlating IAT to MLSS or performance. 
 
Study Participants Training status Methods Findings 
Stegmann and 
Kindermann [159] 
19 rowers; males 
(n = 9) and 
females (n = 10) 
Trained (V̇O2max; 
males 56.0 ± 5.7 
mL·kg-1·min-1; 
females 53.4 ± 3.3 
mL·kg-1·min-1) 
Rowing MLSS (1 x 50 
min constant load test at 
each of IAT workload 
and OBLA workload)  
Workload at IAT lower than the workload at OBLA in 15 of the 19 
participants; 
Since workload at OBLA ≠ workload at IAT, workload at OBLA ≠ workload 
at MLSS (indirect evidence); 
Exercise maintained for 50 min at IAT workload but not at OBLA workload 
(14.4 ± 6.3 min), therefore IAT must = MLSS (indirect evidence). 
Beneke [7] Male rowers (n = 
9) 
Trained (maximal 
workload at end of 
incremental test = 
363.3 ± 45.1 W; 
V̇O2max not 
reported) 
Rowing MLSS (highest 
[La-] increasing by no 
more than 1 mmol·L-1 
within last 20 min of 
constant workload) 
IAT correlated with MLSS (r = 0.81; p < 0.01); 
Workload at IAT higher than workload at MLSS (13%; p < 0.01). 
Amann, Subudhi 
and Foster [93] 
Male road cyclists 
(n = 15) 
Highly trained 
(V̇O2max 68.6 ± 4.2 
mL·kg-1·min-1) 
40 km cycle time trial; 
2 x IAT protocols: 
(1) those of Stegmann & 
Kindermann [159] and; 
(2) those of Baldari & 
Guidetti [165] 
The Baldari method correlated with 40 km cycling time trial performance (r 
= 0.72; p < 0.01); 
The Stegmann method did not correlate with 40 km cycling time trial 
performance (r = 0.52; p > 0.05); 
Power output (Baldari) was significantly lower than power output during 
the time trial (14%; > 3 IQR from the scores at the 25th and 75th 
percentiles). 
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Baldari and 
Guidetti [165] 
41 athletes; 
males (n = 21) 
and females (n = 
20) of varying 
training 
backgrounds 
Mixed (V̇O2max; 
males 59.0 ± 4.2 
mL·kg-1·min-1; 
females 49.6 ± 3.7 
mL·kg-1·min-1) 
Running MLSS (increase 
in [La-] of < 0.5 mmol·L-1 
during final 10 or 15 
min); 
2 IAT protocols: 
(1) traditional (V̇O2 vs. 
[La-] from same 
workload); 
(2) new (V̇O2 vs. [La-] 
from previous workload) 
No difference between [La-] at IAT and MLSS at 10, 15, 20 or 25 min in 
males or females (p > 0.05) with new protocol; 
Increase in [La-] of 1.1 mmol·L-1 and 2.0 mmol·L-1 between 10-30 min in 
males and females, respectively with traditional protocol. 
Bourgois and 
Vrijens [163] 
Male rowers (n = 
10) 
Trained (V̇O2max;  
4.17 ± 0.48 L·min-1) 
Constant Load test (30 
min at IAT workload; 
steady state [La-] 
determined as increase 
in [La-] of < 1 mmol·L-1 
between 10 and 30 min, 
or < 0.5 mmol·L-1 in final 
10 min) 
All participants completed 30 min rowing at IAT workload but only 6 
elicited a steady state [La-]; 
On average, steady state [La-] during 30 min test   
Hauser, Adam 
and Schulz 
Hauser, Adam 
[115] 
Male participants 
(n = 57) of varying 
endurance levels 
Varied (training 
volume: n = 20 
between 10 and 14 
h·week-1, n = 19 
between 2 and 8 
h·week-1, n = 18 
no sport) 
Cycling MLSS (several 
constant load tests; 
highest workload with an 
increase in [La-] ≤ 0.05 
mmol·L-1 in final 20 min) 
Power output at IAT correlated with power output at MLSS (r = 0.83; p < 
0.01); 
Power output at IAT higher than power output at MLSS (6.8%; p < 0.05) 
IAT: individual anaerobic threshold; OBLA: onset of blood lactate accumulation; MLSS: maximal lactate steady-state; PO: power output; V̇O2peak: peak 
oxygen uptake; V̇O2max: maximal oxygen uptake; mL·kg-1·min-1: millilitres, per kilogram, per minute; [La-]: lactate concentration; mmol·L-1: millimoles per litre; 
km: kilometres; W: Watts 
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Table 2.6. A summary table outlining the pros and cons of the IAT method. 
 
PROS CONS 
Highly objective, reliable and insensitive to changes in some aspects of 
original protocol (not reaching exhaustion, performing preliminary exercise 
and step duration) [162] 
Sensitive to changes in speed increment during incremental testing [162] 
Reliable and reproducible when detected by a maximal incremental test with 
a light active recovery period [160] 
Over-estimates the true IAT for some individuals [7, 160, 163] 
Appears to be representative of a true physiological break-point [161] Inconsistent determination of MLSS in which to compare IAT with [160, 161, 165] 
IAT: individual anaerobic threshold; MLSS: maximal lactate steady-state. 
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2.3.4 Maximum-deviation (D-max) and modified maximum-deviation 
(modified D-max)  
 
2.3.4.1 Introduction 
The D-max method for LT2 identification involves calculating the point that yields the 
maximal perpendicular distance to the straight line formed by the two end data points 
of the lactate vs. time or workload curve [169]. The principle of this method is not only 
to create a linear regression line between the blood [La-] at the beginning and end of 
an incremental test, but also to establish a third order polynomial regression line that 
represents the blood lactate kinetics during exercise [170]. This method of threshold 
detection was developed with the aim of improving objective methods such as 
OBLA, which do not take into account individual variation in lactate levels and have 
been shown to be dependent on a number of external factors such as test protocol 
and alimentation [156, 171]. As discussed, an IAT method has also been derived which 
takes into account individual lactate kinetics in the blood during and immediately 
after incremental exercise to exhaustion, based on lactate diffusion along gradients 
and its simultaneous elimination [159]. However, numerous flaws have also been 
identified with this method, with evidence suggesting it is influenced by changes in 
speed increments during incremental testing [162] and it may over-estimate a true 
threshold point [7, 160, 163]. More recently, the D-max method [172] and its modified 
version (modified D-max) have been analysed for reliability and validity, and their 
relationships with endurance performance have been established. The modified D-
max method has been described as the point on the polynomial regression curve 
that yields the maximal perpendicular distance to the straight line formed by LT1 (the 
point preceding the first 0.4 mmol·L-1 rise in [La-]) and the final lactate point [10] 
(Figure 2.1). It was designed to eliminate the influence of the first lactate point (by 
replacing it with LT1) which was used in the original D-max method[172] and resulted 
in it being prone to variability [24]. 
 
74 
 
 
Figure 2.1. Modelling process of the modified D-max method for the 
determination of LT2. 
 
2.3.4.2 Reliability, reproducibility, validity and objectivity 
Zhou and Weston [170] examined the test-retest reliability of the D-max method to 
define blood lactate kinetics in response to incremental exercise and compared the 
physiological responses with two other threshold methods; (1) OBLA and, (2) VT2 
(defined as the second breakpoint when detecting nonlinear changes in ventilation, 
V̇CO2 and the fraction of O2 in expired gas) determined both visually and by 
computerised analysis, in male cyclists and triathletes (n = 10). No significant 
differences were found between the two tests in terms of V̇O2peak, heart rate, [La-] 
or time to exhaustion, nor were there differences between mean threshold values 
(expressed as %V̇O2peak). A high test-retest reliability was found in all of the 
measurements except %V̇O2peak at OBLA. As a result, the authors concluded that 
D-max, OBLA and the two VT2 measurements were equally reliable. However, it was 
proposed that the D-max method, in addition to the computerised VT2 method, had 
the advantage of individuality and objectivity. This addressed flaws previously 
associated with OBLA and other methods which, although out of the scope of this 
review, are reliant on skilled scientists to identify visual breakpoints.  
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More recently, the capacity of the D-max and modified D-max methods to elicit a 
similar [La-] and heart rate to those reflective of VT2 and OBLA, was examined in 
elite cross-country skiers (n = 12 males and 11 females) who completed a maximal 
incremental roller-ski test on a treadmill [169]. The results revealed that mean [La-] at 
VT2 (4.16 ± 0.8 mmol·L-1) was not significantly different from the mean [La-] reflective 
of the modified D-max (3.94 ± 0.6 mmol·L-1) or OBLA (4.00 ± 0.00 mmol·L-1). 
However, all methods produced significantly higher [La-] than the D-max method 
(p < 0.01). Furthermore, mean heart rate was significantly lower at D-max (176 ± 7.6 
beats·min-1) than at VT2 (180 ± 8.0 beats·min-1). Strong correlations were found 
between all methods and VT2 in relation to heart rate and the strongest correlation 
was between VT2 heart rate and modified D-max heart rate (r = 0.99; p < 0.01). The 
authors concluded that the modified D-max was more reliable than the original 
D-max method and OBLA, and extremely accurate in predicting VT2 in elite cross-
country skiers.  
 
The reproducibility of the D-max method (along with the Rest+1, 2.0 and 
4.0 mmol·L-1 markers, Nadir, Lactate Slope Index and Visual Lactate Turnpoint) was 
assessed by Morton et al. [173] during six to seven repeated maximal incremental 
cycling tests in physically active men (n = 11). Of all the LT2 markers, D-max was the 
only one considered to have good within-participant reproducibility (ICC = 0.903; 
SEM = 2.5 W) with a capacity to detect small though meaningful changes in training 
status within the participants (statistical power of detecting a 30 W increment = 0.98; 
p < 0.05). These findings suggest that the D-max method of LT2 power output 
determination is highly reproducible, with a strong capacity to assess changes in 
response to training.  
 
Since the identification of LT2 by the D-max method is reliant on the shape of the 
lactate-exercise intensity curve, using the D-max method requires three key 
considerations; (1) the choice of regression method, (2) the initial exercise intensity 
and (3) the final exercise intensity [174]. The impact of these factors on the D-max LT2 
has been investigated in recreational female runners (n = 16) [175] and well-trained 
male runners (n = 23) [174]. Both studies concluded that an exponential model elicited 
an LT2 that produced a stronger correlations with 10 km race pace (r = 0.98; 
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p < 0.01; r = 0.74; p < 0.01, respectively) than a polynomial model (r = 0.89; p < 0.01; 
r = 0.61; p < 0.01, respectively) and as such, an exponential model was suggested 
as the more favourable approach. In regards to the initial exercise intensity, it was 
found in both studies that LT2 increased as the initial intensity increased, without a 
change in the LT2-performance correlation when the exponential model was 
implemented. However, the LT2-performance relationship weakened (r = 0.83; 
p < 0.01 and r = 0.56; p = 0.01 for the recreational females and well-trained males, 
respectively) when the polynomial model was used, providing further support for the 
use of the exponential model. The final exercise intensity was noted as being 
important due to its effect on the shape of the curve. As such, achieving maximal 
exertion prior to test termination is the critical factor. Although the findings of these 
studies suggest that the exponential method is more robust and provides a better 
performance index than the polynomial method independent of training status, both 
studies utilised discontinuous running protocols where a short rest period was 
employed after each stage. The use of a continuous protocol such as those 
commonly adopted in cycling where one stage leads directly into the next, has the 
potential to influence the lactate-exercise intensity curve, however the impact of this 
has not been investigated. Whether this is the case and whether this is influenced by 
the regression method selected, is unknown. Additionally, the same investigation is 
yet to be completed using the modified D-max. 
 
The effect of stage duration on running speed at D-max has also been examined in 
pilot work by Gavin et al. in a group of healthy participants (n = 14 men and 5 
women) [176]. Using four and eight min stage durations, fixed markers of LT2 including 
2.0, 3.5 and 4.0 mmol·L-1 and a 1 mmol·L-1 rise from baseline showed no effect of 
stage duration, however D-max was associated with lower running speeds when 
eight min stages were adopted (-1.7 km·h-1; p < 0.05). All LT2 markers were shown to 
be more reproducible for the prolonged eight min stages when compared to four min, 
however the findings suggest that D-max has poor reproducibility regardless of stage 
duration. Mean bias was low (0.14 km·h−1), but the 95% confidence interval was 
wide (-3.77 to 4.04 km·h−1) for four min trials. This poor reproducibility of D-max 
conflicts with the finding of Morton et al. discussed above [173]. However it was 
noticed that all subsequent trials were terminated at the maximum workload 
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achieved in trial one, potentially over-estimating the true reproducibility in this study 
[176]. Additionally, there were differences in the incremental protocol and training 
status between studies (Table 2.7), therefore more research is needed to establish 
the ideal conditions for use of the D-max method. Collectively, inconsistencies in 
research design limit conclusive recommendations regarding the reliability, 
reproducibility and validity of the D-max method. Although limited research has been 
conducted on the modified D-max method, one study has shown that it was superior 
to the original D-max method in regards to its reliability, and was accurate at 
predicting VT2.  
 
2.3.4.3 Relationship with cycling performance 
The D-max and modified D-max methods have been analysed by Bishop et al. [10] in 
female cyclists and triathletes (Table 2.7). With the aim of comparing six different 
lactate variables with endurance performance, the participants (n = 24) completed an 
incremental cycle test and a one h cycle time trial. Of the six lactate parameters, the 
D-max method was shown to correlate best with endurance performance (r = 0.84; 
p < 0.01), followed closely by the modified D-max (r = 0.83; p < 0.01); indicating that 
of all the LT2 determination methods, the two D-max methods were more successful 
in predicting performance in endurance-trained females. These results are consistent 
with those of Bentley et al. [5] who found that the mean power output at D-max was 
strongly related to 90 min cycling time trial performance (r = 0.77; p < 0.05), third 
only to peak power output and power output at LT2-log in trained male cyclists and 
triathletes (n = 9; Table 2.7). Fell [18] generated strong correlations between the 
power output at modified D-max and the mean power output during a 30 min cycling 
time trial (r = 0.95; p < 0.01) in well-trained veteran cyclists (n = 9). Additionally, 
strong relationships existed between heart rate at modified D-max and mean heart 
rate during the 30 min time trial, with the authors concluding that the modified D-max 
was a valid measure of power and heart rate that was maintainable during 
endurance cycling. Further details of these studies are highlighted in Table 2.7. 
 
Limited research has reported the agreement between the D-max power output and 
heart rate with time trial power output and heart rate. Bishop et al. [10] highlighted that 
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D-max but not modified D-max, produced a power output that was not significantly 
different from the power output during a one hour time trial (178.79 ± 24.07 W and 
183.01 ± 18.88 W for D-max and time trial, respectively), with 79% of participants 
achieving a D-max power output within 10% of their time trial power output. 
Conversely, the modified D-max significantly over-estimated time trial power output 
(~16%; p < 0.05). The study of Fell [18] showed a close agreement between the 
power output and heart rate at modified D-max and their respective values during a 
30 min time trial (power output 95% CI = -14-+3 W; heart rate 95% 
CI = -6   +3 beatsmin-1). Furthermore, although not directly analysed or commented 
on, the findings of Bentley et al. [5] demonstrated that D-max was correlated with 
90 min but not 20 min cycle performance, with the mean power outputs of the two 
time trial distances being significantly different. Collectively, these findings suggest 
that the agreement between time trial power output and the power output reflective 
of both D-max and modified D-max may be both duration and distance dependent. 
However, additional research is need to confirm this. This information will hold 
significance for the wider applicability of both the D-max and the modified D-max 
methods beyond performance prediction; these findings could be used to inform 
exercise intensities relevant to training and competition.  
 
2.3.4.4 Relationship with running performance  
The relationship between D-max LT2 and endurance performance has also been 
examined in running. Nicholson and Sleivert [177] (Table 2.7) examined the 
relationships between running velocity at D-max, OBLA and LT1 (defined as the 
velocity at which the [La-] initially increased by ≥ 1 mmol·L-1 in consecutive 
workloads) with 10 km running velocity in recreational and competitive runners 
(n = 11 women and 19 men). Results demonstrated that 10 km running velocity was 
more strongly correlated with velocity at D-max (r = 0.86; p < 0.01) than velocity 
determined from both OBLA and LT1. Furthermore, D-max velocity was not 
significantly different from 10 km running velocity. Interestingly, when men and 
women were analysed separately, D-max was the only method capable of producing 
a significant relationship with 10 km time trial velocity in women, while men 
maintained a strong relationship with all three methods. This suggests that the 
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D-max method is effective for performance prediction in runners, independent of sex. 
However, a limitation of this study is the inclusion of participants with a broad range 
of training statuses (recreational to competitive). Since the LT2-performance 
relationship has been reportedly different depending on training status [60] this may 
have impacted the results. 
 
This shortcoming was addressed in a more recent study conducted by 
Papadopoulos et al. [178] in well-trained runners (n = 13; Table 2.7). Of all the LT2 
methods utilised ([1] velocity where [La-] was above baseline; [2] velocity where [La-] 
was 1 mmol·L-1 above baseline; [3] velocity at 2.2 mmol·L-1 [La-]; [4] velocity at 
2.5 mmol·L-1 [La-]; [5] velocity at 4 mmol·L-1 [La-]; [6] modified D-max and [7] 
LT2-log), D-max produced the strongest correlation with both 10 km (r = 84; p < 0.05) 
and 21.1 km (r = 0.78; p < 0.05) performance trials. Consistent with Nicholson and 
Sleivert [177], D-max and time trial velocities were not different for the 10 km distance. 
However, D-max significantly over-estimated the mean velocity during 21.1 km 
(~8%; p < 0.05), suggesting that the D-max method may be distance- and duration-
dependent in running. 
 
Consistent with cycling, researchers have also examined the relationship between 
D-max and performance in older athletes. Machado et al. [179] showed that in 
comparison to two other methods of LT2 determination (visual identification of a 
breakpoint and OBLA), speed at D-max produced the highest correlation with mean 
10 km running speed and generated the narrowest limits of agreement in 35-51 yr 
old female runners (n = 16; Table 2.7). Research is yet to examine the relationship 
with and the agreement between physiological variables coinciding with the modified 
D-max and variables of a running time trial of any distance, with participants of any 
training level which highlights a major gap in the literature. However, Chalmers et al. 
[24] investigated the relationship with and agreement between running performance 
and two novel methods of LT2 determination based on the D-max and modified 
D-max in trained male runners and triathletes (n = 13). The methods (single 
standardised LT2 and paired standardised LT2) utilised the same general 
methodology as the D-max and modified D-max methods with different points on the 
[La-]-workload graph used. Furthermore, the single standardised method was 
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designed for single tests and the paired standardised test was designed for 
quantifying changes over time. Results showed that LT2 speed determined by both 
methods was strongly correlated with (Lin concordance correlation coefficient > 0.8; 
p > 0.05) and not significantly different from (≤ 2.3%) performance speeds during 
10 km and 15 km running time trials. However, whilst a prediction equation was 
derived for estimating the percentage of LT2 that was sustainable for longer trials 
(~15-75 min), the relationship with and agreement between these new methods and 
longer running distances were not investigated directly. 
 
2.3.4.5 Relationship with MLSS 
The D-max has also been examined in relation to the MLSS. Hespel et al. [112] 
compared the D-max (determined by two different incremental protocols; (1) each 
stage increased by 5% body mass every 30 s and (2) each stage increased by 60% 
body mass every 6 min) with MLSS in elite cyclists (n = 21; Table 2.7). The results 
indicated that although the D-max method (6 min protocol) was the best correlate of 
power output and heart rate at MLSS and there was agreement between D-max 
(both protocols) and MLSS in regards to heart rate, D-max power output (6 min 
protocol) significantly under-estimated MLSS power output (~38%; p < 0.05). 
Furthermore, only 72% of the variance in power output and 47% of the variance in 
heart rate could be explained by the D-max (6 min). As a result, the authors 
concluded that the D-max was not sufficiently precise to determine MLSS heart rate 
and/ or power output for the purpose of monitoring training intensity in the individual 
cyclist. Relationships have also been reported between D-max and other methods of 
LT2 determination and predictors of endurance performance.  
 
2.3.4.6 Conclusions 
The research evidence relating to the D-max and modified D-max methods of 
assessing endurance capacity is limited in comparison to other methods of LT2 and 
VT2 reported in earlier section of this review. The LT2 determined by the D-max 
method has been reported to correlate more strongly with endurance performance 
than the LT2 estimated by any other method in male and female cyclists [10, 170], 
recreational male and female runners [177, 179] and well-trained male runners [178]. 
However, the agreement between the exercise intensity reflective of D-max (i.e. 
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power output in cycling, velocity in running or heart rate in either mode) and 
performance intensities is not as well established. While some have shown a close 
agreement [10, 18, 101, 177, 179], others have noticed inconsistencies due to performance 
distance or duration [5, 101]. Agreement with time trial intensity in addition to its 
capacity to correlate with endurance performance will allow the D-max method to 
have greater applicability in the training and testing of endurance athletes.  
 
In Australia, the state institutes and academies of sport utilise the modified D-max 
method to determine LT2; this concept forms part of the Australian Triathlon Testing 
Protocol. The reliability and accuracy of the modified D-max have been reported in 
relation to a more well-established method; VT2 [169]. Furthermore, strong correlations 
with cycling performance have been established in well-trained veterans [18] and in 
trained female cyclists [10]. However, knowledge is limited on its capacity to indicate a 
sustainable power output during endurance trials, and thus, its potential for 
establishing training and competition intensities. Although LT2 determined by the 
original D-max method has been reported as sustainable for endurance trials of 
approximately 60 min[10], the modified D-max appears to be more consistent with the 
power output produced during a trial of ≤30 min (-2.4 %)[18] than 60 min (+16%)[10]. 
Despite inclusion in the Australian Triathlon Testing Protocol, its capacity to rank the 
performance potential and establish an exercise intensity sustainable over 40 km 
(specific to Olympic-distance triathlon) in endurance-trained men is unknown. 
Furthermore, a direct comparison between men and women, using the same relative 
protocol to determine LT2 by the modified D-max method has not been completed. 
These findings would inform sex-specific exercise testing protocols, performance 
prediction, and training and competition exercise intensities.  
 
For LT2 concepts to be considered valid, it has been suggested that strong 
associations with simulated endurance performance, as well as a close relationship 
with MLSS are required [19]. The latter has been suggested since MLSS appears 
valuable for intensity prescription for endurance training. However, research 
examining whether the D-max and modified D-max methods establish exercise 
workloads and intensities that are maintainable for ~30 min and therefore indicative 
of MLSS is also lacking. These findings are important if these LT2 methods are to be 
82 
 
used for training purposes. Finally, research is yet to compare the D-max or modified 
D-max LT2 at baseline and after a period of training to establish their sensitivity to 
detect improvements in LT2 as a result of training, improvements that have been 
shown more extensively with other methods (as discussed in earlier sections of this 
review). Morton et al. [173] produced promising results with statistical modelling 
showing that D-max can detect small but meaningful changes as a result of training 
with sufficient statistical power. Furthermore, Chalmers et al. [24] created a paired 
standardised LT2 based on the D-max/modified D-max that was reported as 
objective for comparing changes in LT2 over time, however it has not been 
investigated in response to a training intervention. A summary of these and other 
findings associated with the D-max and modified D-max methods are presented in 
Table 2.7, and a summary of the identified pros and cons of the D-max and modified 
D-max methods are presented in Table 2.8.  
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Table 2.7. A summary of studies correlating D-max and modified D-max to MLSS or performance. 
 
Study Participants Training status Methods Findings 
Bishop et al. [10] Female cyclists 
and triathletes 
(n = 24) 
Trained (V̇O2peak 
48.1 ± 6.3 
mL·kg-1·min-1) 
1 h cycle time trial; 
Maximal incremental test 
(began at 50 W, 
increase of 25 W every 3 
min) 
D-max was strongest correlate of time trial performance (r = 0.84, p < 
0.01), followed by modified D-max (r = 0.83, p <  0.01); 
D-max power output not different from the mean 1 h time trial power output 
(p > 0.05); 
Modified D-max significantly great than 1 h time trial power output (16%; p 
< 0.05) 
Bentley et al. [5] Male cyclists 
and triathletes 
(n = 9) 
Trained (V̇O2max 62.7 
± 4.8 mL·kg-1·min-1) 
 
20 min cycle time trial; 
90 min cycle time trial; 
Maximal incremental test 
(began at 50% V̇O2max, 
increase of 5% V̇O2max 
every 3 min)  
D-max power output correlated with 90 min cycling time trial performance 
(r = 0.77; p < 0.05) but not 20 min cycling time trial performance (r = 0.45); 
Mean power output was higher in 20 min time trial than 90 min time trial (p 
< 0.01) 
 
Nicholson and 
Sleivert [177] 
Runners; 
females (n = 
11); males (n = 
19) 
Competitive and 
recreational (V̇O2max; 
female: 47.6 ± 3.3 
mL·kg-1·min-1; male: 
59.4 ± 8.0 
mL·kg-1·min-1) 
10 km running time trial; 
Maximal incremental test 
(began at mean 10 km 
time trial speed minus 2 
km·h-1, increase of 1 
km·h-1 every 5min, 1 min 
rest between stages) 
LT2 velocity from all methods related to 10 km time trial velocity (males and 
females combined; p < 0.01); 
Strongest relationship between D-max and 10 km time trial velocity (males 
and females combined: r = 0.86; p < 0.01); 
Male participants had higher LT2 velocities than females for all methods (p 
< 0.01); 
D-max was only method related to 10 km running velocity in females (r = 
0.84; p < 0.01); 
All methods related to 10 km time trial velocity in males (p < 0.01); 
Strongest relationship between LT2 and 10 km time trial velocity in males 
was D-max: r = 0.78; p < 0.01); 
D-max velocity not significantly different from mean 10 km running velocity 
(p > 0.01) 
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Hespel et al. [112] Cyclists (sex 
not stated; n = 
21) 
Elite (V̇O2max 5.4 ± 
0.2 L·min-1) 
Cycling MLSS (highest 
PO that was maintained 
for 30 min and during 
which [La-] increased ≤ 
1.0 mmol ·L-1 from min 
10 to 30); 
Max incremental test (1. 
began at 100 W, 
increase by 60% body 
mass, in W, every 6 min; 
2. Began at 100 W, 
increase by 5% body 
mass, in W, every 30 
sec) 
D-max (6 min protocol) was best correlate of power output (r = 0.85; p < 
0.05) and heart rate (r = 0.68; p < 0.05) at MLSS ; 
Mean power output, heart rate and [La-] was similar between MLSS and D-
max (30 sec); 
D-max power output (6 min) was ~7% lower than MLSS power output (p < 
0.05); 
D-max [La-] (6 min) was ~38% lower than MLSS (p < 0.05); 
D-max heart rate (6 min) not different to MLSS; 
72% of the variance in power output and 47% of the variance in heart rate 
explained by D-max (6 min protocol) 
Papadopoulos et 
al. [178] 
Endurance 
runners (sex 
not stated; n = 
13) 
Well-trained (V̇O2max 
65.3 ± 3.7 mL·kg-
1·min-1) 
10 km running time trial; 
21.1 km running time 
trial; 
Maximal incremental test 
(began at 4 km·h-1 below 
10 km race-pace, 
increase by 1 km·h-1 
every 4 min until race-
pace reached, then 
gradient increase of 2% 
every 2 min) 
D-max produced highest correlation with performance of both distances 
(10 km: r = 0.84; p < 0.05 and 21.1 km: r = 0.78; p < 0.05); 
Other methods (10 km: 0.61 < r < 0.76; p < 0.05 and 21.1 km: 0.60 < r < 
0.77; p < 0.05); 
D-max speed similar to 10 km time trial speed (second to LT2.2); 
D-max speed over-estimated 21.1 km time trial speed (~8%; p < 0.05); 
No method produced similar LT2 velocity to both time trial distances 
Fell [18] 
 
 
 
Veteran 
cyclists; 
females (n = 
1), males (n = 
8) 
Well-trained (V̇O2max 
57 ± 4 mL·kg-1·min-1) 
 
30 min cycling time trial; 
Maximal incremental test 
(female began at 125 W 
and males at 175 W, 
increase by 25 W every 
min) 
Modified D-max power output correlated with 30 min cycling time trial (r = 
0.95; p < 0.01); 
Modified D-max heart rate correlated with heart rate during 30 min time 
trial (r = 0.88; p < 0.01); 
Close agreement between D-max variables and 30 min time trial variables 
(power output: 95% CI = -14 - +3 W; heart rate: 95% CI = -6 - +3 
beatsmin-1) 
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Machado et al. 
[179] 
 
Middle-aged 
(35 – 51 yr) 
female runners 
(n = 16) 
Recreational (V̇O2max 
53.2 ± 8.0 mL·kg-
1·min-1) 
10 km running time trial; 
Maximal incremental test 
(began at 7 km·h-1, 
increased 1 km·h-1 every 
3 min, 30 sec rest 
between stages) 
D-max speed produced highest correlation with 10 km running speed (r = 
0.98; p < 0.01); 
OBLA correlated with 10 km running speed (r = 0.81; p < 0.05); 
LTvisual correlated with 10 km running speed (r = 0.85; p < 0.05); 
D-max speed generated narrowest limits of agreement (0.3 ± 0.4 km·hr-1); 
LTvisual produced moderate limits of agreement (0.1 ± 1.2 km·hr-1); 
OBLA produced large limits of agreement (0.8 ± 1.4 km·hr-1) 
D-max: maximum deviation method; modified D-max: modified maximum deviation method; OBLA: onset of blood lactate accumulation; MLSS: maximal 
lactate steady-state; PO: power output; V̇O2peak: peak oxygen uptake; V̇O2max: maximal oxygen uptake; mL·kg-1·min-1: millilitres, per kilogram, per minute; 
[La-]: lactate concentration; mmol·L-1: millimoles per litre; km: kilometres; W: Watts; PO: power output. 
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Table 2.8. A summary table outlining the pros and cons of the D-max and modified D-max methods. 
 
PROS CONS 
D-max has good reliability [169, 170]  D-max is influenced by the choice of regression method [174, 175] 
Individually- and objectivity-determined [170] D-max LT2 power output increases as initial exercise intensity increases 
[174, 175] 
D-max has good reproducibility in trained male cyclists and triathletes 
when 3 min stage durations utilised [173] 
D-max has poor reproducibility regardless of stage duration (4 or 8 min) 
in healthy participants (males and females combined) [176] 
D-max has the ability to detect small but meaningful changes as a result 
of training with sufficient statistical power [173] 
D-max correlated with 90 min but not 20 min cycle performance [5], 
inferring that the agreement between D-max and time trial power outputs 
is duration and distance dependent 
LT-performance relationship as determined by D-max is not influenced 
by initial exercise intensity in running [175] or cycling [174] 
D-max may be distance- and duration-dependent in running [178] 
D-max correlated with 1 h cycling time trial in trained female cyclists [10, 
17], 90 min cycling time trial in trained male cyclists [5]  
D-max is insufficiently precise to determine MLSS heart rate and/ or 
power output in elite cyclists [112] 
Modified D-max correlated with 1 h cycling time trial in trained female 
cyclists [10, 17] and 30 min cycling time trial in veteran cyclists [18] 
 
D-max power output not different from the power output during a 1 h time 
trial [10] or 30 min time trial [18] 
 
D-max correlated with 10 km running speed in male and female runners 
[177] and middle-aged female runners [179] 
 
D-max speed not different from mean 10 km running speed in male and 
female runners [177] and middle-aged female runners [179] 
 
D-max: maximum deviation method; modified D-max: modified maximum deviation method; PO: power output; LT2: second lactate threshold. 
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2.4 The Female Athlete 
2.4.1 Introduction 
Evidence of a sex bias towards male participants in sport and exercise medicine 
research has recently been reported in a review of original and epidemiological 
investigations published in three major Sports and Exercise Medicine journals 
(British Journal of Sports Medicine, American Journal of Sports Medicine and 
Medicine and Science in Sport and Exercise) [20]. Women were shown to represent 
only 39% of the literature with the average ratio of men to women per article reported 
as almost two-fold greater (∼65:35) across the three leading journals from 2011 to 
2013 [20]. Following this trend and since well-trained to elite athletes are under-
represented in the exercise science literature compared to their healthy sedentary or 
recreationally active counterparts [180], trained female athletes are also significantly 
under-represented. Anecdotal evidence suggests difficulties associated with the 
recruitment of female athletes into research studies, which may, in part, be due to 
the limited availability of moderate to high-level female athletes compared to male 
athletes. Additionally, fluctuations in ovarian hormones across the menstrual cycle 
add a layer of complexity in regards to study timing and control measures 
implemented, which may also explain the preferential selection of men as research 
participants. As a result, some studies simply combine the findings of men and 
women [88, 181, 182] and make inferences for both sexes. When endurance training and 
performance is concerned, there is research utilising sedentary and recreationally 
active women, however much less is known about well-trained and elite female 
endurance athletes.  
 
2.4.2 The menstrual cycle and hormonal contraceptives 
Female physiology, and especially the ovarian hormones such as oestrogen and 
progesterone, fluctuate during different phases the menstrual cycle (Figure 2.2), as 
opposed to male physiology which remains relatively consistent from day to day [21]. 
This likely contributes, at least in part, to men being the more popular choice for 
study inclusion over women and even when women are recruited, controlling for and 
verification of these ovarian hormones is seldom performed [10, 88, 183]. However, 
these hormonal fluctuations can be controlled by exogenous doses of female 
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reproductive hormones, such as those administered by hormonal contraceptive 
agents. Hormonal contraceptives cause continuous down-regulation of endogenous 
oestrogen and progesterone, which prevents follicular development and ovulation 
and subsequently eliminates cyclical variation in the uterus and ovaries [25]. The use 
of hormonal contraceptives, especially the oral contraceptive (OC) pill are becoming 
increasingly popular in the female athletic population with the most recent data 
showing 83% of elite level athletes were currently using an OC [184]; a considerable 
increase from the 5-12% reported in the early 1980’s [185]. The current formulations 
are typically ‘combined’ in nature, meaning they contain one type of synthetic 
oestrogen; ethinyloestradiol and a progestogen component that can be present in up 
to eight different forms [184]. One complete cycle consists of 28 days; 21 of these are 
known as ‘active days’ where hormonal doses are administered and the remaining 
seven are ‘inactive days’ where withdrawal of the exogenous dose occurs and 
bleeding usually occurs. Of these combined doses, there are monophasic and 
multiphasic (biphasic and triphasic) formulations. Monophasic formulations provide a 
uniform dose of ethinyloestradiol and progestin over the ‘active pills’ during a cycle. 
In contrast, multiphasic formulations vary the dose of either or both hormones (once 
or twice over the 21 day cycle for biphasic and triphasic doses, respectively) with the 
intention of reducing both total hormone exposure as well as potential side effects by 
producing cycles that more closely mimic normal physiology [186]. Although the most 
widely used method of hormonal contraceptive is the OC pill [187], there are other 
combined methods, such as: (1) a vaginal ring (NuvaRing®: currently the only 
commercially available ring for combined hormonal contraception [187]); and (2) a 
transdermal patch (OrthoEvra®) [187]. For additional detail on menstrual cycle 
physiology and hormonal contraceptive agents including common formulations and 
their mechanisms of action, please see appendix three. 
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Figure 2.2. Diagrammatic representation of the cyclical changes in the female 
sex hormones that characterise the various menstrual cycle phases 
(reproduced from Oosthuyse and Bosch [21]). 
EF: early follicular; MF: mid follicular; LF: late follicular; EL: early luteal; ML: mid luteal; LL: late luteal; 
FSH: follicle-stimulating hormone; LH: luteinizing hormone. 
 
2.4.3 Oestradiol and exercise metabolism 
Although the ovarian hormones primarily function to support reproduction, their 
impact on other physiological systems and exercise performance have also been 
examined. The ovarian hormone 17β-oestradiol which is the primary oestrogen 
secreted, appears to play a role in substrate metabolism. Though results in humans 
are conflicting in regards to carbohydrate and fat oxidation, animal studies showed 
that oestradiol enhanced fatty acid oxidation and utilisation [188, 189] and spared tissue 
glycogen during prolonged running [188]. In human studies substrate utilisation is 
most commonly measured via indirect calorimetry with RER used to indicate the 
predominance of fat (RER ~0.7) or carbohydrate (RER ~1.0) metabolism. Some 
studies have reported no difference in RER values between women who were 
amenorrheic (lower oestrogen levels) and eumenorrheic (normal oestrogen levels) 
during maximal [190] or submaximal running [190-192], nor between cycle phases in 
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moderately-trained eumenorrheic females during cycling [193] or running [190]. 
However, others have shown a greater RER in the FP of the menstrual cycle than in 
the LP in untrained [194] and trained [195] women during incremental exercise which is 
suggestive of greater fat metabolism in the LP, when oestradiol levels are elevated. 
One potential reason for the disparity is the high variability in oestradiol 
concentrations between participants and within participants from day to day during 
any menstrual phase. This highlights the necessity to verify menstrual cycle phase 
with a combination of measures such as menstrual cycle mapping, ovulation 
prediction testing and serum/plasma hormone measurement; a three-step method 
shown to be effective at menstrual and oral contraceptive cycle verification [196]. 
None of the studies mentioned above have verified menstrual cycle with this level of 
detail. Furthermore, years of training (9 vs. 5 years) was discussed as a potential 
confounder in one study where it was suggested that adaptations due to more 
training years may have outweighed the differences in ovarian hormones between 
menstrual phases [191]. This is a feasible rationale since endurance training has been 
shown to result in adaptations to energy substrate utilisation that were not seen in 
untrained individuals [197]. Additionally, nutritional status may also explain the 
differences between studies, since it has been shown that differences in substrate 
metabolism only occurred with nutritional manipulation [198]. Collectively, these 
findings highlight the importance of controlling and/or verifying menstrual and 
nutritional status when investigating the influence of oestradiol on substrate 
metabolism.  
 
Furthermore, there is some evidence to suggest that oestradiol suppresses protein 
catabolism, however findings are inconsistent. Although early work shows greater 
urinary nitrogen excretion in the mid-LP than during menses [199], more recent 
studies suggest the opposite is true. For example, when compared to a placebo 
group, a 16% reduction in oxidation of the amino acid leucine occurred at rest and 
during exercise when oestradiol was supplemented to men [200]. Furthermore, a 
reduction in oestradiol has been shown to enhance muscle protein turnover in post-
menopausal women, resulting in a net loss of muscle mass [201]. However, there was 
no effect on muscle protein synthesis or the expression of genes involved in the 
regulation of muscle mass after oestradiol treatment in these women, whereas 
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progesterone was shown to have stimulatory effects on muscle protein synthesis and 
the expression of the growth-regulatory gene; myogenic differentiation 1 mRNA [201]. 
Furthermore, in response to oestrogen-replacement therapy, only minor 
improvements in muscle composition and strength were seen compared to post-
menopausal non-users, with no transfer to improved physical function [202]. 
Therefore, the clinical relevance of oestradiol has been questioned [202] and may 
require further examination. Further details of studies examining the effect of 
oestradiol on substrate metabolism and/ or exercise performance are presented in 
Table 2.9.  
 
It has been suggested that if oestradiol does indeed have an effect on substrate 
metabolism, it might be more pronounced when greater [La-] are produced [203]. This 
suggestion was based on studies showing greater [La-] in the FP after exhaustive 
and near-exhaustive exercise [22] and lower recovery [La-] in LP after exhaustion [204]. 
Further support is shown by research highlighting no difference in [La-] between 
phases during submaximal exercise below LT2, with significantly higher 
concentrations being reported in the FP at intensities beyond LT2 [23].  
 
Collectively, the research that has examined the influence of oestradiol on substrate 
metabolism is inconsistent; this may be attributed to, at least in part, weaknesses in 
menstrual cycle control and/ or verification, or inconsistencies in nutritional status of 
the participants. As a result, it is recommended that future research implements 
tighter control over these variables in order to more accurately assess the effect of 
oestradiol on responses to exercise.  
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Table 2.9. A summary of studies examining the effect of oestradiol on exercise metabolism. 
 
Study Participants Methods Main findings 
Kendrick et al. [188] Female rats; 
8 x oestradiol-replacement 
groups (8 different doses) 
Control group 
Treadmill run to exhaustion 
or 2 h treadmill run 
Oestradiol-replacement group ran significantly longer than control 
group (p < 0.01) in run to exhaustion; 
Significant liver glycogen spared in oestradiol-replacement groups 
(p < 0.01) compared to control group in 2 h run; 
Myocardial glycogen degradation reduced at exhaustion for those 
receiving greater oestradiol dose [10 μg group not different from 2 
and 4 μg groups but less than <2 μg groups (p < 0.05)]. 
Lamont, Lemon 
and Bruot [199] 
Active, eumenorrheic 
females (n = 9) 
60 min cycle at 70% V̇O2max (once 
during menses and once during mid-
luteal phase) 
Nitrogen excretion in sweat and urine was significantly greater in 
the mid-luteal phase compared to menses (p < 0.05)  
Dombovy et al. [194] Untrained, eumenorrheic 
females (n = 8) 
Ventilatory response test; 
Max incremental test 
(each test completed once during mid-
luteal and once during mid-FP phases) 
Ventilatory responses tended to be greater during the mid-luteal 
phase (unrelated to progesterone); 
No difference in V̇O2max, max exercise duration, work efficiency, 
max heart rate, max V̇E, gas exchange, cardiac output, O2 
delivery or VT2 between phases. 
Hatta et al. [189] Female rats; 
Oestradiol treatment group; 
Oestradiol + progesterone; 
treatment group; 
Control group 
60 min run Oestradiol treatment stimulated fatty acid oxidation compared with 
the oestradiol + progesterone treatment (p < 0.05) and tended to 
inhibit glucose oxidation during exercise. 
Nicklas, Hackney 
and Sharp [193] 
Moderately-trained 
eumenorrheic females (n = 6)
Depletion bout: 
90 min cycling at 60% V̇O2max followed 
by 4 x 1 min bouts at 100% V̇O2max; 
Exercise to exhaustion bout: 
Cycle at 70% V̇O2max 
- Each bout completed once during mid-
luteal and once during mid-FP 
Tendency (p < 0.07) for longer exercise to exhaustion during mid-
luteal phase; 
Glycogen repletion after depletion bout was greater during mid-
luteal phase (p < 0.05); 
Glycogen utilisation during exercise to exhaustion not different 
between phases 
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De Souza et al. [190] Amenorrheic (n = 8) and 
eumenorrheic (n = 8) runners 
Maximal test (performed once in early- 
FP and once in mid-luteal phase for 
eumenorrheic group and once in total for 
amenorrheic group); 
40 min running at 80% V̇O2max 
(performed as above) 
No differences between early-FP and mid-LP in amenorrheic 
group for max and submax tests for V̇O2, V̇E, RPE, heart rate, 
peak RER, plasma [La-] or time to fatigue; 
No differences between amenorrheic and eumenorrheic runners 
for max and submax tests for V̇O2, V̇E, RPE, heart rate, peak 
RER, plasma [La-] or time to fatigue.  
Kanaley et al. [191] Amenorrheic (n = 6) and 
eumenorrheic (n = 7) 
aerobically-trained athletes 
90 min running at 60% V̇O2max 
(performed once in early-FP, once in 
late-FP and once in mid-LP for 
eumenorrheic group and once in total for 
amenorrheic group) 
Fat and CHO utilisation, based on R values, were independent of 
menstrual phase and menstrual status; 
No difference in resting or exercising plasma [La-] between 
eumenorrheic and amenorrheic groups; 
No differences in the total GH response during exercise between 
groups. 
Wilmore et al. [192] Amenorrheic (n = 8) and 
eumenorrheic (n = 5) elite 
distance runners; untrained 
eumenorrheic controls (n = 5)
Submax exercise at 60 - 90% V̇O2max 
(15 min on both cycle ergo and 
treadmill); 
Treadmill max test; 
1 h self-selected fixed-pace run 
 
No difference in maximum heart rate, maximum V̇E, maximum 
RER or V̇O2max between eumenorrheic and amenorrheic groups; 
During fixed-pace run, no differences in V̇E, RER, V̇O2 or % 
V̇O2max between eumenorrheic and amenorrheic groups; 
No difference in heart rate during fixed-pace run at 30 min, 
however amenorrheic group ~20 beats·min-1 lower than the 
eumenorrheic group at 60 min (p < 0.05). 
No difference in conservation of energy between groups - resting 
metabolic rate, the thermal effect of a meal and the total and 
adjusted total energy expenditures were not different across the 3 
groups.  
Hackney, 
McCracken-
Compton and 
Ainsworth [195] 
Trained eumenorrheic 
females (n = 9) 
2 x 30 min treadmill run (10 min at 35%, 
60% and 75% V̇O2max) - each test 
completed once during mid-luteal and 
once during mid-FP 
CHO utilisation and oxidation rates at 35% and 60% intensities 
were lower during the mid-luteal phase than during the mid-FP; 
Lipid utilisation and oxidation at 35% and 60% intensities were 
greater the mid-luteal phase than the mid-FP;  
No difference in CHO-lipid utilisation and oxidation between 
phases at 75% intensity. 
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Devries et al. [200] Recreationally active men 
(oestradiol supplemented, n 
= 6; placebo, n = 6) 
90 min cycle at 65% V̇O2max Oestradiol supplementation: 
decreased RER during exercise (p < 0.05); 
decreased CHO oxidation by 5 - 16% (p < 0.04) and leucine 
oxidation by 16% (p < 0.01); 
increased lipid oxidation by 22 - 44% (p < 0.05) at rest and during 
exercise. 
Taaffe et al. [202] Current oestrogen-
replacement therapy users (n 
= 259) and non-users 
(n = 581), aged 70 - 79 years 
old. 
Muscle composition and cross-sectional 
area of quadriceps, hamstrings, 
intermuscular fat and subcutaneous fat; 
Muscle density analysis; 
Isometric hand grip strength; 
Isokinetic knee extensor strength; 
Physical function (6 m walk and narrow 
walk speed, repeated chair stands, and 
standing balance) 
Quadriceps cross-sectional area (~3.3%) and density (~2.5%) 
greater in oestrogen-replacement users than non-users (p < 0.05); 
Grip strength greater (~3.2%) in users than non-users (p < 0.05); 
Knee extensor strength greater (~3.1%; approaching significance) 
in users than non-users (p = 0.10); 
No difference between groups for hamstring muscle, fat cross-
sectional area or physical function. 
Smith et al. [201] Pre-menopausal (n = 12) and 
post-menopausal sedentary 
women (n = 24); 
Post-menopausal groups (n 
= 6 per group):  
(1) testosterone treatment 
(2) oestradiol treatment 
(3) progesterone treatment  
(4) control group 
Basal rate of muscle protein synthesis; 
Expression of muscle growth-regulatory 
genes  
 
Muscle protein synthesis rate was faster (~20%) in post-
menopausal than pre-menopausal women (p < 0.05); 
Three of four muscle growth-regulatory expressions were greater 
(~40-90%; all p < 0.05) in post-menopausal than pre-menopausal 
women; 
Testosterone and progesterone treatments increased the muscle 
protein synthesis rate (~50%; both p < 0.01), however no change 
in oestradiol treatment group and control group. 
CHO: carbohydrate; V̇O2max: maximal oxygen uptake; V̇E: ventilation; VT2: second ventilatory threshold; RER: respiratory exchange ratio; FP: follicular 
phase; LP: luteal phase. 
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2.4.4 Progesterone and exercise metabolism 
It has been suggested that progesterone (the primary progestogenic hormone 
synthesised by the human body) may oppose the physiological effects of oestradiol 
on human physiology during exercise during the LP when both hormones are 
elevated [205]. This suggestion is based on findings of several studies in which 
progesterone was associated with an increased body temperature [206], ventilatory 
drive [207] and heart rate [208, 209] during the LP. There is also evidence showing 
increases in progesterone being associated with a decrease in GLUT4 content, an 
insulin-responsive glucose transporter [210] and insulin-resistance [211]. Further details 
of these studies are presented below in Table 2.10. However, an understanding of 
the interaction between oestradiol and progesterone may indeed be more 
meaningful. A comparison of the oestrogen to progesterone concentration ratio (E/P; 
pmol/nmol appears to be a common and potentially more informative way of 
investigating the effects of the ovarian hormones on physiological and performance 
outcomes, rather than absolute concentrations of oestrogen and progesterone [21]. 
Changes in the metabolic response to exercise suggested as being brought about by 
lower glucose kinetics and muscle glycogen sparing have been proposed when the 
E/P ratio is sufficiently elevated and the magnitude of increase in oestradiol from 
early-FP to late-FP or LP is ≥ 2-fold [212]. In the study of D’Eon et al. [212] (Table 2.10) 
a group supplemented with high levels of oestradiol and low levels of progesterone 
(resulting in a high E/P ratio) had lower carbohydrate oxidation, lower blood glucose 
uptake, higher lipid use and lower estimated muscle glycogen use than groups with 
both hormones of high or low concentrations (low E/P ratios). Based on these 
findings, it could be suggested that the effects of progesterone are indeed capable of 
counteracting those of oestradiol. An important methodological note however, is that 
this estimate is based on the assumption that 100% of blood glucose taken up from 
the blood is oxidised. However, 70-90% oxidation rates have been suggested as 
more likely [213, 214] and the authors commented that this rate may vary across the 
conditions used in this study [212]. Thus, they have stated that the calculation 
underestimates glycogen use and is best described as minimal muscle glycogen 
utilisation. Nevertheless, others provide support for the finding that progesterone 
counteracts the actions of oestradiol. Campbell et al. [215] (Table 2.10) showed that 
despite a 2.5-fold increase in oestradiol in the mid-LP over the mid-FP, the E/P ratio 
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in the mid-LP was lower in comparison, suggesting that the relatively high 
progesterone concentration in this phase may have opposed the benefits of an 
elevated oestradiol concentration. Conversely, numerous studies show that the rate 
of appearance and disappearance of glucose (as influenced by the rate of glucose 
utilisation [216]) during exercise is mitigated by therapeutic increases in oestradiol [200, 
212] or with the rise in oestradiol and progesterone during the mid-LP compared to the 
early-FP [215, 217]. It is important to note that exercise intensity may be important here. 
A study whereby participants exercised at ~42% V̇O2max showed no difference in 
glucose appearance between phases [218] (Table 2.10), whereas participants 
exercising at ~51% [218] and 70% V̇O2max [215] showed noticeable differences.  
 
In opposition to oestradiol, progesterone appears to promote protein catabolism. 
This has been inferred by Kriengsinyos et al. [219] (Table 2.10) who assessed females 
using seven graded levels of lysine intake in order to assess lysine requirements in 
the LP and FP of the menstrual cycle. Results showed lower plasma amino acids 
and higher oxidation of the amino acid phenylalanine in the LP versus the FP [219]. 
However, it has been suggested that future research should determine whether the 
E/P ratio in the LP is an important factor in determining the magnitude of protein 
catabolism during this menstrual phase [21]. 
 
Energy intake and nutritional status appear to impact metabolism, especially 
carbohydrate metabolism and subsequent exercise performance. Although 
oestradiol seems to play a positive role and progesterone a negative role in 
metabolic and performance outcomes, both ovarian hormones suppress 
gluconeogenesis during exercise which may compromise performance in exercise 
involving ultra-endurance distances. For this reason, additional energy intake is 
recommended if the impact of these hormones on performance is to be minimised. 
Additionally, in research studies examining physiological variables and endurance 
performance, it appears optimal that participants be in a fed state to minimise the 
impact of these hormones. 
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Table 2.10. A summary of studies examining the effect of progesterone on exercise metabolism. 
 
Study Participants Methods Main findings 
Hessemer and Bruck 
[206] 
Females of mixed fitness levels (n 
= 10) 
15 min cycle at 70% V̇O2max Pre-exercise oesophageal, tympanic and rectal 
temperatures were higher in LP (all p < 0.01); 
Thresholds for sweating and vasodilation were higher 
in LP (all p < 0.01); 
Above-threshold sweat rate and cutaneous heat 
clearance increased in LP (p < 0.01); 
V̇O2 higher (5.2%) in LP (p < 0.05); 
Metabolic rate higher (5.6%) in LP (p < 0.05); 
Efficiency reduced (5.3%) in LP from 9th min onwards 
(p = 0.01-0.05). 
Pivarnik et al. [208] Trained, eumenorrhoeic females 
(n = 9) 
Cycling incremental test; 
2 x 60 min cycles at ~65-70% V̇O2max (once 
during mid-FP and once during mid-LP) 
 
No difference in V̇O2, sweat loss or skin temperature 
between phases; 
Pre- (0.3°C) and post-exercise (0.6°C) rectal 
temperatures were higher during mid-LP (p < 0.01); 
Heart rate was higher (~10 beats·min-1) during mid-
LP at all times (p < 0.01); 
RPE was greater during mid-LP after 50 min cycling 
(p < 0.01). 
Ezenwaka et al. [211] Sedentary, eumenorrhoeic 
females; FP (n = 7), LP (n = 7), 
male controls (n = 7) 
Insulin responses to intravenous glucose 
(300 mg·kg-1) were assessed for up to 3 h. 
Females in LP had the greatest integrated first-phase 
insulin response (p < 0.05) and insulin/glucose ratios 
(p < 0.05). 
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Campbell, Angus and 
Febbraio [215] 
Moderately trained, eumenorrhoeic 
females (n = 8) 
1 x maximal incremental cycle test (during 
FP); 
4 x steady-state trials (2 during FP and 2 
during LP), consisting of: 
2 h cycle at 70% V̇O2peak and a 4 kJ·kg-1 
time trial as quickly as possible, consuming 
either: 
1) 6% CHO solution, (FP-glucose and LP-
glucose) or 
2) placebo (FP-control and LP-control) 
Glucose rates of appearance and disappearance 
were higher during the second hour of exercise in 
FP-control than in LP-control (p < 0.05); 
The percent contribution of CHO to total energy 
expenditure was greater in FP-control than in LP-
control (p < 0.05); 
Performance was improved (13%) in FP-control over 
LP-control (p < 0.05); 
Performance improved in FP-glucose (19%) and LP-
glucose (26%) compared with FP-control and LP-
control, respectively (p < 0.05). 
Zderic, Coggan and 
Ruby [218] 
Recreationally active 
eumenorrhoeic females (n = 6) 
25 min at 70% LT followed by 25 min at 90% 
LT 
At rest and during exercise at 70% LT, there were no 
differences in glucose rates of appearance or 
disappearance between phases;  
CHO and fat oxidation were not different between 
phases at 70% LT;  
At 90% LT, glucose rates of appearance (~17%) and 
disappearance (~20%) were lower during the LP than 
FP (both p < 0.05); 
At 90% LT, CHO oxidation was lower (~14%) during 
the LP than FP (p < 0.05); 
At 90% LT, total fat oxidation was greater (~23%) 
during the LP than FP (p < 0.05); 
At 90% LT, plasma [La-] was lower (~24%) during the 
LP than FP (p < 0.05); 
The lower CHO utilisation during the LP was 
associated with elevated resting oestradiol (p < 0.05). 
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D’Eon et al. [212] Recreationally active, 
eumenorrhoeic females (n = 8). 
Tested in 3 conditions: (1) baseline 
(low oestradiol and progesterone), 
(2) oestradiol-only and (3) 
oestradiol + progesterone (both 
levels high) 
60 min cycling at 60% V̇O2max; 
 
Oestradiol-only group had lower CHO oxidation than 
baseline and oestradiol + progesterone groups 
(p < 0.05); 
Blood glucose uptake tended to be lower with 
oestradiol-only and oestradiol + progesterone groups 
relative to baseline (p = 0.05-0.10); 
Oestradiol-only group had lower (25%) estimated 
muscle glycogen use than other groups (p < 0.05); 
Oestradiol-only group had higher lipid use than other 
groups (p < 0.05); 
Oestradiol-only group had lower RER than other 
groups (p < 0.05). 
Seebauer, Fruhwirth 
and Moser [209] 
Healthy, eumenorrhoeic females 
(n = 26) 
Beat-to-beat heart rate recorded during two 
consecutive menstrual cycles 
Minimum heart rate occurred in the early-FP and the 
maximum in the late-LP; 
Participants with a low heart rate had higher heart 
rate variation in the LP compared 
to the FP, whereas the trend was reversed in those 
with a high heart rate; 
The difference in extreme points of fluctuations (early 
FP and mid-LP) correlated to average heart rate (r = -
0.64; p < 0.01). 
Campbell and 
Febbraio [210] 
Female rats: 
Sham operated group (C); 
Ovariectomised and treated with 
(1) placebo (O); (2) oestradiol (E), 
(3) progesterone (P), or (4) both 
hormones at (a) 
physiological doses (P + E) or (b) 
the same dose of progesterone 
with a high dose of oestradiol (P + 
HiE) 
Glucose injection on day of trial; 
Exercised for 30 min on treadmill at 0.35 m·s-
1 or; 
Remained sedentary. 
Glucose uptake was decreased (p < 0.05) in O, P, 
and P + E rats during exercise in the red quadriceps 
compared with C rats; 
E and P + HiE treatment restored glucose uptake; 
Post-exercise red quadriceps glycogen levels were 
higher (p < 0.05) in the E and P + HiE rats compared 
with O and P; 
P rats decreased (21%; p < 0.05) GLUT4 content in 
the red quadriceps compared with C rats. 
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Kriengsinyos et al. 
[219] 
Untrained eumenorrhoeic females 
(n = 5); 
Seven graded levels of lysine 
intake (10, 25, 30, 35, 40, 45, and 
60 mg·kg-1·day-1) in both FP and 
LP. 
Tracer protocol Phenylalanine oxidation was higher in the LP than 
the FP (p < 0.01) and was positively associated with 
oestradiol concentration (r = 0.37; p < 0.01), 
progesterone concentration (r = 0.53; p < 0.001) and 
the E/P ratio (r = -0.38; p < 0.01); 
The lysine requirement in the LP was higher (~8%) 
than in FP (p < 0.05). 
Oosthuyse, Bosch 
and Jackson [205] 
Trained (n = 5) and untrained (n = 
8) eumenorrhoeic females 
Maximal incremental test during FP; 
3 x performance time trials (one during each 
of early-FP, late-FP and mid-LP): 15 km 
(untrained) and 30 km (trained)  
 
No significant difference in performance time 
between phases in trained or untrained; 
Combined trained and untrained (n = 13) revealed 
trend for a faster time (p < 0.05) in the late-FP 
compared to the early-FP.  
Devries et al. [217] Recreationally active females (OC 
users, n = 6; non-OC users, n = 7) 
and recreationally active male 
controls (n = 11) 
1 x maximal incremental cycle test; 
2 x 90 min cycle at 65% V̇O2peak (one in FP 
and one in LP; males completed one trial) 
Lower glucose rate of appearance, rate of 
disappearance and metabolic clearance rate at 90 
min of exercise in LP compared with FP (all p < 
0.05); 
Lower proglycogen, macroglycogen and total 
glycogen utilisation during exercise in LP compared 
with FP (all p < 0.05);  
Higher RER (p < 0.05), glucose rate of appearance 
(p < 0.05), rate of disappearance (p < 0.05) and 
metabolic clearance rate (p ≤ 0.01) during exercise in 
men compared with women in FP; 
Higher RER in men at 75 and 90 min of exercise 
(p < 0.05), glucose rate of appearance (p ≤ 0.01), 
rate of disappearance (p ≤ 0.01), metabolic clearance 
rate (p ≤ 0.001) and a greater proglycogen utilisation 
(p ≤ 0.05) compared with women in LP phase. 
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Von Duvillard et al. 
[207] 
Recreationally active, 
eumenorrhoeic females (n = 19) 
2 x cycling incremental tests (completed once 
in FP and once in LP); 
Threshold measures: 
(1) Lactate turnpoint 1 (the point immediately 
before [La-] began to increase systematically 
above resting values); 
(2) Lactate turnpoint 2 (the point immediately 
before the abrupt increase in [La-]); 
(3) Anaerobic threshold (a faster increase in 
V̇E and V̇CO2 in contrast to V̇O2, an upward 
inflection of V̇E/ V̇O2 with no increase in V̇E/ 
V̇CO2, and an upward inflection of PETO2; 
(4) Respiratory compensation point (an 
upward inflection of V̇E/ V̇CO2 and a 
downward inflection of PETCO2). 
No difference in PO, V̇O2, [La-], heart rate or RER at 
rest, at maximal PO, at any stage of incremental test 
or at any threshold point between LP and FP; 
Higher V̇E/ V̇O2, V̇E/ V̇CO2, and V̇E at rest, at 
exhaustion and at anaerobic threshold during the LP 
(p < 0.01-0.05). 
CHO: carbohydrate; V̇O2max: maximal oxygen uptake;  V̇E: ventilation; V̇CO2: volume of CO2 expired; VT2: second ventilatory threshold; RER: respiratory 
exchange ratio; FP: follicular phase; LP: luteal phase; E/P: oestrogen to progesterone ratio; PETO2: end tidal oxygen tension; PO: power output. 
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2.4.5 Ovarian hormones and exercise performance  
In addition to the literature examining substrate metabolism during different 
menstrual cycle phases, there has been research examining the effects of menstrual 
cycle phases on other physiological responses to exercise, and measures of 
exercise performance. An example of three physiological variables; plasma glucose, 
plasma [La-] and respiratory exchange ratio, and their responses during exercise can 
be seen in Figure 2.3 below. Since they are specifically related to this thesis, a closer 
examination of the studies investigating the blood and/ or plasma lactate response to 
exercise and LT2 are warranted.  
 
 
Figure 2.3. Plasma glucose, plasma [La-] and respiratory exchange ratio at rest 
and during exercise and recovery during various menstrual cycle phases, and 
in amenorrheic women (adapted from Kanaley et al. [191]). 
mmolL-1: millimoles per litre. 
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Early studies began to show that hormonal fluctuations during the menstrual cycle 
had no effect on [La-] in response to exercise. An early study by Bonen et al. [198] 
(Table 2.11) compared the [La-] in response to 60 min of submaximal exercise in the 
FP and LP with three different nutritional interventions. Although results indicated a 
similar [La-] regardless of nutritional group and cycle phase, there were limitations in 
menstrual cycle phase verification, which was determined by progesterone (but not 
oestradiol) concentrations. Additionally, basal body temperature results were 
disregarded due to results being too variable and as such, the results may have 
been impacted by these methodological limitations. Others have also verified cycle 
phases by serum progesterone levels and basal body temperatures, and shown no 
significant differences between cycle phases for [La-] at rest or 3 min post-exercise in 
a treadmill test to exhaustion [220]. However, in addition to the cycle phase verification 
limitations, resting and post-exercise [La-] do not provide much insight into the 
physiological capacity of women during different cycle phases, such as when they 
reach LT2 or switch from aerobic to anaerobic metabolism. Nevertheless, similar 
findings were confirmed in a subsequent study where no phase differences in [La-] 
were shown during maximal or constant load exercise (40 min of treadmill running at 
80% V̇O2max; Table 2.9) [190]. Cycle phases were more stringently assessed by 
researchers in this study, and were documented by urinary luteinising hormone and 
progesterone concentrations, and plasma oestradiol and progesterone 
concentrations. 
 
More recently, Redman et al. showed no differences in [La-] at rest, at LT2 
(determined by a log-log transformation method) or post-exercise in response to both 
maximal incremental exercise and submaximal exercise between LP and FP in 
young, sedentary women [23] (Table 2.11). These researchers however, failed to 
verify cycle phases by serum oestradiol and progesterone concentrations, and 
limited their cycle verification to recording menstrual cycle histories and home 
ovulation testing. More precise verification of cycle phase was completed by Dean et 
al. who assessed ovulation (by luteinising hormone surge and increase in basal body 
temperature), cycle histories and oestradiol and progesterone concentrations in 
recreationally-active women [221]. This study confirmed no significant differences in 
[La-] at rest, at LT2 (determined by a log transformation method) or at exhaustion 
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among the early-FP, mid-FP and mid-LP [221]. In addition to LT2 (determined by the 
lactate turnpoint method), Smekal et al. [207] (Table 2.10) investigated the impact of 
menstrual cycle phase on variables reflective of VT2. They showed that in 
recreationally-active, eumenorrheic females, there were no significant differences 
between phases for power output, V̇O2, [La-], heart rate or RER at either LT2 or VT2 
(or any other time points including rest and each incremental test stage). This study 
expanded on earlier studies by implementing an additional threshold measure (VT2) 
while reaffirming no differences in [La-] or LT2 between menstrual cycle phases. 
Again, previous cycle history and basal body temperature were used to identify 
ovulation and cycle phases (although no hormonal confirmation of ovulation was 
implemented), and ovarian hormone concentrations were assessed on testing days. 
Details of these studies are presented in Table 2.11. 
 
In addition to the physiological responses to exercise, numerous studies have 
examined the effect of menstrual cycle phase on endurance performance outcomes. 
One study examined cycling time trial performance between three menstrual cycle 
phases and two training statuses (15 km performance trial for untrained participants 
and 30 km for trained participants) [205] (Table 2.10). Although they revealed no 
differences in finishing time between phases for both trained and untrained groups, 
the results of this study may have been related to the low statistical power in relation 
to the small sample sizes, as was acknowledged by the authors. When greater 
statistical power was generated by combining the participants into one group, there 
was a trend for a significantly faster time in the late-FP compared to the early-FP, 
and thus, significant differences in performance between phases cannot be 
disregarded. 
 
Forsyth and Reilly [222] showed in eumenorrheic, recreationally-trained female 
participants, there was no significant difference in 2000 m rowing time trial 
performance between mid-LP and mid-FP (Table 2.11). However, there was a higher 
LT2 (as determined by OBLA) in the mid-FP than the mid-LP. These results suggest 
that the LT-performance relationship may be altered between menstrual cycle 
phases, at least when methods utilising fixed [La-] are used [222]. Despite thorough 
cycle verification (cycle diaries, basal body temperature charts, core temperature, 
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urine ovulation test and serum oestradiol and progesterone measurements), mean 
2000 m rowing time trial time was ~8 min, and therefore the findings cannot be 
generalised to other endurance events lasing ~1 h.  
 
Collectively, of the available evidence that suggests there are no differences in [La-] 
and/or endurance performance between menstrual cycle phases, there are 
methodological weaknesses and inconsistencies that limit their implications. The 
majority of studies were weakened by a lack of (or limited) phase verification – a 
process recommended to include menstrual cycle mapping, urinary ovulation 
prediction and serum/plasma hormone measurement [196]. Furthermore, the impact of 
training on the capacity of menstrual cycle phase to influence exercise performance 
is not well understood, since the current body of literature consists of sedentary and 
recreationally-active women. 
 
2.4.6 Differences in performance/physiology between phases 
In contrast, other researchers have shown significant differences in physiological 
measures such as V̇O2max, VT2 and LT2 between cycle phases, suggesting the 
influence of ovarian hormones. In women of at least moderate fitness (V̇O2max ≥ 
50 mL·kg-1·min-1), a significant increase in absolute (but not relative) V̇O2max was 
reported in the early-FP than the mid-LF (p < 0.05) [223] (Table 2.11). Although 
Bemben et al. [220] showed no significant difference in V̇O2max between phases in 
moderately-active women, they showed that VT2 occurred at a significantly higher 
percentage of V̇O2max in the early-FP compared with the late-FP and mid-LP [220] 
(Table 2.10). Moreover, when using the fixed LT2 method of OBLA, Forsyth et al. [224] 
found that exercise intensity, heart rate and V̇O2 corresponding to OBLA were higher 
(p < 0.01-0.05) in the LP than the FP in recreationally-active women (Table 2.11). 
However, no such differences were seen when other methods of LT2 were utilised, 
including D-max and a visual method; both of which were based on the shape of the 
lactate versus time curve [224]. Although training status of the participants was 
deemed irrelevant by the authors who stated that it would have minimal effect on LT2 
when determined by examination of the shape of the lactate curve [224], no known 
study has examined the effect of menstrual cycle phase on LT2 in endurance-trained 
women. In other studies not specifically reporting LT2, [La-] has been reported as 
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lower during exercise in the LP compared with the FP [22, 204, 218], which may suggest 
a higher LT2 (potentially as a result of improved lactate kinetics) in this phase. A 
lower [La-] suggests decreased blood lactate accumulation, a higher LT2, lower 
anaerobic glycolysis and the potential for improved endurance performance in the LP 
than the FP. Although no differences in [La-] or LT2 were seen between cycle phases 
in the study of Redman et al. [23] (Table 2.11), as suggested above, a significant 
effect for cycle phase was seen at exercise intensities above LT2 (which occurred at 
~50% peak workload), whereby plasma [La-] was lower in the LP at all exercise 
intensities during both incremental and submaximal exercise at 75% V̇O2peak. 
Therefore, these findings suggest that the influence of ovarian hormone 
concentrations on [La-] is intensity dependent, and subsequently, differences may be 
amplified during high-intensity exercise that is performed above LT2 intensity. 
 
Additionally, some researchers have shown significant differences in exercise 
performance between menstrual cycle phases. For example, Jurkowski et al. [22] 
showed a significant increase in time to exhaustion at 90% peak power output in the 
mid-LP compared to the mid-FP (p < 0.02) in healthy women. These findings were 
supported by Nicklas et al. [193] who reported a strong tendency for a longer time to 
exhaustion at 70% V̇O2max in the mid-LP compared to the mid-FP (p < 0.07) in 
healthy women. Furthermore, in moderately-trained women, performance in a 
4 kJ·kg-1 body weight time trial was significantly enhanced (13%; p < 0.05) in the FP 
compared to the LP [215] (Table 2.10). However, this study also showed that 
performance was improved after ingestion of a 6% glucose solution during exercise 
(vs. placebo), and that the difference between cycle phases was eliminated with the 
carbohydrate supplement. As discussed earlier, this suggests that carbohydrate 
intake is a potential confounder when examining differences between cycle phases, 
and therefore, should be controlled to minimise its influence on performance. This 
discrepancy in dietary intake may partly explain the conflicting findings when 
comparing performance and/ or substrate metabolism between cycle phases in 
previous research since some reported that participants were fasted [22, 23, 218, 223] 
whilst others were fed [194, 204, 205, 224].  
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When analysed in relation to the studies mentioned above that showed no significant 
differences between cycle phases [205, 222], it appears that differences in the ratio of 
oestradiol concentration to progesterone concentration (E/P ratio) in the LP may be 
influential. Oosthuyse and Bosch [21] identified that those who showed significant 
differences in performance between phases had a higher E/P ratio (i.e. a lower 
relative progesterone concentration) in the LP, whereas those who showed no 
difference between phases reported lower E/P ratios. This supports earlier findings 
of Campbell et al. [215] who showed no difference in endurance performance between 
cycle phases (the E/P ratio was low in the LP; E/P = 6.0), whilst Jurkowski et al. [22] 
showed a significant performance improvement in the mid-LP compared to the mid-
FP (the E/P ratio was high in the LP; E/P = 21.3). This difference in E/P ratio 
between studies existed despite a similar magnitude of increase in oestrogen in the 
LP above the FP in both studies (2.3-fold [215] and 2-fold [22]) and suggests that higher 
relative concentrations of progesterone may impede the metabolic benefits of 
oestradiol. Additionally, these findings provide support for the measurement of both 
oestradiol and progesterone concentrations when assessing the impact of ovarian 
hormones on measures of exercise performance. Further details of these studies are 
presented in Table 2.11.  
 
Furthermore, Vanheest et al. [225] investigated the effect of ovarian hormone 
concentrations on performance adaptations in junior (age 15-17 years) elite female 
swimmers in response to a 12-week training intervention. Results showed that those 
with cyclic menstrual function (serum progesterone concentrations ≥ 15.9 nmol·L-1 
during the LP at week 0 or 2; n = 5) significantly improved their 400 m swim 
performance (8.2%; p ≤ 0.001), compared to those with ovarian suppressed 
menstrual function (serum progesterone concentrations < 15.9 nmol·L-1 at both week 
0 and week 2, and the absence of cyclical increases in oestradiol) whose 400 m 
swim performance declined significantly (9.8%; p ≤ 0.001) post-training. Although the 
findings were confounded by significantly lower energy intake (p < 0.01) and energy 
availability (p < 0.01) in the ovarian suppressed menstrual function group compared 
to the cyclic menstrual function group, suggestive of impaired menstrual health, they 
also suggest that ovarian hormones may play a role in training-related performance 
adaptations. The findings relating to energy deficit support those of others who have 
108 
 
also shown that glucose kinetics are influenced by menstrual phase [215] when the 
energy demands of exercise are high enough to stress endogenous glucose 
production [21]. 
 
Collectively, studies showing significant differences between cycle phases in 
physiological responses to exercise, and measures of endurance performance 
highlight the influence of exercise intensity, dietary intake, the change in ovarian 
hormones and/or the E/P ratio. However, the influence of training status is not well 
understood. Given the known physiological and performance adaptations that occur 
with training and the impact of training status on the rate and magnitude of 
improvements, the influence of menstrual cycle phase and ovarian hormone 
concentrations on the physiological responses to exercise, and exercise 
performance, warrants further investigation. Additionally, exercise intensity, dietary 
intake and the E/P ratio have all been suggested as potentially influential variables 
on exercise physiology and performance, and should be considered when assessing 
the influence of ovarian hormones in responses to exercise.     
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Table 2.11. A summary of studies examining the effects of oestradiol and progesterone on exercise performance and 
variables associated with exercise performance. 
 
Study Participants Methods Major findings 
Jurkowski et al. [22] Healthy females (n 
= 9) 
Tested in FP and LP: 
(1) Maximal incremental test 
(2) ventilatory response to 
hypercapnia 
Within 48 h: 
(3) 20 min cycle at 1/3 max PO 
(light); 
(4) 20 min at 2/3 max PO 
(heavy); 
(5) Time to fatigue at 90% max 
PO with 60 rpm (exhaustive) 
Incremental test: Max PO and heart rate not different between phases; 
Ventilation greater (~10%) in LP than FP (p < 0.05) 
Hypercapnia: Ventilation greater (~49%) in LP than FP (p < 0.05); 
No difference in heart rate, ventilation, V̇O2, CO2 between phases during 
light and heavy exercise; 
No difference in cardiac output between phases during light and heavy 
exercise; 
Time to fatigue longer (~89%) during LP (p < 0.02); 
[La-] higher (~35%) after heavy exercise (p < 0.05) and at exhaustion 
(~20%; p < 0.01) in FP. 
Bonen et al. [198] Eumenorrheic 
females;  
(1) control group (n 
= 8); 
(2) fasted group (n 
= 6) and;  
(3) glucose-loaded 
group (n = 5) 
60 min submaximal treadmill 
walk (30 min at 40% V̇O2max 
and 30 min at 8% V̇O2max) 
The metabolic and endocrine responses to exercise were similar between 
groups in the two phases for glucose, [La-], glycerol, LH, FSH and cortisol; 
In the glucose group the FFA response was lower in the LP (p < 0.05); 
In the fasted subjects insulin and GH responses were elevated in the LP 
(p < 0.05); 
Progesterone responses in the control and glucose groups were greater in 
the LP (p < 0.05); In the fasted group no alteration in progesterone occurred 
in either phase (p < 0.05); 
In the fasted group the LH concentration was lower relative to the control 
group (p < 0.05). 
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McCracken, Ainsworth 
and Hackney [204] 
Recreationally 
active, 
eumenorrheic 
females (n = 9) 
Completed once in mid-LP and 
once in mid-FP; 
Incremental, continuous  
Test: 1 - 10 min at 35%  
V̇O2max, 11 - 20 at 60%  
V̇O2max, 21 - 30 at  
75% V̇O2max and until 
exhaustion at 90% V̇O2max 
No difference in resting [La-] between phases;  
Recovery [La-] was lower in the LP compared to the FP at 3 and 30 min 
post-exercise (p < 0.05); 
No difference in running time to exhaustion between phases. 
  
 
Lebrun et al. [223] Trained 
eumenorrheic 
females (n = 16) 
 
Testing on 2 successive days (in 
early-FP and mid-LP); 
Day 1) Maximal incremental 
treadmill test and anaerobic 
speed test 
Day 2) Time to fatigue at 90% 
V̇O2max and isokinetic strength 
(knee flexors and extensors) 
Higher absolute (p < 0.05) but not relative V̇O2max during FP; 
No differences in maximum V̇E, maximum heart rate or maximum RER 
between phases; 
No differences in the anaerobic speed test, time to fatigue or isokinetic 
strength between phases. 
Bemben, Salm and 
Salm [220] 
Moderately active, 
eumenorrhoeic 
females (n = 5). 
Tested in: early-FP, 
late-FP and mid-LP 
Maximal incremental treadmill 
test 
No difference in body weight or plasma volume changes between phases; 
No difference in V̇O2max, V̇E max, V̇CO2max, post-exercise [La-] or time to 
exhaustion between phases; 
Relative ventilatory threshold occurred at a higher  percentage of V̇O2max 
in the early-FP compared to mid-LP (p < 0.05). 
Janse de Jonge et al. 
[226] 
Eumenorrheic, 
recreationally-
active females (n = 
19) 
Isometric strength and fatigue 
testing (quadriceps), isokinetic 
strength and fatigue testing 
(knee flexors and extensors) 
and handgrip strength (each test 
performed during menstruation, 
late-FP and LP) 
No difference in any of the strength parameters including maximal isometric 
quadriceps strength with superimposed electrical stimulation, isokinetic 
knee flexion and extension strength at 60 and 240 °·s-1 and handgrip 
strength between phases; 
No difference in quadriceps contractile properties, the electrically stimulated 
quadriceps fatigue and the isokinetic knee flexor and extensor fatigue 
between phases. 
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Redman, Scroop and 
Norman [23] 
Young, sedentary 
females (n = 14) 
One of each test in FP and LP; 
1) Maximal incremental test  
2) Submaximal test (20 min at 
25% V̇O2peak and 20 min at 
75% V̇O2peak)  
 
LT = log-log transformation 
method 
Max test: no difference in time to exhaustion, maximal PO and total work 
done between phases; 
No difference in V̇O2peak, V̇E, respiratory frequency or heart rate between 
phases; 
Resting, end-exercise and peak (post-exercise) plasma [La-] and LT were 
not 
different between phases; 
As workloads increased during the incremental protocol, plasma [La-], V̇CO2 
and RER were all lower during LP (p < 0.05), while V̇O2 was higher (p < 
0.05); 
No difference in heart rate, plasma [La-] or PO at LT2 between phases; 
Submax test: At both intensities, V̇O2 was higher (0.05 < p < 0.01) and RER 
was lower (p < 0.05) during LP; 
At 25% V̇O2peak, no difference in plasma [La-] between stages; 
At 75% V̇O2peak, plasma [La-] was higher during FP at min 15 (~8%) and 
20 (~12%; both p < 0.02) of exercise and at end-exercise (~9%; p < 0.03). 
Horton et al. [221] Recreationally 
active, 
eumenorrheic 
females (n = 8) 
3 x maximal incremental cycle 
tests (once in early-FP, mid-FP 
and mid-LP); 
LT = log-transformation method 
No differences in LT when expressed as % absolute or relative V̇O2max, or 
heart rate between phases; 
No difference in V̇O2max, maximal heart rate or final [La-] between phases. 
 
Forsyth and Reilly [224] Eumenorrheic, 
recreationally-
active females (n = 
12) 
Maximal incremental rowing test 
(performed at 06:00 and 18:00 
in both mid-FP and mid-LP) 
 
LT = D-max, visual method and 
OBLA 
OBLA occurred at a higher mean intensity (p < 0.01), heart rate (p < 0.01) 
and V̇O2 (p < 0.05) in the mid-LP than the mid-FP; 
[La-] at ventilatory threshold (~15% at 06:00 and ~23% at 16:00; p < 0.01) 
and at D-max LT (~7% at 06:00 and ~16% at 16:00; p < 0.05) were lower in 
the mid-LP than mid-FP; 
No interaction effects (phase x time of day) for any LT method or for [La-] at 
rest or maximum; 
Pre-exercise [La-] was higher in mid-FP (~8% at 06:00 and ~23% at 16:00; 
p < 0.05) than mid-LP; 
No differences between phases when LT2 visual method used. 
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Forsyth and Reilly [222] Eumenorrheic, 
recreationally-
active females (n = 
10) 
1) Maximal rowing power test; 
2) Maximal incremental rowing 
test and; 
3) 2000 m rowing time trial 
(all performed in mid-FP and 
mid-LP) 
OBLA occurred at a higher mean intensity (~6%; p < 0.05), heart rate (~3%; 
p < 0.01) and V̇O2 (~9%; p < 0.05) in the mid-LP than the mid-FP; 
No difference in 2000 m time trial speed between phases (~0.5%); 
Little variation in the correlation coefficients between OBLA parameters and 
2000 m time trial performance between mid-LP (r = 0.4-0.82) and mid-FP (r 
= 0.54-0.82). 
Jurimae et al. [227] Eumenorrheic 
rowers (n = 24); 
Competitive (n = 8), 
recreationally-
trained (n = 7) and 
recreationally-
trained taking oral 
contraceptive pills 
(n = 9) 
2 x maximal incremental rowing 
tests (once in FP and once in 
LP) 
 
Anaerobic threshold = linear 
regression turn point analysis 
method 
No differences in PO, V̇O2, heart rate and [La-] at maximal load and 
anaerobic threshold between phases; 
V̇E/V̇CO2 was higher at maximal load and at anaerobic threshold in LP than 
FP in the oral contraceptive group (p < 0.05); 
RER was higher in the recreationally-trained (OC users and non-OC users) 
athletes than the competitive athletes (p < 0.05); 
PO at anaerobic threshold, and V̇E during LP were lower in the 
recreationally-active athletes than the competitive athletes (p < 0.05). 
 
V̇O2max: maximal oxygen uptake; V̇E: ventilation; V̇CO2: volume of CO2 expired; RER: respiratory exchange ratio; FP: follicular phase; LP: luteal phase; PO: 
power output; [La-]: lactate concentration; OC: oral contraceptive. 
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A common consensus is yet to be reached in the literature on the impact of 
oestradiol and progesterone on physiological responses to exercise and athletic 
performance. According to Elliott-Sale et al. [25] the research that does exist is 
weakened by inconsistencies in the definition and measurement of reproductive 
hormone status and methodological inconsistencies. Additional weaknesses 
reported are inappropriate verification of menstrual cycle phase, small subject 
numbers, high intra- and inter-individual variability in oestradiol and progesterone 
concentrations and the pulsatile secretion of these hormones [21, 184]. To address this, 
it has been suggested that the relationship between metabolic parameters, exercise 
performance and ovarian hormonal changes over the menstrual cycle be established 
to improve the sensitivity of studies identifying performance changes caused by 
ovarian hormones [21]. Nevertheless, the literature to date suggests that oestradiol 
may enhance endurance performance by altering substrate metabolism, while 
progesterone often appears to act antagonistically. Dietary influences on metabolism 
also appear to play a role in subsequent endurance performance and for this reason, 
it could be suggested that controlling for these potentially confounding variables in 
research will allow more valid performance studies to be conducted and 
comparisons between males and females to be made.  
 
2.4.7 Hormonal contraceptives and research 
There are a number of reasons hormonal contraceptives have been used in 
research. Elliott-Sale et al. [25] concluded that researchers have previously used OC 
users as; (1) an experimental group to examine the effects of down-regulation of 
oestradiol and progesterone concentrations on performance; (2) an experimental 
group to examine the effects of the exogenous synthetic component on performance; 
and (3) a control group with which the effects of the menstrual cycle can be 
compared. The implementation of OC users as a control group is effective due to the 
consistent concentrations of endogenous oestradiol and progesterone, thereby 
negating the fluctuations in hormone concentration seen in normally menstruating 
(eumenorrheic) females [25]. However, despite having the same mechanism of action 
in the down-regulation of oestradiol and progesterone, significant differences in 
circulating oestradiol and progesterone concentrations as a result of OC type (n = 2) 
and brand (n = 11) have been shown [25]. As a result, it has been recommended that 
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studies avoid using a combination of OC brands within one sample, thus reducing 
the chance of type II errors. Additionally, the type of progestin contained within an 
OC has been suggested to influence athletic performance through its actions on 
oestradiol [228] so tighter control of progestin type may be warranted. A six month 
history of constant OC use has been recommended as sufficient when recruiting 
participants [25]. However, the researchers did not recruit participants who had been 
taking an OC for less than six months, so it is unknown whether there is a minimum 
acceptable time. 
 
Recruiting participants who all use the same type and brand of OC creates a 
significant challenge, especially if the desired sample is quite specific in nature, i.e. a 
group of trained endurance athletes. For this reason, it may be more appropriate to 
specify one type of OC during recruitment, such as monophasic, or to standardise 
testing sessions where participants taking triphasic doses are in a phase of similar 
hormonal concentrations as monophasic users. Other hormonal contraceptive 
methods, such as the transdermal patch and NuvaRing® have been compared to the 
OC in regards to ethinylestradiol exposure. Van den Heuvel et al. [229] reported that 
ethinylestradiol exposure was significantly higher in patch users than NuvaRing® 
users (3.4 times; p < 0.05), and OC users (1.6 times; p < 0.05). Furthermore, others 
have shown that although exposure to ethinylestradiol in OC users was twice as 
great as that of the NuvaRing® users, the bioavailability of ethinylestradiol was 
similar between formulations [230]. Therefore, it seems acceptable to recruit 
NuvaRing® and OC users in the same study. However, patch users should be 
excluded due to their significantly higher ethinylestradiol exposure, unless they make 
up the entire sample. Finally, since OC users experience greater daily fluctuations in 
hormonal concentrations compared to NuvaRing® users [229], a consistent time of 
day for physiological testing is warranted. 
 
2.4.8 Hormonal contraceptives and exercise performance 
As for the menstrual cycle, research has investigated the effect of hormonal 
contraceptive agents, mainly the OC, on physiological responses to exercise and 
exercise performance outcomes (Table 2.12). Isacco et al. [231] showed that although 
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OC users had increased lipid mobilisation compared to non-users in the postprandial 
state, this effect was blunted when lipolytic activity was stimulated by exercise. The 
authors stated that the greater lipolytic mobilisation in the OC users may have been 
a result of the elevated hormonal concentration of atrial natriuretic peptide in the OC 
users, since plasma concentrations were higher at baseline than in the non-OC 
users. These findings built on an earlier study from the same laboratory which 
showed no differences in substrate oxidation, or metabolic or hormonal responses 
during exercise postprandially between OC users and non-users, despite a greater 
reliance on fat (shown through lower plasma insulin concentrations and higher 
plasma free fatty acid and glycerol levels) and a decreased carbohydrate oxidation in 
both OC users and non-users when fasted [232]. Both of these studies highlight the 
greater importance of energy intake, rather than OC use, on substrate metabolism. 
 
In recreationally-active women, the effect of long-term OC use compared to non-use 
has been examined in relation to endurance cycling performance [233]. Although 
V̇O2peak and V̇O2 at anaerobic threshold were significantly higher in non-users than 
OC users (p < 0.05), there were no differences in physiological responses to 
constant load exercise or time to exhaustion between users and non-users [233]. 
Furthermore, the relative intensity of the anaerobic threshold was similar between 
groups, and overall, the impact of OC use on endurance performance parameters 
was suggested as negligible. A weakness of this study was its cross-sectional rather 
than longitudinal design and as such, it is unknown whether a change in OC status 
would indeed result in changes in these physiological variables over time. 
Nevertheless, a reduction in V̇O2peak (5-15%) between OC users and non-users, 
and within individuals before and after OC use, has been shown by others [234-236]. 
Conversely, the lack of performance change in response to OC use has been shown 
in sedentary females performing a multistage fitness test [237], in competitive 
swimmers and water polo players during a 200 m swimming time trial [238] and in 
well-trained cyclists over a 1 h cycle time trial [239], suggesting that any changes in 
V̇O2peak in response to OC use are independent to endurance performance 
changes. 
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Despite no difference in a 200 m swimming time trial performance in competitive 
swimmers and water polo players (mentioned above) between the consumption 
phase (pills with hormonal dose) and withdrawal phase (pills without hormonal dose), 
Rechichi and Dawson [238] showed a reduction in mean peak [La-] (~17%) and an 
increase in mean pH (~0.3%) during the late withdrawal phase compared to the 
consumption phase. Although not directly measured, these results suggest that LT2 
may be altered with exogenous hormone doses, especially if a fixed method of 
determination such as OBLA was used. This is in contrast to the findings of Joyce et 
al. [233] who showed that the relative intensity of the anaerobic threshold was similar 
between OC users and non-users. However, the anaerobic threshold was 
determined via gas exchange parameters (V-slope and ventilatory equivalent 
methods) [233] and subsequently, it appears that blood and ventilatory measures 
respond differently to variations in ovarian hormone concentrations. It is important to 
note that along with the changes in [La-] and pH in the late withdrawal phase 
compared to the consumption phase, a concomitant increase in serum oestradiol 
concentration occurred during the late withdrawal phase compared to both the 
consumption phase (p < 0.05) and the early withdrawal phase (p < 0.05), without a 
difference in serum progesterone concentration [238]. This study indicates a possible 
potentiation effect of oestradiol within OC phases, which supports the studies 
discussed earlier regarding menstrual cycle phases. These findings support those of 
an earlier study conducted in the same laboratory which showed a significantly 
higher [La-] in the late withdrawal phase compared to the consumption phase 
(p < 0.05), despite no difference in 1 h cycling performance in well-trained female 
cyclists [239]. Therefore, it appears that although there are some differences in 
physiological responses to exercise between OC users and non-users, and between 
consumption and withdrawal phases within OC users, endurance performance is 
unaffected by the down regulation of ovarian hormones brought upon by OC use.      
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Table 2.12. A summary of studies examining the effects of hormonal contraceptive agents on physiological responses to 
exercise and exercise performance. 
 
Study Participants Methods Major findings 
Bryner et al. [240] Male (n = 15) controls; 
Females tested before and after 
21 days of placebo (n = 3) or 
monophasic OC use (n = 7) 
Maximal incremental treadmill 
test; 
Endurance run: incremental up to 
80% maximum heart rate, then 
until volitional fatigue. 
Females tested in mid-FP and 
mid-LP before OC use and on 
days correlating with these 
phases during OC use. 
No difference in % change in total test time, V̇O2max or 
breathing frequency between males and females in either test;  
Incremental test: no difference in total test time, V̇O2 or 
breathing frequency between phases before OC use or 
between phases during OC use;  
Endurance test: no difference in total test time, V̇O2 or 
breathing frequency between phases before OC use or 
between phases during OC use. 
 
Giacomoni and 
Falgairette [241] 
Physical education students (n = 
10) currently taking a monophasic 
OC 
Submaximal treadmill test (4 min 
at 50, 60 and 65% V̇O2max) 
completed during; 
1) menstruation (days 2 - 4); 
2) early OC use (days 7 - 9) and; 
3) late OC use (days 19 - 21) 
No differences between phases for heart rate, V̇E or V̇CO2 for 
any intensity;  
V̇O2 was lower (3 - 5.8%) during early and late OC use 
compared to menstruation for all intensities (p < 0.01); 
Running economy was improved during late OC use compared 
to menstruation for all intensities (p < 0.05). 
Casazza et al. [234] Moderately active, eumenorrheic 
females 
(n = 6) before and after 4 months 
of triphasic OC use 
Maximal incremental cycle test; 
Tested during the FP and LP 
before OC and the inactive and 
high-dose phases after OC 
No difference in dietary composition, exercise patterns or peak 
heart rate, V̇E and RER with OC use; 
An increase in body weight (~3%) and fat mass (~9%; both p ≤ 
0.05) occurred after OC use; 
A decrease in V̇O2peak (~11%; p ≤ 0.05) occurred after OC 
use. 
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Lebrun et al. [235] Trained females (n = 14) 
randomised into placebo (n = 7) 
or triphasic OC (n = 7) 
1) Maximal incremental running 
test; 
2) Anaerobic speed test; 
3) Time to fatigue test at 90% 
V̇O2max; 
4) Isokinetic strength test (knee 
flexors and extensors). 
 
All completed in FP and LP 
(before randomisation) and after 
14-17 days of second cycle of OC 
or placebo 
Absolute and relative changes in V̇O2max from FP to OC 
phase decreased in OC group (4.7%) and increased in placebo 
group (1.5%; both p ≤ 0.05); 
Larger increase in sum of skinfolds in OC group compared with 
placebo (group x phase: p < 0.01);  
No differences in V̇E, heart rate, RER or packed cell volume 
between OC and placebo groups; 
No differences in anaerobic speed test, time to fatigue or 
isokinetic strength between OC and placebo groups. 
Suh et al. [236] Moderately active, eumenorrhoeic 
females (n = 8) before and after 4 
cycles of triphasic OC use 
1) Maximal incremental cycling 
test; 
2) 2 x stable isotope tracer 
infusion trials: 90 min rest (while 
glucose infused), 60 min cycle at: 
- 45% V̇O2peak and; 
- 65% V̇O2peak (separated by 3 - 
5 days). 
All completed in early-FP and 
mid-LP before OC use, and 
during the week of inactive pills 
and the week when hormone 
dose was high during OC use 
Reduction in glucose rate of appearance (16% and 20%; 
p < 0.05) during exercise at 45 and 65% V̇O2peak, respectively 
with OC use compared with before OC use; 
Reduction in glucose rate of disappearance (p < 0.05) during 
exercise at 65% V̇O2peak with OC use compared with before 
OC use; 
No differences in glucose rates of appearance and 
disappearance at rest between OC use and before use; 
No difference between phases on substrate oxidation during 
rest or exercise; 
V̇O2peak decreased (13 - 15%) with OC compared to before 
OC, both in relative and absolute terms (p < 0.05). 
Rickenlund et al. [237] Endurance-trained females with 
oligo-/amenorrhea (n = 13), and 
eumenorrhoea (n = 13); and 
sedentary eumenorrhoeic controls 
(n = 12) before and after 10 
months of monophasic OC use 
1) Maximal incremental treadmill 
test 
2) Multistage fitness test 
3) Isometric leg extension 
strength 
No changes in V̇O2max or rate of perceived dyspnea-exertion 
in athletes or controls with OC use; 
Decline (6%) in multistage fitness test performance in oligo-
/amenorrheic group with OC use (p < 0.05). 
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Rechichi, Dawson 
and Goodman [239] 
Trained female cyclists and 
triathletes (n = 13) taking 
monophasic OC 
1 h cycle test performed during; 
1) the OC consumption phase; 
2) early in the OC withdrawal 
phase and; 
3) late in the OC withdrawal 
phase. 
No differences in mean power output, heart rate, V̇O2, RER, 
RPE or blood glucose concentration between OC phases; 
Mean V̇E and V̇E/V̇O2 were higher during the consumption 
phase compared to both the early (~5% and ~4%) and late 
(~9% and ~8%) withdrawal phases (p ≤ 0.001); 
Mean [La-] was higher in the consumption phase compared to 
the early withdrawal phase (~22%; p < 0.05). 
Rechichi and 
Dawson [238] 
Competitive swimmers and water 
polo players (n = 6) currently 
taking a monophasic OC 
200 m swim performance 
completed in; 
1) consumption phase (days 17 - 
21 of active pills); 
2) early withdrawal phase (2 - 3 
days post-active pill cessation) 
and; 
3) late withdrawal phase (6 - 7 
days post-active pill cessation) 
No differences between OC phases for 200 m swim time, 
mean stroke rate, peak heart rate, blood glucose or and body 
composition; 
Mean peak [La-] was lower (~17%) during the late withdrawal 
phase compared with the consumption phase (ES = 95%); 
Mean pH was higher during the late withdrawal phase (~0.3%) 
compared with the consumption phase (ES = 89%). 
Isacco et al. [232] Recreationally active females (n = 
21) including monophasic OC 
users (n = 11) and eumenorrhoeic 
non-OC users (n = 10) 
1) 45 min cycle at 65% V̇O2max 
(fasted); 
2) 45 min cycle at 65% V̇O2max 
(postprandial); 
- both (1) and (2) completed 
during consumption phase for OC 
users and LP for non-OC users. 
At rest, OC users had higher LDL cholesterol (p < 0.01), total 
cholesterol (p < 0.01) and triglyceride (p < 0.05) concentrations 
than non-users; 
No difference in substrate oxidation or metabolic or hormonal 
responses during exercise between OC users and non-users; 
Greater lipid and less CHO oxidation in fasted than fed state, 
regardless of OC status (p < 0.01); 
No difference between OC users and non-users for insulin 
concentration; 
Higher average insulin (p < 0.05) and lower free fatty acid 
concentrations (p < 0.01) in the fed compared with fasted 
state. 
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Joyce et al. [233] Recreationally active females (n = 
16) including monophasic OC 
users (n = 8) and eumenorrhoeic 
non-OC users (n = 8) 
Maximal incremental cycle test; 
2 x constant-load submaximal 
cycling tests (2 x 6 min below 
anaerobic threshold, and 1 x 6 
min above anaerobic threshold 
until exhaustion). 
V̇O2max (~22%) and V̇O2 at anaerobic threshold (~25%) were 
higher in non-users than OC users (p < 0.05); 
No difference in V̇E, heart rate, blood pressure, [La-] or cycling 
economy in any constant-load stage between OC users and 
non-users; 
No difference in time to exhaustion between OC users and 
non-users. 
Isacco et al. [231] Recreationally active females (n = 
21) including monophasic OC 
users (n = 11) and eumenorrhoeic 
non-OC users (n = 10) 
Two lab visits: 
1) Resting session 
2) Exercise session: 45 min cycle 
at 65% V̇O2max  
(both visits during consumption 
phase for OC users and LP for 
non-OC users) 
No difference in energy expenditure between OC users and 
non-users; 
Atrial natriuretic peptide concentrations were higher in OC 
users compared with non-users at baseline (p < 0.05);  
Plasma glycerol, free fatty acids, atrial natriuretic peptide and 
noradrenaline were higher in OC users compared with non-
users when both resting and exercise sessions were pooled 
(all p < 0.05); 
No difference in growth hormone, IGF-1 or adrenaline 
concentrations between OC users and non-users; 
No difference in any metabolic or hormonal variable when the 
effect of exercise was isolated to overcome food intake and 
daytime variations (exercise per se using the area under the 
curve). 
V̇O2max: maximal oxygen uptake; V̇O2peak: peak oxygen uptake; OC: oral contraceptive; IGF-1: insulin-like growth factor 1; V̇E: ventilation; V̇O2: oxygen 
consumption; RER: respiratory exchange ratio; RPE: rating of perceived exertion; LP: luteal phase; FP: follicular phase. 
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Collectively, the available evidence on the impact of ovarian hormones on exercise 
highlights that exercise intensity, dietary intake, the change in ovarian hormones 
and/or the E/P ratio may explain differences between cycle phases in women, and 
should be considered when assessing the influence of ovarian hormones in 
responses to exercise. However, methodological weaknesses and inconsistencies 
limit the implications of research comparing the [La-] and/or endurance performance 
between menstrual cycle phases. The impact of training on the capacity of ovarian 
hormones to influence exercise performance is not well understood, since the 
current body of literature consists of sedentary and recreationally-active women. 
Finally, although it appears that there are some differences in physiological 
responses to exercise between OC users and non-users, and between consumption 
and withdrawal phases within OC users, endurance performance appears unaffected 
by the down-regulation of ovarian hormones brought upon by OC use. This 
discrepancy between physiological responses to exercise and performance 
outcomes has implications for exercise testing and exercise research. When the 
purpose of exercise testing is to predict endurance performance and assess the 
impact of a previous training phase/intervention, physiological variables influenced 
by ovarian hormones will provide limited information on endurance performance 
adaptations. 
 
Therefore, future research examining physiological variables in response to exercise, 
exercise performance outcomes and adaptations to training in women should: 
(1) Ensure participants are in a fed state to minimise the impact of ovarian 
hormones (especially during endurance exercise); 
(2) Consider, control for, and verify ovarian hormone status with methods such as 
menstrual cycle mapping (when recruiting normally-menstruating women), 
ovulation prediction testing and serum/plasma hormone measurement (when 
recruiting normally-menstruating women and/or hormonal contraceptive 
users); 
(3) Recruit participants who use a hormonal contraceptive (the NuvaRing® and 
OC seem to provide consistent bioavailability of ethinylestradiol and therefore 
may be used by participants in the same study) in order to minimise the 
influence of ovarian hormones on outcome measures; 
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(4) Compare the results to those of men whilst ensuring down-regulation of 
ovarian hormones in women; this will provide important information on the 
differences in physiological responses to exercise and adaptations to training, 
whilst minimising the impact of these hormones. This information will allow 
more sex-specific exercise testing to be conducted, and sex-specific training 
to be prescribed, to maximise performance adaptations in men and women. 
 
2.5 High-intensity interval training (HIIT) in trained 
endurance athletes 
2.5.1 Introduction 
HIIT has become a popular means of improving cardiovascular fitness since Hickson 
et al. [63] demonstrated an improvement in V̇O2max (44%) and time to fatigue (during 
exercise at workrate resulting in fatigue within 2-5 min at baseline; linear increase 
across 10 weeks) after ten weeks of training (6 days per week, alternating: 6 x 5 min 
cycling at workrate eliciting V̇O2max, with 2 min active recovery, with continuous 
running at highest sustainable speed for 30-40 min) in previously untrained 
participants (n = 7 men and 1 women). The physiological remodelling in response to 
HIIT has been reported as similar to those resulting from traditional endurance 
training despite a markedly lower total exercise volume and training time 
commitment [242-244]. The prescription of HIIT is almost infinitely variable due to the 
many possible combinations of exercise mode, exercise intensity, duration and 
number of intervals performed, and the durations and nature of the recovery periods 
between exercise bouts [245]. However, the common characteristics of HIIT are: (1) it 
involves repeated short-to-long bouts of rather high-intensity exercise interspersed 
with recovery periods [27]; (2) the intensity is between 80-100% peak heart rate [26] 
(compared to ≥ 100% V̇O2max, which is classified as ‘sprint-interval training’ [26]); and 
(3) the intensity of the relief intervals are characterised in alignment with the intensity 
of the work intervals, that is, higher intensity relief intervals are prescribed for lower 
intensity work intervals [246] and lower intensity relief intervals are prescribed for work 
intervals of higher intensities and durations [247-249]. The aim of this section is to 
123 
 
review the physiological and performance adaptations to HIIT in endurance-trained 
athletes. 
 
2.5.2 HIIT and endurance performance 
The intensity of training became a focus of exercise science research when an early 
study showed that increasing the training intensity in three out of eight training 
sessions per week resulted in endurance performance improvements in male, 
endurance-trained distance runners (n = 7) [108]. Participants completed one interval 
session (running at 90-95% of maximal heart rate with recovery until heart rate 
reached 120 beats·min-1) and two fartlek sessions (6-10 miles of running at slightly 
below, to slightly above, 10 km race pace, with a slower pace between bouts to allow 
for minimal recovery) per week for eight weeks. Results showed an improvement in 
10 km race time (3%; p < 0.05) and time to exhaustion at a pace similar to the initial 
10 km pace time (+ 15 s) with a 2% grade (20%; p < 0.05). Additionally, a higher 
relative exercise intensity was required to elicit 2.5 mmol·L-1 and 4 mmol·L-1 plasma 
[La-] post-training (both by 5%; both p < 0.05), suggesting an increased LT2. 
Furthermore, changes in plasma [La-] at 85 and 90% V̇O2max were correlated with 
improvements in 10 km race time (r = 0.69; p < 0.05 and r = 0.73; p < 0.05, 
respectively) but not time to exhaustion (p > 0.05). Despite details of the training 
sessions being vague, these early findings suggested a positive association between 
an increased training intensity and improved physiological and performance 
outcomes in trained endurance athletes.  
 
Subsequent studies confirmed these findings and showed improvements in 
endurance performance of various exercise modes and durations in athletes who 
were endurance-trained. For example, running performance improvements have 
been reported over 10 km in response to seven weeks of HIIT consisting of 3-4 x 
5 min running, interspersed by 2 min of rest (each 5 min interval consisted of 5 x 1 
min runs divided into 30 s, 20 s, and 10 s at an intensity corresponding to 30%, 60%, 
and 90-100% of maximal intensity, respectively), three times per week [250]. 
Furthermore, 5 km running performance in a triathlon-specific time trial was 
improved after six HIIT sessions over three weeks consisting of 6-8 x 5 min cycling 
intervals at 80% V̇O2peak power output, interspersed by 1 min rest [30]. Furthermore, 
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highly-trained junior cross-country skiers improved their 7 km hill run (6.8%) and 12 
km roller skiing performances (4.8%) after an eight week period of HIIT, consisting of 
two sessions per week of 5-10 min at their maximal sustainable intensity, and a total 
session duration of 40-45 min) [31]. In endurance-trained cyclists, performance 
improvements have been reported over 10-40 km [32-40, 251, 252] (details provided in 
Table 2.13). Despite these multi-modal HIIT interventions, the majority of studies 
involved men only [30, 32-40, 251-254], whilst two combined the findings of men and 
women [31, 250]. This highlights a major gap in the current literature and confirms 
findings that women are significantly under-represented in the exercise science 
literature, with only 39% of studies published across three leading journals from 2011 
to 2013 incorporating women in any capacity (single-sex or mixed samples), and 
only 4-13% of studies recruited women only [20]. 
 
Despite consistent performance improvements in endurance-trained male cyclists in 
response to HIIT (Table 2.13), only four studies examined the association between 
changes in physiological variables and changes in performance [33, 36-38], and thus, 
investigated which variable(s) may explain these HIT-related performance 
improvements. Relationships were found between performance improvements and 
increases in skeletal muscle buffering capacity (n = 6; r = -0.74; exact p value not 
reported) [38], anaerobic capacity (r = 0.40; p < 0.05), VT2 (n = 41; r = 0.42; p < 0.01) 
[36], and peak power output (n = 20; r = -0.92; p < 0.01) [33]. However, similar 
investigations in well-trained women, or in both men and women for comparison, 
have not been published. Therefore, significant gaps in the literature remain 
surrounding which variable(s) consistently explain performance improvements in 
response to HIIT in trained men and women. These findings will allow sex-specific 
exercise testing to be conducted and enhance HIIT prescription in both men and 
women. 
 
The weight of evidence surrounding endurance performance adaptations to HIIT in 
endurance-trained athletes suggests that men improved their performance by 2.1-
20% in response to 4-12 sessions consisting of short (5-60 s) to long (2-8 min) 
intervals at moderate to high intensities (80-175% peak power output/ maximum 
heart rate/ V̇O2peak; although some of these are more accurately classified as ‘sprint 
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interval training’ given the intensities ≥ V̇O2max). However, it is unknown whether 
endurance-trained women respond in the same capacity to the same HIIT 
interventions as men and thus, future research should investigate this. Furthermore, 
the mechanisms that explain HIIT-related performance improvements are unclear; 
this should be investigated further, and compared between men and women. These 
findings will have implications for physiological testing to predict endurance 
performance and assess the impact of training interventions. 
 
2.5.3 HIIT and V̇O2max 
Although V̇O2max has been shown to increase in response to various HIIT programs 
in untrained and recreationally-active individuals [63, 250], the weight of evidence 
suggests the contrary for well-trained populations. One of the first studies 
highlighting the beneficial effects of HIIT in already well-trained athletes (discussed 
above; [108]) showed improvements in endurance performance and lactate responses 
without concomitant improvements in ventilatory measures including V̇O2max and 
VT. Since then, research has shown HIIT-related improvements in running 
performance over 3 km (3%; p < 0.05; HIIT: 6 intervals at 100% V̇O2max for a 
duration equivalent to 60% of the time for which the velocity at V̇O2max can be 
sustained, for 8 sessions), 10 km (3.1%; p < 0.01; HIIT: 6-12 x 30 sec sprint runs, 3-
4 times per week for 6-9 weeks) [28] and the maximum running distance in 20 min 
(3.8%; p < 0.01; HIIT: ~10 h per week of 40 sec-7 min intervals at 80-90% V̇O2max 
for 5 months) [41] without significant improvements in V̇O2max. Despite one study 
showing a correlation between the change in V̇O2max and the change in 3 km 
performance (r = 0.78; p < 0.05; HIIT: ), the authors concluded that the more likely 
mechanism behind the performance improvement was the improvement in VT from 
pre- to post-training (6.8%; p < 0.05) despite the fact that changes in VT were not 
correlated with changes in performance (r = 0.32) [29]. These findings provide further 
evidence (as reviewed in section 2.1.2 of this thesis) of a stronger relationship 
between fractional utilisation of V̇O2max and endurance performance, compared to 
V̇O2max and endurance performance. 
 
The influence of HIIT on V̇O2max has also been examined in well-trained cyclists. 
Laursen et al. [71] (Table 2.13) showed that a demanding HIIT program was capable 
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of producing improvements in VT1 and VT2, peak power output and time to fatigue, 
without a chance in V̇O2max. More recently, Swart et al. [35] (Table 2.13) reported 
similar findings whereby improvements in 40 km cycle time trial time and relative 
peak power output were seen in response to four weeks of HIIT without concomitant 
increases in V̇O2max. It is also common for researchers not to report V̇O2max 
changes of well-trained participants after an acute bout of HIIT [32, 33, 37, 38]. This 
provides further support for the lower relative importance of V̇O2max in relation to 
endurance performance in comparison with other measures such as peak power 
output, LT2, VT2 and exercise economy, as discussed in section 2.1.2 of this thesis.  
 
Nevertheless, some have reported the contrary and shown that V̇O2max can indeed 
improve even in a group of well-trained cyclists. Lindsay et al. [32] (Table 2.13) have 
suggested indirectly, that improvements in V̇O2max were possible after only six 
sessions of HIIT in competitive cyclists. The authors noted that since a relationship 
between V̇O2max and peak power output had previously been established, and their 
results showed a large (~5%) increase in peak power output, this was consistent with 
a theoretical increase in V̇O2max. However, without a direct comparison, the 
suggestion that HIIT improves V̇O2max in trained cyclists is not strong. Laursen et al. 
[34] (Table 2.13) demonstrated moderate to large improvements in V̇O2peak in 
response to different HIIT programs which the authors related to either; (1) the 
intensity of the intervals, whereby exhaustion was reached in nearly every session 
and only 64% of intervals were able to be completed or; (2) the participants 
performed mid-HIIT testing which allowed for adjustments in training intensity to be 
made.  
 
A subsequent study by the same group [36] (Table 2.13) showed that changes in 
V̇O2peak produced a weaker correlation (r = 0.41; p < 0.05) with performance 
improvements than changes in VT2 and variables measured during the time trial 
(r = 0.42-0.53; all p < 0.01). These results provide further evidence for the relatively 
low importance of V̇O2max improvements, if they do indeed occur, compared to 
other physiological and performance variables in trained cyclists. Although 
impressive, the improvement in V̇O2max (10.3%) reported in a case study of an elite 
national cyclist was smaller than the improvement in 15 km ergometer time trial 
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performance (equivalent to ~23 km on the road; 14.9%) after one year of mixed-
modal HIIT consisting of running and cycling [40] (Table 2.13).  
 
Therefore, it appears that HIIT interventions where the intensity is so high that 
almost half of the intervals are unable to be completed, or the HIIT intervention is 
periodised across a whole year, are needed to elicit improvements in V̇O2max. 
However, the influence of V̇O2max improvements on performance adaptations is 
minimal in comparison to other variables and therefore, it could be suggested that 
variables other than V̇O2max be examined preferentially when assessing the 
influence of a HIIT intervention in trained endurance athletes. 
 
2.5.4 HIIT and LT2  
Much less research has been conducted on the influence of HIIT on LT2 which, 
considering its consistently strong relationship with performance, such research is 
warranted. An early suggestion of an improvement in LT2 in response to HIIT was 
shown by Acevedo and Goldfarb [108] and has been discussed above. The lower 
plasma [La-] at the same relative exercise intensities (85 and 90% V̇O2max) after vs. 
before training (with no change in V̇O2max) signifies a shift to the right in the 
[La-]-workload curve and an improved LT2. Perhaps more importantly, the correlation 
between changes in plasma [La-] at 85% and 90% V̇O2max and 10 km race time 
improvement supports the importance of changes in the lactate response as a 
contributor to performance improvements post-HIIT in trained participants. More 
recently, despite similar improvements in LT2 (as determined by the modified D-max 
method) between moderate intensity training (10.8%; p < 0.05) and HIIT (7.0%; 
p < 0.05) in previously untrained females, only the HIIT group improved their muscle 
buffering capacity (25%; p < 0.05) [183]. Since the HIIT and moderate intensity training 
groups were matched for training volume, this study was the first to demonstrate 
larger improvements in muscle buffering capacity when the intensity but not the 
volume was increased in previously untrained participants. However, it also suggests 
that LT2 is not sensitive to detect adaptations to HIIT at the muscular level. 
 
Furthermore, when participants were already endurance-trained, Evertsen et al. [41] 
showed that LT2 improved significantly more (p = 0.03) in response to five months of 
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“mixed training” in junior elite cross-country skiers (n = 11 males and 9 females) 
when training consisted mostly (83% of total training) of HIIT (3.2%; p < 0.01; HIIT: 
~10 h per week of 40 sec - 7 min intervals at 80 - 90% V̇O2max), compared to mostly 
(86% of total training) moderate intensity training (-1.1%; p = 0.50). These LT2 
improvements were accompanied by significantly greater improvements in running 
performance in the HIIT group compared to the moderate intensity group (3.8% vs. 
1.9%, respectively; p < 0.05). However, despite recruiting a mixed sample of men 
and women, sex-specific adaptations to LT2 were not reported.   
 
Adaptations to LT2 in response to HIIT in endurance-trained male cyclists have been 
investigated over one year [40], and in one short-term study where seven HIIT 
sessions were completed in seven days  [39] (Table 2.13). Although both of these 
studies reported improvements in LT2, methods of LT2 determination were not based 
on the entire workrate-[La-] curve, but rather the lowest blood [La-] + 2.3 mmol·L-1 [40] 
and OBLA (the power output eliciting 4 mmol·L-1 [La-]) [39] and thus, it is unknown 
how HIIT influences other methods of LT2 determination. Given the previously 
discussed disadvantages of LT2 methods such as OBLA (section 2.2.2), it is 
important that research establishes the influence of HIIT on other LT2 methods, such 
as those that explore the entire workrate-[La-] curve. Although significant 
performance improvements were reported in these studies [15 km cycling (~15%) 
[40], and 20 km cycling (8-10%) [39]], the capacity of LT2 to predict the changes in 
performance was not reported in any study. Together with the findings of Edge et al. 
[183], these studies suggest that LT2 may be more sensitive to detect changes in 
response to HIIT in trained vs. untrained participants.  
 
Collectively, the current literature suggests that LT2 is capable of adapting to short-
term (7 days) and long-term (1 year) HIIT interventions in trained cyclists. However 
gaps in the literature remain, such as: (1) whether LT2 adaptations to HIIT are the 
same for endurance-trained men and women, and with different LT2 determination 
methods; (2) whether the more commonly reported intervention lengths of 4-6 weeks 
(which has shown performance improvements and other physiological adaptations 
(Table 2.13) are capable of influencing LT2; and (3) whether changes in LT2 are 
related to changes in performance. These findings will help to establish the 
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sensitivity of LT2 as an endurance performance indicator, and determine whether 
peripheral mechanisms related to LT2 are capable of explaining performance 
adaptations in response to HIIT, in both men and women.   
  
2.5.5 HIIT Protocols 
The acute training variables such as the number, duration and intensity of interval 
and recovery bouts coupled with the frequency of sessions per week and number of 
weeks where any one program is implemented, have varied considerably across 
HIIT studies, with those involving well-trained cyclists reported in Table 2.13. In a 
recent review of the available evidence, Buchheit and Laursen [27] suggested that for 
well-trained endurance athletes to induce maximal cardiovascular and peripheral 
adaptations the time spent at intensities ≥ 90% V̇O2max is critical. They have also 
suggested that V̇O2max can be reached between 80 and 140 s (when intervals are 
repeated), irrespective of training status and exercise mode and that an accumulated 
high intensity (≥ 90% V̇O2max) exercise time of 10 min per session is ideal to 
maximise adaptations to training [27]. These findings are in close agreement with an 
earlier review reporting that the aerobic energy system is dominant in energy 
production during intense exercise periods lasting longer than 75 s [255]. This 
statement arose due to findings suggesting that 75 s [256] and 600 m in near-maximal 
running [257-259] reflects the crossover point where aerobic and anaerobic energy 
contributes equally. Based on these findings, maximising time at or near V̇O2max by 
implementing intervals between 80 and 140 s, will have the greatest potential to 
improve measures of aerobic (and to a slightly lesser extent anaerobic) performance 
in aerobically-trained endurance athletes. Prescribing a work/ relief ratio of > 1 has 
been suggested to enhance the adaptations in well-trained athletes due to the 
greater exercise time at V̇O2max/ exercise time ratio [27]. As seen in Table 2.13, a 
number of researchers have shown physiological and performance improvements by 
utilising some or all of these training variables. 
 
2.5.6 Summary 
Collectively, there is strong evidence surrounding the benefits associated with HIIT in 
individuals of various training statuses, including trained endurance athletes. As 
discussed, various physiological improvements have also been noted, with many 
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more that remain out of the scope of this thesis. Furthermore, consistently significant 
improvements in performance (2-20%) in response to 4 - 12 HIIT sessions have 
been reported in endurance-trained men, however the underlying mechanisms 
explaining these improvements are unclear.  
 
There is a large body of literature reporting the effects of HIIT on changes in V̇O2max 
with the weight of evidence suggesting that this variable is resistant to acute HIIT 
interventions in trained athletes. Researchers supporting the contrary have either 
derived their findings indirectly, through the measurement of variables other than 
V̇O2max itself, or have shown that the change in variables other than V̇O2max 
produced stronger relationships with performance improvements.  
 
Given the strong relationships consistently shown (and discussed in earlier sections 
of this thesis) between LT2 and endurance performance, further investigations into 
adaptations of LT2 in response to HIIT are warranted. These findings will allow 
recommendations surrounding the effectiveness of various HIIT programs and the 
timing of an acute HIIT block for optimising LT2 and subsequence performance to be 
made. The extent to which changes in performance are related to changes in LT2 is 
not well understood, and should be addressed in future research. This will provide 
valuable knowledge on the contribution of LT2 adaptations to performance 
improvements, and inform best-practice exercise testing. 
 
Furthermore, females are significantly under-reported in the HIIT literature, with no 
published studies available investigating the influence of HIIT on physiological or 
performance outcomes in endurance-trained female athletes. Research surrounding 
female athletes will be discussed in subsequent sections of this thesis. 
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Table 2.13. A summary of HIIT studies in well-trained cyclists. 
 
Study Participants Number of 
weeks/ 
sessions 
Training protocol Physiological adaptations Performance adaptations 
Lindsay et 
al. [32] 
Males (n = 12) ~ 4 (6 
sessions) 
6 - 8 x 5 min at 80% peak PO, 60 
s recovery 
↑ peak PO (absolute; 8%; p < 0.01 and 
relative; 4%; p < 0.06) 
↓ 40 km cycle TT time (4%; 
p < 0.01); 
↑ time to fatigue at 150% peak PO 
(20%; p < 0.01) 
Westgarth-
Taylor et al. 
[37] 
Males (n = 8) 6-7 (12 
sessions) 
6 - 9 x 5 min at 80% peak PO, 60 
s recovery (passive or active ≤ 
100 W) 
↑ peak PO (5%; p < 0.01); 
CHO oxidation (↓ at same absolute 
intensity; p < 0.05; no change at same 
relative intensity); 
↑ fat oxidation at same absolute intensity 
(28 - 100%; p < 0.05); 
Plasma [La] (↓ at same absolute intensity 
(23 - 42%; p < 0.05); no change at same 
relative intensity); 
Plasma glucose (no change) 
↓ 40 km cycle TT time (2.5%; p < 
0.05); 
∆ peak PO not correlated with ∆ 
TT time 
Weston et al. 
[38] 
Males (n = 6) 4 (6 
sessions) 
6 - 8 x 5 min at 80% peak PO, 60 
s recovery at 100 W 
↑ peak PO (3.5%; p < 0.05); 
PFK activity (no change); 
HK activity (no change); 
3-HAD activity (no change); 
CS activity (no change); 
↑ buffering capacity (16%; p < 0.05) 
↑ time to fatigue at 150% peak PO 
(22%; p < 0.05); 
↓ 40 km cycle TT time (2.2%; p < 
0.05); 
∆ buffering capacity related to ∆ 
TT time (r = -0.74; not quite 
significant; p value not reported) 
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Stepto et al. 
[33] 
Males (n = 19) 3 (6 
sessions) 
5 training groups: 
G1) 12 x 30 s at 175% peak PO, 
4.5 min recovery (n = 4); 
G2) 12 x 1 min at 100% peak PO, 
4 min recovery (n = 3); 
G3) 12 x 2 min at 90% peak PO, 
3 min recovery (n = 4); 
G4) 8 x 4 min at 85% peak PO, 
1.5 min recovery (n = 4); 
G5) 4 x 8 min at 80% peak PO, 1 
min recovery; (n = 4). 
Recovery = 100 W 
CHO oxidation (no change); 
Plasma [La-] (no change); 
Heart rate (no change); 
Peak PO increased maximally (~4%) in G4. 
 
↓ 40 km cycle TT time in group 4 
(2.8%; CI = 4.3 - 1.3%) and group 
1 (2.4%; CI = 4.0 - 0.7%); 
%∆ peak PO not related to %∆ in 
TT time; 
%∆ sustainable peak PO related 
to ∆ TT time (r = -0.92; p < 0.01); 
Training intensity related to ∆ TT 
time (max enhancement (~2.5%) 
predicted with 3 - 6 min bouts at 
85% peak PO) 
Laursen, 
Blanchard 
and Jenkins 
[71] 
Males (n = 14) 2 (4 
sessions) 
20 x 60 s at peak PO, 120 s 
recovery 
V̇O2peak (no change); 
↑ VT1 (22%; p < 0.05); 
↑ VT2 (15%; p < 0.05); 
Heart rate at VT1 (no change); 
Heart rate at VT2 (no change); 
↑ peak PO (4.3%; p < 0.05) 
↑ time to fatigue (time at peak PO 
after 20th interval) from session 1 
to session 4 (p < 0.05); 
∆ time to fatigue related to ∆ RER 
(r = -0.94; p < 0.01) 
Laursen et 
al. [34] 
Males (n = 41) 4 (8 
sessions) 
3 training groups: 
G1) 8 x 60% Tmax at peak PO, 
120% Tmax recovery duration 
G2) 8 x 60% Tmax at peak PO, 
recovery until 65% maximum 
heart rate achieved 
G3) 12 x 30 s at 175% PO, 4.5 
min recovery duration 
↑ V̇O2peak (G1: 5.2%, G2: 8.0%; p < 0.01, 
G3: 3.0%; p < 0.05); 
↑ peak PO (G1: 5%; p < 0.01, G2: 6%; p < 
0.01, G3: 3%; p < 0.05); 
↑ peak power output (3-6.2%; p < 0.05) 
Time to fatigue at peak PO (no 
change); 
↑ work during time to fatigue at 
peak PO (G1; p < 0.05); 
↑ 40 km cycle TT speed (G1: 5%; 
p < 0.01, G2: 6%; p < 0.01, G3: 
4%; p < 0.05) 
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Laursen et 
al. [36] 
Males (n = 41) 4 (8 
sessions) 
3 training groups: 
G1) 8 x 60% Tmax at peak PO, 
120% Tmax recovery duration 
G2) 8 x 60% Tmax at peak PO, 
recovery until 65% maximum 
heart rate achieved 
G3) 12 x 30 s at 175% peak PO, 
4.5 min recovery duration 
Plasma volume (no change); 
↑ Anaerobic capacity (G1: 104.5%, G2: 
54.4%; p < 0.05, G3: 75.3%; p < 0.01); 
↑ V̇O2peak (G1: 5.4%, G2: 8.1%; p < 0.01, 
G3: 3.8%; ns); 
↑ VT1 (G1: 15.1%, G2: 21.4%, G3: 16.8%; p 
< 0.01); 
↑ VT2 (G1: 15.7%, G2: 15.4%, G3: 8.6%; p 
< 0.01) 
↑ 40 km cycle TT speed (G1: 5%; 
p < 0.01, G2: 6%; p < 0.01, G3: 
4%; p < 0.05); 
↑ mean TT heart rate (all groups; 
p < 0.05); 
↑ mean [La-] (G1; p < 0.05) 
↑ mean V̇O2 (G1, G2; p < 0.05, 
G3; p < 0.01); 
RER (no change); 
∆ TT performance related to ∆ TT 
V̇O2 (r = 0.53; p < 0.01), ∆ TT [La-] 
(r = 0.43; p < 0.01), ∆ TT heart 
rate (r = 0.42; p < 0.01), ∆VT2 (r = 
0.42; p < 0.01), ∆V̇O2peak (r = 
0.41; p < 0.05);  anaerobic 
capacity (r = 0.40; p < 0.05) 
Swart et al. 
[35] 
Males (n = 17) 4 (8 
sessions) 
2 training groups: 
1) Training by heart rate: 
8 x 4 min at heart rate eliciting 
80% peak PO, 90 s self-paced 
recovery; 
2) Training by PO: 
8 x 4 min at 80% peak PO, 90 s 
self-paced recovery  
V̇O2max (no change) 
 
↓ 40 km cycle TT time (power 
group: 2.3%; p < 0.01, heart rate 
group: 2.1%; p < 0.01); 
↑ relative peak PO (power group: 
3.5%; p < 0.05, heart rate group: 
5.0%; p < 0.01) 
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Storen et al. 
[40] 
Male case study 
(n = 1) 
1 year (29 
running 
sessions in 
total, 
separated by 
cycling 
sessions) 
Uphill running on a treadmill; 4 x 4 
min at 90 - 95% maximum heart 
rate (3 min jogging recovery at 
70% maximum heart rate) 
2 blocks; 
November 2010: 14 HIIT sessions 
in 9 days 
January 2011: 15 HIIT sessions in 
10 days 
Between blocks, cycling HIIT; 
3 per week 
↑ V̇O2max (absolute: 8.7%; p value not 
reported, relative: 10.5%; p value not 
reported); 
↑ [La-] at V̇O2max (15.2%; p value not 
reported);  
↑ PO at V̇O2max (15.5%; p value not 
reported);   
↑ PO at LT2 (14.0%; p value not reported);  
↑ LT2 as %V̇O2max (5.2%; p value not 
reported) 
↓ 15 km cycle TT time 
(representative of 23 km on the 
road; 14.9%; p value not 
reported); 
↑ mean [La-] during TT (17.2%; p 
value not reported) 
Extebarria et 
al. [30] 
Moderately-
trained males 
(V̇O2peak 58.7 ± 
8.1 
mL·kg−1·min−1; n 
= 14) 
3 (6 
sessions) 
2 training groups: 
SHORT: 
Week 1: 3 reps (10, 20 and 40 s) 
at max, 1:3 work/recovery ratio, 2 
x 3 reps with 1:2; 
Week 2: As above, with extra set 
of 1:3 
Week 3: As for week 2, with extra 
set of 1:2; 
LONG: 
Week 1: 6 x 5 min at 80% 
V̇O2peak PO, 1 min recovery; 
Week 2: 7 x 5 min; 
Week 3: 8 x 5 min 
Small ↑ maximal aerobic power (3.1 ± 3.8%, 
LONG: 5.8 ± 2.1%); 
Small ↑ V̇O2peak (SHORT: 7.3 ± 4.6%, 
LONG: 7.5 ± 1.7%) 
 
1 h variable power cycle (same 
absolute PO pre and post) and a 
subsequent 5 km running TT 
(trivial ↑ in SHORT; 2.8 ± 3.1%, 
small ↑ in LONG; 4.9 ± 4.7%) 
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Clark et al. 
[39] 
Males (n = 30) 7 sessions in 
7 days 
Control group 
2 training groups: 
SHORT: 
25 x (5, 10, 20 s each with work: 
rest ratio of 1:5) 
LONG: 
10 x (15, 30, 45 s each with work: 
rest ratio of 1:5) 
Intensity = highest possible (self-
selected) 
Recovery = 30-40% peak PO 
↑ peak PO (3.6 ± 3.0% (ES 0.57); p < 0.01) 
and OBLA (3.6 ± 3.5% (ES 0.47); p < 0.05) 
in SHORT vs. control; 
↑ peak PO (7.6 ± 2.3% (ES 0.76); p < 0.01) 
and OBLA (2.9 ± 5.3% (ES 0.24); p < 0.05) 
in LONG vs. control; 
↑ peak PO (7.6 ± 2.3% (ES 0.76)) in LONG 
vs. SHORT (3.6 ± 3.0% (ES 0.57); p < 
0.05); 
Small ↑ in V̇O2peak (SHORT: 2.3 ± 4.8% 
(ES 0.27), LONG: 3.5 ± 6.2% (ES 0.34)); 
Small ↑ in OBLA (SHORT: 3.6 ± 3.5% (ES 
0.47), LONG: 2.9 ± 5.3% ES 0.24)); 
↑ in exercise economy (SHORT: 3.9 ± 2.8% 
(ES 0.64), LONG: 4.6 ± 3.5% (ES 0.84)); 
↑ in gross efficiency (SHORT: 3.2 ± 2.4% 
(ES 0.53), LONG: 5.1 ± 3.9% (ES 1.02)) – 
tendency for greater improvement in LONG 
than SHORT 
↓ 20 km cycle TT time (-2.9 ± 
2.6% (ES 0.59); p < 0.01) and ↑ 
20 km cycle TT PO (64.6 ± 4.4% 
(ES 0.51); (p = 0.06)) in SHORT 
vs. control; 
↓ 20 km cycle TT time (-4.4 ± 
3.7% (ES 0.74); p < 0.01)) and ↑ 
20 km cycle TT PO (6.8 ± 5.8% 
(ES 0.63); p < 0.01) in LONG vs. 
control; 
No differences in 20 km TT time 
or power output between SHORT 
and LONG. 
PO: power output; V̇O2: oxygen uptake; V̇O2max: maximal oxygen uptake; V̇O2peak: peak oxygen uptake; ∆: change in; RER: respiratory exchange ratio; 
PFK: phosphofructokinase; HK: hexokinase; 3-HAD activity: 3-hydroxyacyl-CoA dehydrogenase; CS: citrate synthase; VT1: first ventilatory threshold; VT2: 
second ventilatory threshold; [La-]: lactate concentration; LT2: second lactate threshold; ↑: increase; ↓: decrease; CHO: carbohydrate; OBLA: onset of blood 
lactate accumulation; ES: effect size; h: hour; min: minute; s: second; Tmax: time to exhaustion at V̇O2peak power output; TT: time trial. 
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2.6 Summary 
This review highlighted that although V̇O2max is an important physiological variable 
since it sets the upper limit for aerobic metabolism, its capacity to predict endurance 
performance is limited to previously untrained individuals. In endurance-trained 
athletes, LT2 has been more strongly associated with endurance performance. 
However, there are numerous methods of LT2 detection, each with their own 
strengths and weaknesses. For LT2 methods to be considered valid, it has been 
suggested that strong associations with simulated endurance performance and 
MLSS are required. In Australia, the modified D-max method is utilised to determine 
LT2 by the state institutes and academies of sport, and it forms part of the Australian 
Triathlon Testing Protocol. However, research to support its capacity to assess 
endurance capacity is limited in comparison to other methods. Of specific importance 
is its capacity to rank performance potential (to assess effectiveness of a training 
program), establish an exercise intensity sustainable over 40 km (specific to 
Olympic-distance triathlon; to set performance intensities), and to establish an 
exercise intensity sustainable for ~30 min (indicative of MLSS which is valuable for 
intensity prescription of endurance training). 
 
Additionally, this review highlighted evidence of a sex bias towards men in sport and 
exercise medicine research. However, it also highlighted the potential influence of 
female ovarian hormones on physiology and performance-related outcomes, and 
therefore, the need to consider their control and verification when recruiting women. 
Research to date has not placed tight control on ovarian hormones, and therefore 
female-specific responses to exercise and training, and comparisons to men (albeit 
limited) are flawed and warrant future investigation. Research on HIIT as a method 
of improving endurance performance in trained endurance athletes has been well-
documented, however less is known about the association between changes in 
physiological variables and changes in performance, and therefore, which variable(s) 
may explain these HIIT-related performance improvements, in both men and women. 
137 
 
CHAPTER THREE 
 
Relationships between laboratory-derived data and 
cycling performance in endurance-trained men: 
Experimental study one 
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3.1 Abstract 
In Australia, the state institutes and academies of sport currently utilise the modified 
D-max method to determine LT2 [15]. However, it is unknown whether LT2 determined 
by this method is related to, or predictive of, endurance performance in trained men, 
or whether it establishes a valid exercise intensity for use in training and competition. 
Therefore, the objectives of this study were to: (1) examine the relationships 
between, and the predictive capacity of, the modified D-max LT2 and other 
laboratory-measured variables (V̇O2max and peak power output), and 40 km cycling 
time trial performance in trained cyclists and triathletes. A secondary objective was 
to establish the validity of the modified D-max LT2 by: (1) comparing it to VT2, and (2) 
investigating whether 30 min of exercise at LT2 power output (a) was maintainable; 
(b) corresponded to a steady state [La-]; and (c) elicited similar physiological 
responses to those produced during a 40 km cycle time trial. 
 
Ten competitive male cyclists and triathletes (V̇O2max 59.7 ± 5.2 mL·kg·min-1; mean 
± SD) completed an incremental cycle trial to volitional fatigue, a 30 min constant 
load trial at LT2 power output, and a 40 km cycle time trial. Results showed five 
maximal variables and three LT2 variables were significantly correlated with time trial 
performance, and the strongest determination of time trial performance resulted 
when combining three maximal and three LT2 variables (r2 = 0.95; p < 0.05). LT2 and 
VT2 were comparable, since power outputs at LT2 and VT2 were significantly 
correlated, and not significantly different. Only 50% of constant load trials were 
successfully completed at LT2 power output with a steady-state [La-]. On average, 
there were no significant differences among variables elicited at LT2, during constant 
load exercise or during the 40 km time trial. In conclusion, although LT2 as 
determined by the modified D-max method is recommended for determining the 
power output, heart rate, V̇O2 and [La-] maintainable during 40 km cycling 
performance in endurance-trained men, its relationship with endurance performance 
is only modest. The strongest determination of performance resulted when 
combining both maximal and LT2 variables. 
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3.2 Introduction 
Endurance performance capacity has long been associated with V̇O2max, both in 
relatively untrained populations and heterogeneous groups [47, 260]. For example, 
strong relationships have been demonstrated between V̇O2max and 10 mile running 
time (r = -0.91; p < 0.01) in men with a wide range of V̇O2max values (54.8 to 81.6 
mL·kg-1·min-1; n = 16) [260] and between V̇O2max and ~30 min cycling performance 
(r = 0.89; p < 0.01) in untrained men (n = 24) [47]. However, compared to untrained or 
heterogeneous groups, V̇O2max provides little insight into the current performance 
status of well-trained endurance athletes, since their V̇O2max values change 
minimally over time, regardless of whether periods of training [71, 254] or rest/taper 
were adopted [261, 262]. Furthermore, numerous endurance training studies involving 
well-trained endurance athletes have reported no change in V̇O2max after training, 
despite improvements in 40 km cycling performance (3.7% [32], 2.4% [37], 2.1% [38] 
and 2.4 - 2.8% [33]), further questioning the importance of this variable as a measure 
sensitive to detect training-induced changes in this population.  
 
Evidence suggests submaximal blood lactate and ventilatory measures derived 
during incremental exercise to fatigue produce stronger correlations with endurance 
performance in trained endurance athletes compared to V̇O2max [69, 76]. Over many 
years, these measures have been used to establish the highest percentage of 
V̇O2max an athlete is able to sustain for extended periods of time, with examples 
including cycling power output, running speed, heart rate, [La-] or V̇O2 reflective of 
LT2 or VT2. Numerous methods of LT2 determination have been investigated in the 
literature; some of these include OBLA [93], IAT [93], D-max [10, 17], modified D-max [10, 
17], and MLSS [126, 127]. These threshold measures have also been shown to reflect 
the power output, speed and physiological responses including heart rate and/ or 
[La-] sustained during 30 min [18] and 40 km [93, 127] cycling performances, and 8 km 
[125] and 10 km [177, 178] running performances in trained men. For LT concepts to be 
considered valid, it has been suggested that strong associations with endurance 
performance, and with MLSS (in view of its value in prescribing endurance training 
intensity) are required [19]. The MLSS has been reported to reflect the highest 
sustainable rate of aerobic metabolism (known as ‘critical power’) [119, 120] and has 
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consistently been found to predict endurance performance [19, 121, 122]. Of the LT2 
methods mentioned above, none have shown consistently strong associations with 
MLSS. The comparison of power output at OBLA with power output at MLSS has 
shown both large individual differences [115] and significant mean differences [263] [150]. 
Research comparing the IAT and MLSS is inconsistent, with some [161] but not all [160, 
165] showing agreement between work rates at IAT and work rates at MLSS. 
Furthermore, MLSS determination methods were inconsistent so comparing between 
studies was not possible. The D-max was reported as not sufficiently precise to 
determine MLSS heart rate and MLSS power output in elite cyclists [112] despite 
showing a high concordance with MLSS power output in a sample heterogeneous in 
their exercise capacity [263], whilst the association between MLSS and the modified 
D-max has not yet been examined. 
 
In Australia, the state institutes and academies of sport currently utilise the modified 
D-max method to determine LT2. As described in section 2.2.4.1, the modified D-
max method is defined as the point on the intensity-[La-] polynomial regression curve 
that yields the maximal perpendicular distance to the straight line formed by LT1 (the 
point preceding the first 0.4 mmol·L-1 rise in [La-]), and the final lactate point [10]. 
However, data on the usefulness of the modified D-max for performance and training 
are lacking. To date, three studies have investigated the relationship between the 
modified D-max LT2 and endurance performance. Strong relationships were found 
between the modified D-max LT2 and 30-min cycling time trial performance in well-
trained veteran cyclists (n = 8 men and 1 woman) [18] and 1 h cycling performance in 
trained female cyclists and triathletes (n = 24 [10] and n = 12 [17], respectively). 
However, further investigation into the modified D-max method for use by coaches 
and sports scientists to predict endurance performance and establish competition 
intensities is warranted, since it remains unknown whether the modified D-max LT2 is 
also strongly correlated with endurance performance in endurance-trained younger 
men; a population for which this method is currently used. Furthermore, comparing 
the capacity of the modified D-max LT2 to correlate with endurance performance 
alone, and in combination with other laboratory-measured variables examined by the 
National Triathlon Testing Protocol such as V̇O2max and peak power output will 
provide further verification on the relevance of this measure in elite athletes. 
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Examining these relationships is necessary if accurate and efficient monitoring of 
athletes is to occur; small performance changes need to be detectable in order to 
evaluate the effectiveness of a training block. 
 
Additionally, knowledge is limited on the capacity of the modified D-max LT2 to 
identify a sustainable power output during endurance trials, and thus, its potential for 
establishing training and competition intensities. Although the original D-max method 
reported LT2 as sustainable for endurance trials of approximately 60 min[10], the 
modified D-max appears to be more consistent with the power output produced 
during a trial of ≤ 30 min (-2.4%)[18] than 60 min (+16%)[10]. Furthermore, its 
comparability to VT2 in cycling, and its capacity to establish performance potential 
and an exercise intensity that is sustainable over 40 km (specific to Olympic-distance 
triathlon) in young, endurance-trained men is unknown. Since this method has been 
implemented nationally (and internationally) without investigation into its efficacy, 
further research is warranted.  
  
The primary objective of this study was to examine the relationships between, and 
the predictive capacity of, the modified D-max LT2 and other laboratory-measured 
variables (V̇O2max and peak power output), and 40 km cycling time trial 
performance in trained cyclists and triathletes. A secondary objective was to 
establish the validity of the modified D-max LT2 by: (1) comparing it to VT2, and (2) 
investigating whether 30 min of exercise at LT2 power output (a) was maintainable; 
(b) corresponded to a steady state [La-]; and (c) elicited similar power outputs and 
physiological responses (heart rate, [La-] and V̇O2) to those produced during a 40 km 
cycle time trial. The primary hypothesis was that the modified D-max LT2 would be 
significantly related to 40 km cycle time trial performance and comparable to VT2. 
Furthermore, it was hypothesised that 30 min of exercise at the modified D-max 
power output would be maintainable, produce a steady state [La-] and elicit similar 
physiological responses to those produced during a 40 km cycle time trial in trained 
cyclists and triathletes.  
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3.3 Methods  
3.3.1 Experimental Overview 
Participants reported to the Human Performance Laboratory of the School of Human 
Movement and Nutrition Sciences at The University of Queensland on five 
occasions, each separated by a minimum of 48 h. The five trials completed were: (1) 
an incremental cycle trial for familiarisation; (2) a 20 km cycle time trial for 
familiarisation; (3) an incremental cycle trial (‘V̇O2max’) (for determination of 
V̇O2max, LT2 and VT2); (4) a constant load exercise trial of 30 min duration at the 
power output that elicited LT2 and (5) a 40 km cycle time trial. With the exception of 
the constant load trial, the order of the two familiarisation trials, and the order of the 
three investigative trials were randomised; the constant load trial was completed by 
participants after the incremental trial due to the necessary load calculation (power 
output eliciting LT2). A schematic overview of the experimental period is presented in 
Figure 3.1. The first familiarisation trial was immediately preceded by a self-selected 
warm-up. Details of this warm-up including duration, intensity, heart rate and rating 
of perceived exertion were recorded and replicated in all subsequent trials. All trials 
were conducted on an air- and mechanically-braked cycle ergometer (Wattbike Ltd, 
Nottingham, UK) modified with clip-in pedals for each participant’s cleated cycle 
shoes; the set-up was individualised for each participant, recorded, and repeated for 
subsequent trials. Heart rate was recorded during all trials (Suunto t6c, Suunto Oy, 
Vantaa, Finland). Each participant completed their trials at a similar time of the day in 
controlled environmental conditions (temperature 23.1 ± 1.4 °C, relative humidity 
56.4 ± 10.8% and barometric pressure 768.5 ± 4.1 mm Hg). Dietary and training 
controls were put in place (section 3.3.4); all participants agreed to these as part of 
the consent procedure. 
 
3.3.2 Participants 
Based on other studies examining performance predictors [95, 264, 265] and the validity 
of various LT2 methodology [17, 78, 103, 141] in trained endurance athletes (n = 6-12), the 
target sample size for the present study was n = 10. A sample size calculation for 
multiple regression analysis indicated that to detect an r2 = 0.95 with five predictor 
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variables, alpha = 0.05 and power = 80%, nine participants would be required [266]. 
Participants were recruited through word of mouth and email advertisements sent to 
local cycling and triathlon clubs and distributed through family and friends involved in 
cycling and triathlon. Inclusion criteria were: (1) male; (2) aged 18-35 years 
(inclusive); (3) trained to well-trained (according to previously-described criteria 
relating to training and race status [4]); and (4) satisfactory self-described health 
status. Exclusion criteria were: (1) self-report of cardiovascular disease; (2) any 
disease state/contraindication that may be affected by exercise; (3) any current injury 
or disease state that may affect participation; and (4) heart conduction defect(s) 
treated with an implantable pacemaker, defibrillator or any other implantable device 
such as a nerve stimulator and/or medication. Participants were informed of the risks 
of the study, completed a medical history questionnaire and provided their written 
informed consent. The investigation was approved by the Medical Research Ethics 
Committee of The University of Queensland (approval number HMS10/2106). 
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V̇O2max: Maximal incremental trial to determine maximal oxygen uptake; Constant load: Trial of a maximum of 30 min duration at 
the power output corresponding with LT2, as determined from the V̇O2max test. 
* The constant load trial was always performed following the V̇O2max trial due to the necessary load calculation (i.e. LT2 power 
output).  
 
 
Figure 3.1. Overview of the experimental protocol. 
Randomised trials; V̇O2max and 40 km time trial 
Randomised trials; V̇O2max, constant load* and 40 km time trial 
48 h 48 h 48 h 48 h
Familiarisation Investigative trials 
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3.3.3 Familiarisation Trials 
The familiarisation trials involved a maximal incremental test to fatigue and a 20 km 
time trial. Body mass was measured on a calibrated scale with a precision of ±0.02 
kg (A and D Co., Tokyo, Japan) prior to the first familiarisation trial for the calculation 
of the pre-trial meal quantities. The V̇O2max trial began with an initial work rate of 
100 W, which increased by 50 W every 5 min until volitional exhaustion. Participants 
were provided with visual feedback on their power output from a monitor mounted to 
the front of the cycle ergometer, and the resistance was self-selected to enable 
maintenance of 90-105 revolutions per min (rpm) cadence. When the cadence was 
faster or slower than 90-105 rpm, participants would increase or decrease the 
resistance, respectively. Verbal feedback was provided if the required power output 
was too high or began to fall and the test was terminated when participants could no 
longer maintain the required power output. 
 
Gas exchange variables (V̇O2 and carbon dioxide production (V̇CO2)) were 
measured continuously during the V̇O2max trial to familiarise participants with the 
mouthpiece and headset. Expired air was analysed for FEO2 and FECO2 every 30 
sec during exercise (Ametek SOV S-3A/1 and COV CD3A, Pittsburgh, PA) from a 
mixing chamber, minute ventilation (VE) was recorded every 30 sec using a turbine 
ventilometer (Morgan, Model 096, Kent, UK) and heart rate was recorded every 60 
sec. The gas analysers were calibrated immediately prior to testing and verified after 
each test using a certified beta gas mixture (80.08% N, 15.94% O2, 3.98% CO2; 
Commonwealth Industrial Gas Ltd., Brisbane, Australia). The volume turbine sensor 
was calibrated using a 3 L syringe.  
 
The 20 km time trial was included to familiarise participants with the cycle ergometer 
and the testing procedures. A 40 km time trial was not implemented for 
familiarisation because: (1) pacing research indicates that an even distribution of 
work rate is optimal for all time trials lasting longer than 10 min [267]; therefore, 
different pacing strategies for 20 and 40 km were not expected; and (2) all of the 
participants were cyclists and triathletes were already familiar with cycling for 40 km. 
Consequently, importance was placed on familiarisation with the equipment rather 
than the distance. The only instruction provided to the participants was to finish the 
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20 km in the shortest possible time. Finger-tip capillary blood was sampled after 10 
km and gas exchange data were collected from 8-10 km; both procedures were 
performed to familiarise participants with the test conditions. Participants were able 
to view the distance remaining, speed, heart rate and cadence on a monitor mounted 
to the front of the cycle ergometer for the entire duration of the time trial. 
 
3.3.4 Diet and Exercise Control 
3.3.4.1 Dietary Intake 
Prior to all trials, participants were asked to maintain a hydrated state and avoid 
consuming alcohol for 24 h, as well as avoid consuming caffeine within 6 h of 
beginning each trial. For 24 h before the first trial, participants were asked consume 
a high-carbohydrate diet and record all foods and beverages consumed; this diet 
was replicated as closely as possible in subsequent trials. A standardised pre-
exercise meal (1.2 ± 0.1 g·kg-1 CHO) consisting of multigrain bread with butter and 
honey, a muesli bar (Uncle Toby’s® Chewy; Nestlé, Sydney, Australia) and sports 
drink (Staminade®; Steric Trading Pty Ltd, Sydney, Australia) was consumed within 
2.5 h (± 0.5 h) prior to exercise. This pre-exercise meal timeframe is in accordance 
with guidelines (i.e. consume a high carbohydrate meal 3 - 4 h prior to exercise and 
a high carbohydrate snack 1-2 h prior to exercise) [268]. Upon arrival at the laboratory, 
participants completed a pre-trial checklist confirming their compliance with these 
pre-trial conditions. All foods and beverages recorded in the 24 h food diary were 
entered into FoodWorks© Nutrition Software (FoodWorks© Professional 7, Xyris 
Software, Australia, Pty Ltd) and analysed for total weight, energy, carbohydrate, 
protein and fat content. Participants were asked to maintain their usual diet 
throughout the duration of the study, with the exception of pre-trial and trial days. 
 
3.3.4.2 Exercise 
In the 24 h period prior to all investigative trials, participants were asked to avoid all 
vigorous or higher intensity exercise (defined as ≥70% maximum heart rate, ≥60% 
V̇O2max and rating of perceived exertion (RPE) ≥ 14 out of 20) [269]. Participants 
completed a training log detailing the volume and intensity of their training; training 
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diaries were completed and checked upon arrival at the laboratory to ensure 
compliance (Appendix 3.1). 
 
3.3.5 Investigative Trials 
3.3.5.1 V̇O2max  
The procedures used in the V̇O2max trial were identical to those described above for 
the V̇O2max familiarisation trial, with the addition of finger-tip capillary blood 
sampling. Oxygen uptake was calculated by averaging the 30 sec readings recorded 
during the final two minutes of each work rate for use in the modified D-max 
calculation. Whilst there are suggested criteria involving the RER, RPE and heart 
rate measurements for establishing whether V̇O2max is achieved [270], given the well-
trained status of the participants and their familiarity with maximal exercise, V̇O2max 
was calculated as the average of the two highest consecutive V̇O2 readings (as per 
the National Triathlon Testing Protocol). Finger-tip capillary blood (25 μL) was 
sampled pre-warm-up and during the last 30 sec of each 5 min stage for the later 
analysis of plasma [La-]; RPE was recorded in the final 15 sec of each stage. LT2 
was determined by the modified D-max method, as described in section 3.2, in a 
custom-built spreadsheet (Microsoft Excel, 2013). Peak power output was calculated 
as the power output from the last completed stage of the incremental exercise test, 
plus the fraction of time spent in the next stage [i.e. time (min) completed / 5 min] 
multiplied by 50 W; this method has been used previously [271, 272]. Peak power 
output was also expressed relative to body mass (W·kg-1) and relative to body mass 
adjusted to the power of 0.32 (allometrically-scaled peak power output; W·kg-0.32); 
both of which have been used previously [4, 273]. Determination of VT2 was made 
using the ventilatory equivalent of O2 method (VE/V̇O2; both L·min-1); the power 
output corresponding with a systematic increase in VE/V̇O2 without a concomitant 
increase in the ventilatory equivalent of CO2[274]. Previously, VE/V̇O2 has been 
reported as highly reliable and consistently able to accurately predict mean 40 km 
cycling time trial power output across a competitive season [91]. Detection of VT2 was 
made by visual inspection by two investigators independently (SMH and TLS) and in 
the case of a disagreement, a third investigator (DGJ).  
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3.3.5.2 30 min constant load trial 
Participants completed a 30 min maximum duration trial at the power output 
corresponding with their LT2, as determined from the incremental test. Participants 
were able to view the time, power output, heart rate and cadence on a monitor 
mounted to the front of the cycle ergometer for the entire duration of the constant 
load trial. Finger-tip capillary blood was sampled pre-warm-up and every 10 min 
during exercise for the later analysis of plasma [La-]. Expired air was analysed at 
9-10 min, 19-20 min and 29-30 min according to the procedures outlined in section 
3.3.3, while heart rate was recorded every 1 min. When participants were unable to 
maintain the required power output (± 5%) at any time during the 30 min period, 
verbal encouragement and warning that the power output was insufficient or too 
high, was provided. When the required power output was unable to be maintained 
after these verbal cues, participants ceased exercising and their total duration was 
recorded. For the trial to be considered ‘steady state’, the power output was required 
to be maintained for 30 min (± 5%) and plasma [La-] to increase no more than 
1 mmol·L-1 between 10 and 30 min. Although no criteria of power output control has 
previously been reported, the steady-state [La-] criteria has been used consistently to 
establish MLSS [105, 112, 125, 127].  
 
3.3.5.3 40 km time trial 
Participants were required to cycle 40 km as quickly as possible at a self-selected 
work rate and cadence. Average power output, elapsed time and heart rate were 
recorded every 1 km throughout the trial. Finger-tip capillary blood was sampled pre-
warm-up and every 10 km throughout the trial for the later analysis of plasma [La-]. 
Expired air was analysed at 8-10 km, 18-20 km, 28-30 km and 37-39 km according 
to the procedures outlined in section 3.3.3. Participants viewed the distance 
remaining, speed, heart rate and cadence on a monitor mounted to the front of the 
cycle for the entire duration of the time trial. 
 
3.3.6 Blood Sampling, Storage and Analysis 
Finger-tip capillary blood (25 μL) was collected into capillary sampling tubes 
(Microvette CB300 Sarstedt, Numbrecht, Germany) containing heparin and fluoride 
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as a glycolysis inhibitor. Samples were stored on ice for < 1 h before centrifugation at 
6500 x g at 30°C for 5 min. The plasma supernatant was removed and stored in 
single aliquots in polypropylene microcentrifuge tubes at -80°C until later analysis of 
plasma [La-]. When necessary (details below), finger-tip capillary blood (5 μL) was 
collected for the immediate analysis of whole blood [La-] (Lactate-Pro, ARKRAY Inc., 
Kyoto, Japan). 
 
Plasma samples were allowed to thaw at room temperature and mixed with a Vortex 
mixer (Vortex Genie 2, Scientific Industries, NY, USA) prior to processing. Plasma 
[La-] was analysed using a Cobas Integra clinical autoanalyser (Lactate Gen 2; 
n = 58) or by hand with a Unicam 5625 UV/VIS Spectrometer when insufficient 
sample volume was available for the autoanalyser (n = 278). Both analysers involved 
the use of a modified Trinder reagent [275] as applied to lactate measurement [276]. 
The coefficient of variation (CV) in this laboratory for the Cobas is 4.1% and the 
Spectrometer is 2.8% (n = 10; average [La-]: zone 1: 2.9 and 3.4 mmol·L-1; zone 2: 
7.5 and 8.6 mmol·L-1; and zone 3: 12.9 and 16.8 mmol·L-1 for the Cobas and 
Spectrometer, respectively). However, the agreement between analysers was poor 
with the Spectrometer producing a significantly higher [La-] than the Cobas at all 
three [La-] zones. Due to problems with laboratory analysis of plasma [La-] with 
certain samples which required the trials to be completed a second time (n = 7), 
whole blood samples were collected and corrected to reflect plasma levels via a 
correction curve. The seven trials consisted of four V̇O2max trials, two constant load 
trials and one time trial; the method used in each trial was consistent. Based on data 
from this laboratory, the difference between whole blood and plasma [La-] appears to 
depend on [La-] since differences at low (~2.6 mmol·L-1 whole blood), moderate 
(~6.2 mmol·L-1 whole blood) and high (~12.5 mmol·L-1 whole blood) concentrations 
were 20 ± 9, 43 ± 5 and 103 ± 5%, respectively. 
 
3.3.7 Statistical Analysis 
Data were analysed using IBM SPSS (version 22.0, SPSS Inc., Chicago, IL) 
statistical software package. Normality of the distribution for outcome measures was 
tested using the Shapiro-Wilk test. To analyse the primary objective, Pearson’s 
product moment (r) or Spearman rank (ρ) correlations were used as appropriate to 
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examine relationships between peak power output, relative peak power output 
(W·kg-1), allometrically-scaled peak power output (W·kg-0.32), absolute V̇O2max, 
relative V̇O2max, and variables reflective of LT2: power output, heart rate, V̇O2 and 
[La-], with variables obtained during the constant load trial (including mean heart 
rate, mean V̇O2 and mean [La-]) and 40 km time trial performance. Additionally, 
multiple regression analyses were used to examine the combination of variables 
producing the strongest prediction of time trial performance. Variables for the 
multiple regression were selected based on the bivariate correlations performed and 
were included in the regression based on rank. 
 
To examine the secondary objective, Paired t-tests or Wilcoxon signed-rank tests 
were used as appropriate to examine differences between variables reflective of LT2 
and VT2 and repeated measures analyses of variance (ANOVA) and Friedman’s 
ANOVAs were used as appropriate to compare differences in the aforementioned 
variables among the three trials, whilst the Bonferroni post-hoc test was employed to 
locate the source of any significant differences. These analyses were completed for 
mean values (i.e. values at LT2 vs. mean values across the constant load and 40 km 
time trials) as well as for more specific periods of the 30 min constant load trial (0-10, 
11-20 and 21-30 min) and the 40 km time trial (0-10, 11-20 and 21-30 km). Finally, 
variables coinciding with LT2 as determined from the V̇O2max trial were compared 
with those produced at 31-40 km of the 40 km time trial. To assess whether 
differences existed between LT2 variables and variables elicited in the final 9 km of 
the time trial, paired t-tests and Wilcoxon Signed-Rank tests were used as 
appropriate.  
 
Mean nutritional content (total weight, total energy intake, carbohydrate, protein and 
fat) of the foods and beverages consumed in the 24 h prior to each trial was 
calculated and ANOVAs and Friedman’s ANOVAs were used as appropriate to 
identify differences among trials. All tests were two-tailed with an alpha level of 0.05. 
Results are reported as the mean ± SD (95% CI), unless stated otherwise. 
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3.4 Results 
Ten competitive male cyclists and triathletes (aged 27.7 ± 4.7 years; body mass 72.5 
± 5.0 kg) volunteered to participate in the study. Diet diaries showed that no 
significant differences (p > 0.05) were evident among the three trials in mean total 
weight, total energy intake, carbohydrate and protein content, or volume of water 
consumed in the 24 h prior to each trial, although a higher fat and saturated fat 
intake was reported prior to the V̇O2max trial than the 40 km time trial (both p < 0.01; 
Table 3.1). Training diaries showed that all participants avoided vigorous intensity 
exercise in the 24 h prior to each trial. Each trial was separated by a minimum of 48 
h and the mean time between trials was 6 ± 5 days. 
 
Table 3.1. Dietary intake per trial.  
Non-normally distributed data are expressed as median (interquartile range). 
 VȩO2max  Constant load  Time trial 
Energy (kJ) 
13384 ± 4242 (10349-
16418) 
11356 ± 4843 (7892-
14821) 
9758 ± 2502 (7968-
11458) 
CHO (g) 377 ± 119 (292-462) 284 ± 95 (217-352) 299 ± 133 (204-394) 
Protein (g) 156 ± 77 (100-211) 91 (62) 101 ± 26 83-120) 
Fat (g) 112 ± 41 (82-141)* 102 ± 50 (66-138) 67 ± 27 (48-86) 
Sat fat (g) 51 ± 19 (37-64)* 44 ± 20 (29-58) 25 ± 10 (17-32) 
Water (mL) 979 ± 388 (701-1256) 832 ± 393 (551-1113) 968 ± 385 (693-1243) 
kJ: kilojoule; CHO: carbohydrate; g: grams; sat fat: saturated fat; mL; millilitres; VȩO2max: maximal incremental 
trial; *p < 0.01 compared to time trial. 
 
3.4.1 V̇O2max trial 
Mean values for the variables recorded during the V̇O2max trial are shown in Tables 
3.2 (absolute and relative V̇O2max, absolute and relative peak power output) and 3.3 
(variables corresponding to LT2 and VT2 including power output, heart rate, V̇O2 and 
[La-]). Where LT2 values (power output, heart rate, V̇O2 and [La-]) were expressed 
relative to their respective maximal values (% max), power output and V̇O2 produced 
identical percentages of maximum (76.1%). There were no significant differences 
(p > 0.05) between LT2 and VT2 for any of the measured variables, except for [La-] 
which was significantly higher at VT2 than LT2. 
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Table 3.2. Maximal variables recorded during the V̇O2max trial (n = 10).  
 
Variable Mean ± SD 95% CI 
V̇O2max (L·min-1) 4.3 ± 0.4 4.1-4.6 
V̇O2max (mL·kg-1·min-1) 59.7 ± 5.2 56.1-63.4 
Peak power output (W) 312 ± 28 291-332  
Relative peak power output (W·kg-1) 4.3 ± 0.3 4.1-4.5 
Allometrically-scaled peak power output 
(W·kg-0.32) 
79.1 ± 6.3 74.6-83.6 
V̇O2max: maximal oxygen uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres per kilogram of 
body mass, per minute; W: Watts; W·kg-1: Watts per kilogram of body mass; W·kg-0.32: Watts per 
kilogram of body mass to the power of 0.32; SD: standard deviation 
 
Table 3.3. LT2 and VT2 variables recorded during the V̇O2max trial (n = 10).  
Non-normally distributed data are expressed as median (interquartile range). 
Variable Mean % max 
 LT2 VT2 LT2 VT2 
Power output (W) 238 ± 28 (218-
257) 
240 ± 24 (223-
257) 
76 ± 4  
(73-79) 
77 ± 6  
(73-81) 
Heart rate (beats·min-1) 163 ± 9  
(157-170) 
164 ± 12 (155-
172) 
88 ± 3  
(86-90) 
88 ± 4  
(85-91) 
V̇O2 (L·min-1) 3.3 ± 0.3  
(3.1-3.5) 
3.3 ± 0.3  
(3.1-3.5) 
76.0 ± 4.3 (72.9-
79.1) 
76.5 ± 5.6 (72.5-
80.4) 
V̇O2 (mL·kg-1·min-1) 45.3 ± 2.1 (43.7-
46.8) 
45.6 ± 3.3 (43.2-
47.9) 
76.1 ± 4.7 (72.7-
79.4) 
76.5 ± 5.7 (72.4-
80.6) 
[La-] (mmol·L-1) 
 
5.0 (1.8) 6.9 (3.0)** 40.5 ± 3.6  56.6 ± 7.9** 
LT2: second lactate threshold; VT2: second ventilatory threshold; W: Watts; beats·min-1: beats per 
minute; V̇O2: oxygen uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres per kilogram of body 
mass, per minute; [La-]: lactate concentration; mmol·L-1: millimoles per litre; max: maximum; 
**p < 0.01 compared to LT2. 
 
3.4.2 30 min constant load trial 
Mean and percentage of maximum values for the physiological variables recorded 
during the constant load trial, including mean time at target power output, mean [La-], 
peak [La-], mean V̇O2 and mean [La-], are shown in Table 3.4. All participants (n = 
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10) successfully maintained their target power output (LT2 power output ± 5%) for 30 
min (mean difference 1.9 ± 1.5%), whilst only five participants produced a steady 
state [La-], defined as an increase of no more than 1 mmol·L-1 between 10 and 30 
min. Therefore, 50% of participants completed ‘successful’ trials by satisfying both 
criteria with a mean change in [La-] between 10 and 30 min of -0.8 ± 0.9 mmol·L-1. 
The remaining five participants produced a mean increase in [La-] from 10 to 30 min 
of 1.6 ± 0.7 mmol·L-1. 
 
Table 3.4. Time at target power output and physiological responses during the 
constant load trial at LT2 power output (n = 10).  
 
Variable Mean ± SD % max 
Time at target power output (min) 30.0  0 - 
[La-] (mmol·L-1) 6.7 ± 2.2 (5.0-8.3) 53.2 ± 19.3 (39.4-66.9) 
Peak [La-] (mmol·L-1) 7.6 ± 2.2 (6.1-9.2) 59.5 ± 20.8 (44.6-74.4) 
V̇O2 (mL·kg-1·min-1) 44.5 ± 4.3 (41.4-47.5) 74.9 ± 9.2 (68.3-81.4) 
Heart rate (beats·min-1) 164 ± 13 (154-173) 88 ± 7 (83-93) 
Min: minutes; [La-]: plasma lactate concentration; mmol·L-1: millimoles per litre; V̇O2: oxygen uptake; 
mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; beats·min-1: beats per minute; max: 
maximum. 
 
3.4.3 40 km time trial  
Mean and percentage of maximum values for the physiological variables recorded 
during the 40 km time trial, including time to completion, power output, [La-], peak 
[La-], V̇O2 and heart rate are shown in Table 3.5. Power output and V̇O2 produced 
similar percentages of maximum (~73 and 76%, respectively). Table 3.6 shows there 
were no significant differences among mean heart rate (p = 0.06) or mean V̇O2 
(p = 0.83) responses across various sections of the 40 km time trial. 
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Table 3.5. Time to completion and physiological responses during the 40 km 
time trial (n = 10).  
Non-normally distributed data are expressed as median (interquartile range).  
Variable Mean ± SD % max 
Time to completion (min) 62.1  4.9 (58.6-65.6)  
Power output (W) 227  43 (196-258) 72 ± 9 (66-79) 
[La-] (mmol·L-1) 7.0  2.4 (5.3-8.7) 56.1 ± 19.9 (41.8-70.3) 
Peak [La-] (mmol·L-1) 12.1 (3.7) 85.1 ± 25.5 (65.5-104.7) 
V̇O2 (mL·kg-1·min-1) 45.4  7.8 (39.8-51.0) 75.6 ± 8.5 (69.5-81.7)  
Heart rate (beats·min-1) 163  10 (155-170) 88 ± 4 (85-91) 
Min: minutes; sec: seconds; W: Watts; [La-]: plasma lactate concentration; mmol·L-1: millimoles per 
litre; V̇O2: oxygen uptake; mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; beats·min-1: 
beats per minute; max: maximum. 
 
Table 3.6. Heart rate and V̇O2 responses during the 40 km time trial at 10 km 
intervals (n = 10).  
 
Distance (km) Heart rate (beats·min-1) V̇O2 (mL·kg-1·min-1) 
0–10 156 ± 8 (150-161) 44.1 ± 6.9 (39.2-49.0) 
11–20 162 ± 8 (156-168) 44.7 ± 7.5 (39.3-50.1) 
21–30 164 ± 12 (156-173) 45.4 ± 9.7 (38.5-52.3) 
31–40 169 ± 14 (159-179) 47.5 ± 9.4 (40.8-54.1) 
Km: kilometre; beats·min-1: beats per minute; V̇O2: oxygen uptake; mL·kg-1·min-1: millilitres per 
kilogram of body mass, per minute. 
 
There were significant relationships between V̇O2max, peak power output, relative 
peak power output and 40 km time trial performance time (Figure 3.2). Additionally, 
there were significant relationships between some (power output and V̇O2) but not all 
(heart rate and [La-]) LT2 variables and 40 km time trial performance time (Figure 
3.3). The strongest relationships with time trial performance were allometrically-
scaled peak power output (W·kg-0.32; r = -0.90; p < 0.01), absolute peak power output 
(W; r = -0.88; p < 0.01) and absolute V̇O2max (L·min-1; r = -0.87; p < 0.01). Five 
other variables – relative V̇O2max (mL·kg-1·min-1; r = -0.65; p < 0.05), relative peak 
power output (W·kg-1; r = -0.73; p < 0.01) LT2 power output (W; r = -0.69; p < 0.05), 
LT2 V̇O2 (L·min-1; r = -0.77; p < 0.01) and LT2 relative V̇O2 (mL·kg-1·min-1; r = -0.77; 
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p < 0.01) – also displayed significant relationships with time trial performance. Only 
variables related to heart rate [maximum heart rate (r = 0.03; p = 0.92) and LT2 heart 
rate (r = 0.40; p = 0.25)] and [La-] [maximum [La-] (r = -0.15; p = 0.97) and LT2 [La-] 
(r = 0.37; p = 0.33)] produced weak, non-significant correlations with time trial 
performance. Power output (r = -0.64; p < 0.05) but not heart rate, V̇O2 (L·min-1 or 
mL·kg-1·min-1) or [La-] (p > 0.05) reflective of VT2 produced a significant correlation 
with time trial performance. The strongest combination of variables using multiple 
regression analysis included absolute peak power output, absolute V̇O2max, V̇O2 at 
LT2 (L·min-1 and mL·kg-1·min-1) relative peak power output (W·kg-1) and power output 
at LT2 (r2 = 0.95; p < 0.05). 
 
The regression equation generated was:  
 
40 km time trial time = 9108.47 + (72.10 x absolute peak power output) + (62.29 x 
absolute V̇O2max) + (-7986.89 x absolute V̇O2 at LT2) + (-5521.96 x relative peak 
power output; W·kg-1) + (459.89 x relative V̇O2 at LT2) + (4.29 x power output at LT2). 
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Figure 3.2. Correlations between time trial performance time (n = 10) and; (a) 
absolute V̇O2max, (b) relative V̇O2max, (c) peak power output, (d) relative peak 
power output (W·kg-1) and (e) allometrically-scaled peak power output 
(W·kg-0.32).  
Min: minutes; V̇O2max: maximal oxygen uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres 
per kilogram of body mass, per minute; W: Watts; W·kg-1: Watts per kilogram of body mass; W·kg-0.32: 
Watts per kilogram of body mass to the power of 0.32; *p < 0.05; **p < 0.01. 
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Figure 3.3. Correlations between time trial performance time and; (a) LT2 power 
output (W), (b) LT2 heart rate (beats·min-1), (c) absolute LT2 V̇O2 (L·min-1), (d) 
relative LT2 V̇O2 (mL·kg-1·min-1) and (e) LT2 [La-] (mmol·L-1).  
Min: minutes; LT2: second lactate threshold; W: Watts; beats·min-1: beats per minute; V̇O2: oxygen 
uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; 
[La-]: lactate concentration; mmol·L-1: millimoles per litre; *p < 0.05; **p < 0.01. 
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Detection of VT2 was made in 100% of participants, and both researchers were in 
agreement in six (60%) of the trials. In the four cases where the opinion of a third 
observer was sought, there always existed agreement with one of the two 
researchers. Significant relationships were observed between LT2 and VT2 for power 
output (r = 0.81; p < 0.01) heart rate (r = 0.93; p < 0.01), absolute V̇O2 (L·min-1; r = 
0.78; p = 0.01) and [La-] (r = 0.79; p = 0.01), but not relative V̇O2 (mL·kg-1·min-1; r = 
0.54; p = 0.10). 
 
Mean power output, heart rate, V̇O2 and [La-] (1) at LT2, (2) during 30 min of constant 
load exercise and (3) during the 40 km time trial are shown in Table 3.7. Although 
relationships between heart rate, V̇O2 and [La-] and LT2, constant load exercise and 
40 km time trial performance were explored, power output at LT2 was only compared 
to mean 40 km time trial power output (since LT2 power output determined constant 
load power output). No significant differences were found among LT2, constant load 
and 40 km time trial for heart rate (p = 0.79), absolute V̇O2 (p = 0.93), relative V̇O2 
(p = 0.92) or [La-] (p = 0.17). Additionally, no differences were observed between 
power output at LT2 and mean power output during the time trial (p = 0.34).  
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Table 3.7. Variables reflective of the second LT, elicited during constant load 
exercise and during the 40 km time trial.  
Non-normally distributed data are expressed as median (interquartile range). 
Variable LT2 Constant load Time trial 
Power output (W) 238 ± 28 (218-257) 237 ± 30 (216-258) 227  43 (196-258) 
Heart rate 
(beats·min-1) 
163 ± 9 (157-170) 164 ± 13 (154-173) 163  10 (155-170) 
Absolute V̇O2 
(L·min-1) 
3.3 ± 0.3 (3.1-3.5) 3.2 ± 0.4 (2.9-3.5) 3.3 ± 0.6 (2.8-3.7) 
Relative V̇O2 
(mL·kg-1·min-1) 
45.3 ± 2.1 (43.7-46.8) 44.5 ± 4.3 (41.4-47.5) 45.4  7.8 (39.8-51.0) 
[La-] (mmol·L-1) 5.0 (1.8) 6.7 ± 2.2 (5.0-8.3) 7.0  2.4 (5.3-8.7) 
LT2: second lactate threshold; W: Watts; beats·min-1: beats per minute; V̇O2: oxygen uptake; L·min-1: 
Litres per minute; mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; [La-]: plasma lactate 
concentration; mmol·L-1: millimoles per litre. 
 
 
Heart rate, absolute V̇O2, relative V̇O2 and [La-] were compared between 0-10, 11-20 
and 21-30 min of the constant load trial (time points 1-3, respectively), at 0-10, 
11-20, 21-30 and 31-40 km of the 40 km time trial (time points 1-4, respectively) and 
at LT2. No significant differences were found among trials at time points 1 [heart rate 
(p = 0.10), absolute V̇O2 (p = 0.68), relative V̇O2 (p = 0.70) and [La-] (p = 0.90)], 2 
[heart rate (p = 0.69), absolute V̇O2 (p = 0.85), relative V̇O2 (p = 0.81) and [La-] 
(p = 0.55)] or 3 [heart rate (p = 0.63), absolute V̇O2 (p = 0.92), relative V̇O2 (p = 0.90) 
and [La-] (p = 0.37)]. Furthermore, no significant differences were found between LT2 
and time point 4 of the time trial [heart rate (p = 0.18), absolute V̇O2 (p = 0.36) and 
relative V̇O2 (p = 0.41). However, [La-] from 31 – 40 km during the time trial was 
significantly higher than LT2 [La-] (p = 0.01). Power output at LT2 was not significantly 
different from mean power output maintained during a 40 km time trial (p = 0.34). 
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3.5 Discussion 
The objective of the present study was to examine the relationships among the 
modified D-max LT2 and other laboratory-measured variables (V̇O2max and peak 
power output), and 40 km cycling time trial performance in trained cyclists and 
triathletes. A secondary objective was to establish the validity of the modified D-max 
LT2 by: (1) comparing it to VT2, and (2) investigating whether 30 min of exercise at 
LT2 power output (a) was maintainable; (b) corresponded to a steady state [La-]; and 
(c) elicited similar physiological responses (heart rate, [La-] and V̇O2) to those 
produced during a 40 km cycle time trial. In response to the first objective, it was 
found that five out of five maximal variables [peak power output, relative peak power 
output (W·kg-1), allometrically-scaled peak power output (W·kg-0.32) and absolute and 
relative V̇O2max] and three out of five LT2 variables (LT2 power output and absolute 
and relative V̇O2 at LT2) were significantly correlated with 40 km cycling time trial 
performance. Secondly, LT2 was comparable to VT2 when expressed as power 
output, heart rate and V̇O2 (L·min-1), since the variables were significantly correlated 
and not significantly different between threshold methods. Furthermore, all 30-min 
constant load trials were completed but only five (50%) were completed with a 
steady-state [La-]. Finally, there were no significant differences in mean values or 
time-specific values among the measured variables (power output, heart rate, 
absolute and relative V̇O2max and [La-]) at LT2, during constant load exercise and 
during the 40 km time trial, except during the final 31-40 km of the time trial ([La-] 
was significantly higher than LT2 [La-]). This is likely explained by an increased effort 
to complete the final stages of the time trial.  
 
3.5.1 Correlations with 40 km time trial performance 
The primary outcome of the present study was that three LT2 variables determined 
by the modified D-max (absolute V̇O2 at LT2, relative V̇O2 at LT2 and power output at 
LT2) were significantly related to 40 km time trial performance in trained male cyclists 
and triathletes. Although of similar strength to the relationships between peak power 
output (W·kg-1), and VT2 power output with performance, the LT2 variables produced 
weaker relationships with performance than those between peak power output (W), 
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allometrically-scaled peak power output (W·kg-0.32) and absolute V̇O2max (L·min-1) 
with performance (Figure 3.2). These results suggest the modified D-max may not 
be superior to maximal variables when assessing performance outcomes in well-
trained endurance athletes. Although it is difficult to speculate on potential reasons 
for this, one may be that participants’ training intensities prior to the study 
involvement were not controlled, and therefore may have influenced the intensity 
reflective of LT2. Of the variables producing significant relationships with 
performance time, V̇O2 at LT2 [87], power output at LT2 [5, 93], power output at VT2 [91, 
93], relative peak power output (W·kg-1) [273], allometrically-scaled peak power output 
(W·kg-0.32) [273, 277, 278] and absolute peak power output [181, 273, 279, 280] have previously 
been shown to be related to measures of endurance performance in trained cyclists. 
However, the relationships between time trial performance and absolute and relative 
V̇O2max were unexpected given the high training status of the participants [19, 97, 281]; 
this will be discussed in further detail below. Since multiple regression analysis 
revealed that a combination of six variables, including both maximal and submaximal 
variables explained 95% of the variance in performance (p < 0.05), it can be 
suggested that the modified D-max is most effective when used in conjunction with 
maximal variables. 
 
3.5.1.1 LT2 power output and V̇O2 
Three LT2 variables produced significant relationships with 40 km cycling 
performance. Although these relationships were of moderate strength (r = -0.69-0.77; 
p < 0.05-0.01), power output at LT2, absolute V̇O2 at LT2 and relative V̇O2 at LT2 
were not as strongly correlated with time trial performance as the maximal variables 
[absolute and allometrically-scaled peak power output (W·kg-0.32) and V̇O2max 
(L·min-1); all r ≥ 0.87]. The relationship between LT2 power output and performance 
(r = -0.69; p < 0.05) was lower than previous research utilising the modified D-max 
method, although this relationship has not been reported in trained younger men, but 
rather veteran cyclists (n = 8 men and 1 woman; r = 0.95; p < 0.01) [18] and trained 
female triathletes and cyclists (n = 24; r = 0.83; p < 0.01) [10]. This could be 
explained, at least in part, by the exercise protocols adopted or the variance in LT2 
power output. The study of Bishop et al. [10] reported stage durations of 3 min, 
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however it has been concluded that stages shorter than 5 min may over-predict LT2. 
Alternatively, 5-8 min stages have been recommended to attain steady-state [La-] 
and therefore an accurate determination of LT2 [282-284]. The study of Fell [18] reported 
a larger variation in LT2 power output (260 ± 42 W) than the present study (238 ± 28 
W), and larger variation is known to result in stronger relationships with endurance 
performance [1]. Studies in trained male cyclists have also produced moderate-to-
strong relationships between LT2 and endurance performance, albeit with different 
LT2 determination methods such as the D-max method (r = 0.77; p < 0.05 [5]), OBLA 
(r = 0.60-0.90; p < 0.05-0.001 [93, 149]), IAT (r = 0.72; p < 0.01) [93] and the point 
reflective of a 1 mmol·L-1 increase in [La-] above baseline (r = -0.93; p < 0.01) [87]. 
 
3.5.1.2 LT2 heart rate 
In contrast to the significant relationships found between the three aforementioned 
LT2 variables and performance, heart rate at LT2 was not related to cycling 
performance. This was consistent with the weak relationship exhibited between VT2 
and cycling performance in the present study. Whilst previous research conducted in 
endurance-trained men has shown moderate-to-strong relationships between heart 
rate at VT2 and average heart rate during the cycle (r = 0.81; p < 0.01) and run 
(r = 0.64; p < 0.01) phases of an ultra-endurance triathlon [96], the use of mean heart 
rate as the performance measure, rather than performance time, may be responsible 
for the discrepancy. Furthermore, it is important to note the relationship between LT2 
and VT2 appears coincidental, and therefore they may occur at very different times 
and at very different intensities during exercise. This has been demonstrated in 
previous research where an elevated blood [La-] had no effect on ventilation during 
incremental exercise [285] or on VT2 [286], with other findings suggesting a larger 
discrepancy between LT2 and VT2 in glycogen-depleted states [287]. LT2 and VT2 have 
also been shown to improve by different magnitudes in response to identical training 
interventions, suggesting the two thresholds are regulated by different mechanisms 
[288, 289]. In response to a HIIT intervention, VT2 improved significantly more than LT2 
(p < 0.05), whilst LT2 improved significantly more than VT2 after continuous training 
(p < 0.05), with the authors proposing that the significant training-induced 
dissociation suggests the relationship is coincidental rather than causal [289]. 
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Incongruence between the two thresholds was also shown in the present study, 
where V̇O2 reflective of LT2 but not VT2 was significantly correlated with cycling 
performance, and VT2 [La-] was significantly higher than LT2 [La-]. Therefore, the 
present study suggests that heart rate at LT2 is not recommended as a physiological 
measure to predict endurance performance.  
 
The study by Lucia et al. [290] demonstrated that mean heart rate at LT2 and VT2 
remained stable during the course of a training year for professional cyclists, despite 
significant improvements in the power output at both thresholds. Despite the sex of 
the participants not being identified, the omission of a performance time trial and a 
different method of LT determination (LT was defined as the highest work rate not 
associated with a rise in [La-] ≥ 0.2 mmol·L-1 above baseline), the findings of Lucia et 
al. [290] suggest a weak relationship between heart rate at LT2 and heart rate at VT2 
with endurance performance due to heart rate having a lack of sensitivity to training 
compared to power output. This supports the present findings, suggesting that power 
output and/ or V̇O2, but not heart rate, reflective of the modified D-max LT2 are good 
indicators of cycling performance. 
 
3.5.1.3 LT2 [La-] 
Since the introduction of LT2 determination methods such as the D-max and 
modified D-max, which exploit the entire [La-] curve (or close to the entire curve in 
the case of the modified D-max) in their LT2 calculation, consistent relationships with 
endurance performance have been reported [10, 17]. These relationships are 
commonly stronger than those reported by other methods such as OBLA, which 
uses an absolute concentration of lactate (4 mmol·L-1) to indicate the inflection point 
[10, 177]. Additionally, numerous problems have been documented with methods 
utilising absolute [La-], including the inability to reflect inter-individual differences in 
lactate accumulation [156, 157]. This has been consistently reported independent of 
training status [103-106] and for the same relative exercise intensity [152]. Furthermore, 
different exercise protocols [16] and modes [121, 143] influence the work rate attained, 
which also affects the robustness of LT2 methods employing absolute [La-]. These 
limitations in using fixed [La-] may explain why the weak relationship between the 
[La-] at LT2 and performance time was seen in the present study. Furthermore, the 
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inconsistency in [La-] reflective of LT2 and VT2, despite a consistent power output, 
suggests that the use of power output is superior to [La-] measures in a practical field 
setting for cyclists. The findings of the present study, together with the 
aforementioned limitations when observing raw [La-], imply that although the [La-] at 
LT2 as determined by the modified D-max method can provide information on an 
individual’s LT2 status, it is not a valid measure to compare among individuals, and 
[La-] more generally appears to be inferior in comparison to power output. 
Furthermore, the present findings recommend [La-] at LT2 be used in conjunction 
with [La-] measures over several time points if it is to be used as a performance 
indicator. 
 
3.5.1.4 V̇O2max 
The finding that absolute V̇O2max produced a significant relationship with 
performance time (r = -0.87; p < 0.01), and one stronger than between the variables 
associated with LT2 and performance (r = 0.20-0.77; p < 0.05-0.01), was unexpected 
due to the moderate-to-high V̇O2max values (59.8 ± 5.2 mL·kg-1·min-1) and 
experienced training history (had completed training of consistently high loads for 
≥ 2 months, with competitive racing experience of ≥ 1 season) of the participants in 
this study. Previous research has shown that V̇O2max produced strong relationships 
with performance when a large range of V̇O2max values existed within a sample, 
such as 54.8 to 81.6 mL·kg-1·min-1 in distance runners [260], or when performances 
were varied within a sample, such as a range of average rowing speeds of 4.3-5.1 
m·s-1 in club-standard rowers [291]. However, the strength of the V̇O2max and 
performance relationship significantly reduced when the participants were more 
homogeneous [19, 97, 281]. In the present study, ~80% of the variance in 40 km 
performance times could be explained by V̇O2max, whereas the strongest LT2 
correlate (LT2 V̇O2; r = -0.77; p < 0.01) could only explain ~60% of the variance. 
However, 40 km performance times ranged from 56-71 min (~27%), absolute 
V̇O2max values from 3.72-4.80 L·min-1 (~29%) and relative V̇O2max values from 
48.8-69.2 mL·kg·min-1 (~42%), which may help to explain these relationships. 
According to Bassett and Howley [1], stronger relationships exist between endurance 
performance and independent variables such as V̇O2max, exercise economy and 
%V̇O2max at LT2 when larger variations exist among the measured values. This was 
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consistent with the present study, since a smaller range of values was produced by 
LT2 V̇O2 (40.1-47.6 mL·kg-1·min-1; ~19%) than by V̇O2max (~42%), with a 
subsequently weaker relationship and a reduced capacity to predict performance.   
 
A similarly large range of 40 km performance times (60-75 min) and V̇O2max values 
(2.9-5.6 L·min-1 and 45.3-72.5 mL·kg·min-1) and were also reported by Lamberts et 
al. [273] in their group of competitive male cyclists. These researchers also found a 
relationship (albeit an indirect one) between V̇O2max and 40 km performance 
through the combination of strong relationships between absolute peak power output 
and absolute V̇O2max [r = 0.96; standard error of the estimate (SEE): 0.15], and 
between absolute peak power output and performance time (r = -0.90; SEE: 81 s). 
Additionally, Bentley et al. [5] reported a mean V̇O2max value higher than the present 
study (4.85 L·min-1), suggesting participants were experienced athletes with a high 
endurance capacity, with a significant relationship observed between V̇O2max and 
cycling performance (r = 0.69; p < 0.05). These studies provide some support to the 
present findings. Therefore, although V̇O2max was capable of predicting ~80% of the 
variance in 40 km cycling performance time in this study, and LT2 V̇O2 was only 
capable of predicting ~60%, this is likely a result of the large variation in both 
independent variables. The addition of peak power output and LT2 power output 
strengthened the performance prediction capacity in this study, suggesting that a 
combination of maximal and fractional utilisation variables is more valuable for 
predicting endurance performance outcomes. 
 
3.5.1.5 Absolute and relative peak power output 
As the present study confirms, absolute peak power output has been shown by 
others to correlate strongly with time to completion during endurance trials in trained 
cyclists over 40 km (r = -0.90; p < 0.01; n = 45 men [273], r = 0.91; p < 0.01; n = 5 men 
and 5 women [292]), 20 km (r = -0.91; p < 0.01; n = 54 men and 46 women [279]), 16.1 
km (r = 0.99; p < 0.01; n = 16 men [280]), and 26 km (p < 0.01; data not shown; n = 15 
men and 1 woman [181]). Although 40 km performance was assessed as time to 
completion in the present study, Balmer et al. reported a stronger relationship 
between peak power output and mean 16.1 km time trial power output (r = 0.99; 
p < 0.01) than between peak power output and time to completion (r = 0.46; 
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p > 0.05) [280]. Nevertheless, replacing time to completion with mean power output 
during the time trial did not strengthen the relationship with peak power output in the 
present study (r = -0.88; p < 0.01 vs. r = 0.83; p < 0.01; data not reported).  
 
It has been reported that body mass plays an important role when predicting cycling 
performance, whereby a higher body mass is an advantage when performing a flat 
cycling time trial and a disadvantage for cycling capacity whilst climbing [277, 278]. 
Although a significant predictor of performance in this study and the study of 
Lamberts et al. [273], peak power output expressed as W·kg-1 has been more 
commonly reported as a predictor of climbing capacity compared to flat cycling time 
trial performance [4, 42]. Fittingly, allometrically-scaled peak power output (W·kg-0.32) 
produced a stronger relationship with performance than relative peak power output 
(W·kg-1) in this study and the study of Lamberts et al. [273] when level-ground testing 
was conducted. Therefore, adjusting body mass to the power of 0.32 has been 
suggested for the purpose of predicting flat time trial performance [42, 277, 278]; the 
present study provides some support for this approach. However, the correlations 
produced in the present study for absolute (r = -0.88) and allometrically-scaled 
(W·kg-0.32; r = -0.90) peak power output were similar, indicting the body mass 
adjustment is not necessary. This is in contrast to the study of Lamberts et al., who 
showed a stronger relationship between allometrically-scaled peak power output and 
performance (r = -0.96) than absolute peak power output and performance 
(r = -0.90) [273].  
 
Differences in protocol for peak power output determination may be responsible for 
the discrepancies between studies – Lamberts et al. [273] used a steep body mass-
specific protocol beginning at 2.50 W·kg-1, which increased by 20 W·min-1 until the 
cadence could not be maintained above 70 rpm. The present study calculated peak 
power output from extended 5 min stage durations with work rates beginning at 100 
W and increasing by 50 W for all participants – this may, at least in part, have 
contributed to the marginally higher average V̇O2max (59.8 ± 5.2 vs. 57.3 ± 6.2 
mL·kg-1·min-1) compared to Lamberts et al. [273], but a lower absolute (312 ± 28 vs. 
381 ± 42 W) and allometrically-scaled (79.1 ± 6.3 vs. 95.1 ± 9.4 W·kg-0.32) peak 
power output. A negative relationship between peak power output and an increased 
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stage duration has been reported by others [293]. Specifically, peak power output 
appears lower when the stage duration is increased from 1 to 5 min, which may 
negatively influence the relationship between peak power output and endurance 
performance [293, 294]. The latter is also consistent with the present study (r = -0.80 
and r = -0.90 in the present study, and r = -0.90 and r = -0.96 reported by Lamberts 
et al. [273] for absolute and relative peak power output, respectively). Therefore, the 
specificity (i.e. establishing starting work rates based on body mass) of the protocol 
adopted by Lamberts et al. [273] may explain the greater association between relative 
peak power output and performance time compared to absolute peak power output. 
It may also explain why the more generic protocol adopted in the present study 
produced similar relationships with performance time, regardless of whether absolute 
or relative peak power output was used. Furthermore, the shorter stage durations 
may explain why peak power output was higher, and why relationships between 
absolute and relative peak power output with performance were stronger in the study 
of Lamberts et al. [273] compared to the present study. 
 
3.5.2 Comparability with VT2 
The current data suggest that LT2 determined by the modified D-max method was 
comparable to VT2 as assessed by the VE/V̇O2 method, when expressed as power 
output, heart rate and V̇O2 (L·min-1). These variables were significantly correlated 
and not significantly different between threshold methods and this supports, at least 
in part, previous literature showing no significant differences between heart rate and 
[La-] at VT2 and LT2 when determined by the modified D-max method in elite cross 
country skiers [169]. However, in the present study the [La-] reflective of VT2 was 
significantly higher than the [La-] reflective of LT2, although this is in contrast to the 
aforementioned study, it may be explained by the previously mentioned coincidental 
relationship between the two thresholds. Furthermore, power output but not V̇O2 
(L·min-1 or mL·kg-1·min-1), heart rate or [La-] at VT2 was significantly correlated with 
time trial performance (r = -0.64; p < 0.05). The relationship was of similar strength to 
that produced by power output at LT2 and performance (r = -0.69; p < 0.05). 
Therefore, the most comparable measure between LT2 and VT2 was power output 
since these measures were strongly correlated with each other and with endurance 
performance, and were not significantly different. Additionally, the modified D-max 
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calculation of LT2 has the benefit of being a more objectively quantified measure than 
VT2. Subsequently, power output reflective of LT2 appears suitable to be used 
interchangeably with power output at VT2.  
 
3.5.3 Constant load exercise at LT2 power output 
All participants in the present study maintained exercise at the LT2 power output for 
30 min, but only 50% of participants produced a steady state [La-]. The discrepancy 
between LT2 power output and steady state [La-] provides support for the large inter-
individual differences in lactate responses to exercise and athletes’ abilities to 
tolerate different [La-], as reported elsewhere [113]. This lack of relationship between 
[La-] and work rate (power output and heart rate) to reflect MLSS has been 
reinforced by Hauser et al. [114], who reported that [La-] showed greater day-to-day 
variability and lower reliability than power output. These findings also question the 
validity of MLSS as an endurance performance indicator, since MLSS appears to 
under-estimate the maximal sustainable power output and therefore endurance 
performance. Further investigations may be warranted to examine whether this 
mismatch between a maintainable LT2 power output and a [La-] that continues to rise 
are evident in larger samples, with female athletes and in other exercise modes such 
as running and rowing. Research has shown time to fatigue at MLSS to be ~38 [128] 
to 55 min [113] in trained male cyclists, with the present study suggesting this may be 
even longer, since half of the participants maintained an average power output 
above MLSS for ~62 ± 5 min. The discrepancy between these studies and the 
present study is a likely consequence of the inter-individual differences in lactate 
responses to exercise and suggests, at least with trained cyclists and triathletes, the 
power output at LT2 rather than the MLSS may be more indicative of endurance 
performance.  
 
3.5.4 Difference between variables at LT2, during constant 
load exercise and during a 40 km time trial 
The lack of significant differences within the present study among mean power 
output, heart rate, absolute and relative V̇O2 and [La-] across the three trials (LT2, 
constant load trial and  40 km time trial), are in accordance with some [93, 95, 96, 127], 
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but not all [95, 295, 296], studies in this area. Whilst no significant differences were found 
between the heart rate at VT2 and the heart rate during the cycle [95, 96] or run [96] 
phases of an ultra-endurance triathlon in highly-trained men, the power output 
corresponding to VT2 over-estimated the power output produced during the triathlon 
by ~9% (p < 0.05) [95]. Since the cycle distance of 180 km is likely responsible for 
significant cardiovascular drift and therefore a higher heart rate over time due to 
thermal stress, a reduced blood volume and a large volume of active muscle mass 
[124], this could explain why the heart rate reached the level of VT2, but power output 
did not. This increase in heart rate over time has also been reported by others when 
participants exercised at their MLSS intensity [113, 123]. The shorter time trial duration 
of 40 km in the present study may not have been long enough to induce the same 
cardiovascular drift (data confirmed this by showing no significant difference among 
mean heart rate from 1-10, 11-20, 21-30 and 31-40 km), and therefore power output 
and heart rate at LT2 as determined by the modified D-max method appear equally 
capable of determining 40 km performance intensity.  
 
Others have also shown no significant differences between mean power output 
reflective of various threshold measures (V̇E/ V̇O2, RER0.95 and OBLA) and mean 
power output elicited during a 40 km cycling time trial in experienced male cyclists 
[93]. Furthermore, Harnish et al. [127] demonstrated that mean [La-] and heart rate at 
MLSS (as determined by multiple 30-min constant load trials) were not different to 
the mean lactate and heart rate data collected during a 40 km cycle time trial in 
trained cyclists. For a time trial distance of 20 km (rather than the 40 km distance 
used in the present study), Morris and Shafer [295] found that mean time trial power 
output was significantly higher than mean power output at LT2 [determined by two 
methods – (1) the highest power output that did not result in consecutive and 
continued increases in blood [La-] from baseline (~17%); and (2) the highest power 
output that did not result in consecutive increases of ≥ 1 mmol·L-1 in blood [La-] from 
baseline (~14%)] in a mixed sample of trained male and female cyclists and 
triathletes. Additionally, mean time trial power output was significantly higher than 
power output at MLSS (~10%) [295]. Similar findings were reported by Kenefick et al. 
[296] in competitive male cyclists whereby power output at LT2 (~15%), [La-] at LT2 
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(~252%), heart rate at LT2 (~9%) and V̇O2 at LT2 (~27%) significantly under-
estimated 20 km cycling time trial intensity.  
 
The dependence of performance distance on the capacity of LT2 to elicit the same 
physiological responses as those elicited during a time trial has also been reported 
by Padilla et al. [297]. Using two LT2 methods, OBLA and LT2 (defined as a 1 mmol·L-1 
increase in [La-] above baseline when exercising at 40-60% maximal aerobic power 
output), the authors showed that for short time trials (≤ 30 min), professional cyclists 
spent 55% of total time below OBLA heart rate and 70% of total time above LT2 
heart rate. For longer time trials (~60 min), the cyclists spent 85 and 50% of their 
time below OBLA and above LT2 heart rates, respectively [297]. Therefore, it was 
recommended that heart rate at OBLA be used to establish training and competition 
pace for events lasting ≤ 30 min, and heart rate at LT2 for events lasting ≥ 60 min 
[297]. The present findings add to this by suggesting that the modified D-max method 
is more accurate in producing a heart rate that is maintainable for 30-60 min than 
OBLA and LT2 (when defined as a 1 mmol·L-1 increase in [La-] above baseline when 
exercising at 40-60% maximal aerobic power output). However, the percentage of 
time spent at different intensities was not specifically monitored in the present study, 
which would have allowed for more precise intensity monitoring in relation to LT2 and 
practical outcomes to be established, such as the maximum amount of time spent 
above LT2. Nevertheless, the present study provides support for the use of the 
modified D-max LT2 as an appropriate power output to maintain during 40 km cycling 
performance. Although the MLSS was over-estimated in 50% of participants, the lack 
of significant difference between power output at LT2 and mean 40 km performance 
power output suggests there is no need for multiple testing sessions to detect the 
MLSS. 
 
Collectively, research suggests that a certain distance/ time limit or ‘threshold’ exists, 
whereby LT2 is capable of producing a power output, heart rate, [La-] and/or V̇O2 that 
is sustainable during performance trials. Whilst LT2 appears to under-estimate these 
variables for shorter trials (≤ 20 km) [295, 296], the present study showed that a time 
trial of 40 km produced a similar power output and comparable physiological 
responses to those associated with exercise at LT2. Although VT2, but not LT2, has 
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been compared to performance distances in excess of 40 km, it could be anticipated 
that LT2 power output may over-predict performance power output at least with 
performance distances of 180 km, as shown with VT2 [95], whilst heart rate is likely to 
be influenced by cardiovascular drift. Furthermore, Bentley et al. [5] showed the mean 
power output was significantly higher (~14%) during a 20 min compared to a 90 min 
cycling time trial in male cyclists, providing further evidence that the capacity of LT2 
power output to reflect mean time trial power output is distance-dependent. Further 
research is required to establish limits of precision for the modified D-max LT2 to 
predict performance between distances of 40 and 180 km, especially for half-
Ironman athletes who cycle a distance of 90 km. This will guide the use of the 
modified D-max LT2 for setting distance-specific exercise intensities. The present 
study is the first to show that LT2 determined by the modified D-max was accurate in 
estimating mean 40 km time trial power output, heart rate, V̇O2 and [La-] in 
endurance-trained men. These findings, together with the significant relationships 
established between LT2 and 40 km performance time, suggest power output and 
V̇O2 at LT2 may be more valuable than heart rate and [La-] at LT2 for predicting 
endurance cycling performance and establishing maintainable endurance cycling 
intensities since they are (1) associated with 40 km cycle performance, and (2) 
equivalent to the power output and V̇O2 produced during exercise of 30-~62 min. 
 
3.6 Conclusions 
In conclusion, this was the first study to examine the relationships between 
laboratory-derived variables, including the modified D-max method and 40 km 
cycling time trial performance in endurance-trained younger men. It was found that 
the combination of absolute peak power output (W), relative peak power output 
(W·kg-1), absolute V̇O2 at LT2 (L·min-1), relative V̇O2 at LT2 (mL·kg-1·min-1), power 
output at LT2 and absolute V̇O2max (L·min-1) produced the strongest prediction of 
performance, and the regression equation provided can be used by sports scientists 
in an applied setting. Constant load exercise at LT2 power output (± 5%) was 
successfully maintained for 30 min by all participants, with a steady-state [La-] 
occurring in only 50% of participants, questioning the validity of the MLSS as an 
endurance performance indicator. However, these findings should be interpreted 
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with caution since there were methodological issues with [La-] determination. 
Furthermore, the finding that power output, heart rate, V̇O2 and [La-] elicited at the 
modified D-max LT2 were not different from those elicited during the 30-min constant 
load trial and the 40 km time trial suggest determining MLSS from multiple testing 
sessions may not be required. Based on the findings of the present study, LT2 as 
determined by the modified D-max method is recommended for prescribing the 
power output, heart rate, V̇O2 and [La-] maintainable during 40 km cycling 
performance in endurance-trained men, however the inconsistency in [La-] reflective 
of LT2 and VT2, despite a consistent power output, heart rate and V̇O2, suggests that 
[La-] is inferior to the other methods. Whilst only a moderate correlate of endurance 
performance when expressed as power output and V̇O2 in isolation, LT2 explained 
95% of the variance in 40 km performance when used in conjunction with peak 
power output and V̇O2max. Therefore, the use of the modified D-max for LT2 
determination by coaches, athletes and sports scientists is recommended for: (1) 
establishing competition intensities of 30-~60 (or 40 km) min; (2) predicting 40 km 
endurance performance in conjunction with absolute and relative (W·kg-1) peak 
power output by using the supplied regression equation. Although it is unlikely that 
[La-] will be monitored during competition for practical reasons, values elicited in the 
final 10 km of a 40 km time trial may begin to rise as effort increases towards trial 
completion, so the use of power output, heart rate and V̇O2 (although V̇O2 also 
impractical during competition) appear more advantageous.    
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Appendix 3.1. Health and training diary. 
PRE-TEST HEALTH AND TRAINING QUESTIONNAIRE 
 
PARTICIPANT NUMBER:  _________________ 
 
 
DATE OF TEST:  _________________________ 
 
 
TYPE OF TEST:  
_____________________________________________________________________
 
 
TRAINING LAST 2 DAYS (Volume and Intensity):  
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
 
 
RECENT HEALTH STATUS (Last 2 days):  
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
 
 
STAGE OF TRAINING:  
____________________________________________________________________ 
 
 
OTHER COMMENTS (health, training, injuries):  
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
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CHAPTER FOUR 
 
Relationships between laboratory-derived data and 
cycling performance in endurance-trained women: 
Experimental study two 
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4.1 Abstract 
There are fewer published studies in sport and exercise medicine involving moderate 
to highly-trained women compared to men. The potential influence of ovarian 
hormones on performance and the challenges researchers face controlling and 
verifying these hormones may explain, at least in part, this bias. Despite previous 
studies showing significant relationships between the modified D-max LT2 and 
endurance cycling performance in women, the strength of the relationship needs 
clarifying after accurately controlling for additional influencing factors, such as female 
sex hormones. Therefore, the objectives of this study were to replicate the 
investigations in experimental study one of the present thesis in endurance-trained 
women, whilst controlling for ovarian hormone concentrations through the use of 
hormonal contraceptives. 
 
Twelve competitive female cyclists and triathletes (V̇O2max 54.5 ± 5.3 mL·kg-1·min-1; 
mean ± SD) who had been using a hormonal contraceptive for ≥ 3 months 
completed an incremental cycle trial to volitional fatigue, a 30 min constant load 
exercise trial at LT2 power output, and a 40 km cycle time trial. Four out of five 
maximal variables, and three out of five LT2 variables were significantly correlated 
with 40 km cycling time trial performance. However, the strongest determination of 
cycling performance resulted when combining three maximal and three LT2 variables 
(r2 = 0.87; p = 0.04).  
 
The comparability of LT2 and VT2 was only partially confirmed since power output, 
heart rate, absolute V̇O2, relative V̇O2 and [La-] were significantly correlated between 
threshold methods; however, all were significantly (p < 0.01) higher at VT2 than at 
LT2. Furthermore, only 73% of constant load trials were successfully completed at 
LT2 power output with a steady-state [La-]. No significant differences (p = 0.37-0.93) 
were observed among measured variables (heart rate, absolute and relative V̇O2max 
and [La-]) at LT2, during constant load exercise or during a 40 km time trial. However, 
mean power output was ~6% higher at LT2 than the mean self-selected power output 
during the time trial, suggesting that a higher mean 40 km time trial power output 
may have been tolerable. In conclusion, although the modified D-max LT2 is 
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recommended for prescription of a sustainable heart rate, V̇O2 and [La-] during 40 km 
cycling in endurance-trained women, the strongest determination of performance 
resulted when combining both maximal and LT2 variables.  
 
4.2 Introduction 
Although various laboratory-measured variables have been associated with 
endurance performance in untrained, moderately- and highly-trained men [47, 93], with 
further confirmation of this in study one of the present thesis, the extent and strength 
of these relationships are less clear in women. A sex bias towards men participating 
in sport and exercise medicine research has been highlighted, with women 
representing only 39% of the literature (whether the samples were single-sex or 
mixed), with 4-13% incorporating females only, across three leading journals from 
2011 to 2013 [20]. In addition to the difficulties associated with recruitment of female 
athletes into research studies, there are challenges surrounding the control and 
verification of ovarian hormone levels - oestrogen and progesterone, which fluctuate 
during different phases the menstrual cycle, as opposed to male physiology which 
remains relatively consistent from day to day [21]. This likely contributes, at least in 
part, to men being the preferred choice for study inclusion over women and even 
when women are recruited, controlling for and verification of these ovarian hormones 
is seldom performed [10, 88, 183]. The present research, as per the body of literature 
reviewed, considers biological sex rather than gender. This distinction is made on 
the basis of sex hormones and other physiological differences between males and 
females, and the influence of these differences on exercise performance. 
Consideration of intersex and trans-sexual athletes was beyond the scope of the 
present research. 
 
Complications surrounding the fluctuating concentrations of ovarian hormones are 
based upon their potential to influence physiological responses to exercise 
performance. A lower [La-] during exercise at and above LT2 intensity (~70% and 
90% V̇O2max, respectively) in the luteal phase (LP; when oestradiol concentrations 
are higher) vs. the follicular phase (FP) of the menstrual cycle [22] suggests oestradiol 
has a protective effect or capacity to improve lactate kinetics. This has been shown 
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to influence LT2 (determined by the onset of blood lactate accumulation; OBLA), 
which was higher in the LP when expressed as power output (p < 0.01), heart rate 
(p ≤ 0.001) and V̇O2 (p < 0.05), compared to the FP in recreationally-active women 
(n = 12) [224]. Although no changes in LT2 were seen when methods based on the 
shape of the lactate vs. time curve were used (D-max, a visual identification method 
and a log transformation method) [23, 224], this has not been investigated with the 
modified D-max method. Since the modified D-max can be prone to artificial changes 
to LT2 if the initial 0.4 mmol·L-1 rise in [La-] occurs at a different stage [24], and 
significantly higher [La-] have been shown at rest [22] and in response to exercise at 
25% V̇O2max [23] in the FP, the modified D-max curve and subsequent LT2 may be 
influenced by ovarian hormone concentrations.  
 
In regards to endurance performance, the general evaluation by researchers is that 
the evidence regarding the influence of ovarian hormones remains equivocal, and 
according to Elliott-Sale et al. [25], the extant research is weakened by 
inconsistencies in the definition and measurement of reproductive hormone status, 
methodological inconsistencies, inappropriate verification of menstrual cycle phase, 
small participant numbers, high intra- and inter-individual variability in oestradiol and 
progesterone concentrations and the pulsatile secretion of these hormones [21, 184]. 
Continuous down-regulation of endogenous oestrogen and progesterone, which 
prevents follicular development and ovulation and subsequently eliminates cyclical 
variation in the uterus and ovaries, is achieved through the use of hormonal 
contraceptive agents [25]. As a result, controlling for ovarian hormone concentrations 
through the use of hormonal contraceptives in female-specific and sex-based 
comparative research is warranted, and has been recommended [196].  
 
To date, a limited number of studies have examined the relationships between 
laboratory-derived measures and endurance performance in trained women. Bishop 
et al. examined the relationships between 1 h cycle time trial performance and LT2 
as determined from six methods (in addition to V̇O2max) in female cyclists and 
triathletes in two separate studies (n = 24 [10]; n = 12 [17]). It was shown that each of 
the six LT2 parameters (r = 0.61-0.84; p < 0.01 [10] and r = 0.71-0.89; p < 0.05 [17]) 
and peak power (r = 0.81; p < 0.01 [10]) produced stronger relationships with 
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endurance performance than V̇O2peak (r = 0.55; p < 0.01 [10] and r = 0.65; p < 0.05 
[17]). Of these LT2 methods, D-max (r = 0.84; p < 0.001 [10] and r = 0.89; p < 0.01 [17]) 
and modified D-max (r = 0.83; p < 0.01 [10] and r = 0.79; p < 0.05 [17]) produced the 
strongest relationships. Additionally, the modified D-max also produced a strong 
relationship with 30-min cycling time trial performance in well-trained veteran cyclists 
[18], although the men to women ratio was skewed (8:1), so the strength of the 
relationship in women is unknown. Furthermore, ovarian hormone concentrations 
were not controlled or measured in the women participating in these studies, and 
therefore their potential influence cannot be disregarded. Absolute peak power 
output has also produced significant relationships with 40 km cycling performance 
(r = -0.82; p < 0.01; n = 20 [298] and r = 0.81; p < 0.01 [10]), and the relationship was 
even stronger when peak power output was expressed relative to body mass, to the 
power of 0.32 (allometrically-scaled; W·kg-0.32; r = -0.87; p < 0.01 [298]). The study of 
Lamberts et al. was the only one to attempt to control for ovarian hormone status by 
limiting physiological testing to days 7 - 21 of the menstrual cycle [298]. However, 
there was no concomitant analysis of ovarian hormone concentrations, either via 
blood or urinary measures. Considering the high intra- and inter-individual variability 
in endogenous oestradiol and progesterone concentrations within a menstrual phase 
[21], and the large range of cycle lengths (29-38 days [196], it is unknown whether 
these hormones were truly controlled for in this study. 
 
As discussed in section 3.2 of this thesis, the state institutes and academies of sport 
in Australia utilise the modified D-max method to determine LT2. However, the two 
studies by Bishop et al. [10, 17] mentioned above are the only ones identified to 
evaluate the relationship between the modified D-max and endurance performance 
in trained women. Therefore, investigating the same research questions as 
experimental study one (section 3.2) of the present thesis is warranted in women, 
whilst minimising the potential influence of ovarian hormones on outcomes with the 
use of hormonal contraceptives. When ovarian hormone concentrations were 
controlled in women, the hypotheses remained the same as for experimental study 
one (section 3.2). Specifically, it was hypothesised that the modified D-max LT2 
would be significantly related to 40 km cycle time trial performance and comparable 
to VT2. Furthermore, it was hypothesised that 30 min of exercise at the modified D-
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max power output would be maintainable, produce a steady state [La-] and elicit 
similar physiological responses to those produced during a 40 km cycle time trial in 
trained cyclists and triathletes.  
 
4.3 Methods  
4.3.1 Experimental Overview 
Unless specifically identified, all methodological procedures were identical to those 
described in Chapter 3 of the present thesis. Heart rate was monitored continuously 
during all trials using a different device (Polar Electro Oy, KY, Finland) and 
environmental conditions were controlled similarly (temperature 22.7 ± 1.8 °C, 
relative humidity 67.5 ± 11.9% and barometric pressure 759.8 ± 4.6 mm Hg). 
 
4.3.2 Participants 
Competitive female cyclists and triathletes (n = 12) were recruited for this cross-
sectional study via email advertisements sent to local cycling and triathlon clubs and 
through family and friends involved in cycling and triathlon. A sample size calculation 
for multiple regression analysis indicated that to detect an r2 = 0.87 with five predictor 
variables, alpha = 0.05 and power = 80%, 10 participants would be required [266]. 
Inclusion criteria different to those of chapter 3 were: (1) female; (2) aged 18-40 
years (inclusive); and (3) taking a combined hormonal contraceptive for ≥ 3 months. 
The investigation was approved by the Medical Research Ethics Committee of The 
University of Queensland (approval number HMS11/0511.R1).  
 
4.3.3 Familiarisation Trials 
The V̇O2max trial began with an initial work rate of 100 W, and this increased by 
25 W every 5 min until volitional exhaustion. This protocol is a slight modification of 
the National Testing Protocol for women (which used 3 min stages); this was done to 
more closely match the number of stages and time per stage with the men’s protocol 
(which used 50 W increments every 5 min) and therefore allow a more direct 
comparison between results of experimental studies one and two in the present 
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thesis. Furthermore, it has been recommended by others that incremental stage 
duration is a minimum of 5 min for accurate LT2 identification [15].  
 
Expired air was analysed for FEO2 and FECO2 every 15 sec during exercise from a 
mixing chamber using a different device (due to a recent laboratory upgrade) to that 
described in section 3.3.3 (Parvo Medics, True One 2400, Sandy, Utah, USA), while 
VE was recorded every 15 sec using a heated pneumotach (Hans Rudolph, Kansas, 
USA). The pneumotach was calibrated using a 3 L syringe as per the manufacturer’s 
instructions.  
 
During the 40 km time trial, the only instruction provided to the participants was to 
finish the 40 km in the shortest possible time. The familiarisation distance of 40 km 
(as opposed to 20 km selected for the male participants in chapter 3) was 
implemented in this study based on findings surrounding pacing in elite female 
cyclists. Research has suggested that power output during a criterium, a road race 
and a time trial are all highly variable [299], implying that distance and duration 
significantly influence the exercise intensity selected by female cyclists. Furthermore, 
the distance used within this study (40 km) is not commonly performed by female 
cyclists (although it is highly specific for Olympic distance triathletes), who more 
often complete distances of 25-30 km (time trials) and 110-130 km (road cycling 
events at World Championships and Summer Olympics) [300]. Therefore, a 40 km 
familiarisation trial has been recommended for women [298].  
 
4.3.4 Diet and Exercise Control 
4.3.4.1 Dietary Intake 
In addition to the pre-trial dietary controls (as described in section 3.3.4.1), hydration 
status was measured. Prior to arrival at the laboratory, participants were requested 
to complete a hydration self-assessment based on body mass change, thirst and 
urine colour. Risk factors for dehydration were considered a loss of >1% body mass, 
persistent thirst or dark urine (as determined by a colour chart [301]). The volume of 
fluid intake recommended to participants to maintain euhydration was based on the 
number of risk factors experienced; this volume was provided in a table within the 
self-assessment tool (Appendix 4.1). Upon arrival at the laboratory, participants 
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completed a pre-trial checklist confirming their compliance with the pre-trial 
conditions, and provided a urine sample that was analysed for urine osmolality 
(Osmocheck, Vitech Scientific, West Sussex, Great Britain) to confirm euhydration 
status (≤ 700 mOsmol/kgH2O) [302, 303]. Where participants produced a result 
≥ 700 mOsmol/kgH2O, they were requested to continue to consume water until 
producing a urine sample below the required result; this process was required to be 
implemented in one trial for one participant.  
 
4.3.4.2 Exercise 
Upon arrival at the laboratory, participants completed a well-being questionnaire: a 
modified version of the general recovery-stress questionnaire [304] (RESTQ-Basic). 
This tool has previously been used within the study’s laboratory to determine 
physical and psychosocial recovery levels (Appendix 4.2). The questionnaire 
responses were checked and compared among trials; no responses indicated further 
questioning regarding suspected mental or physical fatigue leading into an exercise 
trial was warranted.  
 
4.3.5 Hormonal Status 
Trials (excluding familiarisation) were scheduled to coincide with the high-hormone 
phase of each participant’s contraceptive formulation. All participants were taking a 
combined oral contraceptive (OC) pill. Each packet contained 28 pills, 21 of which 
were ‘active’ (containing a combination of oestrogen and progestogen), and seven of 
which were ‘inactive’ pills. Combined pills are available in monophasic preparations 
(in which each pill contains an equal dose of oestrogen and progestogen throughout 
the cycle), and biphasic and triphasic preparations (in which the dose of both 
oestrogen and progestogen changes once or twice respectively, over the 21-day 
period). Monophasic (Table 4.1; n = 11) and triphasic (Table 4.2; n = 1) preparations 
were used by participants in this study. For participants taking a monophasic OC, all 
trials (with the exception of the familiarisation trials) were completed between days 
eight and 21 of their cycle (with day one classified as the first active pill for the new 
cycle) to enhance consistency of hormone concentrations, based on concentration-
time curves for oestradiol [229]. For the participant taking a triphasic OC, all trials (with 
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the exception of the familiarisation trials) were completed between days 12 and 21 
(the high-dose phase) to ensure hormone concentrations were similar to those of the 
monophasic pill users during testing. Testing days are further outlined in Tables 4.1 
and 4.2 below.  
 
Table 4.1. Testing days and non-testing days for users of monophasic OC 
formulations.  
Numbers refer to days of the month, beginning with the day the first active pill is 
taken. 
1st Active pill 2 3 4 5 6 7 
8 9 10 11 12 13 14 
15  16 17 18 19 20 21 
22 Inactive 
pill 
(Menstruation) 
23 24 25 26 27 28 
 
 
 
Table 4.2. Testing days and non-testing days for users of triphasic OC 
formulations.  
Numbers refer to days of the month, beginning with the day the first active pill is 
taken. 
1st Active pill 
Low dose 
2 3 4 5 6 7 Moderate  
dose 
8 9 10 11 12 High 
dose 
13 14 
15  16 17 18 19 20 21 
22 Inactive 
pill 
(Menstruation) 
23 24 25 26 27 28 
 
 
Non-testing days 
Testing days 
Non-testing days 
Testing days 
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Large inter- and intra-individual differences in the pharmacokinetics of plasma 
ethinyl-estradiols and progestins exist, however concentrations appear more 
consistent after 6 h [305, 306]. As such, participants were requested to take their pill 
before they went to bed at night to ensure sufficient time (> 6 h) for plasma hormone 
levels to stabilise. Participants were required to record any menstrual-related 
symptoms that occurred within 48 h of a trial (excluding familiarisation) in a 
questionnaire (Appendix 4.3).  
 
All participants completed an ovulation test (Discover® 7-Day Pregnancy Planning 
kit, Church and Dwight Australia Pty Ltd.; 95% specificity; 99% accuracy) on day 
seven of the cycle to confirm anovulation. Day seven was chosen to increase the 
likelihood of ovulation detection given the ovulation test manufacturer suggested 
testing between days four and 10. For further verification of intra-participant 
consistency in hormone concentrations among trials, venous blood was sampled on 
the day of each trial for the later analysis of oestrogen and progestogen 
concentrations. This three-step process including (1) step-wise menstrual cycle 
mapping (Table 4.1 and 4.2), home urinary ovulation prediction testing, and (3) 
serum/plasma hormone verification has been recommended for confirmation of 
exogenous hormone control [196]. 
 
4.3.6 Investigative Trials 
4.3.6.1 V̇O2max  
There was one difference between the protocol described in section 3.3.5.1 and the 
present study - peak power output calculation involved multiplication by 25 W, rather 
than 50 W, to reflect the difference in work rate increase between men and women.  
 
4.3.6.2 30 min constant load trial 
Details of the constant load trial are identical to those described in section 3.3.5.2 of 
the present thesis. 
 
4.3.6.3 40 km time trial 
Details of the 40 km time trial are identical to those described in section 3.3.5.3 of 
the present thesis. 
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4.3.7 Blood Sampling, Storage and Analysis 
4.3.7.1 Plasma [La-] 
Finger-tip capillary blood (25 μL) was collected and stored as described in section 
3.3.6. Samples were analysed using a Cobas Integra clinical autoanalyser (Lactate 
Gen 2) at an external pathology laboratory (Sullivan Nicolaides Pathology, Brisbane). 
The method used by this laboratory was identical to the method used in section 
3.3.6). The laboratory reported a CV of 4.8%, 2.8% and 0.5% for low (3.1 ± 0.1 
mmol·L-1), moderate (8.9 ± 0.3 mmol·L-1), and high (25.5 ± 0.1 mmol·L-1) plasma 
[La-], respectively. 
 
4.3.7.2  Oestradiol and progesterone 
Venous blood (4 mL) was sampled from participants prior to each trial (excluding 
familiarisation trials). Samples were collected in serum vacutainers (4 mL) from the 
antecubital veins, and left to clot for 45 - 90 min before centrifugation at 1000 x g at 
4°C for 10 min. The serum was removed, stored in polypropylene microcentrifuge 
tubes in 0.4 mL aliquots and frozen at -80°C until analysis. Oestradiol and 
progesterone concentrations were analysed at an external pathology laboratory 
(Sullivan Nicolaides Pathology, Brisbane) using the Architecht chemiluminescence 
immune-autoanalyser (Abbott Laboratories, Longford, Ireland). The laboratory 
reported values for CV were 9%, 3% and 3% for low (108.7 ± 9.7 pmol·L-1), 
moderate (864.7 ± 25.0 pmol·L-1) and high levels (1790.6 ± 47.1 pmol·L-1) of 
oestradiol, respectively, and 7% for each of low (2.76 ± 0.18 nmol·L-1), moderate 
(27.53 ± 1.90 nmol·L-1) and high (68.72 ± 4.73 nmol·L-1) levels of progesterone. 
 
4.3.7.2.1 Oestradiol 
Oestradiol concentrations were analysed as per the manufacturer’s instructions [307]. 
The sample (35 μL) was incubated with an oestradiol-specific biotinylated antibody, 
thereby forming an immunocomplex, the amount of which was dependent upon the 
analyte concentration in the sample. After the addition of streptavidin-coated 
microparticles and an oestradiol derivative labelled with a ruthenium complex, the 
still-vacant sites of the biotinylated antibodies became occupied, with formation of an 
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antibody-hapten complex. The entire complex became bound to the solid phase 
microparticles via interaction of biotin and streptavidin. The reaction mixture was 
aspirated into the measuring cell where the microparticles were magnetically 
captured onto the surface of the electrode. Unbound substances were then removed 
with Pro-Cell reagent. Application of a voltage to the electrode then induced 
chemiluminescent emission measured by a photomultiplier. Results were determined 
via a calibration curve which was instrument-specifically generated by two-point 
calibration and a master curve provided via the reagent barcode. 
 
4.3.7.2.2 Progesterone 
Progesterone concentrations were analysed as per the manufacturer’s instructions 
[308]. The sample (30 μL) was incubated with Danazol in the presence of a 
biotinylated monoclonal progesterone-specific antibody and a progesterone 
derivative labelled with ruthenium complex to release progesterone. Progesterone 
from the sample competed with the labelled progesterone derivative for the antibody 
binding site. After the addition of streptavidin-coated microparticles, the complex 
became bound to the solid phase microparticles via interaction of biotin and 
streptavidin. The amount of the labelled progesterone derivative bound to the solid 
phase was inversely proportional to the progesterone content of the sample. The 
reaction mixture was aspirated into the measuring cell where the microparticles were 
magnetically captured onto the surface of the electrode. Unbound substances were 
then removed with Pro-Cell reagent. Application of a voltage to the electrode then 
induced chemiluminescent emission which was measured by a photomultiplier. 
Results were determined via a calibration curve which was instrument specifically 
generated by two-point calibration and a master curve provided via the reagent 
barcode. 
 
4.3.8 Statistical Analysis 
Data were analysed as per section 3.3.7 of the present thesis. The mean of the 
seven questions on the modified RESTQ-Basic was calculated for each participant 
prior to each trial, whereby the trial number reflected the randomised order that each 
participant was assigned, not a particular trial (i.e. trial one could have been the 
V̇O2max or 40 km time trial for different participants). This was done to assess 
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whether fatigue accumulated during the study. ANOVAs and Friedman’s ANOVAs 
were used as appropriate to compare differences among trials for well-being, dietary 
nutritional content and urine osmolality. All tests were two-tailed with an alpha level 
of 0.05. Results are reported as the mean ± SD (95% CI), unless stated otherwise. 
 
4.4 Results 
Twelve participants (27.3 ± 6.2 years of age; body mass 57.1 ± 5.1 kg) volunteered 
to participate in this study. Diet diaries showed that no significant differences 
(p > 0.05) were evident among the three trials in total energy intake, carbohydrate 
and protein content, or volume of water consumed in the 24 h prior to each trial, 
although a higher fat and saturated fat intake was reported prior to the V̇O2max trial 
compared to the 40 km time trial (p < 0.01; Table 4.3). Upon commencing each trial, 
all participants produced a urine osmolality result ≤ 700 mOsmol/kgH2O, and there 
were no significant differences in urine osmolality among the three trials (p = 0.56; 
Table 4.4). Training diaries confirmed that all participants avoided vigorous or higher 
intensity and high volume exercise in the 24 h prior to each trial. The mean scores of 
all seven questions on the modified RESTQ-Basic for trials one, two and three were 
4.1 ± 1.0, 4.1 ± 1.0 and 4.0 ± 1.2, respectively, with no differences among trials 
(p = 0.94).  
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Table 4.3. Diet diary results per trial.  
Non-normally-distributed data are expressed as median (interquartile range).  
 V̇O2max Constant load Time trial 
Energy (kJ) 
10336 ± 3259 (8265-
12406) 
8440 ± 3321 (6330-
10550) 
8883 ± 2970 (6997-
10770) 
CHO (g) 303 ± 114 (230-375) 244 ± 126 (163-324) 269 ± 108 (200-338) 
Protein (g) 100 ± 28 (82-118) 90 ± 21 (77-104) 96 ± 33 (75-116) 
Fat (g) 89 ± 40 (64-115)* 70 ± 37 (46-93) 67 ± 36 (44-90) 
Sat fat (g) 35 ± 16 (25-45)* 27 ± 16 (17-36) 23 ± 14 14-32) 
Water (mL) 1250 (844) 1250 (269) 1225 (450) 
kJ: kilojoule; CHO: carbohydrate; g: grams; sat fat: saturated fat; mL; millilitres; V̇O2max: maximal 
incremental trial; *p < 0.01 compared to time trial. 
 
Table 4.4. Urine osmolality (mOsmol/kgH2O) results per trial.  
 
Trial V̇O2max Constant load 40 km time trial 
Mean ± SD 228 ± 157 228 ± 163 246 ± 196 
95% CI 128-328  124-331  173-320  
V̇O2max: maximal incremental trial; CI: confidence interval. 
 
 
 
 
4.4.1 V̇O2max trial 
Mean values for the variables recorded during the V̇O2max trial are shown in Table 
4.5 (absolute and relative V̇O2max, absolute and relative peak power output) and 
Table 4.6 (variables corresponding to LT2 and VT2 including power output, heart rate, 
V̇O2 and [La-]). There was a large variation among LT2 values (power output, heart 
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rate, V̇O2 and [La-]) when expressed as percentages of their respective maximal 
values (~41-90% maximum). However, power output and V̇O2 produced similar 
percentages of maximum (~83 and 82%, respectively). VT2 was significantly higher 
than LT2 with respect to power output (+17 W; p < 0.01), heart rate (+6 beats·min-1; 
p < 0.01), absolute V̇O2 (+0.2 L·min-1; p < 0.01), relative V̇O2 (+2.9 mL·kg-1·min-1; 
p = 0.01) and [La-] (+2.4 mmol·L-1; p < 0.01). 
 
Table 4.5. Maximal variables recorded during the V̇O2max trial (n = 12).  
Non-normally distributed data are expressed as median (interquartile range).  
 Mean ± SD 95% CI 
V̇O2max (L·min-1) 3.1  0.3 2.9-3.3 
V̇O2max (mL·kg-1·min-1) 54.5  5.3 51.2-57.9 
Peak power output (W) 242  26 225-258  
Relative peak power output (W·kg-1) 4.0 (1.1) 3.9-4.6 
Allometrically-scaled peak power output 
(W·kg-0.32) 
66.3 ± 7.1 61.8-70.8 
V̇O2max: maximal oxygen uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres per kilogram of 
body mass, per minute; W: Watts; W·kg-1: Watts per kilogram of body mass; W·kg-0.32: Watts per 
kilogram of body mass to the power of 0.32; SD: standard deviation; CI: confidence interval. 
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Table 4.6. LT2 and VT2 variables recorded during the V̇O2max trial (n = 11).  
Non-normally-distributed data are expressed as median (interquartile range).  
 Mean ± SD % max 
LT2 VT2 LT2 VT2 
Power output (W) 
200 ± 26  
(183-217) 
217 ± 31  
(197-238)* 
83 ± 4  
(80-85) 
89 ± 7  
(85-94)* 
Heart rate 
(beats·min-1) 
171 ± 8  
(166-177) 
178 ± 8 
(172-183)* 
90 ± 2  
(89-91) 
94 ± 3 
(92-96)* 
V̇O2  
(L·min-1) 
2.5 ± 0.3  
(2.3-2.7) 
2.7 ± 0.4  
(2.5-3.0) 
81.5 ± 2.6 
(80-83) 
87.3 ± 5.8 
(83-91)* 
V̇O2  
(mL·kg-1·min-1) 
44.6  4.7  
(41.6-47.6) 
47.5 ± 5.2  
(44.0-51)* 
81.8 ± 3.4 
(80-84) 
86.4 (12.6)* 
[La-]  
(mmol·L-1) 
4.4  1.0  
(3.7-5.0) 
6.8 ± 1.6  
(5.8-7.9)* 
36.3 (9.3) 
62.9 ± 12.0  
(54.8-70.9)* 
LT2: second lactate threshold; VT2: second ventilatory threshold; W: Watts; beats·min-1: beats per 
minute; V̇O2: oxygen uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres per kilogram of body 
mass, per minute; [La-]: plasma lactate concentration; mmol·L-1: millimoles per litre; max: maximum; 
*p ≤ 0.01 compared to LT2. 
 
4.4.2 30 min constant load trial 
The mean and percentage of maximum values for the variables recorded during the 
constant load trial are shown in Table 4.7. Results from one participant were 
excluded due to a spurious plasma [La-] result suspected due to equipment 
malfunction and a subsequent error in LT2 power output determination. Of the 11 
participants who completed the constant load trial, nine successfully maintained their 
target power output (LT2 power output ± 5%) for 30 min (mean difference 1.5 ± 1.4%) 
and eight produced a steady-state [La-], defined as an increase of no more than 
1 mmol·L-1 between 10 and 30 min. The two participants who could not maintain 
their LT2 power output (± 5%) exercised for 23 and 10 min, respectively. Therefore, 
~73% of participants (n = 8) completed ‘successful’ trials by satisfying both criteria 
with a mean change in [La-] between 10 and 30 min of 0.2 ± 0.6 mmol·L-1. The 
remaining participant produced an increase in [La-] from min 10 to min 30 of 5.1 
mmol·L-1. 
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Table 4.7. Time at target power output and physiological responses during the 
constant load trial at LT2 power output (n = 11).  
Non-normally-distributed data are expressed as median (interquartile range).  
 Mean ± SD % max 
Time at target power output (min) 30.0 (0.0) - 
[La-] (mmol·L-1) 4.5  1.2 (3.6-5.3) 40.8 ± 22.1 (25.9-55.6) 
Peak [La-] (mmol·L-1) 5.0  1.5 (4.0-6.0) 44.7 ± 22.5 (29.6-59.9) 
V̇O2 (mL·kg-1·min-1) 46.0  4.6 (42.9-49.1) 83.6 ± 4.3 (80.7-86.5) 
Heart rate (beats·min-1) 172  10 (165-178) 90 ± 3 (89-92) 
min: minutes; [La-]: plasma lactate concentration; mmol·L-1: millimoles per litre; V̇O2: oxygen uptake; 
mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; beats·min-1: beats per minute; max: 
maximum. 
 
4.4.3 40 km time trial  
The mean and percentage of maximum values for the physiological variables 
recorded during the 40 km time trial, including time to completion, power output, 
[La-], peak [La-], V̇O2 and heart rate are shown in Table 4.8. Relative to their 
respective maximal values (% maximum), there was a large variation among 
variables (~41-91%), although power output and V̇O2 were similar (~78 and 83%, 
respectively). Table 4.9 shows there was a significant difference in mean heart rate 
(p = 0.01), but no difference in mean V̇O2 (p = 0.66) responses among participants in 
the 40 km time trial. 
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Table 4.8. Time to completion and physiological responses during the 40 km 
time trial (n = 12).  
Non-normally-distributed data are expressed as median (interquartile range).  
 Mean ± SD % max 
Time to completion (min) 66.9  3.3 (64.8-68.9) - 
Power output (W) 187  24 (172-202) 77 ± 5 (74-81) 
[La-] (mmol·L-1) 4.6  2.1 (3.2-5.9) 41.2 ± 16.4 (30.8-51.6) 
Peak [La-] (mmol·L-1) 6.6  3.2 (4.5-8.6) 59.4 ± 25.5 (43.2-75.6) 
V̇O2 (mL·kg-1·min-1) 47.1 (12.3) 82.5 ± 5.9 (78.8-86.3) 
Heart rate (beats·min-1) 173  8 (168-178) 91 ± 3 (89-93) 
min: minutes; sec: seconds; W: Watts; [La‐]: plasma lactate concentration; mmol·L‐1: millimoles per litre; VȩO2: 
oxygen uptake; mL∙kg‐1∙min‐1: millilitres per kilogram of body mass, per minute; beats·min‐1: beats per minute; 
max: maximum. 
 
Table 4.9. Heart rate and V̇O2 responses during the 40 km time trial at 10 km 
intervals (n = 12).  
Distance (km) Heart rate (beats·min-1) V̇O2 (mL·kg-1·min-1) 
0-10 166 ± 13 (157-174) 44.8 ± 4.8 (41.1-48.4) 
11-20 173 ± 9.3 (167-179) 44.0 ± 6.2 (40.1-48.0) 
21-30 175 ± 7 (170-179) 44.5 ± 5.0 (41.3-47.7) 
31-40 180 ± 8 (174-185)* 47.0 ± 7.5 (42.2-51.8) 
km: kilometre; beats·min-1: beats per minute; V̇O2: oxygen uptake; mL·kg-1·min-1: millilitres per 
kilogram of body mass, per minute; *p ≤ 0.01 compared to 0-10 km. 
 
Relationships between V̇O2max, peak power output and relative peak power output 
with 40 km time trial performance time are shown in Figure 4.1, while relationships 
between variables at LT2 (power output, heart rate, V̇O2 and [La-]) and 40 km time 
trial performance time are displayed in Figure 4.2. Variables producing the strongest 
relationships with time trial performance were peak power output (r = -0.87; 
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p < 0.01), allometrically-scaled peak power output (W·kg-0.32; r = -0.86; p < 0.01) and 
LT2 power output (r = -0.75; p < 0.01). In addition, four other variables [relative peak 
power output (W·kg-1; r = -0.68; p < 0.05), absolute V̇O2max (L·min-1; r = -0.66; 
p < 0.05), LT2 absolute V̇O2 (L·min-1; r = -0.66; p < 0.05) and LT2 relative V̇O2 
(mL·kg-1·min-1; r = -0.63; p < 0.05)] also displayed significant relationships with time 
trial performance. Variables related to heart rate and [La-] produced weak, non-
significant correlations with time trial performance. These were maximum heart rate 
(r = 0.34; p = 0.28), LT2 heart rate (r = 0.20; p = 0.54)], maximum [La-] (r = -0.04; 
p = 0.92) and LT2 [La-] (r = 0.10; p = 0.77). Although approaching significance, the 
relationship between relative V̇O2max (r = -0.57; p = 0.05) and time trial performance 
was also non-significant. Power output (r = -0.75; p < 0.01) and relative V̇O2 
(r = -0.73; p = 0.01), but not heart rate, absolute V̇O2 or [La-] reflective of VT2 
(p = 0.10-1.00), produced a significant correlation with performance. Collectively, 
peak power output, power output at LT2, relative peak power output (W·kg-1), V̇O2 at 
LT2 (L·min-1 and mL·kg-1·min-1) and absolute V̇O2max significantly explained the 
variance in time trial performance (r2 = 0.87; p < 0.05). The regression equation 
generated was:  
 
 40 km time trial time = 5883.77 + (-0.42 x absolute peak power output) + (18.57 x 
power output at LT2) + (-1196.43 x relative peak power output; W·kg-1) + (1019.09 x 
absolute V̇O2max) + (-3409.76 x absolute V̇O2 at LT2) + (114.15 x relative V̇O2 at 
LT2). 
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Figure 4.1. Correlations between time trial performance time (n = 12) and; (a) 
absolute V̇O2max, (b) relative V̇O2max, (c) peak power output, (d) relative peak 
power output (W·kg-1) and (e) allometrically-scaled peak power output 
(W·kg-0.32).  
Min: minutes; V̇O2max: maximal oxygen uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres 
per kilogram of body mass, per minute; W: Watts; W·kg-1: Watts per kilogram of body mass; W·kg-0.32: 
Watts per kilogram of body mass to the power of 0.32; *p < 0.05; **p < 0.01. 
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Figure 4.2. Correlations between time trial performance time and; (a) LT2 power 
output (W), (b) LT2 heart rate (beats·min-1), (c) absolute LT2 V̇O2 (L·min-1), (d) 
relative LT2 V̇O2 (mL·kg-1·min-1) and (e) LT2 [La-] (mmol·L-1).  
Min: minutes; LT2: second lactate threshold; W: Watts; beats·min-1: beats per minute; V̇O2: oxygen 
uptake; L·min-1: Litres per minute; mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; 
[La-]: lactate concentration; mmol·L-1: millimoles per litre; *p < 0.05; **p < 0.01. 
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VT2 was detected in 11 out of 12 (92%) participants, and both independent 
researchers were in agreement (determined by visually detecting VT2 at the same 
work rate) in seven (64%) of the trials. In the four cases where the opinion of a third 
observer was sought, there always existed agreement with one of the two 
researchers. Significant relationships were observed between LT2 and VT2 in relation 
to power output (r = 0.91; p < 0.01), heart rate (r = 0.71; p < 0.05), absolute V̇O2 
(L·min-1; r = 0.91; p < 0.01), relative V̇O2 (mL·kg-1·min-1; r = 0.82; p < 0.01) and [La-] 
(r = 0.79; p < 0.01).  
 
Mean power output, heart rate, V̇O2 and [La-] firstly at LT2, secondly, during 30 min of 
constant load exercise, and thirdly, during the 40 km time trial, are shown in Table 
4.10. All variables were compared among LT2, constant load exercise and 40 km 
time trial, except for power output which was compared between LT2 and time trial 
only (since LT2 power output determined constant load power output). No significant 
differences were found among LT2, constant load and 40 km time trial for heart rate 
(p = 0.37), absolute V̇O2 (p = 0.65), relative V̇O2 (p = 0.53) and [La-] (p = 0.93). 
However, power output at LT2 was significantly higher than the mean power output 
maintained during the 40 km time trial (6%; p = 0.03).  
 
196 
 
Table 4.10. Variables reflective of LT2, elicited during constant load exercise 
and during a 40 km time trial.  
Non-normally-distributed data are expressed as median (interquartile range).   
Variable LT2 Constant load Time trial 
Power output (W) 200 ± 26 (183-217)* 197 ± 26 (179-214) 187  24 (172-202) 
Heart rate (beats·min-1) 171 ± 8 (166-177) 172  10 (165-178) 173  8 (168-178) 
Absolute V̇O2 (L·min-1) 2.5 ± 0.3 (2.3-2.7) 2.6 ± 0.3 (2.4-2.8) 2.5 ± 0.3 (2.4-2.7) 
Relative V̇O2 (mL·kg-1·min-1) 
44.6  4.7 (41.6-
47.6) 
46.0  4.6 (42.9-
49.1) 
47.1 (12.3) 
[La-] (mmol·L-1) 4.4  1.0 (3.7-5.0) 4.5  1.2 (3.6-5.3) 4.6  2.1 (3.2-5.9) 
LT2: second lactate threshold; W: Watts; beats·min-1: beats per minute; V̇O2: oxygen uptake; L·min-1: 
Litres per minute; mL·kg-1·min-1: millilitres per kilogram of body mass, per minute; [La-]: plasma lactate 
concentration; mmol·L-1: millimoles per litre; *p < 0.05 compared to time trial.  
 
 
Heart rate, absolute V̇O2, relative V̇O2 and [La-] were compared between 0-10, 11-20 
and 21-30 min of the constant load trial (time points 1-3, respectively) and 0-10, 
11-20, 21-30 and 31-40 km of the 40 km time trial (time points 1-4, respectively) and 
at LT2. No significant differences among trials were found at time point 1 [heart rate 
(p = 0.18), absolute V̇O2 (p = 0.91), relative V̇O2 (p = 0.79) and [La-] (p = 0.92)], time 
point 2 [heart rate (p = 0.14), absolute V̇O2 (p = 0.32), relative V̇O2 (p = 0.39) and 
[La-] (p = 0.60)] or time point 3 [heart rate (p = 0.33), absolute V̇O2 (p = 0.39), relative 
V̇O2 (p = 0.38) and [La-] (p = 0.47)]. At time point 4, there was no significant 
difference between LT2 and time trial for relative V̇O2 (p = 0.13), absolute V̇O2 
(p = 0.24) and [La-] (p = 0.17); however, heart rate was significantly higher during the 
40 km time trial than at LT2 (p < 0.01). 
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4.4.4 Hormone Status 
4.4.4.1 Ovulation Test 
Ovulation tests were administered a total of 18 times across all participants (one 
participant completed exercise trials over two menstrual cycles, so was tested during 
both cycles). Eight ovulation tests returned a negative result (62%; indicating 
anovulation), three results were deemed inconclusive (23%), one returned a positive 
test result (8%), and one participant forgot to complete the test. When tests were 
inconclusive or the participant forgot to complete the test, testing was postponed 
until a negative result was obtained. For the participant who returned a positive 
result, testing was postponed until serum hormone concentrations confirmed 
anovulation. 
 
4.4.4.2 Blood hormone concentrations 
The total number of participants where blood sampling and hormone analysis was 
possible for all three trials was eight for oestradiol and nine for progesterone. Blood 
was unable to be sampled due to difficulty obtaining blood intravenously a total of 
nine times across four different participants. Across all participants and trials where 
blood was successfully sampled, mean oestradiol and progesterone concentrations 
were 37.9 ± 2.7 pmol·L-1 and 1.3 ± 1.0 nmol·L-1, respectively. Mean concentrations 
of oestradiol and progesterone for trials one, two and three are presented in Table 
4.11, along with the mean intra-participant CV for oestradiol and progesterone 
concentrations among trials. The trial number reflected the randomised order that 
each participant was assigned, not a particular trial (i.e. trial one may have been the 
V̇O2max or 40 km time trial for different participants). A Friedman’s ANOVA revealed 
no significant difference in oestradiol (p = 0.78) or progesterone (p = 0.84) 
concentrations among trials and the mean intra-participant CV was within the 
acceptable range for precision reported by the manufacturers for both oestradiol 
(≤ 7%) [307] and progesterone (≤ 10%) [308]. These results suggest that hormone 
concentrations were not different among all trials and therefore hormone control was 
successful. 
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Table 4.11. Serum oestradiol and progesterone concentrations for trials one, 
two and three, and intra-participant CV values.  
Non-normally-distributed data are expressed as median (interquartile range). 
CV: coefficient of variation; pg·mL-1: picograms per millilitre; ng·mL-1: nanograms per millilitre. 
 
 
A cross-check of individual ovulation and serum hormone concentration results 
revealed that the participant who obtained a positive ovulation test result elicited an 
oestradiol concentration of 12.3 pg·mL-1 and a progesterone concentration of 
0.7 ng·mL-1, which are lower than the expected ranges (5th-95th percentiles) of 
86-498 pg·mL-1 and 0.8-3.0 ng·mL-1 during ovulation respectively, and it is therefore 
unlikely that ovulation truly took place. 
 
4.5 Discussion 
The primary objective of the present study was to examine the associations between 
physiological variables including the modified D-max LT2 and 40 km cycling time trial 
performance in well-trained female endurance athletes. Control and verification of 
ovarian hormone concentrations in this study addresses a limitation of the few 
studies in this area that have included women to enable (1) more accurate female-
specific results to be derived, and (2) more meaningful comparisons with men. It was 
found that: (1) four out of five maximal variables [peak power output, relative peak 
power output (W·kg-1), allometrically-scaled peak power output (W·kg-0.32) and 
absolute V̇O2max] and three out of five LT2 variables (LT2 power output and absolute 
and relative V̇O2 at LT2) were significantly correlated with 40 km cycling time trial 
performance; (2) LT2 was not highly comparable to VT2 when expressed as power 
output, heart rate and V̇O2 (L·min-1), since each variable was significantly higher at 
VT2 than LT2; (3) all 30-min constant load trials were completed, but only eight 
Oestradiol (pg·mL-1) (n = 8) Progesterone (ng·mL-1) (n = 9) 
Trial one  Trial two  Trial three  CV (%) Trial one Trial two Trial three  CV (%) 
10.1 (0.5) 10.1 (0.1) 10.1 (0.5) 3.8 0.2 (0.6) 0.2 (0.5) 0.2 (0.6) 7.5 
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(~73%) were completed with a steady-state [La-]; and (4) there were no significant 
differences between physiological responses (heart rate, absolute and relative 
V̇O2max and [La-]) at LT2, during constant load exercise and during the 40 km time 
trial, although power output was significantly higher at LT2 than during a 40 km time 
trial. 
 
4.5.1 Correlations with 40 km time trial performance 
The primary outcome of the present study was that three LT2 variables determined 
by the modified D-max (power output at LT2, absolute V̇O2 at LT2 and relative V̇O2 at 
LT2) were significantly related to 40 km time trial performance time in endurance-
trained female cyclists and triathletes. However, the relationships between these LT2 
variables and performance were not as strong as those produced between peak 
power output (W) or allometrically-scaled peak power output (W·kg-0.32) and 
performance, suggesting the modified D-max may not be superior to maximal 
variables when assessing performance outcomes. As discussed in study one, the 
intensity of participants’ training prior to their study involvement was not monitored 
and therefore may have influenced the sensitivity of LT2 and peak power output 
differently. Therefore, although 56% of the variance in time trial performance could 
be explained by LT2 power output, 76% and 74% could be explained by absolute (W) 
and allometrically-scaled (W·kg-0.32) peak power output, respectively. When multiple 
regression analysis was performed, the strongest combination of variables was peak 
power output, power output at LT2, relative peak power output (W·kg-1), absolute 
V̇O2max, absolute V̇O2 at LT2 and relative V̇O2 at LT2; this model explained 87% of 
the variance in performance (p < 0.05). The finding suggests that both maximal and 
fractional utilisation variables are important for predicting endurance performance; 
this combination is more important than any single variable.  
 
The three strongest correlates of performance in the present study [absolute and 
allometrically-scaled (W·kg-0.32) peak power output and LT2 power output] have 
previously been found to be significantly related to measures of endurance 
performance in trained women [10, 17, 298], although a limited number of studies have 
examined this. Of these three studies, only one considered the influence of ovarian 
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hormone concentrations by limiting physiological and performance testing to days 
seven to 21 of the menstrual cycle [298]. However, concomitant analysis of ovarian 
hormone concentrations, either via blood or urinary measures, was not implemented, 
and therefore, intra- and inter-individual hormonal fluctuations may have influenced 
the results.  
 
4.5.1.1 LT2 power output and V̇O2 
Three LT2 variables produced significant relationships with 40 km cycling 
performance. The present findings support those of Bishop et al. [10] who examined 
the relationships between LT2 power output and endurance cycling performance and 
found strong correlations between 1 h cycling mean power output and LT2 power 
output (determined using six different LT2 determination methods) in well-trained 
women (r = 0.61-0.84; p < 0.001). Similar correlations were found in a subsequent 
study (r = 0.71-0.89; p < 0.05) [17]. Of particular note is the inclusion of the modified 
D-max in both studies (r = 0.83; p < 0.001 [10] and r = 0.79; p < 0.05 [17]), which 
produced similarly strong correlations with performance as the present study (Figure 
4.2; r = -0.75; p < 0.01). However, neither of those studies reported the V̇O2 at LT2. 
The present study is the first to show that although not as strong as power output, 
the V̇O2 (absolute and relative) corresponding to the modified D-max produced a 
significant relationship with endurance performance in trained female cyclists and 
triathletes. The present study also suggests that fractional utilisation of oxygen is 
more important than the absolute rate of uptake for predicting endurance 
performance. Furthermore, it also confirms the close association between power 
output and V̇O2 reflective of LT2 as percentages of maximum power output (~83%) 
and V̇O2 (~82%), respectively. This suggests that the upper level of power that can 
be supported primarily by aerobic metabolism occurs at the same relative point as 
the upper level of oxygen consumption. In addition to the studies of Bishop et al. [10, 
17], one other study has examined the relationship between LT2 using the modified 
D-max method and endurance performance. Fell [18] recruited one female veteran 
cyclist (along with eight men) and showed a significant relationship between LT2 and 
30 min cycling performance (r = 0.95; p < 0.001).  
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Of these three studies [10, 17, 18], none considered or controlled for ovarian hormone 
concentrations. Therefore, a strength of the present study lies with the control of 
intra-individual ovarian hormone concentrations throughout the study period. This 
hormonal control process allows female-specific results to be interpreted with 
confidence that the impact of these hormones on physiological and performance 
outcomes have been minimised.  
 
4.5.1.2 LT2 heart rate 
In contrast to the significant relationships produced between the three 
aforementioned LT2 variables and 40 km time trial performance, heart rate at LT2 
was not related to cycling performance. This result was somewhat unexpected. 
Although heart rate at LT2 was not reported in either of the studies conducted solely 
in women discussed above [10, 17], the study that included one female cyclist found a 
strong relationship between modified D-max heart rate and mean 30 min time trial 
heart rate (r = 0.88; p < 0.01) [18]. Furthermore, research conducted in endurance-
trained men has shown significant relationships between VT2 heart rate and the 
mean heart rate during the cycle [95, 96] and run phases of an ultra-endurance 
triathlon [96]. However, the use of mean heart rate as the performance measure, 
rather than performance time, as well as the suggested coincidental, rather than 
causal relationship between LT2 and VT2 [285-289] (as discussed in greater detail in 
section 3.5.1.2 of the present thesis), may explain, at least in part, this discrepancy. 
Furthermore, heart rate is known to be influenced by numerous factors, many of 
which are unrelated to the muscle’s capacity to re-synthesise ATP, such as 
ventilation, thermal load, sympathetic nervous system activation and various plasma 
hormone levels, including catecholamine concentrations [309]. These factors may at 
least in part, explain the weak relationship between heart rate at LT2 and 
performance in the present study. Therefore, it is recommended that coaches and 
athletes preference the use of power output and/or V̇O2 when the modified D-max is 
the utilised method of LT2 determination, and disregard the heart rate response at 
LT2, when the goal is to assess cycling performance in women. 
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4.5.1.3 LT2 [La-] 
Similarly to Study one of the present thesis, a weak relationship was found between 
LT2 [La-] and endurance performance, which, together with the known large inter-
individual variability in [La-] for the same relative exercise intensities [152], were 
expected, and confirm that absolute [La-] is insignificant when predicting endurance 
performance across individuals. The present findings are also in agreement with 
others regarding the [La-] at MLSS. Beneke et al. [105] found that MLSS [La-] was not 
significantly related to power output at MLSS or peak work rate in young men, and 
Myburgh et al. [310] reported no relationship between plasma [La-] during a 1 h self-
selected cycling trial in well-trained endurance athletes (sex not stated). 
Furthermore, the [La-] at LT2 also appears to be unrelated to physical fitness [311, 312] 
and sex [312], which provides further evidence for its independence to exercise 
performance. Therefore, similar conclusions can be drawn as for the men in Study 
one; comparing absolute [La-] at LT2 between individuals has no value when the 
objective is to predict endurance performance in women. However, if individual LT2 
[La-]-performance relationships are assessed over time, the value of LT2 [La-] for 
each individual can be established. Nevertheless, when practicality is considered, 
other measures of LT2, including power output and V̇O2, are superior for the purpose 
of predicting endurance performance. 
 
4.5.1.4 V̇O2max 
Absolute, relative (W·kg-1) and allometrically-scaled (W·kg-0.32) peak power output 
and LT2 power output all produced stronger correlations with performance 
(r = -0.75-0.87; all p < 0.01) than absolute (r = -0.66; p < 0.05) and relative (r = -0.57; 
p > 0.05) V̇O2max. This finding is consistent with the limited data from other studies 
reporting maximal values or measures of LT2 in well-trained female cyclists 
(maximal/LT2 measures: r = 0.61-0.84; all p < 0.001 vs. V̇O2max: r = 0.55; p < 0.01; 
n = 24 [10]; maximal/LT2 measures: r = 0.71-0.89; p < 0.05 vs. V̇O2max: r = 0.65; 
p < 0.05; n = 12 [17]) and runners (maximal/LT2 measures: r = -0.77; p < 0.01 vs. 
V̇O2max: r = -0.06; p = 0.86; n = 11 [313]; maximal/LT2 measures: r = -0.97 vs. 
V̇O2max: r = 0.90; p values not reported; n = 7). A stronger relationship between 
peak power output and performance than between V̇O2max and performance is 
supported by the concept that peak power output is influenced by numerous factors 
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in addition to V̇O2max, including exercise economy, anaerobic capability, muscular 
power and neuromuscular skill [314].  
 
Collectively, the findings suggest that although absolute V̇O2max provided a 
moderate correlation with endurance performance, other variables produce stronger 
relationships, and should be preferentially used as indicators of endurance 
performance capacity in endurance-trained women. However, when combined into a 
multiple regression equation, absolute V̇O2max, absolute and relative peak power 
output and two LT2 measures (power output and V̇O2) were capable of explaining 
87% of the variance in performance time. This suggests that both maximal and 
fractional utilisation variables are more valuable for predicting endurance 
performance when used collectively.  
 
4.5.1.5 Absolute and relative peak power output 
The present study is consistent with others in finding that absolute peak power 
output correlated strongly with measures of endurance performance in trained 
women. Lamberts and Davidowitz [298] found a strong relationship (r = -0.82; 
p < 0.001) between peak power output and 40 km cycle time trial time in well-trained 
female cyclists (n = 20) and Bishop et al. [10] showed a strong correlation between 
peak power output and 1 h cycle performance (r = 0.81; p < 0.001) in trained female 
cyclists and triathletes (n = 24). Although correlations were of a similar strength to 
the present study, it is important to note that peak power output in those studies was 
determined as the mean power during the final 60 s of a peak power output test [298] 
and the peak power output achieved at the end of the incremental test [10]. In 
contrast, the method employed in the present study was: [time (min) completed / 
5 min)] multiplied by 25 W, which has been used by others [271, 272]. Others have also 
shown strong correlations in trained athletes between peak power output and mean 
26 km cycle time trial power output (r = 0.91; p < 0.001; n = 15 men and 1 woman 
[181]), 16 km run time trial time (r = -0.89; p value not reported; n = 10 men and 7 
women [88]), 40 km cycle time trial time (r = 0.91; p < 0.01; n = 5 men and 5 women 
[292]) and Olympic-distance triathlon time (r = 0.86; p < 0.01; n = 5 men and 5 women 
[292]). However, all of these studies combined the results of men and women, and it is 
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not clear whether these relationships were as strong for women alone. Nevertheless, 
with the limited research available, the strong relationship between peak power 
output and endurance performance appears consistent independent of the method 
used. 
 
Although variables such as V̇O2max and peak power output are commonly 
expressed in both absolute and relative terms [6, 17, 273], only one of the 
aforementioned studies recruiting women assessed the relationship between 
performance and peak power output relative to body mass (no significant 
relationship) [298]. The present study showed that the relationship between absolute 
peak power output and performance was of similar strength to the relationship 
between relative peak power output and performance, suggesting minimal influence 
of body mass on level-ground cycling. This supports the findings of others who have 
shown that peak power output expressed as W·kg-1 was a good predictor of climbing 
capacity during cycling [4, 42], and suggests that unless there is a significant climbing 
component in a cycling road race or triathlon course, scaling peak power output 
relative to body mass does not provide additional performance prediction strength 
above absolute peak power output. 
 
Consistent with Lamberts and Davidowitz [298], the present investigation also found a 
strong, significant relationship between performance and allometrically-scaled peak 
power output (W·kg-0.32; r = -0.86; p < 0.01). Although this allometrically-scaled 
adjustment of peak power output has been suggested by others when predicting flat 
time trial performance [42, 277, 278], the relationship with performance was of similar 
strength to the relationships between performance and both absolute peak power 
output, and relative peak power output. Although this appears to suggest there is no 
additional benefit in scaling peak power output relative to the power of 0.32, it is 
important to note that the laboratory-based nature of the time trial in the present 
study may have dampened the impact of external factors (such as frontal drag [278]) 
on performance. Therefore, it appears that both absolute and allometrically-scaled 
peak power output have an important role in predicting cycling performance in 
women. 
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There have been limitations in previous research in women regarding menstrual 
status and ovarian hormone control. Of the studies reporting results for women either 
exclusively or independently to men’s results that have been reviewed above [10, 17, 
177, 298], only one controlled for ovarian hormone status [298]. Despite conducting 
physiological and performance testing on days seven to 21 of the menstrual cycle, 
validation using concomitant analysis of serum hormone concentrations was omitted. 
In addition to hormone verification, step-wise menstrual cycle mapping and urinary 
ovulation prediction testing has also been recommended when testing 
eumenorrhoeic women [196]. Furthermore, it has been recommended that testing is 
conducted during the mid-luteal phase when determining the influence of ovarian 
hormone concentrations on physiological and performance adaptations in exercise 
science, with the highest likelihood of correct phase identification being 7-9 days 
following positive ovulation prediction testing or 20-22 days following onset of 
menstruation [196]. Therefore, the present study confirms significant relationships 
between absolute peak power output, relative peak power output, allometrically-
scaled peak power output and LT2 power output determined via the modified D-max 
method, with endurance cycling performance whilst minimising the influence of 
ovarian hormone concentrations. 
 
4.5.2 Comparability with VT2 
The current data suggest that LT2 determined by the modified D-max method was 
somewhat comparable to VT2 as assessed by the VE/V̇O2 method when expressed 
as power output, heart rate, V̇O2 (L·min-1 and mL·kg-1·min-1) and [La-]. These 
variables were significantly correlated between threshold methods; however, all 
variables were significantly higher at VT2 than at LT2 (p < 0.01). This may be 
explained by the previously suggested coincidental, rather than causal, relationship 
between LT2 and VT2 [285-289] (as discussed in greater detail in section 3.5.1.2 of the 
present thesis). However, other potential reasons for this dissociation between 
thresholds cannot easily be explained. Ventilation during exercise in women has 
been reported as higher during the luteal phase (when endogenous ovarian 
hormones are at their highest) than the follicular phase [22, 315, 316]. This suggests a 
potentially higher VT2 (i.e. later onset of increase in ventilation in response to 
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increased CO2) in hormonal contraceptive users whose oestradiol concentrations are 
lower (~20 times) than in women not using contraceptives, and may explain why VT2 
was higher than LT2 in the present study. However, a comparison between men and 
women, and between menstrual cycle phases in women, has shown that VT2 
(calculated as the ventilatory recruitment threshold for CO2) was lower in women 
during all menstrual cycle phases than men, and therefore determined that there was 
a hormonally-related lowering of VT2 [317], which is in contrast to the present findings. 
Alternatively, the influence of ovarian hormones on [La-], rather than ventilation, may 
explain the difference between the two thresholds. A higher [La-] after high-intensity 
exercise when oestradiol concentrations are low, rather than high [22, 23], may explain 
an earlier onset of LT2 in hormonal contraceptive users, such as those in the present 
study, and therefore why LT2 and VT2 were different. Therefore, further research is 
needed to investigate the potential influence of ovarian hormones on the disparity 
between LT2 and VT2 in endurance-trained women.  
 
These findings, when interpreted together with (1) the lack of an identifiable VT2 in 
one participant, (2) the method of LT2 determination by the modified D-max method 
being more objectively quantified, and (3) the strongest correlation with time trial 
performance being exhibited by the power output at LT2, suggest that LT2 rather than 
VT2 may be a preferred fractional utilisation method for predicting endurance 
performance in trained women. Investigation of this phenomenon was beyond the 
scope of this thesis, and further comparison between LT2 and VT2 should be tested 
in subsequent research. 
 
4.5.3 Constant load exercise at LT2 power output 
Nine (82%) of the 11 participants who attempted the 30 min constant load trial 
maintained exercise at their individually-determined LT2 power output for 30 min, and 
eight (89% of those who sustained 30 min) elicited a steady-state [La-]. This 
consistency between sustainability of exercise and steady-state [La-] provides some 
support for the MLSS concept. However, this is weakened by the finding that only 
73% of participants completed ‘successful’ trials by satisfying both criteria (sustained 
exercise for 30 min and elicited a steady-state [La-]). This suggests a discrepancy 
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between LT2 and MLSS that may be explained, at least in part, by the large inter-
individual differences in lactate responses to exercise and athletes’ abilities to 
tolerate different [La-], as previously reported [113]. Further support for this is evident 
in two participants (18%) who could not sustain exercise at LT2 power output for 
30 min. However, for the majority of participants who sustained 30 min of exercise 
and elicited a steady-state [La-], it is still unknown whether LT2 power output was 
their maximal sustainable cycling power output over 30 min, or whether they were 
capable of sustaining a higher power output. Despite no research available on the 
time to fatigue at MLSS in trained female cyclists, data on trained male cyclists have 
reported anywhere between ~38 [128] and 55 min [113] was sustainable with a steady-
state [La-]. However, based on the limited available research, women appear to 
show less fatigue than men when assessed as either time to task failure [318] or as a 
loss of maximum torque [319]. Furthermore, fewer women (42%) than men (58%) 
were shown to develop diaphragmatic fatigue during a cycling time to exhaustion test 
at 90% peak power output, with the magnitude of fatigue being 9%-10% greater 
(p < 0.01-0.05) in men compared to women post-exercise [320], which suggests that 
time to fatigue at MLSS may indeed be longer in women than men. 
 
The presence of oestrogen may explain the disparity in the onset of fatigue between 
men and women. Lipid metabolism in skeletal muscle of females has been related to 
the presence of oestrogen [195, 321], whereby high levels of oestrogen appear to be 
effective at sparing muscle glycogen and delaying fatigue. Collectively, research 
suggests that differences in skeletal muscle metabolism between males and females 
may favour females during, and in recovery from, moderate- and high-intensity 
exercise by minimising fatigue and enhancing recovery [318]. Subsequently, it could 
be anticipated that women may have an increased time to fatigue at MLSS 
compared to men, although more research is needed to confirm this. 
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4.5.4 Differences among LT2, constant load exercise and 
40 km time trial variables 
4.5.4.1 Heart rate, [La-] and V̇O2 
The lack of significant differences within the present study between mean heart rate, 
absolute and relative V̇O2 and [La-]) (1) reflective of LT2, (2) elicited in response to 
constant load exercise, and (3) elicited during a 40 km time trial, are in agreement 
with the work of others [18, 95, 96, 127].  Fell [18] showed no significant difference between 
the heart rate reflective of modified D-max and the heart rate elicited during a 30-min 
time trial (95% CI = -6-+3 beatsmin-1) in trained veteran cyclists (n = 8 men and 1 
woman). Furthermore, Laursen et al. showed no significant differences between 
heart rate during the cycle [95, 96] and run [96] phases of an ultra-endurance triathlon 
and the first VT (VT1) in highly-trained men. It is important to note here that VT1 was 
reported, rather than VT2. However, since VT2 was significantly greater than LT2 in 
the present study, it could be suggested that VT1 may be more closely associated 
with LT2 in the present study. In a study involving multiple 30 min constant load trials 
to determine MLSS, Harnish et al. [127] demonstrated that mean [La-] and heart rate 
at MLSS were not different to corresponding 40 km cycle time trial values in trained 
cyclists (n = 6 men and 3 women), despite data from men and women being grouped 
together, and the control and verification of ovarian hormones was omitted. This 
latter study suggests that the 30 min constant load trial at LT2 intensity in the present 
study may indeed reflect the heart rate and [La-] at MLSS, with a strength of the 
present study being the control of ovarian hormone concentrations, subsequently 
minimising their potential influence on [La-] and heart rate. Additionally, Padilla et al. 
[297] demonstrated that for cycling events ≥ 60 min, mean heart rate was similar to 
heart rate at LT2 (defined as a 1 mmol·L-1 increase in [La-] above baseline when 
exercising at 40%-60% maximal aerobic power output). Despite acknowledging 
confounding variables such as race duration, individual vs. group racing, team 
strategies, and race profile that can potentially influence the physiological responses 
of field-based cycling time trials, the researchers failed to report the sex of their 
participants. Therefore, the present findings extend those of Padilla et al. [297] by 
supporting the use of heart rate reflective of a metabolic threshold to establish 
competition intensities in endurance-trained women. However, it should be noted 
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that mean heart rate was significantly higher in the final 10 km than in the first 10 km 
of the 40 km time trial (~8%; p = 0.01). This is most likely representative of a 
cardiovascular drift which has been reported by others in response to thermal stress, 
reduced blood volume and magnitude of muscle mass activation [124]. 
 
The present findings of a similar mean heart rate and [La-] between the 40 km time 
trial and the 30 min constant load trial contrast with the findings of Nichols et al. [322] 
in female master cyclists (n = 13) and Kenefick et al. [296] in competitive male cyclists 
(n = 13). Nichols et al. [322] found heart rate (~4 and ~6%) and [La-] (165 and 144%) 
at LT2 were significantly lower than those elicited during 13.5 and 20 km time trials, 
respectively, while Kenefick et al. [296] noted that LT2 under-estimated the [La-] 
(~252%), heart rate (~9%) and V̇O2 (~27%) responses in comparison to a 20 km 
cycling time trial. However, different methods of LT2 determination and different time 
trial distances were utilised compared to the present study, and ovarian hormones 
were not controlled or verified in women. Based on these earlier findings and the 
findings of the present study, it could be suggested that a threshold exists whereby 
LT2 is capable of producing a heart rate, [La-] and V̇O2 similar to those elicited during 
performance trials. LT2 appears to under-predict these variables for shorter trials 
(≤ 20 km), whilst in the present study, a longer trial of 40 km produced comparable 
physiological responses with LT2. Further research is required to establish whether a 
more precise threshold between 20 and 40 km exists. This threshold will guide the 
use of LT2 for setting distance-specific exercise intensities in women. Furthermore, 
whether ovarian hormone concentrations influence the capacity for LT2 to reflect 
competition intensities across different distances should be explored. 
 
4.5.4.2 Power output 
The present finding that mean power output at LT2 was significantly higher (~6%; 
p < 0.05) than the mean power output maintained during a 40 km cycle time trial is 
both consistent with and in contrast to the findings of others. For example, the 
present findings were in direct contrast to those of Morris and Shafer [295] who found 
the mean power output at LT2 (determined by two different methods) and at MLSS 
were significantly lower than the mean power output during a 20 km cycle time trial 
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(~17, ~14 and ~10%, respectively; all p < 0.05) in trained male and female cyclists 
and triathletes. However, there are numerous methodological differences between 
this study and the present investigation that may provide some insight into the 
differences. The mixed sample of men and women (n = 10 and 3, respectively) did 
not allow for female-specific results to be derived, ovarian hormone concentrations 
were not controlled or verified, the LT2 was determined by two methods that did not 
include the modified D-max, MLSS was determined via 9 min steady-state trials, and 
the time trial distance was half that of the present study. For the same competition 
distance (20 km; albeit in men), Kenefick et al. [296] also that LT2 power output was 
lower (~15%) than mean 20 km time trial power output in competitive male cyclists 
(n = 13).  
 
Alternatively, others have shown no significant differences between mean power 
output determined by various threshold methods (V̇E/ V̇O2, RER0.95 and OBLA) and 
40 km cycling performance in experienced male cyclists (n = 15) [93], or between the 
modified D-max power output and 30-min cycling time trial power output in veteran 
cyclists (n = 8 men and 1 woman) [18]. Furthermore, Bishop’s group [10] highlighted 
that two methods of LT determination (LT2 via the D-max method and LT1 defined as 
the power output at which [La-] increases by 1 mmol·L-1 or more) produced a power 
output that was not significantly different from the power output during a 1 h time trial 
in trained female cyclists and triathletes (n = 24), with ~79% and ~63% of 
participants achieving a D-max and LT1 power output within 10% of their time trial 
power output. These are higher percentages than the present study, with ~58% of 
participants achieving a modified D-max power output within 10% of the mean time 
trial power output. However, similar to the present findings, the aforementioned study 
reported that power output reflective of the modified D-max LT2 was significantly 
higher than mean time trial power output (~16%; p value not reported). Therefore, 
the present findings extend those of Bishop et al. [10] by confirming that LT2 power 
output, when determined by the modified D-max method elicits a power output that is 
higher than the self-selected power output during 40 km cycling performance in 
endurance-trained women, when ovarian hormone concentrations are controlled and 
verified. 
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4.5.4.3 Changes between 30-40 km  
The present finding that mean heart rate was significantly higher during the final 
10 km of the 40 km time trial than it was at LT2 is not unexpected, as it is possible 
that the participants increased their power output in the final stages of the trial. 
Furthermore, heart rate was significantly higher in the final 10 km than it was in the 
first 10 km, which is also suggestive of an increase in work rate, effort and 
cardiovascular drift [124] during the final stages of the trial. Although it would be 
recommended that athletes disregard their heart rate response in the final stages of 
a time trial, individual responses should be acknowledged and therefore the point 
during the time trial where each athlete makes this decision should be assessed 
independently. The lack of change in [La-] among time points and the finding that a 
change did not occur concomitantly with heart rate may be explained by the different 
temporal responses between these two variables. For example, lactate has been 
shown to take ~3 min to reach peak concentrations after submaximal exercise at 
85% V̇O2max in trained women [323] and 1 min after a maximal incremental test in 
experienced male cyclists [93]. This would likely explain the lack of significant 
increase in [La-] upon completion of the time trial. 
 
4.6 Conclusions 
This was the first study to examine the relationships between physiological variables 
obtained during laboratory testing (including the modified D-max LT2) and 40 km 
cycling time trial performance in endurance-trained women, whilst controlling for and 
verifying ovarian hormone concentrations. It was found that the combination of 
absolute and relative peak power output, LT2 power output absolute V̇O2, relative 
V̇O2 and absolute V̇O2max produced the strongest prediction of performance. 
Furthermore, the regression equation provided can be used by sports scientists in an 
applied setting. LT2 power output elicited a steady-state [La-] in ~73% of participants, 
despite being ~6% higher than the self-selected power output during a 40 km time 
trial. This suggests that on average, participants may have been capable of 
performing the 40 km time trial at a higher power output. Future research could 
examine this further by investigating whether LT2 power output was sustainable for 
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40 km; this would confirm whether women in the present study were too 
conservative in their power output selection. Finally, whether ovarian hormone 
concentrations influence the capacity for LT2 to reflect competition intensities across 
different distances should also be explored. Based on the present findings, LT2 as 
determined by the modified D-max can be used to establish the heart rate, V̇O2 
(L·min-1 and mL·kg-1·min-1) and [La-] sustained during 40 km cycling performances in 
endurance-trained women, with heart rate the preferred method for practicality in the 
field. However, if power output is used, an adjustment to 6% below LT2 power output 
is recommended.  
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Appendix 4.1. Hydration self-assessment tool. 
 
HYDRATION TESTING 
 
RECORD OF BODY MASS, THIRST, AND URINE COLOUR 
 
Loss of > 1% body mass or persistent thirst or dark urine indicates possible dehydration. 
If any two of these indicators occurs, dehydration is likely. 
If all three occur, dehydration is very likely. 
 
PLEASE NOTE: If you do not have a set of scales at home, please just answer the 
other two questions. 
Date 
Nude 
Weight 
Yesterday 
Morning 
(kg) 
Nude 
Weight 
This 
Morning 
(kg) 
Weight 
Change 
(kg) 
Thirsty 
(Yes/No) 
Urine 
Colour 4-
8 on 
Chart? 
(Yes/No) 
Outcome 
 
 
 
 
 
 
   
 
 
 
  1 risk factor 
- drink 500 mL 
 
2 risk factors 
- drink 1 L 
 
3 risk factors 
- drink 1.5 L 
If more 
than 1%, 
this is 
one risk 
factor. 
NOTE: 
Divide by 
body 
weight, 
times by 
100 
If yes, 
this is 
one risk 
factor 
If yes, 
this is 
one risk 
factor 
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Please tick: 
HYDRATION TESTING: URINE COLOUR CHART [301] 
 
Please note: Taking vitamin supplements will make your urine appear darker, even if you are 
hydrated. If you are currently taking vitamins, please bring your sample with you to your testing 
rather than using the above chart. 
Please record how much fluid you consumed after your hydration test: _________ mL (1 
small glass = 250 mL) 
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Appendix 4.2. Well-being questionnaire. 
 
1. How much effort was required to complete my workouts in the past few 
days? 
 
6      5         4         3         2         1         0 
Hardly any effort    Excessive effort 
 
 
2. How recovered did I feel before my workouts in the past few days? 
 
6      5         4         3         2         1         0 
Energised and recharged   Still not recovered 
 
 
3. How successful was I at rest and recovery activities in the past few 
days? 
 
6      5         4         3         2         1         0 
    Successful       Not successful 
 
 
4. How well did I recover physically in the past few days? 
 
6      5         4         3         2         1         0 
      Very well        Not well at all 
 
 
5. How satisfied and relaxed was I as I fell asleep in the past few days? 
 
6      5         4         3         2         1         0 
       Satisfied          Not satisfied 
 
 
6. How much fun did I have in the past few days? 
 
6      5         4         3         2         1         0 
        Always          Never 
 
 
7. How convinced was I that I could achieve my goals during performance 
in the past few days? 
 
6      5         4         3         2         1         0 
      Always          Never 
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Appendix 4.3. Pre-trial questionnaire. 
 
Pre-Trial Meal 
 
Time of pre-trial food intake: : 
                     (24 hour time)         hh      mm 
 
 
 
 
Oral Contraceptive Pill 
                                      YES     NO 
OCP taken last night:                             Time of intake last night: :  
Taken night before:                                                 (24 h time)           hh        mm   
                                                                                                                                               
                                                                                                                                     YES    NO  
- Are you currently experiencing any hormonal symptoms, e.g. bloating, nausea?             
If yes, please state: 
- Have you experienced any breakthrough bleeding or spotting?                                      
If yes, please state which day/s: 
 
Training and Health Status 
Training last 2 days (volume and intensity):   
 
Recent health status (last 2 days): 
 
Stage of training: 
Other comments (injuries etc.): 
 
24 hr Pre-Trial Food Diary 
                                                    
                                                          YES      NO
Pre-trial food diary completed:            
                            (24 hours prior) 
 
Any comments related to food diary: 
217 
 
CHAPTER FIVE 
 
Discussion of findings from chapters three and four: 
A sex-based comparison 
 
5.1 Introduction 
Despite evidence of physiological differences between males and females, such as 
muscle fibre-type composition [324, 325], cardiac structure and function [326-328] and 
respiration [320], comparisons between sexes in relation to laboratory-based 
predictions of endurance performance are lacking. Research to date has either (1) 
failed to report the sex of their participants [329, 330], (2) grouped the results of males 
and females together and therefore disregarded sex-specific findings [181, 292] and/or 
(3) lacked control of ovarian hormone concentrations in women [88, 181]. A direct 
comparison between men and women has the potential to provide important sex-
specific findings and recommendations for establishing training and competition 
intensities, and evaluating endurance performance status. Therefore, this chapter 
furthers the findings from the previous two studies in order to compare: (1) the 
correlates and predictors of 40 km cycling performance; (2) the capacity to sustain 
30 min of exercise at LT2 power output with a steady-state [La-]; and (3) the power 
output, heart rate, V̇O2 and [La-] elicited at LT2, during 30-min of constant load 
exercise, and during a 40 km time trial, between men and women. 
 
5.2 Method Comparison 
Due to equipment functionality and availability, different metabolic systems were 
utilised between men and women in experimental studies one and two in the present 
thesis. The agreement between and reliability of, the two systems (Ametek and 
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Parvomedics) have been determined and are presented in Appendix one. Briefly, the 
metabolic systems showed good inter-system reliability at submaximal workloads for 
V̇O2 (L·min-1; CV = 1.5-2.9%; r = 0.76-0.86) and V̇CO2 (CV = 2.0-3.9%; 
r = 0.91-0.92), and at maximal workloads for V̇O2 (CV = 4.6%; r = 0.89) and V̇CO2 
(7.4%; r = 0.81). Therefore, any differences in V̇O2 and V̇CO2 between sexes as a 
result of measuring techniques can be assumed to be minimal. Additionally, although 
an identical method of plasma [La-] determination was used in the two studies, there 
were some differences in the analysers used. The study in men utilised either a 
Cobas Integra clinical autoanalyser (Cobas HMNS) or a Unicam 5625 UV/VIS 
Spectrometer (Spec) when insufficient sample volume was available for the 
autoanalyser. The study in women utilised a Cobas Integra clinical autoanalyser 
located at a commercial pathology laboratory (Sullivan Nicolaides Pathology, 
Brisbane; Cobas SNP). The agreement between, and reliability of, the three 
analysers (Cobas HMNS, Spec and Cobas SNP) have been determined, and are 
presented in Appendix two. Briefly, the three methods of detecting plasma [La-] 
elicited poor agreement, dependent on the [La-], suggesting that absolute values of 
[La-] should not be directly compared between methods. 
 
5.3 Results, Discussion and Conclusions 
5.3.1 Correlates and predictors of 40 km cycling 
performance 
Although LT2 was significantly correlated with 40 km cycling performance time in 
both men and women, and the relationships were of equal strength for power output 
(r = -0.69; p < 0.05 in men and r = -0.75; p < 0.01 in women), LT2 expressed relative 
to V̇O2 produced a stronger relationship with cycling performance in men (r = -0.77; 
p < 0.01 for both L·min-1 and mL·kg-1·min-1) than women (L·min-1; r = -0.66; p < 0.05 
and mL·kg-1·min-1; r = -0.63; p < 0.05). It is difficult to speculate as to why differences 
between men and women were seen in the relationship between V̇O2 at LT2 and 
endurance performance, especially since Hopker et al. showed there were no 
differences in gross efficiency at LT2 power output in competitive male and female 
cyclists [331]. However, women were shown to have a significantly higher cycling 
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gross efficiency than men across absolute intensities of 150 and 180 W (p < 0.01) 
[331]. Furthermore, women have been shown to oxidise proportionately more lipid 
compared with men during submaximal endurance exercise, regardless of training 
status [332-336] or exercise intensity [335, 337]. Either of these physiological differences 
between men and women may help to explain why there were differences in the 
strength of the relationship between V̇O2 at LT2 and 40 km cycling performance 
between sexes. 
 
The relationships between peak power output and performance, and allometrically-
scaled peak power output (W·kg-0.32) and performance, were of similar strength in 
men (peak power output: r = -0.88; p < 0.01; allometrically-scaled peak power 
output: r = -0.90; p < 0.01) and women (peak power output: r = -0.87; p < 0.01; 
allometrically-scaled peak power output: r = -0.86; p < 0.01), which is consistent with 
the findings of others [298]. However, when peak power output was expressed relative 
to body mass (W·kg-1), the relationships were weaker for both men (r = -0.73; 
p < 0.01) and women (r = -0.68; p < 0.05). These findings confirm that endurance 
cycling performance is more strongly related to absolute peak power output than 
relative peak power output, independent of sex. These findings are consistent with 
those who reported peak power output expressed as W·kg-1 was a stronger predictor 
of climbing capacity (rather than flat or ergometer-based performance) during cycling 
[4, 42]. Therefore, the present findings suggest that absolute peak power output is the 
single strongest correlate of 40 km cycling performance for both men and women, 
and therefore is the best variable to assess endurance performance capacity and 
changes in response to training. 
 
In both men and women, the strongest determination of 40 km cycling performance 
resulted when combining the same variables: (1) peak power output (W and W·kg-1); 
(2) LT2 V̇O2 (L·min-1 and mL·kg-1·min-1); (3) LT2 power output; and (4) V̇O2max 
(L·min-1). However, in men, these variables explained 95% of the variance in 40 km 
cycling performance, compared to only 87% in women. Therefore, 13% of variance 
in the females’ time trial performance was explained by other measures. It is difficult 
to speculate on the source of the remaining variance, however, given the known sex 
differences in skeletal muscle metabolism [318], muscle fibre-type composition [324, 325], 
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gross efficiency [331], and lean and fat mass composition [338], any combination of 
these variables may contribute to the discrepancy in variables capable of predicting 
endurance performance outcomes in men and women. Others who assessed sex 
differences in cycling performance prediction found that although allometrically-
scaled peak power output (W·kg-0.32) was the best predictor of 40 km cycling 
performance in trained men (r = -0.96) and women (r = -0.87; p < 0.01), the 
relationship was weaker in women, and different regression equations were required 
when predicting cycling performance in men and women [273, 298]. However, no 
control or verification of ovarian hormones was completed, so there was potential for 
these hormones to influence physiological responses to exercise in women, and 
therefore impact the comparison with men. Therefore, the findings of the present 
studies add to the existing literature by confirming that when the influence of ovarian 
hormones was minimised, LT2 power output, peak power output, relative peak power 
output and allometrically-scaled peak power output produced equally strong 
correlations with cycling performance in both men and women. However, different 
regression equations are required when predicting performance in male and female 
cyclists.  
 
5.3.2 30 min constant load exercise test at LT2 power 
output  
There were differences between men and women in their capacities to sustain 30 
min of exercise and elicit a steady-state [La-] at LT2 power output. Whilst all of the 
men maintained their LT2 power output for 30 min, only 50% elicited a steady-state 
[La-], as reported in section 3.4.3. Conversely, fewer women maintained their LT2 
power output for 30 min (82%), but a larger proportion elicited a steady-state [La-] 
(89% of those who sustained 30 min). These findings suggest that eliciting a steady-
state [La-] is a more important indicator of exercise tolerance for women than men 
when determining an exercise intensity that is sustainable for 30 min, since 50% of 
men tolerated a [La-] above LT2, compared to only 11% of women. Subsequently, 
the validity of MLSS as an endurance performance indicator is more strongly 
supported in women than men. The limited number of participants in the present 
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studies should be acknowledged as a limitation and therefore, the findings should be 
interpreted with caution. 
 
Nevertheless, the disparity between men and women may be explained by higher 
concentrations of oestradiol in women than men, despite the women in the present 
study having supressed endogenous ovarian hormone concentrations compared to 
women not using a hormonal contraceptive. In women, a lower [La-] during exercise 
at and above LT2 intensity in the luteal versus the follicular phase of the menstrual 
cycle (when oestradiol concentrations are higher) [22] suggests oestradiol has a 
protective effect or capacity to improve lactate kinetics. This suggests that in women 
not using a hormonal contraceptive, the capacity for LT2 to reflect a sustainable 
power output and elicit a steady-state [La-] may be increased, further exacerbating 
the difference between men and women. These findings have implications for 
exercise testing and training in men and women. Determining LT2 by the modified 
D-max is not recommended in either men or women, unless individual suitability is 
tested via multiple constant load trials below, at, and above LT2 power output. The 
large variation in the capacity for individuals to elicit a steady-state [La-] at LT2 power 
output does not support the modified D-max for the purpose of establishing a 
sustainable cycling intensity that elicits a steady-state [La-], and subsequently, to 
establish training zones. 
 
5.3.3 Difference between LT2, constant load and 40 km 
time trial variables 
Despite there being no significant differences between heart rate, V̇O2 or [La-] elicited 
at LT2, during a 30 min constant load trial or during a 40 km time trial for either sex, 
power output at LT2 was 6% higher (p < 0.05) than mean time trial power output in 
women, despite no significant difference in men. This discrepancy in self-selected 
power output could be partially explained by the two women who could not maintain 
their LT2 power output for 30 min during the constant load trial. These two women 
self-selected their 40 km time trial power outputs at an average of 17% and 13% 
below their LT2 power output, respectively. However, there were two other women 
who maintained 30 min of exercise at their LT2 power outputs despite their LT2 power 
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outputs being 13% and 19% higher than their self-selected time trial power outputs. 
Therefore, an alternative explanation may be that women were more conservative in 
their power output selection during the 40 km time trial, and may have been capable 
of sustaining a higher power output during the time trial. This is supported by 
research demonstrating that women tended to over-estimate their perceived exertion 
(as measured by Borg’s RPE scale) in comparison to accelerometer output more 
frequently than men (81% vs. 19%, respectively) [339]. Furthermore, women reported 
a significantly higher RPE (p ≤ 0.05) than men following a 50 min cardio tennis 
training session, despite a similar maximal heart rate, step number, stroke count and 
total hitting duration [340]. Therefore, future research could investigate whether 
women are capable of sustaining a mean power output equivalent to their LT2 power 
output, during a 40 km cycling time trial.  
 
5.3.4 Limitations 
It should be recognised that there are several limitations of the present studies. 
Firstly, the use of different equipment (for analysis of V̇O2 and plasma [La-]) in men 
and women suggests that the comparison between sexes should be interpreted with 
caution. Although the metabolic analysers showed good inter-system reliability and 
agreement, the lactate analysers did not. However, direct comparisons between men 
and women were not made for absolute [La-], but rather for the relationships 
between variables related to [La-] (i.e. LT2) and performance, and the difference 
between [La-] at LT2, during constant load exercise and during a 40 km time trial. 
Therefore, the lack of agreement between [La-] detection methods should have had 
minimal influence on these comparisons between men and women.  
 
The recruitment of women who were hormonal contraceptive users (in comparison to 
both hormonal contraceptive users and naturally-menstruating women in separate 
groups) is another limitation of the present study, and reduces the generalisability of 
the findings to hormonal contraceptive users but not those who are naturally 
menstruating. However, the use of hormonal contraceptives, especially the OC pill, 
are becoming increasingly popular in the female athletic population, with the most 
recent data showing 83% of elite level athletes use an OC [184], a considerable 
increase from the 5 -12% reported in the early 1980s [185]. Nevertheless, future 
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research should aim to compare the performance predicting capacity of laboratory-
based variables in women who use hormonal contraceptives with naturally-
menstruating women to provide more comprehensive findings for all female athletes.  
 
The sample size of the present studies should also be acknowledged as a limitation. 
Although the number of participants recruited were based on published literature 
examining performance predictors [95, 264, 265] and the validity of various LT2 
methodology [17, 78, 103, 141] in trained endurance athletes (n = 6-12), spurious readings 
have the potential to significant impact the findings. Therefore, it is recommended 
that replications of the present research be considered with larger, perhaps more 
diverse (i.e. sprint endurance and ultra-endurance specialists) samples. 
 
Finally, urinary ovulation prediction was undertaken by women in the present study, 
rather than a direct measure of ovulation. However, this method is cost-effective and 
minimally invasive, and therefore was a practical choice for a research study. This 
justification supports others who assessed ovulation by this method [196]. 
Furthermore, compared to other methods of ovulation prediction, urinary ovulation 
prediction has been shown to be superior [341-343]. 
 
5.3.5 Conclusions 
The combination of maximal and fractional utilisation variables assessed in the 
present studies provided a better prediction of 40 km cycling performance in men 
than women using hormonal contraceptives. It is possible that this difference may be 
related to differences in skeletal muscle metabolism, muscle fibre-type composition, 
lean and fat mass composition, higher concentrations of oestradiol in women 
(despite these being supressed in hormonal contraceptive users) than men, and/or 
the tendency of some women to self-select an exercise intensity during a 
performance trial that is below their highest sustainable intensity. Nevertheless, 
power output and V̇O2 reflective of LT2 are good correlates of endurance cycling 
performance in both men and women.  
 
Furthermore, the use of either heart rate, V̇O2 (L·min-1 and mL·kg-1·min-1) or [La-] 
reflective of LT2 is recommended for establishing an appropriate 40 km performance 
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regardless of sex, with heart rate being the most practical method. However, the use 
of power output, by the use of a power metre, is suggested for use in men only, 
since at LT2 power output over-predicted what was sustainable during a 40 km time 
trial in women. It should be noted that the results of these studies only apply to 
women using hormonal contraceptives, and may be different to studies involving 
non-users. However, the use of hormonal contraceptives, and their suppression of 
endogenous ovarian hormone concentrations in women, allowed comparisons to be 
made between men and women, whilst minimising the influence of these hormones 
on physiological and performance data. Further research into sex-specific correlates 
of performance should be investigated in response to a training intervention. 
Examining the variable(s) related to endurance performance improvements and 
whether these are different between men and women will allow more specific 
endurance exercise training prescription, and subsequently, the potential for 
improved endurance performance outcomes for men and women. 
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CHAPTER SIX 
 
Sex differences in adaptations to high-intensity 
interval training: Experimental study three 
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6.1 Abstract 
The efficacy of high-intensity interval training (HIIT) to elicit physiological adaptations 
that improve performance in endurance-trained athletes has been established in 
men but has been examined to a far lesser extent in women. Furthermore, despite a 
significant relationship reported between LT2 and endurance performance in men 
(chapter 3) and women (chapter 4), the sensitivity of these relationships and whether 
there are differences between men and women in response to a HIIT intervention, 
are yet to be reported. Therefore, the primary objective of this study was to compare 
the physiological and performance adaptations to 10 HIIT sessions between 
endurance-trained men and women, whilst controlling for and verifying female 
ovarian hormonal concentrations. A secondary objective was to determine the effect 
of HIIT on the LT2-performance relationship.  
 
Competitive cyclists and triathletes (n = 17; nine men and eight women) completed 
an incremental cycle trial to fatigue, and a 40 km cycling time trial before (baseline), 
and after, five (mid-HIIT) and 10 (post-HIIT) HIIT sessions. Each HIIT session 
consisted of 10 x 90 s at peak power output, separated by 60 s low-intensity, active 
recovery. Women had been using a hormonal contraceptive for ≥ 3 months and 
serum oestradiol and progesterone concentrations were measured to confirm 
hormone status. 
 
There were no significant differences in any of physiological improvements between 
sexes from baseline to post-HIIT (p = 0.08-0.51). Furthermore, there were no 
significant physiological improvements (p = 0.44-0.92) from baseline to mid-HIIT, or 
baseline to post-HIIT in men. In contrast, women significantly improved relative peak 
power output (W·kg-1; 2.4%; p = 0.04) from baseline to mid-HIIT, and peak power 
output (4.0%; p < 0.01), relative peak power output (W·kg-1; 4.8%; p = 0.01), 
allometrically-scaled peak power output (W·kg-0.32; 4.2%; p < 0.01) and incremental 
time to fatigue (5.4%; p < 0.01) from baseline to post-HIIT. Mean 40 km time trial 
time (-0.8%; p = 0.02) and power output (2.3%; p = 0.01) significantly improved by 
mid-HIIT in women, and from baseline to post-HIIT in men (-1.7%; p = 0.01 and 
4.8%; p = 0.02, respectively) and women (-2.6%; p < 0.01 and 8.0%; p < 0.01, 
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respectively), with no difference in the magnitude of changes between sexes (time: 
p = 0.08 and power output: p = 0.92). The improvement in LT2 power output was the 
only variable significantly related to time trial performance improvement in women 
(r = -0.88; p < 0.01), but no variable could explain the performance improvement in 
men. LT2 power output was correlated with 40 km cycling performance post-HIIT 
only in both men (r = -0.86; p < 0.01) and women (r = -0.81; p = 0.02).  
 
Despite significant physiological improvements in response to 10 HIIT sessions in 
women, and significant 40 km cycling performance improvements in both men and 
women, there were no differences in the magnitude of improvements between 
sexes. Although LT2 power output explained 77% of the improvement in 40 km 
cycling performance in women, none of the measured variables explained the 
performance improvement in men, suggesting that mechanism(s) other than those 
responsible for the LT2 were involved. The LT2-performance relationship was 
consistent in men and women and since it was significant post-HIIT only, it can be 
suggested as training intensity-dependent. Although it was speculated that these 
sex-based differences in adaptations to HIIT may be related to different training 
stimuli thresholds (in relation to total exercise volume), different muscle fibre size 
and/or type, and/or the influence of oestradiol in women, future research should 
endeavour to directly investigate the mechanisms responsible.  
 
6.2 Introduction 
High-intensity interval training (HIIT) has become a popular exercise training 
modality due to its time-efficient nature and capacity to rapidly induce physiological 
and performance improvements of at least the same magnitude as lower-intensity 
continuous training [244]. Most studies that have used HIIT with well-trained athletes 
have replaced a fraction (typically ∼15-25%) of base/normal training with 2-3 HIIT 
sessions per week for 4-8 weeks. The HIIT sessions have consisted of a variety of 
training stimuli, from 5 min intervals at ~80% V̇O2max to 30 s intervals at an all-out 
intensity as high as 175% V̇O2max [245] [although this has been more accurately 
termed ‘sprint interval training’ (SIT) when the target intensity is ≥ 100% V̇O2max [26]] 
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. Improvements in running (3-10 km) [28-30, 253, 254], roller skiing (12 km) [31] and cycling 
(10-40 km) [32-40, 251, 252] performances have been reported in endurance-trained 
athletes following HIIT. Despite these multi-modal HIIT interventions, the majority of 
studies involved men only [28, 30, 32-40, 251-254], with one combining men and women [31] 
and another not stating the sex of participants [29]. The need to understand sex-
based differences in training adaptations is crucial to shed light on the benefits and 
limitations of certain training regimen for men and women. This will inform best-
practice training prescription and optimise physiological and performance 
adaptations. 
  
Using well-trained male cyclists, 12 studies have reported physiological adaptations 
to HIIT/SIT (4-18 sessions of 4-25 reps x 5 sec-6 min at 70-175% peak power 
output) with improvements reported in absolute (3-8%) [32-34, 37-39, 71, 251, 252] and 
relative (3.5-5.0%) [32, 35] peak power output, skeletal muscle buffering capacity 
(16%) [38], the first (15.0-21.4%) and second (8.6-15.7%) VT [36, 71], OBLA (2.9-3.6 %; 
effect size: 0.24-0.47) [39], LT (defined as the first increase in [La-] above baseline; 
4%) [251] and LT2 (defined as the second steep increase in [La-]; 5%) [251]. Of those 
studies that examined the association between changes in physiological variables 
and changes in performance [33, 36-38], relationships were found between performance 
improvements and increases in skeletal muscle buffering capacity (n = 6; r = -0.74; 
exact p value not reported) [38], anaerobic capacity (r = 0.40; p < 0.05), the second 
VT (n = 41; r = 0.42; p < 0.01) [36], and peak power output (n = 20; r = -0.92; p < 
0.001) [33]. Similar investigations in well-trained women, or in both men and women 
for comparison, have not been published. 
 
Limited research has examined the impact of HIIT on the LT2. Considering its 
consistently strong relationship with, and capacity to, predict endurance performance 
in men and women (as addressed in Chapters 3 and 4 of this thesis), such research 
is warranted. Adaptations of LT2 in response to HIIT in endurance-trained athletes 
have been completed over one year [40], five months [41], and in one short-term study 
where seven HIIT sessions were completed in seven days (group 1: 25 reps x 5, 10, 
20 sec at maximal intensity each, with a work:rest ratio of 1:5; group 2: 10 reps x 15, 
30, 45 sec at maximal intensity each, with a work:rest ratio of 1:5) [39]. These studies 
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reported improvements in LT2, as determined using the following methods: (1) the 
lowest blood [La-] + 2.3 mmol·L-1 [40]; (2) speed eliciting 4 mmol·L-1 [La-] [41], and (3) 
power output eliciting 4 mmol·L-1 [La-] [39]. Although significant performance 
improvements were reported in these studies [15 km cycling (~15%)[40], 20 min 
running (~4%)[41] and 20 km cycling (8-10%) [39]], the capacity of LT2 to predict the 
changes in performance was not reported in any study.  
 
Furthermore, despite the significant relationship between LT2 and endurance 
performance shown in both men (study one) and women (study two) in the present 
thesis, the consistency and strength of this relationship after a HIIT intervention is yet 
to be established in both men and women. Assessing the sensitivity and robustness 
of the LT2 as a performance indicator is important for trained endurance athletes, 
where small improvements in performance are critical to success. Investigating this 
relationship in both men and women will explain whether changes in LT2 are equally 
associated with changes in performance between sexes, and thus create a pathway 
for understanding whether similar mechanisms are responsible for physiological and 
performance improvements after HIIT. Whether the power output and/or heart rate 
reflective of LT2 are the same as those elicited during endurance trials after a period 
of HIIT, in men and women, is yet to be examined. This would expand on the 
findings of experimental studies one and two of the present thesis, where for men, 
there was no significant difference between LT2 and 40 km cycling power output and 
heart rate, but women exhibited a power output at LT2 that was significantly higher 
than the power output sustained over a 40 km cycling time trial. Examining the 
difference between power output and heart rate reflective of LT2 and the power 
output and heart rate sustained during an endurance time trial after a bout of HIIT 
will inform the sensitivity of LT2 as means for establishing an intensity that is 
sustainable during performance trials of ~1 h in men and women. 
 
To date, only two HIIT interventions have been conducted where LT2 and/or VT2 
adaptations were investigated in women. In recreationally-active women, HIIT (15 
sessions of 6-10 reps x 2 min at 120-140% LT2 with 1 min rest; n = 8) resulted in 
improvements in power output at the modified D-max LT2 and muscle buffering 
capacity [183], and V̇O2 at VT2 (determined by two methods: VE/V̇O2 and respiratory 
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compensation threshold; 18 sessions of 6 reps x 60 s at maximal intensity with 3 min 
rest; n = 28) [344]. However, these interventions failed to report ovarian hormone 
concentrations or changes in endurance performance as a result of the intervention. 
Ovarian hormones have the capacity to influence HIIT because of the potentially 
protective effect of oestrogen on skeletal muscle-mediating strength, endurance, 
resistance to fatigue, and inflammation during and after exercise [345-347]. 
 
Studies comparing the adaptations to HIIT between men and women are limited and 
conflicting. One study reported that HIIT (12 sessions of 3 reps x 30 s sprint, with 20 
min rest) increased mean power output, type II fibre size and glycogen content in 
women but not men, and that total creatine content increased in men significantly 
more than women in recreationally-active individuals (n = 6 men and 10 women) [348]. 
In contrast, others found a similar magnitude of change in V̇O2max, relative peak 
power output, mean power output and fatigue index between recreationally-active 
men (n = 11) and women (n = 9; 6 HIIT sessions of 4-6 reps x 30 s at maximal 
intensity, with 5 min rest) [349]. As mentioned above, ovarian hormone concentrations 
have been identified as a potential confounder when investigating the adaptations to 
HIIT in women, or when comparing adaptations between men and women [350]. 
Despite this, no published study has controlled for, or verified, ovarian hormone 
concentrations during physiological or performance assessments. 
 
Whether men and women respond in the same way to HIIT is not clear, and the 
relationship between LT2 and endurance performance been not been described pre- 
and post-HIIT for both men and women in the same study; this has implications with 
regard to testing and assessing changes in exercise capacity. Therefore, the primary 
objective of this study was to compare the adaptations of maximal incremental 
variables (absolute and relative peak power output, and incremental time to fatigue), 
LT2 variables (power output, heart rate and [La-]), and 40 km cycling performance to 
10 HIIT sessions between endurance-trained men and women, whilst controlling for 
female ovarian hormone concentrations.  
 
A secondary objective was to determine the effect of HIIT on the LT2-performance 
relationship. Based on differences between men and women in oestrogen 
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concentration and subsequent skeletal muscle mediating strength, endurance, and 
fatigue resistance, the primary hypothesis was that women would respond to HIIT to 
a relatively greater extent than men, by producing larger relative improvements in 
maximal incremental variables, LT2 variables and 40 km cycling performance. 
Furthermore, it was hypothesised that due to improvements in type II fibre size and 
glycogen content in women, changes in LT2 and peak power output in response to 
HIIT would significantly predict mean time trial improvement in women, but not men. 
Finally, it was hypothesised that the LT2-performance relationship would be 
significant before and after 10 HIIT sessions for both men and women. 
 
6.3 Methods 
6.3.1 Participants 
Other HIIT interventions that elicited significant performance improvements in trained 
endurance athletes recruited 4-14 participants per group [30, 32-38]). A sample size 
calculation indicated that to detect a 2.0% difference in performance (assuming 63 
min to complete 40 km = 76 s) with a SD of 2 min with alpha = 0.05, 10 participants 
would be required [351]. 
 
Competitive cyclists and triathletes were recruited for this study using the methods 
described in section 3.3.2. Inclusion criteria were: (1) aged 18-40 years (inclusive); 
(2) experience with racing competitively for ≥ 1 season; (3) satisfactory self-
described health status; (4) (for women) use of a combined hormonal contraceptive 
for ≥ 3 months; and (5) completion of consistently high-volume training for 
≥ 2 months. Exclusion criteria were as described in section 3.3.2. Participants were 
also required to have refrained from participation in HIIT sessions, as defined by 
Buchheit and Laursen [27] for ≥ 2 months. Participants were informed of the risks of 
the study, completed a medical history questionnaire, and provided their written 
informed consent. The investigation was approved by the Medical Research Ethics 
Committee of The University of Queensland (approval number HMS13/0221). 
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6.3.2 Experimental Overview 
Participants reported to the Human Performance Laboratory of the School of Human 
Movement and Nutrition Sciences at The University of Queensland on 18 occasions 
over approximately eight weeks (range 7-11 weeks), as depicted in Figure 6.1. All 
testing sessions were performed a minimum of 48 h after a HIIT session. The order 
of the familiarisation trials and the order of the testing sessions were randomised 
prior to the study commencement. This order was revealed to the tester prior to the 
study commencement, and to each participant prior to their first trial. All testing and 
HIIT sessions were conducted on the same cycle ergometer, as described in section 
3.3.1. Heart rate was recorded during all testing and HIIT sessions (Suunto t6c, 
Suunto Oy, Vantaa, Finland). Each participant completed their trials at a similar time 
of the day in controlled environmental conditions (temperature 22.3 ± 1.4°C, relative 
humidity 64.3 ± 8.6% and barometric pressure 756.2 ± 5.4 mm Hg).  
 
On arrival at the laboratory for each testing session, participants completed a 
questionnaire confirming their compliance with the pre-trial conditions (Appendix 
6.1), a well-being questionnaire (as previously described in section 4.3.4.2) and 
provided a urine sample for determination of hydration status (as previously 
described in section 4.3.4.1). All testing and familiarisation sessions were 
immediately preceded by a self-selected warm-up, as described in section 3.3.1.  
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Figure 6.1. Overview of the experimental period. 
 
 
 
 
HIIT: high-intensity interval training; h: hours; final power output: final power output attempted in the incremental test, regardless of the duration completed at 
this intensity. 
Randomised trials; Incremental trial and 40 km time trial
HIIT sessions; 10 x (90 s final power output: 60 s active recovery at 20-30% final power output) 
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6.1.1  Familiarisation Trials 
The familiarisation trials involved: (1) a maximal incremental test to fatigue and half 
of a HIIT session (i.e. five intervals; as described below) on one visit; and (2) a 40 
km time trial on a separate visit at least 48 h later. The incremental test was 
completed using the same procedures as reported in sections 3.3.5.1 and 4.3.6.1 for 
men and women, respectively. Gas analysis procedures were identical to those 
described in section 4.3.3. The 40 km time trial was completed as per section 
3.3.5.3, with the exclusion of gas exchange data collection, because participants 
were exposed to this procedure in the incremental test. 
 
6.1.2 Diet and Exercise Control 
6.1.2.1 Dietary Intake 
Details of dietary intake prior to all trials were identical to those described in section 
3.3.4.1, with additional instruction provided to participants regarding their dietary 
intake in the 24 h prior to each trial: consume 7.5 g·kg-1 body mass carbohydrate for 
women and 8 g·kg-1 carbohydrate for men [352]. Sample meal plans were supplied 
with examples of foods and quantities. Participants were asked to avoid consuming 
caffeine for 24 h before all testing sessions and before the first and tenth HIIT 
sessions, and to maintain a hydrated state (as described in section 4.3.4.1). A 
standardised pre-exercise meal (1.5 g·kg-1 body mass carbohydrate for women and 
2 g·kg-1 body mass carbohydrate for men) consisting of the same food and beverage 
items described in section 3.3.4.1 was consumed 1-2 h prior to exercise. Procedures 
upon arrival at the laboratory were identical to those described in section 4.3.4.2.  
 
6.1.2.2 Exercise 
Details of exercise restrictions in the 24 h period prior to all testing and HIIT sessions 
were identical to those described in section 3.3.4.2. Participants were asked to avoid 
significant changes to their training for the duration of their involvement in the study, 
with the exception of reducing their weekly training duration by ~25 min per week to 
account for each HIIT session completed, and refraining from additional HIIT 
sessions outside of the study. Training diaries were completed and checked for the 
seven days prior to baseline, mid-HIIT (after five HIIT sessions) and post-HIIT (after 
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10 HIIT sessions) testing to ensure compliance (Appendix 6.2). Training session load 
for the seven days prior to baseline, mid- and post-HIIT testing was quantified by 
multiplying intensity (where ‘light’, ‘moderate’ and ‘hard’ were represented by an RPE 
of 9, 12 and 15, respectively [269]) by duration. 
 
6.1.3 Hormone status 
For women, procedures relating to hormonal contraceptives were consistent with 
methods previously described (sections 4.3.2 and 4.3.5). Participants were asked, 
but not required, to skip the withdrawal phase of their contraceptive method (i.e. the 
inactive pills for those taking an OC pill) and continue with the active hormone phase 
for the duration of the study. This was to ensure consistency in hormone 
concentrations throughout the testing and training phases. There appears to be no 
medical evidence suggesting women need monthly withdrawal bleeding or menstrual 
periods, nor is there evidence of health problems associated with skipping or 
eliminating monthly bleeding [353, 354]. Participants were encouraged to seek advice 
from their doctor if they had any questions or concerns regarding skipping the 
inactive pills. For those participants who chose to skip the withdrawal phase of every 
cycle (n = 6), testing was performed on any day at baseline, mid-HIIT and post-HIIT. 
For those who chose to include the withdrawal phase at least once throughout the 
study (n = 2), scheduling ensured the withdrawal phase occurred during the training 
phase. Trials (excluding familiarisation) were scheduled to coincide with the high 
hormone phase based on each participant’s contraceptive formulation to ensure 
consistent hormone concentrations among all testing sessions. 
 
6.1.4 Testing 
At baseline, mid-HIIT and post-HIIT, participants completed two trials: (1) an 
incremental cycle test to volitional fatigue (V̇O2max), and (2) a 40 km cycle time trial 
(Figure 6.1). Mid-HIIT testing was conducted for the primary purpose of assessing 
changes in peak power output and therefore, whether changes in HIIT intensities 
were required, i.e. to ensure progressive overload. However, this sub-analysis 
allowed the determination of any time-course differences in HIIT adaptations 
between men and women.  
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6.1.4.1 V̇O2max  
Procedures performed in this V̇O2max trial were identical to those during the 
maximal incremental trial for familiarisation, with the addition of blood sampling. The 
blood sampling site and [La-] analysis method were different from earlier studies 
(Chapters 3 and 4): 5 μL of blood was sampled from the earlobe, and [La-] was 
analysed using a hand-held device (Lactate-Pro, ARKRAY Inc., Kyoto, Japan). The 
use of blood [La-] rather than plasma [La-] (as per Chapters 3 and 4) was due to the 
availability of new equipment in the laboratory allowing a more time efficient and 
simple analysis of whole blood [La-], compared to the previously conducted plasma 
[La-] analyses. The reliability of, and difference between, the two methods is reported 
in Appendix two. The total number of blood samples taken from each participant was 
greater than those reported in Chapters 3 and 4, and hence the simplified method of 
blood [La-] was preferred. Peak power output was calculated with the same formulas 
as reported in sections 3.3.5.1 and 4.3.6.1 for men and women, respectively.  
 
6.1.4.2 40 km time trial 
The 40 km time trial was conducted as described in section 3.3.5.3 with the following 
differences: (1) average power output, elapsed time (hh:mm:ss) and heart rate were 
recorded every 4 km; (2) water was consumed ad libitum during the baseline time 
trial, with the volume consumed measured and then replicated in mid- and post-HIIT 
trials; and (3) participants viewed the distance remaining, speed, heart rate and 
cadence on a monitor mounted to the front of the cycle ergometer for the first 4 km, 
after which time, they were blinded to viewing the monitor for the remainder of the 
trial; this was due to multiple time trials being completed in the present study. 
 
6.1.5 HIIT sessions 
A total of 10 HIIT sessions were performed with one to three sessions performed per 
week, depending on each participant’s availability. Each HIIT session was preceded 
by a pre-determined and individualised warm-up consisting of 2 min at each of 40% 
and 60% of the final power output attempted in the incremental test, regardless of 
the duration completed at this intensity. A self-selected cool-down was performed at 
the conclusion of each training session. 
 
237 
 
Each training session consisted of: 
 
10 x (90 s at final power output: 60 s active recovery at 20-30 % final power output) 
 
To date, no study has reported this exact combination of training variables in a HIIT 
session. However, research suggests that for already well-trained endurance 
athletes to induce maximal cardiovascular and peripheral adaptations, the time spent 
at intensities ≥ 90% V̇O2max is critical [27]. Buchheit and Laursen [27] have suggested 
that V̇O2max can be reached between 1 min 20 s and 2 min 20 s (when intervals are 
repeated), irrespective of training status and exercise mode with an accumulated 
high intensity (≥ 90% V̇O2max) exercise time of 10 min per session. Prescribing 10 
repetitions per session at the intensity achieved as the final power output during the 
incremental test (15 min at final power output in total) aims to elicit a V̇O2max 
response for at least 10 min. An active recovery was prescribed to accelerate the 
time taken to reach V̇O2max in subsequent intervals [355]. The recovery intensity 
range of 20 - 30% of final power output was selected based on mean data from pilot 
testing, in which athletes self-selected an intensity to cycle at for the 60 s recovery 
periods. Prescribing a work:recovery ratio (i.e. exercise time at V̇O2max:active 
recovery time ratio) > 1 has been suggested to enhance the adaptations in already 
well-trained athletes [27]; the work:recovery ratio in the present study was 1.5.  
 
Mean power output and end heart rate were recorded at the conclusion of each 90 s 
interval. Recovery heart rate was recorded as the heart rate at the conclusion of the 
60 s recovery period. RPE was recorded after five (halfway-RPE) and 10 (end-RPE) 
intervals. Earlobe capillary blood was sampled immediately after the tenth interval of 
the first and tenth HIIT sessions for the analysis of blood [La-]. Further blood [La-] 
samples were collected at 3 min intervals (while the participant remained stationary) 
until a peak blood [La-] (identified as the highest concentration attained before a 
subsequent decline) was reached. Participants were permitted to consume water ad 
libitum throughout the HIIT sessions. Participants viewed the time remaining, power 
output, heart rate and cadence on a monitor mounted to the front of the cycle 
ergometer, and strong verbal encouragement was provided by the same person to 
ensure consistency. When the required power output was not able to be maintained 
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(for the work or recovery intervals), the highest sustainable power output was 
encouraged in order to complete the session.  
 
6.1.6 Measurements 
6.1.6.1 Body Composition 
Body mass was measured as per section 3.3.3, prior to each of the six testing 
sessions. Height was measured to the nearest mm using a wall-mounted 
stadiometer (Seca, Hamburg, Germany), with a precision of ±1 mm prior to the first 
trial. Whole body-composition measurements were determined by dual energy x-ray 
absorptiometry (DXA; Hologic Discovery W, Waltham, MA, USA) at baseline and 
post-HIIT. Wearing minimal clothing and with all metal objects removed (jewellery, 
zippers etc.), participants laid supine on the DXA table (scan region 195 cm x 65 cm) 
whilst a scanning arm moved back and forth above the whole body. The participants’ 
arms were secured at their side with the aid of masking tape. Masking tape around 
the legs was also used to minimise body movement during each scan while feet 
were maintained in a dorsi-flexed position. A low-dosage x-ray passed from 
underneath the table to the scanning arm above the participant. The scan time for 
the whole body was approximately 7 min, and the radiation dose was 2.6 Sv for the 
whole body. A three-compartmental model for body composition was then derived 
based on bone mineral content, lean tissue mass (LTM) and fat mass (FM). Percent 
body fat (BF %) was also calculated from each scan. The CV in the study laboratory 
for LTM, FM and BF % are < 1 %. All DXA measurements were made by trained 
technicians, and all scans were analysed by the same technician. 
 
6.1.7 Blood Sampling, Storage and Analysis 
Venous blood was sampled from women as per section 4.3.7.2. Serum samples 
were thawed at room temperature prior to processing. Serum oestradiol and 
progesterone concentrations were analysed in duplicate using the Cobas e411 
electrochemiluminescence immuno-autoanalyser (Roche Diagnostics, Mannheim, 
Germany). The CV in the study laboratory is 0.4% for both oestradiol and 
progesterone. Analyses were completed with similar principals of measurement as 
reported in sections 4.3.7.2.1 and 4.3.7.2.2, but with an electrochemiluminescence 
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measurement technique and the Cobas immune-autoanalyser. The differences in 
measurement techniques and analysers between studies two and three were a result 
of internal equipment availability which replaced the need to send samples to an 
external pathology laboratory (as described in sections 4.3.7.1 and 4.3.7.2). 
 
6.1.8 Statistical analysis 
Data (n = 17) were analysed using IBM SPSS (v 22.0, SPSS Inc., Chicago, IL). 
Normality of the distribution for outcome measures was tested using the Shapiro-
Wilk test and via boxplots. Changes in descriptive statistics of the participants from 
baseline to post-HIIT, the physiological responses of the participants to each of the 
10 HIIT sessions (including mean power output, end heart rate, recovery heart rate, 
halfway RPE, end RPE and peak [La-] after sessions one and 10), and the 
differences between men and women, were assessed by one-way repeated 
measures analysis of variance (ANOVA). The Greenhouse-Geisser correction was 
used to account for the sphericity assumption of unequal variances across groups. 
When ANOVA results were significant, the Bonferroni post-hoc test was employed to 
locate the source of any significant differences. Differences in mean nutritional intake 
among trials were examined as per section 3.3.7. 
 
To assess the primary objective of comparing the adaptations from baseline to post-
10 HIIT sessions between men and women, a one-way repeated ANOVA was used 
with the Greenhouse-Geisser correction. The dependent variables were absolute 
peak power output, relative peak power output (W·kg-1), relative peak power output 
(W·kg0.32), incremental time to fatigue, LT2 power output, LT2 heart rate, LT2 [La-], 
time trial time, time trial power output and time trial heart rate. Dependent variables 
were compared between baseline and post-HIIT, and between men and women. 
Additionally, a paired t-test or Wilcoxon signed-rank test was used as appropriate to 
examine changes from baseline to post-HIIT in men and women independently. As a 
sub-analysis, dependent variables were compared between baseline and mid-HIIT 
for men and women independently by a paired t-test or Wilcoxon signed-rank test, as 
appropriate. 
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To assess the secondary objective of determining the effect of HIIT on the LT2-
performance relationship, Pearson or Spearman correlations were used, as 
appropriate. Maximal incremental variables (peak power output and incremental time 
to fatigue) and LT2 variables (power output, heart rate and [La-]) were assessed to 
determine the strongest correlates of 40 km cycling performance time. Correlation 
coefficients were also used to determine relationships between post-HIIT changes 
(expressed relative to baseline results) in maximal incremental/LT2 variables and 
changes in time trial performance. To assess whether the power output and heart 
rate corresponding to LT2 were the same as those elicited during a 40 km time trial 
at both baseline and post-HIIT, paired t-tests and Wilcoxon signed-ranks tests were 
used as appropriate. All tests were two-tailed with an alpha level of 0.05. Results are 
reported as the mean ± SD (95% CI) unless stated otherwise.  
 
6.4 Results 
Twenty-one competitive cyclists and triathletes (n = 12 men and 9 women) 
volunteered to participate in this study. Three male participants were unable to 
complete the study due to illness (n = 2) or injury (n = 1; sustained outside of the 
study), and one female participant was excluded due to an anomaly in oestradiol 
concentration on one of the trial days. The physical characteristics of the participants 
before and after 10 HIIT sessions are presented in Table 6.1. There were no 
significant main effects of HIIT, or sex-specific differences between baseline and 
post-HIIT for any of the physical characteristics. At both baseline and post-HIIT, men 
were significantly heavier than women, and women had a significantly higher body 
fat percentage than men. At post-HIIT but not baseline, men had a significantly 
higher resting heart rate compared to women. 
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Table 6.1. Physical characteristics of the participants at baseline and after 10 
HIIT sessions.  
Non-normally distributed data are expressed as median (interquartile range).  
kg·(m2)-1: kilograms of body mass per metre of height, squared; %: percentage; beats·min-1: beats per 
minute; [La-]: lactate concentration; mmol·L-1: millimoles per litre; *p < 0.05 compared to women at the 
same time-point; **p < 0.01 compared to women at the same time-point. 
 
Results for dietary intake, urine osmolality, training load and well-being are shown in 
Appendices 6.3 to 6.6, respectively. Over 10 trials, five different participants 
produced a urine osmolality result > 700 mOsmol/kgH2O and therefore were required 
to sip water until producing a urine sample below this result. Upon commencing each 
trial, all participants produced a urine osmolality result ≤ 700 mOsmol/kgH2O. 
Provided participants completed the training diaries accurately and honestly (signed 
consent forms confirmed compliance to avoid HIIT outside of the study), the diaries 
showed that all participants avoided HIIT outside of their study involvement, as well 
as high volume and intensity exercise in the 24 h prior to each trial; there was no 
significant main effect for time (p = 0.62) or sex (p = 0.76). 
 
 
Men (n = 9) Women (n = 8) 
Baseline Post-HIIT Baseline Post-HIIT 
Age (years) 29 ± 6 (24-34)  30 ± 5 (26-34)  
BMI (kg·[m2]-1) 22.5 ± 2.5 (20.6-24.4) 
22.6 ± 2.4 (20.8-
24.5) 
22.8 ± 1.9 (21.-
24.4) 
22.6 ± 1.9 (21.1-
24.2) 
Body mass (kg) 73.2 ± 7.0 (67.9-78.6)* 
73.5 ± 6.9 (68.1 -
78.8)* 68.7 (14.6) 68.4 (13.8) 
Body fat (%) 18.4 ± 4.1 (15.3-21.6)** 
18.0 ± 4.3 (14.6-
21.3)** 
27.3 ± 4.6 (23.5-
31.2) 
27.2 ± 4.4 (23.6-
30.8) 
Resting heart rate 
(beats·min-1) 70 ± 12 (61-79) 69 ± 8 (63-75)* 58 (13) 58 (15) 
Resting [La-] (mmol·L-1) 1.4 ± 0.6 (1.0-1.9) 
1.4 ± 0.4 (1.1-
1.8) 
1.3 ± 0.3 (1.0-
1.5) 
1.4 ± 0.4 (1.1-
1.8) 
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6.4.1 Responses to HIIT in men and women 
Mean responses to each of the 10 HIIT sessions including power output, exercise 
and recovery heart rate, and RPE, along with peak [La-] elicited after sessions one 
and 10 are shown in Figure 6.2 for men and women. In men, there were 15 HIIT 
sessions completed by three different participants where the power output sustained 
was ≥ 5% below the target power output, for ≥ 5 reps. In women, there were three 
HIIT sessions completed by two different participants where the power output 
sustained was ≥ 5% below the target power output, for ≥ 5 reps. 
 
Men produced a higher power output than women across the HIIT sessions 
(p < 0.01). No further differences were found between sexes for end heart rate 
(p = 0.83), recovery heart rate (p = 0.47), halfway RPE (p = 0.62), end RPE 
(p = 0.65) or peak [La-] (p = 0.86). There was a significant main effect of HIIT 
session on power output (p < 0.01); however, post-hoc analysis did not reveal the 
source of the significant difference/s (p = 0.06-0.10). No further differences were 
found among HIIT sessions for end heart rate (p = 0.08), recovery heart rate 
(p = 0.94), halfway RPE (p = 0.46), end RPE (p = 0.13) or peak [La-] (p = 0.06). 
When men and women were analysed separately, no differences (p = 0.08-0.95) 
were found in any variable among all 10 HIIT sessions (or between the first and tenth 
HIIT session for peak [La-]) in men. However, in women, there was a significant main 
effect of HIIT session on power output (p < 0.01), however post-hoc analysis did not 
reveal the source of the significant difference/s (p = 0.11-0.10). No further 
differences were found in women among HIIT sessions for any other variable 
(p = 0.11-0.99).  
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Figure 6.2. Variables produced during HIIT sessions for men (n = 9) and 
women (n = 8); (a) power output (W), (b) end heart rate (beats·min-1); (c) 
recovery heart rate (beats·min-1), (d) RPE at halfway (after 5 intervals), (e) RPE 
at end (after 10 intervals) and (f) peak [La-1] (mmol·L-1) for men (n = 9) and 
women (n = 8).  
W: Watts; beats·min-1: beats per minute; [La-]: lactate concentration; mmol·L-1: millimoles per litre; 
RPE: rating of perceived exertion †p < 0.01 among HIIT sessions for women (main effect); *p < 0.01 
compared to women. 
 
6.4.2 Maximal incremental variables and LT2 
Gas exchange data were unable to be collected due to technical problems unable to 
be rectified until after study completion. Since the timing of testing was critical to the 
training intervention (i.e. to allow sufficient recovery, as well as to detect 
physiological and performance improvements before de-training), re-testing was not 
an option. However, factors other than V̇O2max have consistently been shown as 
better correlates of endurance performance in endurance-trained populations [273, 298]. 
This was confirmed by the findings of studies one and two of the present thesis, 
which showed absolute peak power output and allometrically-scaled peak power 
output (W·kg0.32) in men and women, and relative peak power output (W·kg-1) and 
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LT2 power output in women, produced stronger relationships with endurance 
performance than V̇O2max. These variables were also measured in the present 
study. Furthermore, the extended incremental protocol adopted in the present study 
favours accuracy of the LT2 calculation over V̇O2max attainment. Mean changes in 
maximal incremental variables (including absolute and relative peak power output, 
and incremental time to fatigue), and physiological variables corresponding to LT2 
(including power output, heart rate and [La-]) from baseline to mid-HIIT, and from 
baseline to post-HIIT as a percentage of total change, are shown in Figure 6.3. Mean 
results for the aforementioned variables at each time point can be found in Appendix 
6.7.  
 
Incremental time to fatigue improved post-HIIT, shown by a significant main effect 
(p = 0.05) with no difference between sexes (p = 0.11). There were no significant 
differences in any of the other physiological improvements between sexes 
(p = 0.08-0.51). Within-group analyses revealed no significant changes in any of the 
maximal incremental variables or LT2 variables for men (p = 0.44-0.92). In contrast, 
women significantly improved from baseline to post-HIIT in peak power output 
(p < 0.01), relative peak power output (W·kg-1; p = 0.01), allometrically-scaled peak 
power output (W·kg-0.32; p < 0.01), and incremental time to fatigue (p < 0.01). There 
were no significant changes from baseline to mid-HIIT for men (p = 0.43-0.88). 
Relative peak power output (W·kg-1) significantly improved from baseline to mid-HIIT 
in women (p = 0.04), without a change in any of the other variables (p = 0.07-0.84). 
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Figure 6.3. Changes (%) at mid- and post-HIIT relative to baseline results for (a) 
peak power output (W), (b) relative peak power output (W·kg-1), (c) allometrically-
scaled peak power output (W·kg-0.32), (d) time to fatigue, (e) LT2 power output (W), 
(f) LT2 heart rate (beats·min-1) and (g) LT2 [La-] (mmol·L-1) for men (n = 9) and 
women (n = 8). 
Errors bars represent the 95% confidence intervals. W: Watts; W·kg-1: Watts per kilogram of body mass; 
W·kg-0.32: Watts per kilogram of body mass to the power of 0.32; LT2: second lactate threshold; [La-]: 
lactate concentration; mmol·L-1: millimoles per litre; *p ≤ 0.05; **p ≤ 0.01. 
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6.4.3 40 km time trial 
Mean changes in time trial variables (including time to completion, power output and 
heart rate) from baseline to mid-HIIT, and from baseline to post-HIIT as a percentage 
of total change are shown in Figure 6.4. Furthermore, mean results for the 
aforementioned variables at each time point can be found in Appendix 6.8. Mean 
time trial time and power output significantly improved from baseline to post-HIIT 
(both p < 0.01), without a significant sex x time interaction (p = 0.08 and p = 0.92, 
respectively). Separate analyses for men and women revealed both sexes 
significantly improved from baseline to post-HIIT in mean time trial time (p = 0.01 and 
p < 0.01, respectively) and time trial power output (p = 0.02 and p < 0.01, 
respectively). From baseline to mid-HIIT, mean time trial time and power output 
improved in women (p = 0.02 and 0.01, respectively), with no significant changes 
observed in men (p = 0.11-0.85). 
 
There were no significant relationships between the change in any of the maximal 
incremental variables [peak power output (W, W·kg-1 and W·kg-0.32), incremental time 
to fatigue], or LT2 variables (power output, heart rate and [La-]) and time trial 
performance time or mean time trial power output from baseline to post-HIIT (in 
absolute terms or as percentage of baseline values; all p ≥ 0.05) in men. In women, 
the change in LT2 power output was strongly correlated with the change in time trial 
performance time and time trial power output when expressed in absolute terms 
(r = 0.80; p = 0.02, and r = -0.77; p = 0.03, respectively), and as percentages of 
baseline values (r = 0.88; p < 0.01, and r = -0.88; p < 0.01). 
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Figure 6.4. Changes (%) at mid- and post-HIIT relative to baseline results for (a) 
time trial time, (b) time trial power output and (c) time trial heart rate for men 
(n = 9) and women (n = 8).  
Errors bars represent the 95% confidence intervals; *p ≤ 0.05; **p ≤ 0.01. 
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Split times at 4 km intervals during the 40 km time trial at baseline and post-HIIT are 
shown in Figure 6.5. There were significant improvements from baseline to post-HIIT 
for each 4 km split (p < 0.01-0.03) excluding 24-28 km, 28-32 km and 32-36 km 
(p = 0.06-0.15), with a significant sex x time interaction at the 8 km split only (men 
were 50.05 s faster at baseline and 40.07 s faster post-HIIT; p = 0.02). Separate 
analyses for men and women revealed men were significantly faster post-HIIT than 
baseline from 8-12 km (p = 0.05) and 16-20 km (p = 0.01), whilst women were 
significantly faster at post-HIIT compared to baseline for all splits (p < 0.01-0.05) 
except for 24-28 km (p = 0.21).  
 
 
Figure 6.5. Split times every 4 km during the 40 km time trial at baseline and 
post-HIIT in men (n = 9) and women (n = 8).  
Error bars represent the 95% confidence intervals. sec: seconds; km: kilometres; *p ≤ 0.05; **p ≤ 0.01 
compared to post-HIIT (women) and compared to baseline (men). 
 
6.4.4 Correlations with time trial performance 
Relationships between maximal incremental variables and LT2 variables with 40 km 
time trial time at baseline and post-HIIT are presented in Table 6.2. The variables 
most consistently related to performance over time were incremental time to fatigue, 
absolute peak power output and allometrically-scaled peak power output; these 
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produced strong correlations at both time points in women (baseline: r = -0.80; 
r = -0.79 and r = -0.70; post-HIIT: r = -0.87, r = -0.82 and r = -0.74, respectively; 
p < 0.01-0.04) and men (baseline: r = -0.81, r = -0.81 and r = -0.68; post-HIIT: 
r = 0.88, r = 0.88 and r = -0.80, respectively; all p < 0.01). Relative peak power 
output (W·kg-1), and LT2 [La-] produced weak, insignificant relationships 
(p = 0.11-0.85) with performance at both time points in men and women. LT2 heart 
rate was correlated with performance time in men post-HIIT (r = -0.80; p < 0.01), but 
not at baseline (p = 0.39), and not in women at either baseline (p = 0.79) or post-HIIT 
(p = 0.38). Power output at LT2 was only related to time trial performance post-HIIT 
in men (r = -0.86; p < 0.01) and women (r = -0.81; p = 0.02). Finally, peak power 
output expressed relative to W·kg-0.32 was correlated with performance in men and 
women at baseline (men: r = -0.68; p = 0.04; women: r = -0.71; p = 0.05) and post-
HIIT (men: r = -0.80; p = 0.01; women: r = -0.74; p = 0.04). 
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Table 6.2. Pearson (r) and Spearman (ρ) correlation coefficients comparing maximal 
incremental variables and LT2 variables with time trial performance at baseline and 
post-HIIT for men (n = 9) and women (n = 8). 
 
Time trial time (men) Time trial time (women) 
Baseline Post-HIIT Baseline Post-HIIT 
Peak power output 
(W) r = -0.81** r = -0.88** r = -0.79* r = -0.82* 
Peak power output 
(W·kg-1) r = -0.37 r = -0.51 ρ = -0.20 ρ = -0.09 
Peak power output 
(W·kg-0.32) r = -0.68* r = -0.80** r = -0.70* r = -0.74* 
Incremental time to 
fatigue (min) r = -0.81** r = -0.88** r = -0.80* r = -0.87** 
LT2 power output (W) r = -0.63 r = -0.86** r = -0.64 r = -0.81* 
LT2 heart rate 
(beats·min-1) r = -0.33 r = -0.80** r = 0.11 r = 0.36 
LT2 [La-]  
(mmol·L-1) 
r = 0.07 r = -0.15 r = -0.61 r = 0.26 
W: Watts; W·kg-1: Watts per kilogram of body mass; W·kg-0.32: Watts per kilogram of body mass to the 
power of 0.32; min: minute; LT2: second lactate threshold; beats·min-1: beats per minute; [La-]: lactate 
concentration; mmol·L-1: millimoles per litre; *p ≤ 0.05; **p ≤ 0.01. 
 
6.4.5 Differences between LT2 and 40 km time trial variables 
No significant differences (p = 0.06-0.82) were found between power output elicited 
at LT2 and mean power output during the time trial at baseline or post-HIIT in men or 
women. Moreover, no significant differences were found between heart rate elicited 
at LT2 and mean time trial heart rate at baseline or post-HIIT in women, or at 
baseline in men (all p ≥ 0.05). However, post-HIIT, men elicited a significantly higher 
mean heart rate during the time trial (167 ± 7 beats·min-1) than at LT2 
(162 ± 6 beats·min-1; p = 0.01). Further analysis of heart rate recorded at 4 km 
intervals throughout the time trial revealed that the difference between heart rate at 
LT2 and mean time trial heart rate post-HIIT was significant at 20 km (p < 0.01), 
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24 km (p = 0.04), 28 km (p = 0.03), 36 km (p < 0.01) and 40 km (p < 0.01) (Figure 
6.6). 
 
 
Figure 6.6. Heart rate splits every 4 km during the 40 km time trial, and mean 
LT2 heart rate post-HIIT in men (n = 9).  
Errors bars represent the 95% confidence intervals. beats·min-1: beats per minute; km: kilometres; 
LT2: second lactate threshold; †p ≤ 0.05 compared to LT2 heart rate; ‡p ≤ 0.01 compared to LT2 heart 
rate; *p < 0.05 compared to 40 km; **p < 0.01 compared to 40 km. 
 
6.4.6 Hormone Status 
Hormonal contraceptive methods used by participants in the present study were 
monophasic OC pill formulations (n = 7) and NuvaRing® (vaginally inserted 
monophasic contraceptive ring; n = 1). 
 
6.4.6.1 Ovulation Test 
Ovulation tests were administered a total of 21 times across all participants (once 
per new menstrual cycle). All ovulation tests returned a negative result, indicating 
anovulation.  
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6.4.6.2 Blood hormone concentrations 
Mean oestradiol and progesterone concentrations were 5.9 ± 2.3 pg·mL-1 and 0.5 ± 
0.3 ng·mL-1, respectively. Mean concentrations of oestradiol and progesterone for 
trials at baseline, mid- and post-HIIT are presented in Table 6.3, along with the mean 
intra-participant CV for oestradiol and progesterone concentrations among trials. The 
trial number reflected the randomised order that each participant was assigned, not a 
particular trial (i.e. trial one may have been the V̇O2max or 40 km time trial for 
different participants). All participants (except one who was excluded) reported 
suppressed oestradiol and progesterone concentrations equal to or lower than those 
previously reported for hormonal contraceptive users [196]. However, the intra-
participant CVs and CVs of the whole sample (oestradiol: 39% and progesterone: 
57%) suggest that endogenous concentrations of oestradiol and progesterone are 
susceptible to variability even when controlled with exogenous doses, such as those 
provided by hormonal contraceptives. 
 
Table 6.3. Serum oestradiol and progesterone concentrations at baseline, mid- 
and post-HIIT, and intra-participant CV values.  
Non-normally distributed data are expressed as median (interquartile range). 
 
Baseline Mid-HIIT Post-HIIT CV 
(%) Trial 1 Trial 2 Trial 1 Trial 2 Trial 1 Trial 2 
Oestradiol 
(pg·mL-1) 
(n = 46) 
5.0 (0.07) 5.0 (4.7) 5.0 (0.0) 5.0 (0.0) 5.0 (0.0) 5.0 (2.4) 13 
Progesterone 
(ng·mL-1) 
(n = 46) 
0.5 ± 0.3 
(0.3-0.8) 
0.5 ± 0.3 
(0.3-0.8) 
0.5 ± 0.3 
(0.2-0.8) 
0.5 ± 0.3 
(0.3-0.8) 
0.5 ± 0.4 
(0.2-0.8) 
0.6 ± 0.3 
(0.3-0.8) 13 
CV: coefficient of variation; pg·mL-1: picograms per millilitre; ng·mL-1: nanograms per millilitre. 
 
6.5 Discussion 
The primary objective of the present study was to compare the adaptations of 
maximal incremental variables, LT2 variables, and 40 km cycling performance in 
response to 10 HIIT sessions between endurance-trained men and women, whilst 
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controlling for female ovarian hormone concentrations. A secondary objective was to 
describe the strength of the LT2-performance relationship post-HIIT in men and 
women. In response to the primary objective, it was found that: (1) there were no 
significant changes in any of the maximal incremental variables or LT2 variables after 
five or 10 HIIT sessions in men; (2) in women there were significant increases in 
absolute peak power output, allometrically-scaled peak power output (W·kg-0.32) and 
incremental time to fatigue after 10 HIIT sessions, and in relative peak power output 
(W·kg-1) after five and 10 HIIT sessions; and (2) mean time trial performance time 
and power output improved significantly in men after 10 HIIT sessions, and in 
women after five and 10 HIIT sessions. In response to the secondary objective, it 
was found that: (1) peak power output and incremental time to fatigue produced 
strong, significant correlations with time trial performance at baseline and post-HIIT 
in men and women, but LT2 power output and time trial performance were 
significantly correlated post-HIIT only, in both men and women; and (2) power output 
and heart rate reflective of LT2 were not significantly different from those elicited 
during the time trial at either baseline or post-HIIT in women, or at baseline in men. 
However, mean time trial heart rate was significantly faster than LT2 heart rate for 
men post-HIIT. 
 
6.5.1 Maximal incremental variables and LT2 
6.5.1.1 Maximal incremental variables 
The first of two primary outcomes in the present study was that four maximal 
incremental variables significantly increased in response to 10 HIIT sessions in 
endurance-trained women, without a concurrent change in any maximal incremental 
variable in men. This finding supports the hypothesis that women would respond to 
HIIT to a relatively greater extent compared to men. Of the 11 available studies 
investigating the short-term adaptations to HIIT in endurance-trained male cyclists 
[32-39, 71, 251, 252], nine measured peak power output and all reported significant 
improvements (3-8%) [32, 34, 36-39, 71, 251, 252], whilst the present study failed to elicit a 
significant improvement (~2%; p = 0.63). Although the interval duration in the present 
study (90 s) was longer than some others who reported improvements in peak power 
output (5-45 s [39] and 60 s [71]), total exercise duration was 15 min per session in the 
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present study compared to 20 min reported by Laursen et al. [71]. Although total 
exercise duration was only 12-15 min in the study of Clark et al. [39], the daily HIIT 
sessions for seven days may have allowed for sufficient overload and subsequent 
peak power output improvements and may explain, at least in part, the improvement 
in peak power output compared to the present study. Therefore, it may be 
reasonable to suggest that endurance-trained men require interval durations 
> 1.5 min, a total exercise duration per HIIT session > 15 min, or more concentrated 
overload over a shorter time period to significantly improve peak power output.  
 
The improvement in peak power output in women, but not men may be explained by 
a larger increase in type IIB muscle fibre size. This is supported by previous findings 
of a significant increase in type IIB muscle fibre size and mean power output over 
three 30 s sprints after a bout of HIIT in recreationally-active women (n = 10), but not 
men (n = 6) [348]. The authors attributed the increase in type IIB fibre size in women 
to lower pre-training values due partly to less frequent high-intensity muscle 
activation and the increase in power output to increased fibre area (especially type 
II), increased glycogenolytic rate and increased glycogen storage [348]. It is unlikely 
that a lower pre-training status in women than men would explain the findings of the 
present study, since the women compared well to those of other studies in 
endurance-trained female cyclists for mean 40 km time trial time (~68 min vs. 
~74 min [298, 356]), power output (182 W vs. 181 W [298, 356]) and 1 h time trial power 
output (183 W [10] and 184 W [17]). Furthermore, there were no significant differences 
in training load reported in the seven days prior to baseline, mid- and post-HIIT 
testing between men and women (Appendix 6.5). However, perhaps less familiarity 
with HIIT and subsequently less frequent high-intensity muscle activation contributed 
to the magnitude of improvement in women. Nevertheless, these findings, along with 
those confirming a strong activation of anaerobic metabolism in the last stages of an 
incremental exercise test to exhaustion [357], suggest that the adaptation of anaerobic 
energy pathways (resulting in an increase in peak power output and incremental time 
to fatigue) was greater in response to HIIT in women than men and may explain the 
current findings. 
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6.5.1.2 LT2 
None of the variables related to the LT2 (power output, heart rate and [La-]) changed 
in response to HIIT in men or women. Although improvements in VT2 have been 
reported (8.6-15.7%) after only four [71] and eight [36] HIIT sessions in well-trained 
male cyclists, comparing VT2 and LT2 may not be appropriate, since they have been 
shown to respond differently to the same training intervention [288]. To date, LT2 
adaptations to HIIT have been reported in trained male cyclists after one year [40] and 
five months [41] of HIIT periodisation, and in one study of similar duration to the 
present study (8 sessions; 4% improvement when LT2 was determined as the 
second steep increase in [La-]). Furthermore, an improvement in skeletal muscle 
buffering capacity (16%; p < 0.05; n = 6) [38] and a reduction in plasma [La-] at the 
same absolute exercise intensity (23-42%; p < 0.05; n = 8) [37] have been reported in 
trained male cyclists after six and 12 HIIT sessions, respectively. Both studies 
indicated improvements in LT2 resulting from a shift to the right in the [La-]-work rate 
curve post-HIIT. However, total exercise volume was higher in these studies 
(196 min [251], 464 min [40], 315 min [38] and 360-540 min [37] vs. 150 min in the present 
study), which may explain the lack of improvement in LT2 in the present study. 
Therefore, it could be suggested that the minimal volume of HIIT required to elicit 
metabolic-related changes is > 150 min but ≤ 315 min. However, further research 
examining the time-course of adaptation to LT2 in both men and women is 
warranted. 
 
Although not significant, there was a trend for an improvement in LT2 power output in 
women (p = 0.08) but not men. The presence of female ovarian hormones may 
contribute to the potential for differences in adaptations to HIIT in men and women. 
Oestradiol appears to mediate sex-based differences in substrate metabolism by 
acting primarily on the liver, decreasing the release of glucose during endurance 
exercise [358]. This results in a greater reliance on lipid sources for fuel in women 
than men [217, 332], and fatty acid mobilisation appears to be increased to a greater 
extent during exercise eliciting a high [La-] [203]. Additionally, others have shown 
higher [La-] after high-intensity exercise when oestradiol concentrations are low, 
rather than high [22, 23], providing further evidence that oestradiol may delay the onset 
of fatigue by increasing the contribution of aerobic metabolism when exercising at 
256 
 
high intensities. Since women in the current study used hormonal contraceptives, 
their oestradiol concentrations were lower (~20 times) than oestradiol concentrations 
in women not using a contraceptive. This suggests that the sex differences may be 
heightened when comparing men with women who are not using a hormonal 
contraceptive, and this should be explored further. Therefore, the finding that an 
improvement in peak power output and a trend for an improvement in LT2 power 
output were seen in women but not men at post-HIIT in the present study may be 
partially rationalised through the influence of oestradiol, perhaps by the exacerbation 
of the sex-based differences in substrate metabolism and subsequent effects on [La-] 
and fatigue. 
 
6.5.2 40 km time trial 
The second of two primary outcomes in the present study was that 40 km time trial 
time and mean time trial power output improved significantly in both men and 
women. Despite a trend towards a larger improvement from baseline to post-HIIT in 
women than men for 40 km time trial time (-2.93 ± 1.50% vs. -1.67 ± 1.59%, 
respectively; p = 0.08), there was no significant difference between sexes in the 
magnitude of improvement.  
 
Of the 11 available studies investigating the short-term adaptations to HIIT in 
endurance-trained cyclists (all men) [32-39, 71, 251, 252], seven assessed 40 km time trial 
performance, and all seven reported significant improvements (2-6%; n = 6-41) [32-38], 
consistent with the present findings. Furthermore, this study is the first to examine 
endurance performance adaptations to HIIT in endurance-trained women, and to 
compare these with performance adaptations in endurance-trained men. Previous 
research has been limited to recreationally-active women and indirect reporting of 
performance improvements through a reduction in plasma epinephrine and heart 
rate during the final 30 min of a 60 min cycling trial [359].  
 
Pacing results revealed improvements in 4 km split times from baseline to post-HIIT 
were different between men and women (Figure 6.5). Relative to baseline, women 
were significantly faster in nine out of the 10 intervals (excluding 24-28 km) post-
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HIIT, whilst men were only significantly faster in two intervals (8-12 km and 
16-20 km). This more consistent improvement in women throughout the 40 km likely 
contributed to the larger (though non-significant) magnitude of change in time trial 
time from baseline to post-HIIT compared to men (-2.9 vs. -1.7%, respectively; 
p = 0.08). Compared to baseline, the consistently faster splits over ~65 min suggest 
that improved capacity to tolerate higher work rates and maintain metabolic 
equilibrium, which is supported by the finding that the improvement in time trial 
performance was significantly related to the improvement in LT2 power output. The 
mechanism(s) responsible, however, is not clear and requires further investigation. 
Changes in LT2 have been reported in one other HIIT intervention in well-trained 
male cyclists (n = 12) where LT2 improvements were smaller when HIIT was 
conducted in hyperoxic (60% O2; 0.2%) vs. normoxic (21% O2; 3.6%) conditions [251]. 
These findings suggest that the maintenance of adenosine triphosphate, adenosine 
diphosphate and total nicotinamide adenine dinucleotide hydride, and therefore the 
normal contractile properties of muscle actually supressed, rather than enhanced, 
physiological adaptations, and therefore do not seem to explain LT2 or 20 km cycling 
performance improvements post-HIIT [251].  
 
The present finding provides some support for Westgarth-Taylor et al. [37] who 
reported reduced [La-] at the same absolute work rate (80% peak power output) after 
HIIT and Weston et al. [38] who showed an increased buffering capacity was 
correlated with time trial time improvement post-HIIT in trained male cyclists. This 
study is the first to show that when endurance-trained men and women performed 
the same relative HIIT intervention, metabolic adaptations shown by an improvement 
in LT2 explained 77% of the improvement in 40 km cycling performance in women, 
but the performance improvement in men was not related to changes in the LT2. The 
relationship between LT2 power output improvement and time trial performance 
improvement in women was significant despite only a trend for an improvement in 
LT2 power output post-HIIT (p = 0.08). Additionally, none of the other measured 
maximal incremental variables or LT2 variables could explain the improvement in 
time trial time or power output in men or women (all p ≥ 0.05). Future research could 
explore additional hormonal and/or muscular adaptations through the sampling of 
muscle to seek further insight. 
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Endurance performance in well-trained athletes is influenced by physiological factors 
including V̇O2max, lactate threshold/critical power, gross mechanical efficiency and 
genetic predispositions [360]. Since V̇O2max remains fairly stable across an athletic 
career, and therefore has minimal potential for further improvement once high-load 
endurance training has been undertaken for several years [360], it is unlikely that 
changes in V̇O2max resulted over the course of ~3-4 weeks in the present study. 
Therefore, since there was no significant change in LT2 in response to HIIT for men 
or women in the present study, it is possible that an increase in gross mechanical 
efficiency and/or delta efficiency [the ratio of the change in accomplished work 
(kcal·min-1) to the change in expended energy (kcal·min-1)] [361], which has been 
proposed to be the most valid indicator/predictive variable of muscular efficiency in 
road cycling [361, 362], may have contributed to the improvement in time trial 
performance post-HIIT. Mechanisms for improvements in efficiency have been 
suggested as an increase in mitochondrial efficiency [363] and a change in fibre type 
composition and recruitment, i.e. a shift towards more active slow-twitch fibres and 
more efficient recruitment of fibres, resulting in better muscular efficiency [364].  
 
Further support for this is provided by Jeukendrup et al. [4], who estimated a 63 s 
improvement in 40 km cycling time trial if efficiency is improved by 1%. Since men 
improved their 40 km time trial time by 60 ± 56 s, and women by 121 ± 67 s in the 
present study, this would imply a ~0.95% and ~1.92% improvement in efficiency in 
men and women, respectively. If this was indeed the case, this larger improvement 
in efficiency in women than men in the present study may have been influenced by 
the higher proportion of type I skeletal muscle fibres in women [365], as this has been 
reported as an influence on exercise efficiency [361, 366]. Although others have shown 
improvements in 40 km time trial performance were correlated with the change in 
skeletal muscle buffering capacity (n = 6; r = -0.74; exact p value not reported) [38] 
and anaerobic capacity (r = 0.40; p < 0.05; n = 41) [36] in men, the present study does 
not provide any evidence of this indirectly through the variables measured.  
 
The time course of adaptation in 40 km time trial performance was also different 
between sexes. Women significantly improved their time trial time (-1.0 ± 0.92%; 
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p < 0.05) and time trial power output (2.9 ± 2.5%; p < 0.05) by mid-HIIT. However, 
men significantly improved post-HIIT only (mid-HIIT: -0.2 ± 2.6% and 1.6 ± 4.4%; 
both p ≥ 0.05, respectively). This rapid performance improvement in women after 
only five HIIT sessions suggests that a shorter HIIT intervention could be 
implemented into the training program of endurance-trained women for a 
performance ‘boost’ if time is a constraint. However, the majority of the improvement 
in performance actually occurred between HIIT session five and 10 (67%), so 
completing the additional five sessions is nevertheless warranted. Additionally, this 
may provide support for the earlier suggestion that women were perhaps less 
familiar with HIIT and therefore had less exposure to high-intensity muscle activation 
prior to the HIIT intervention, contributing to a larger potential for improvement. The 
lack of change in 40 km time trial performance at mid-HIIT in men is consistent with 
the findings of others after three [32] or four [34, 36] sessions. Although Clark et al. [39] 
showed performance improvements after seven HIIT sessions in seven days 
(2.9-4.4%; n = 28 men), the higher HIIT frequency stimulus (~105 min of maximal 
exercise intensity) and shorter time trial distance (20 km) may explain this.  
 
In summary, despite similar magnitudes of improvement in 40 km cycling time trial 
performance between men and women after 10 HIIT sessions, different physiological 
mechanisms appear to underlie these changes. In women, the improvement in time 
trial performance was related to the improvement in power output at LT2, whilst no 
variable could explain the significant improvement in time trial performance in men. 
Future research should investigate the mechanisms responsible and their time 
course of adaptation for sex-specific performance improvements in response to HIIT. 
 
6.5.3 Correlations with 40 km time trial performance  
The finding that peak power output was a strong correlate of 40 km time trial time at 
baseline and post-HIIT in both men and women suggests that it is a robust and 
sensitive measure to detect performance changes. This extends the findings 
reported in Chapters 3 (men; r = -0.88; p < 0.01) and 4 (women; r = -0.87; p < 0.01) 
of the present thesis, which showed strong correlations at a single time point. These 
findings also extend those of others reporting significant relationships between peak 
power output and 40 km cycling performance via cross-sectional studies in trained 
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male [273] and female [17, 298] cyclists, and those using a combination of men and 
women [292]. Furthermore, this finding also extends those of other HIIT interventions 
in endurance-trained male cyclists who reported significant relationships between 
peak power output and performance both pre- and post-HIIT, although the strength 
of the relationship was only reported pre-HIIT (r = 0.83; p < 0.01 [37] and r = -0.91; p < 
0.01 [38]), or the relationship (r = 0.84; p < 0.01) was reported, but not the time point 
(pre- or post-HIIT) [32]. Although allometrically-scaled peak power output (W·kg-0.32) 
was also significantly related to time trial performance at both baseline and post-HIIT 
in men and women, these relationships were similar to those produced by absolute 
peak power output, making the scaling process redundant. This is consistent with 
findings from Chapter 3 (peak power output: r = -0.88; p < 0.01; allometrically scaled 
peak power output: r = -0.90; p < 0.01) and Chapter 4 (peak power output: r = -0.87; 
p < 0.01); allometrically scaled peak power output: r = -0.86; p < 0.01).  
 
Significant relationships were also found between power output reflective of LT2 and 
40 km time trial performance in both men (r = -0.86; p < 0.01) and women (r = -0.81; 
p = 0.02) post-HIIT, but not at baseline. This finding extends those of Chapters 3 and 
4 that showed significant relationships between power output at LT2 and 40 km 
cycling performance in men (r = -0.69; p < 0.05) and women (r = -0.75; p < 0.01) at a 
single point in time where there was no control over training loads in the months 
prior.  
 
Subsequently, the most robust measures to utilise in physical assessments for the 
purpose of evaluating endurance performance potential appear to be absolute peak 
power output, allometrically-scaled peak power output (although there appears to be 
no additional benefit in scaling peak power output relative to the power of 0.32 
compared to absolute values) and incremental time to fatigue, regardless of training 
intensity and sex. When expressed as power output, LT2 was related to 40 km 
performance post-HIIT only in both men and women, suggesting that training 
intensity is an important cofounder in the LT2-performance relationship in both sexes. 
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6.5.4 Difference between variables elicited at LT2 and during a 
40 km time trial  
No significant differences were found in power output or heart rate reflective of LT2 
compared to their respective responses during a 40 km time trial in women at 
baseline, nor after 10 HIIT sessions. This suggests that both power output and heart 
rate reflective of LT2 may be appropriate for use in establishing and monitoring 
exercise intensity during a performance trial of ~66 to 68 min in women, independent 
of their most recent training focus. These findings extend those of Chapter 4 of the 
present thesis that showed heart rate at LT2 was not different from the mean heart 
rate produced over 40 km of cycling at a single point in time, in trained women. 
However, the present findings conflict with those of Chapter 4 in regard to power 
output: power output at LT2 was significantly higher than mean 40 km time trial 
power output in Chapter 4. This difference cannot easily be explained, since 
participants completed the same testing protocols, and LT2 was detected using the 
same method (modified D-max) in both studies. Inconsistencies in the capacity for 
LT2 power output to reflect mean time trial power output in women have also been 
shown by others. One group reported power output to be significantly lower at LT2 
than during a 20 km cycling time trial [295], whilst others have shown no difference 
during a 30 min time trial [18, 295]. However, methodological differences between 
studies may have contributed to these inconsistencies. For example, different 
methods of LT2 determination (such as the highest power output that did not result in 
consecutive and continued increases in [La-] from exercising baseline [295], the 
highest power output that did not result in consecutive and continued increases of ≥1 
mmol·L-1 in [La-] from exercising baseline [295], and modified D-max) were reported. 
Furthermore, different ages (young [295] vs. veterans [18]) and sexes [pooled results of 
men and women into one group (n = 10 men and 3 women [295] and n = 8 men and 1 
woman [18])] may also have explain these discrepancies. The present study extends 
the findings of Bishop et al. [10] who showed no significant difference between power 
output at LT2 (modified D-max) and mean power output during 1 h cycling 
performance in trained women, with the addition of two training phases and the 
control of ovarian hormones in the present study. 
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Similarly in men, the capacity for LT2 power output to reflect mean time trial power 
output was consistent at baseline and after 10 HIIT sessions. This extends the 
findings of Chapter 3 that found no difference between LT2 power output and self-
selected 40 km time trial power output at a single point in time. Others have also 
shown no differences between the mean power output produced by other threshold 
methods (V̇E/ V̇O2, RER0.95 and OBLA) and mean 40 km cycling trial power output in 
experienced male cyclists [93], with the present study the first to examine the capacity 
of LT2, as determined by the modified D-max method to reflect the mean power 
output over a 40 km time trial after two different training phases. Since LT2 power 
output was reflective of a maintainable intensity over ~58-59 min, regardless of the 
intensity of the previous training block, the finding that LT2 heart rate was lower than 
mean time trial heart rate post-HIIT, but not different at baseline, was unexpected. 
More specifically, this dissociation between heart rate at LT2 and mean time trial 
heart rate was evident between 20 and 40 km, suggesting that a subtle 
cardiovascular drift commenced from ~29 min onwards, resulting in the heart rate, 
but not power output, increasing and remaining above LT2 for ~30 min until time trial 
completion. Others have attributed cardiovascular drift to thermal stress, reduced 
blood volume and magnitude of muscle mass activation [124]. Since heart rate at LT2 
was not different from mean 40 km time trial heart rate in women, it is possible that 
these physiological mechanisms may have contributed to the differences between 
men and women in the present study. Therefore, it could be concluded that despite a 
significant improvement in 40 km time trial time and power output post-HIIT, men 
experienced greater cardiovascular stress than women, specifically during the final 
20 km of a 40 km time trial after 10 HIIT sessions. 
 
Consequently, it appears appropriate to use LT2 power output as a sustainable 
power output over 40 km in both men and women, and to use heart rate reflective of 
LT2 in women, regardless of the intensity of the previous training block. However, 
heart rate at LT2 may be exceeded during performance trials of 40 km (~58 min) 
after 10 HIIT sessions in men, and the use of heart rate to set a sustainable intensity 
is recommended only up until 20 km (~29 min) time trials. 
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6.5.5 Limitations 
A limitation of the present study was the small sample size, which was a result of a 
number of different challenges. Firstly, the criteria surrounding the endurance-trained 
status of participants and their willingness to alter their pre-established training plans 
(which are put in place with strict purpose) for the duration of the study, was too 
difficult to justify for a number of potential participants. To address this, it is 
recommended that the timing of training interventions in athletes consider the off-
season, pre-season and competitive season of participants to establish the most 
appropriate schedule. Recruiting participants from one, rather than two sports, may 
assist with this, and recruiting a number of participants from the same training group 
may also aid in recruitment and compliance. Additionally, training loads prior to the 
intervention were not monitored in the weeks or months prior to baseline testing; 
rather, participants were simply asked to confirm that they had met the inclusion 
criteria of completing consistently high-volume, but not high-intensity training, for ≥ 2 
months. More diligent training load monitoring prior to training interventions is 
recommended, with the potential inclusion of pre-baseline testing to more accurately 
match the two training groups. Furthermore, there were challenges with controlling 
for hormone concentrations in the female participants; women who identify as using 
their hormonal contraceptive are not always compliant. Therefore, serum hormone 
concentrations that objectively measure compliance to hormone control is required in 
studies involving women of child-bearing age; this resulted in the exclusion of one 
participant in the present study. To address the issue of compliance, it is also 
recommended that researchers confirm ovulation test results by photographic 
record. Finally, we recommend oversampling by 10% in studies recruiting women 
using hormonal contraceptives, to account for incompliance. 
 
6.6 Conclusions 
This was the first known study to compare the adaptations of maximal incremental 
variables, LT2 variables, and 40 km cycling performance in response to 10 HIIT 
sessions, between endurance-trained men and women, whilst controlling for female 
ovarian hormone concentrations. Consistent with the first hypothesis relating to 
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women responding to HIIT to a relatively greater extent than men, this study 
revealed women, but not men, significantly improved their peak power output, 
relative peak power output (W·kg-1), allometrically-scaled peak power output 
(W·kg-0.32) and incremental time to fatigue, with a trend for an improvement in LT2 
power output. In contrast however, both men and women improved their 40 km 
cycling performance to a similar extent. Furthermore, the second hypothesis which 
related to changes in LT2 and peak power output predicting performance 
improvements in women, was confirmed, since LT2 power output explained 77% of 
the improvement in 40 km cycling performance in women, whilst none of the 
measured variables could explain the performance improvement in men.  
 
The final hypothesis relating to a strong LT2-performance relationship before and 
after HIIT for both men and women, was rejected. The LT2-performance relationship 
was significant post-HIIT (but not at baseline) for both men and women. This 
suggests that LT2 determined by the modified D-max method is intensity-dependent, 
and is more sensitive for use when establishing performance potential after high, 
rather than low to moderate-intensity training. Furthermore, it appears equally as 
useful for establishing performance potential in men and women. For the purpose of 
setting a sustainable cycling intensity over 40 km (~60 min), LT2 power output is 
recommended in men and women. In contrast, LT2 heart rate was less consistent 
with mean time trial heart rate in men, and would therefore be recommended for use 
in women only. Future research should endeavour to investigate the mechanisms 
responsible for these sex-based differences in adaptations to HIIT, especially at the 
muscular level. 
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Appendix 6.1. Pre-trial questionnaire. 
EXCLUSION CRITERIA – Day of trial 
1. Subject does not report in a euhydrated state (and has not 
followed the pre-trial hydration requirements). 
YES      NO 
         
2. Subject has not followed the pre-trial dietary requirements and 
completed the food diary. 
         
3. Subject has consumed caffeine-containing substance/s in the 
previous 24 hours. 
         
4. Subject has consumed alcohol in the previous 24 hours.          
5. Subject has undertaken excessive exercise within 24 hours of the 
trial beginning. 
         
6. If female; subject has let hormonal contraceptive lapse for more 
than 24 hours. 
         
7. If female; subject has used hormonal contraceptive within 6 hours 
of trial beginning. 
         
 
DIETARY CONTROL 
Pre-Trial Meal 
Time of pre-trial food intake:     : 
                     (24 hour time)           hh      mm 
 
 
24 h PRE-TRIAL FOOD DIARY 
Pre-trial food diary completed:    YES     NO 
                                                             
Any comments related to food 
diary: 
 
HEALTH STATUS 
Recent health status: 
_________________________________________________________________________ 
Other comment (injuries etc.): 
_________________________________________________________________________ 
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FEMALES ONLY 
 
HORMONAL CONTRACEPTIVE 
                                                                                         YES    NO 
If taking a pill, was this taken last night?                
Time of intake last night: :             
(24 hr time)                           hh        mm 
Taken night before?                                                                                              
 
                                                                                                                                         YES    NO    
Are you currently experiencing any hormonal symptoms,                                   
e.g. bloating, nausea? If yes, please state: 
Have you experienced any breakthrough bleeding or spotting?                 
If yes, please state which day/s:                                                                                             
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Appendix 6.2. Training diary. 
 
PLEASE COMPLETE THIS TRAINING DIARY FOR THE 7 DAYS 
PRIOR TO VO2MAX AND 40 KM TIME TRIAL TESTING 
 
You are reminded to: 
1. Refrain from any high intensity training outside of this study; 
2. Maintain the frequency, intensity and volume of your own base training 
throughout the duration of the study; 
3. Reduce your duration of your training by approx. 25 mins per week to 
accommodate the study. 
 
Training Diary 
Participant ID: 
 
 
Testing phase (please 
circle or highlight): 
Baseline/ mid-point/ post-training 
Date Duration Volume Intensity Mode 
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Date Duration Volume Intensity Mode 
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Appendix 6.3. Dietary intake per trial. Non-normally distributed data are expressed as median (interquartile range); p value 
represents level of significance among trials for men and women. 
 
Trial Sex Energy (kJ) CHO (g) Protein (g) Fat (g) Sat fat (g) Water (mL) 
Baseline 
V̇O2max 
Men 
12928 ± 4022 
(9565-16290) 
335 ± 114 
(239-431) 
161 ± 54 
(115-206) 
115 ± 51 
(72-157) 
47 ± 26 (26-69) 
2594 ± 1239 
(1558-3630) 
Women 
10586 ± 1815 
(9068-12103) 
370 ± 96 
(290-450) 
95 ± 24 (75-115) 65 ± 33 (38-92) 19 ± 10 (11-27) 
1444 ± 956 
(645-2243) 
Baseline 
Time 
Trial 
Men 
12497 ± 4616 
(8846-16148) 
354 (129) 
132 ± 53 
(91-173) 
95 ± 42 (91-173) 34 ± 16 (21-46) 
2578 ± 1279 
(1594-3561) 
Women 
10788 ± 2458 
(8734-12843) 
298 ± 51 
(256-340) 
107 ± 27 
(85-130) 
96 ± 43 (61-132) 35 ± 21 (17-53) 
1719 ± 674 
(1155-2282) 
Mid-HIIT  
V̇O2max 
Men 
12008 ± 2461 
(10116-13899) 
341 ± 67 
(290-392) 
143 ± 26 
(123-163) 
94 ± 34 (68-119) 28 ± 11 (20-37) 
2533 ± 1026 
(1745-3322) 
Women 
8115 ± 2306 
(6187-10042) 
243 ± 97 
(162-324) 
84 ± 27 (61-107) 63 ± 28 (40-86) 17 (15) 
1438 414 
(1092-1783) 
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Mid-HIIT 
Time 
Trial 
Men 
11466 ± 2242 
(9743-13189) 
323 ± 89 
(255-391) 
142 ± 46 
(107-177) 
88 ± 35 (61-116) 29 ± 16 (16-42) 2850 (1650) 
Women 
8995 ± 3864 
(5762-12222) 
276 ± 123 
(173-378) 
83 ± 30 (58-108) 71 ± 38 (39-103) 22 ± 15 (9-34) 
1481 ± 439 
(1114-1848) 
Post-
HIIT 
V̇O2max 
Men 
11043 ± 2611 
(8859-13226) 
315 ± 100 
(231-399) 
136 ± 35 
(107-166) 
84 ± 24 (64-104) 27 ± 7 (21-33) 
2325 ± 894 
(1577-3073) 
Women 
9069 ± 3850 
(5851-12288) 
273 ± 111 
(181-366) 
97 ± 26 (76-119) 56 (62) 21 (12) 
1569 ± 438 
(1202-1935) 
Post-
HIIT 
Time 
Trial 
Men 
11373 ± 2998 
(9068-13678) 
324 ± 246 
(246-401) 
130 ± 32 
(106-155) 
92 ± 37 (63-120) 26 ± 12 (17-35) 
2211 1584 
(993-3429) 
Women 
10085 ± 3464 
(7189-12981) 
289 ± 111 
(196-381) 
110 ± 54 
(66-155) 
79 (29) 28 ± 12 (18-39) 1500 (538) 
p value 
Men 0.53 0.79 0.81 0.23 
0.003 
(0.30-0.98) 
0.70 
Women 0.24 0.06 0.37 0.31 0.17 0.16 
kJ: kilojoule; CHO: carbohydrate; g: grams; sat fat: saturated fat; mL; millilitres; V̇O2max: maximal incremental trial. 
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Appendix 6.4. Urine osmolality (mOsmol/kgH2O) per trial. Non-normally distributed 
data are expressed as median (interquartile range); p value represents level of 
significance among trials for men and women. 
 
 
Baseline 
V̇O2max  
Baseline 
Time 
trial 
Mid-
HIIT 
V̇O2max
Mid-HIIT 
Time 
trial 
Post-
HIIT 
V̇O2max 
Post-
HIIT 
Time 
trial 
p 
value 
Men 
415 ± 
157 
(250-580) 
397 ± 
219 
(228-565) 
257 ± 
222 
(86-428)
354 ± 
282 
(118-590)
200 (340)
263 ± 
230 
(50-476) 
0.77 
Women 
373 ± 
213 
(195-550) 
275 (145) 
269 ± 
234 
(52-485)
287 ± 
235 
(91-483) 
293 ± 
195 
(130-455)
310 ± 
181 
(159-461) 
0.89 
V̇O2max: maximal incremental trial. 
 
Appendix 6.5. Training load assessed via training diaries for the seven days prior to 
baseline, mid- and post-HIIT testing. Non-normally distributed data are expressed as 
median (interquartile range).  
 
 Baseline Mid-HIIT Post-HIIT p value 
Men 
5538 ± 1949 
(4040-7036) 
5424 ± 2187 
(3743-7105) 
5875 (1698) 1.00 
Women 
6939 ± 2677 
(4700-9177) 
5673 ± 2105 
(3913-7432) 
4991 ± 3147 
(2361-7622) 
0.20 
Load calculated as: [duration (min) x distance (km) x intensity (RPE)] summated for each seven day 
period. Non-normally distributed data are expressed as median (interquartile range); p value 
represents level of significance among trials for men and women. 
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Appendix 6.6. Well-being questionnaire results per trial, where a score of 0 = 
negative well-being and 6 = positive well-being; p value represents level of 
significance among trials for men and women. 
 
 
Baseline 
V̇O2max 
Baseline 
Time 
trial 
Mid-HIIT 
V̇O2max 
Mid-HIIT 
Time 
trial 
Post-
HIIT 
V̇O2max 
Post-
HIIT 
Time 
trial 
p value 
Men 
4.6 ± 0.7 
(41-5.1) 
4.5 ± 0.9 
(3.9-5.2) 
4.5 ± 0.6 
(4.1-5.0) 
4.4 ± 0.7 
(3.9-5.0) 
4.4 ± 0.7 
(3.9-5.1) 
4.6 ± 0.7 
(4.0-5.1) 
0.92 
Women 
4.6 ± 0.3 
(4.4-4.8) 
4.6 ± 1.0 
(3.7-5.4) 
4.5 ± 0.6 
(4.0-4.9) 
4.4 ± 0.7 
(3.9-5.0) 
4.9 ± 0.6 
(4.4-5.3) 
4.8 ± 0.3 
(4.5-5.1) 
0.57 
V̇O2max: maximal incremental trial. 
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Appendix 6.7. Incremental test maximal and LT2 variables measured at baseline, mid- and post-HIIT for men (n = 9) and women 
(n = 8). Non-normally distributed data are expressed as median (interquartile range).  
 
Variable 
Men Women 
Baseline Mid-HIIT Post-HIIT 
Baseline to 
post-HIIT 
change (%) 
Baseline Mid-HIIT Post-HIIT 
Baseline to 
post-HIIT 
change (%) 
Peak power 
output (W) 
336 ± 31 
(312-360) 
339 ± 22 
(322-356) 
341 ± 25 
(322-360) 
1.7 ± 5.2 
(-2.5-5.8) 
243 ± 20 
(227-260) 
249 ± 18 
(234-264) 
253 ± 19 
(237-269)** 
4.0 ± 2.6 
(1.8-6.2) 
Peak power 
output (W·kg-1) 
4.6 ± 0.6 
(4.1-5.1) 
4.6 ± 0.5 
(4.3-5.0) 
4.7 ± 0.6 
(4.2-5.1) 
1.4 ± 5.9 
(-3.3-5.9) 
3.8 (0.5) 
3.9 ± 0.4 
(3.5-4.2)* 
3.9 (0.5)** 
4.8 ± 2.1 
(3.0-6.5) 
Peak power 
output (W·kg-0.32) 
85.2 ± 8.5 
(78.7-91.7) 
85.8 ± 6.1 
(81.2-90.4) 
86.3 ± 7.1 
(80.9-91.8) 
1.6 ± 5.4 
(-2.7-5.8) 
64.1 ± 4.4 
(60.5-67.8) 
65.6 ± 4.0 
(62.3-68.9) 
66.8 ± 3.9 
(63.5-70.1)**
4.2 ± 2.4 
(2.2-6.3) 
Incremental time 
to fatigue (min)† 
28.6 ± 3.1 
(26.2-31.0) 
28.9 ± 2.3 
(27.1-30.6) 
29.1 ± 2.5 
(27.2-31.0) 
2.0 ± 6.4 
(-2.9-6.9) 
33.6 ± 4.0 
(30.2-37.0) 
34.8 ± 3.6 
(31.8-37.8) 
35.3 ± 4.0 
(32.0-38.7)**
5.4 ± 3.9 
(2.1-8.6) 
LT2 power output 
(W) 
280 ± 37 
(262-308) 
275 ± 21 
(259-291) 
276 ± 22 
(259-292) 
3.5 (12.9) 
200 ± 24 
(180-220) 
206 ± 18 
(192-221) 
209 ± 21 
(191-226) 
3.0 (6.9) 
274 
 
LT2 heart rate  
(beats·min-1) 
163 ± 10 
(155-170) 
164 ± 7 
(158-169) 
162 ± 6 
(158-167) 
0.0 ± 4.2 
(-3.2-3.2) 
160 ± 6 
(155-164) 
159 ± 6 
(154-164) 
162 ± 7 
(156-167) 
1.3 ± 3.5 
(-1.6-4.2) 
LT2 [La-]  
(mmol·L-1) 
3.9 ± 0.8 
(3.3-4.5) 
3.9 ± 0.8 
(3.3-4.4) 
3.7 ± 0.6 
(3.2-4.1) 
-3.3 ± 23.7 
(-21.5-14.9) 
3.4 ± 0.5 
(3.0-3.8) 
3.7 ± 0.6 
(3.2-4.2) 
3.8 ± 0.4 
(3.4-4.1) 
12.9 ± 29.0 
(-11.3-37.2) 
W: Watts; W·kg-1: Watts per kilogram of body mass; W·kg-0.32: Watts per kilogram of body mass to the power of 0.32; min: minutes; LT2: second lactate 
threshold; beats·min-1: beats per minute; [La-]: lactate concentration; mmol·L-1: millimoles per litre; *p < 0.05 compared to baseline; **p < 0.01 compared to 
baseline. 
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Appendix 6.8. Time to completion, and power output and heart rate responses during the 40 km time trial measured at baseline, 
mid- and post-HIIT for men (n = 9) and women (n = 8). Non-normally distributed data are expressed as median (interquartile 
range).  
 
Variable 
Men Women 
Baseline Mid-HIIT Post-HIIT 
Baseline to 
post-HIIT 
change (%) 
Baseline Mid-HIIT Post-HIIT 
Baseline to 
post-HIIT 
change (%) 
Time trial time 
to completion 
(min)† 
58.82 ± 1.79 
(57.45-60.19) 
58.72 ± 2.08 
(57.12-60.31)
57.83 ± 1.70 
(56.52-59.13)** 
-1.7 (3.3) 
66.83 ± 3.18 
(64.17-69.49)
66.30 ± 2.93 
(63.85-68.75)* 
65.05 ± 2.83 
(62.68-67.42)** 
-2.6 ± 1.3 
(-3.7-1.4) 
Time trial 
power output 
(W)† 
259 (13) 
266 ± 22 
(249-283) 
275 ± 22 
(258-292)* 
4.8 (9.7) 
187 ± 24 
(166-207) 
191 ± 23 (171-
210)** 
201 ± 23 
(182-221)** 
8.0 ± 3.9 
(4.7-11.3) 
Time trial 
heart rate 
(beats·min-1) 
165 ± 5 
(160-170) 
167 ± 5 
(163-171) 
164 (14) 
1.1 ± 2.7 
(-1.1-3.4) 
163 ± 9 
(155-171) 
163 ± 11 (154-
172) 
166 ± 10 
(157-175) 
2.1 ± 5.6 
(-2.6-6.8) 
Min: minutes; W: Watts; beats·min-1: beats per minute; *p < 0.05 compared to baseline; **p < 0.01 compared to baseline.
276 
 
CHAPTER SEVEN 
 
Discussion 
 
The studies described in this thesis have provided insight into the modified D-max 
method of LT2 determination in endurance-trained men and women. Study one 
analysed the capacity of the modified D-max LT2 to: (1) relate to 40 km cycling 
performance; (2) reflect a power output that is sustainable for 30 min and elicit a 
steady-state [La-]; and (3) reflect a power output, heart rate, V̇O2 and [La-] that are 
similar to those produced at VT2 and during a 40 km cycling performance trial, in 
trained male cyclists and triathletes. It was concluded that whilst power output and 
V̇O2 at LT2 were related to 40 km performance (confirming the first hypothesis), the 
strongest correlation with performance was produced when combining peak power 
output, V̇O2 at LT2, power output at LT2 and V̇O2max; this combination explained 
95% of the variance in 40 km cycling performance. It was shown that LT2 was not a 
good indicator of MLSS, since only 50% of participants elicited a steady-state [La-] 
(rejecting the second hypothesis). Conversely, LT2 power output was a good 
indicator of VT2 and of the physiological variables elicited during a self-paced 40 km 
cycling time trial, consistent with the final hypothesis.  
 
Study two assessed the same research questions in trained women whilst controlling 
for ovarian hormone concentrations through the use of hormonal contraceptives. It 
was determined that although power output and V̇O2 at LT2 were related to 40 km 
performance (confirming the first hypothesis), the strongest correlation with 
performance was produced when combining peak power output, power output at 
LT2, V̇O2 at LT2 and V̇O2max; this combination explained 87% of the variance in 40 
km cycling performance. Again, LT2 was not a good indicator of MLSS, since only 
73% of participants maintained exercise at LT2 power output for 30 min and elicited a 
steady-state [La-] and thus, the second hypothesis was rejected. Furthermore, LT2 
was significantly higher than VT2 for all variables (power output, heart rate, V̇O2 and 
[La-]; rejecting the hypothesis). It was shown that LT2 power output significantly over-
277 
 
estimated the self-selected power output during a 40 km cycling time trial by 6% 
(which rejected the hypothesis), despite no differences in V̇O2, heart rate or [La-]. 
Therefore, the final hypothesis was only partially confirmed. 
 
A comparison between studies one and two highlighted that power output and V̇O2 
reflective of LT2 are good correlates of endurance cycling performance in both men 
and women. However, combining maximal and fractional utilisation variables 
provided stronger relationships with 40 km cycling performance; these variables 
explained more of the performance variance in men (95%) than women (87%). 
Additionally, eliciting a steady-state [La-] appears to be a more important indicator of 
exercise tolerance for women than men when determining an exercise intensity that 
is sustainable for 30 min, since 50% of men tolerated a [La-] above LT2, compared to 
only 11% of women. For the purpose of establishing competition intensities, the use 
of heart rate, V̇O2 (L·min-1 and mL·kg-1·min-1) or [La-] reflective of LT2 is 
recommended for 40 km performance trials regardless of sex, with heart rate being 
the most practical method. However, the use of power output (e.g. via a power 
metre), is suggested for use in men only, since at LT2 power output over-predicted 
what was sustainable during a 40 km time trial in women. 
 
Study three utilised a 10-session HIIT intervention in trained male and female 
cyclists and triathletes to extend upon the findings of studies one and two which 
examined LT2 at a single point in time, by: (1) examining the sensitivity of LT2 to 
training adaptations; (2) examine the sensitivity of the LT2-performance relationship 
to training adaptations; and, (3) compare these adaptations between men and 
women. The results showed that consistent with the first hypothesis, women, but not 
men, significantly improved their peak power output (absolute, relative to body mass 
and allometrically-scaled; W·kg-0.32). However, in contrast to the hypothesis, neither 
men nor women significantly improved their LT2 power output, and both men and 
women improved their 40 km cycling performance to a similar extent. Despite only a 
trend for a significant improvement in LT2 power output in women, 77% of their 
performance improvement in response to HIIT was explained by LT2 power output 
improvement. However, LT2 variables could not explain the performance 
improvement observed following HIIT in men, suggesting that mechanisms other 
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than those captured by measuring LT2 are responsible, such as an improvement in 
gross mechanical efficiency, or skeletal muscle content or function. Therefore, the 
second hypothesis was accepted. Furthermore, the LT2-performance relationship 
was significant post-HIIT (but not baseline) in both men and women, rejecting the 
final hypothesis which suggested it would be stronger in women than men post-HIIT. 
These findings suggest that LT2 determined by the modified D-max method is 
reasonably sensitive to explain the endurance performance adaptations to 10 HIIT 
sessions in women, but not men, and the LT2-performance relationship is training 
intensity-dependent in both men and women. This extends upon the findings of 
studies one and two which both showed that the LT2-performance relationship was 
significant at a single point in time when previous training intensity was not 
considered. Study three proposes that previous training intensity is indeed important, 
and should be considered when assessing LT2 as a performance indicator. 
 
7.1 Practical implications 
Collectively, the present studies provide a significant contribution to a limited body of 
literature on the efficacy of the modified D-max method of LT2 determination to 
establish performance outcomes, to reflect competition intensities, and respond to 
HIIT in endurance-trained men and women. The practical implications from the 
collective findings of this thesis for coaches, sports scientists and endurance athletes 
in regards to sports science testing, use of the modified D-max method of LT2 
determination and HIIT prescription in men and women, and recommendations for 
hormonal control in female athletes, have been provided: 
 
1) The Australian National Triathlon Testing protocol for women should change 
from 3 min to 5 min stage durations to match the men’s protocol. This 
recommendation also applies to any other incremental protocol where the aim 
is to detect LT2 via the modified D-max method. The 5 min stage duration 
recommendation for accurately determining LT2 is consistent with others [16, 
283, 284], and supported by the results of this thesis that show LT2 elicited a 
V̇O2, heart rate, [La-] and (albeit inconsistently) power output that was similar 
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to those elicited during 40 km cycling time trials. Thus, its validity for 
establishing a performance intensity was confirmed. 
 
2) For the purpose of predicting 40 km cycling performance outcomes, the most 
important variables to collect during laboratory testing are: (i) for men - 
absolute peak power output, relative peak power output (W·kg-1), absolute 
V̇O2max, absolute V̇O2 at LT2, relative V̇O2 at LT2 and power output at LT2; 
and (ii) for women - absolute peak power output, relative peak power output 
(W·kg-1), absolute V̇O2max, power output at LT2, absolute V̇O2 at LT2 and 
relative V̇O2 at LT2. Furthermore, sex-specific equations based on the results 
of this thesis have been provided as a practical tool for predicting 40 km 
cycling performance. 
 
3) For the purpose of establishing a sustainable cycling intensity that elicits a 
steady-state [La-] that can be used to establish training zones, determining 
LT2 by the modified D-max is not recommended in either men or women, 
unless individual suitability is tested via multiple constant load trials below, at, 
and above LT2 power output. The large variation in the capacity for individuals 
to elicit a steady-state [La-] at LT2 power output does not support the 
generalisability of the modified D-max for this purpose. 
 
4) For the purpose of setting performance intensities, LT2 determined by the 
modified D-max method is recommended for use in men (as power output) 
and women (as heart rate) for 40 km cycling trials. 
 
5) For the purpose of improving 40 km cycling performance, HIIT is 
recommended for both men and women. However, sex-specific adaptations 
suggest that there are different optimal stimuli for physiological and 
performance adaptations between men and women. 
 
6) Five HIIT sessions, comprising a total of 75 min at the peak power output 
achieved during an incremental test, appears to be sufficient to elicit an 
improvement in 40 km cycling performance in women but not men. 
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7) Independent of sex, improvements in performance were seen after 10 HIIT 
sessions (a total of 150 min at the peak power output achieved during an 
incremental test). Therefore, the HIIT protocol adopted in the present study is 
recommended for inclusion into the training program of trained endurance 
athletes at a frequency of 1-3 HIIT sessions per week. 
 
8) For the purpose of predicting the magnitude of improvement in 40 km cycling 
performance after 10 HIIT sessions, the magnitude of improvement in LT2 
power output (determined by the modified D-max method) in endurance-
trained women should be used. Although no variable predicted the magnitude 
of performance improvement in men, time to fatigue and peak power output 
achieved in an incremental test were just as strongly (and more consistently) 
related to performance time as the LT2 power output. Therefore, there 
appears no additional benefit of measuring LT2 for the purpose of predicting 
the magnitude of performance improvement following HIIT in men. 
 
9) The use of hormonal contraceptives is recommended for female athletes, 
where not medically contraindicated, since they provide control over 
endogenous ovarian hormone concentrations. Findings from this thesis 
showed that physiological and performance adaptations to HIIT were 
comparable to those of men when hormonal contraceptives were used.  
 
7.2 Conclusions 
The aim of this thesis was to examine the efficacy of the modified D-max method of 
LT2 determination to establish performance outcomes, reflect competition intensities, 
and adapt to training in endurance-trained men and women. It was determined that 
the capacity of LT2 to establish performance outcomes was dependent on previous 
training intensity; this was shown by results highlighting a significant LT2-
performance relationship when prior training consisted of some HIIT, and no 
relationship when prior training was controlled to low-moderate intensity only. Whilst 
LT2 power output and heart rate reflected those elicited during 40 km performance 
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trials in men, only heart rate was consistent between LT2 and 40 km trials in women, 
with power output over-estimating 40 km performance intensity. The capacity of LT2 
to adapt to training was not confirmed in either men or women, despite performance 
improvements; subsequently, its sensitivity to detect performance-related training 
improvements was not established. However, LT2 explained 77% of the performance 
improvement after HIIT in women, but not men, which warrants further investigation. 
 
7.3 Directions for future research 
Given the identified inconsistencies of the modified D-max LT2 both within and 
between sexes for the purposes of predicting cycling performance, setting 
competition intensities and assessing adaptions to HIIT, future research should 
endeavour to identify laboratory-based variables that are more strongly and 
consistently associated with endurance performance in both men and women. 
Compared to men, the combination of maximal and fractional utilisation variables 
were reasonably poor at explaining the performance variance in women, and 
subsequent research should investigate whether better performance indicators exist 
in women, such as gross mechanical efficiency or critical power. The observed 
inconsistency in the capacity of LT2 power output to reflect the self-selected power 
output during 40 km cycling performance in women (i.e. LT2 power output was higher 
than time trial power output in study two, but not different in study three) and the 
inconsistent capacity of LT2 heart rate to reflect mean time trial heart rate in men (i.e. 
heart rates were similar in study one, and at baseline but not post-HIIT in study 
three), warrant future research. These findings suggest that the detection method for 
the modified D-max (i.e. the [La-]-profile curve) requires refining, especially given the 
susceptibility of the initial and final stages of an incremental test to influence LT2 
determination [24]. The trend for an improvement in LT2 power output in response to 
HIIT in women (but not men) warrants future research to investigate the mechanisms 
responsible for these sex-based differences in adaptations to HIIT; the use of larger 
sample sizes is recommended, and the sampling of muscle may provide valuable 
insight into potential differences in peripheral adaptations to training.  
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Other researchers in this field may extend the current investigation into the time-
course of adaptations to HIIT by examining the volume of HIIT that maximises 
performance improvements in both men and women. Differences in the way that 
men and women responded to single bouts of exercise and exercise training 
highlights the need for future research to explore sex-specific findings to enhance 
exercise prescription and subsequent endurance performance outcomes for men 
and women. This research should avoid recruiting both sexes and pooling their 
results, but rather recruit men and women into separate studies, unless sufficient 
sample size is available to determine and compare sex-specific results. Challenges 
in obtaining sufficient numbers of participants for statistical significance of the 
findings are recognised, especially in well-trained populations where logistics issues 
arise around the manipulation of training programs that have been put in place with 
strict purpose. Therefore, careful consideration of the timing of training interventions 
in these populations is crucial. Controlling for and verifying ovarian hormone 
concentrations is recommended for studies involving women, and when comparing 
between men and women. This will minimise the effect that these hormones have on 
physiological and performance responses, and adaptations to exercise, especially 
since differences were found in the current thesis between women using hormonal 
contraceptives (and therefore with low ovarian hormone concentrations), and men.  
 
Further research is required to determine the influence of ovarian hormone 
concentrations on single bouts of exercise and exercise training to ensure that 
different recommendations can be provided for women across the spectrum of 
ovarian hormone concentrations, i.e. during the various phases of the menstrual 
cycle for non-hormonal contraceptive users, as well as for those using hormonal 
contraceptives. This will increase the generalisability and comprehensiveness of the 
findings for women.  
 
Finally, future investigations should expand the present research to include 
endurance athletes of differing competition specialities from ‘sprint-endurance’ 
through to ‘ultra-endurance’ in order to establish the limits of LT2 in its capacity to 
correlate with endurance performance and adapt to training. Furthermore, 
investigating the time-course of de-training after a period of HIIT will expand the 
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present knowledge on the sensitivity of LT2, and establish even more precise 
recommendations regarding the efficacy of LT2 in endurance-trained men and 
women.
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Appendix one 
 
Agreement between and reliability of two metabolic 
systems 
 
i. Purpose 
The purpose of this study was to assess the reliability of, and agreement between 
the Ametek SOV and ParvoMedics TrueOne 2400 metabolic systems. This was 
necessary to complete because these systems were used in studies one and two, 
respectively.  
 
ii. Methods 
a. Experimental Overview 
The study was a randomised cross-over repeat-measures design. Participants 
reported to the Human Performance Laboratory of the School of Human Movement 
and Nutrition Sciences at The University of Queensland on two occasions, separated 
by a minimum of 72 h and a maximum of 10 days. The two trials completed were 
identical incremental cycle trials to volitional fatigue for determination of V̇O2max 
using the Ametek SOV S-3A/1 and COV CD3A (Pittsburgh, PA), and ParvoMedics 
TrueOne 2400 (Sandy, Utah, USA) metabolic systems. All trials were immediately 
preceded by a self-selected warm-up and exercise was conducted on an 
electronically braked cycle ergometer (Lode Excalibur Sport, Quinton). 
 
b. Participants 
Fifteen healthy, recreationally active (≥ 150 min of physical activity per week) men 
aged 18-40 years, volunteered to participate in the study. Participants completed the 
Adult Pre-exercise Screening System (APSS) as described by Exercise and Sport 
Science Australia [367], provided written informed consent and were made aware of 
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the risks and benefits associated with the study. The study was approved by an 
ethics committee of The University of Queensland. 
 
Using a sample size calculator for multiple regressions, it was determined that the 
minimum required sample size was 13. This sample size was calculated using an 
effect size (r2) of 0.75, a statistical power level of 0.8 and a probability level of 0.05 
[266]. Similar studies investigating the agreement between metabolic systems 
reported sample sizes of 10 [368] and 15 [369, 370]. 
 
Participants abstained from alcohol for 24 h and caffeine for 6 h before each test, 
and avoided heavy meals 4 h prior to each trial. Participants were encouraged to 
continue their normal levels of physical activity but abstain from strenuous exercise 
24 h prior to a trial commencing; they were asked to arrive in a well-hydrated state 
and adequately rested. 
 
c. Equipment and Analysis 
V̇O2 was analysed continuously during each exercise trial using two different on-line 
gas analysers: (1) Ametek SOV S-3A/1 and COV CD3A (Pittsburgh, PA); and (2) 
Parvo Medics, True One 2400 (Sandy, Utah, USA). Calibration of the Ametek SOV 
system was performed as described in section 3.3.3 and calibration of the 
ParvoMedics system was performed as described in section 4.3.3. 
 
d. Experimental Protocol 
Prior to each trial, participants were fitted with a mouthpiece, nose clip and headgear 
applicable for one of the metabolic systems. Each trial consisted of three parts; two x 
10 min sub-maximal exercise bouts at a constant load, followed by a ramp protocol 
beginning at 170 W with an increase in 20 W every 30 s until volitional fatigue 
(Figure A.1.1). Both metabolic systems were used in each trial, and participants were 
randomised to the order described in either Trial 1 or Trial 2 (Table A.1.1) before 
cross-over. This format allowed both systems to assess gas exchange during each 
portion of the protocol over the two exercise trials. For each system, the V̇O2, V̇CO2 
and V̇E values were averaged over the final two min of each stage. 
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Figure A.1.1. Exercise protocol. 
HR: heart rate; min: minute; W: Watts 
 
Table A.1.1. Order of metabolic systems used in each of the trial components.  
 Components of trial 
Trial Sub-maximal exercise Part 1 Sub-maximal exercise Part 2 
Ramp to volitional 
fatigue 
1 Ametek (5 min)  Parvo (5 min) Parvo (5 min)  Ametek (5 min) Ametek 
2 Parvo (5 min)  Ametek (5 min) Ametek (5 min)  Parvo (5 min) Parvo 
  
 
e. Statistical Analyses 
Data were analysed using GraphPad Prism (version 6.0, GraphPad Software Inc., 
San Diego, CA) statistical software package. A CV ≤ 10.0% was considered to 
reflect acceptable reliability, as recommended for spots performance research [371]. 
i. Reliability 
The CV was calculated to determine relative variability within and between each 
system, and Pearson’s product moment (r) correlations were used to examine 
relationships within each system for V̇O2, V̇E and V̇CO2. 
 
ii. Agreement 
The Bland-Altman test and 95% limits of agreement were used to examine the bias 
and agreement between the systems at both sub-maximal and maximal workloads.  
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iii. Results 
a. Submaximal workloads 
For V̇O2 (L·min-1), within-system reliability was confirmed for both the Ametek and 
ParvoMedics systems at sub-maximal workloads across the trials (Ametek: 
CV = 4.16% at 100 W and 4.78% at 150 W, and r = 0.72; p < 0.01; ParvoMedics: 
CV = 4.22% at 100 W and 3.14% at 150 W, and r = 0.74; p < 0.01). Between-system 
reliability was also confirmed for V̇O2 with low CVs and strong correlations reported 
at both 100 W (CV = 2.91%; r = 0.76; p < 0.01) and 150 W (CV = 1.49%; r = 0.86; 
p < 0.01). Bland-Altman plots showed good agreement between systems for V̇O2 
with low dispersion beyond the limits (± 1.96 SD) (Figure A.1.2 (a)).  
 
For V̇E, within-system reliability was confirmed for both the Ametek and 
ParvoMedics systems at sub-maximal workloads across the trials (Ametek: 
CV = 6.04% at 100 W and 5.25% at 150 W; ParvoMedics: CV = 6.24% at 100 W and 
5.47% at 150 W). Between-system reliability was also confirmed for V̇E with low CVs 
and strong correlations reported at both 100 W (CV = 2.68%; r = 0.93; p < 0.01) and 
150 W (CV = 1.84%; r = 0.97; p < 0.01). Bland-Altman plots showed good agreement 
between systems for V̇E with low dispersion beyond the limits (± 1.96 SD) (Figure 
A.1.2 (b)). 
 
For V̇CO2, within-system reliability was confirmed for both the Ametek and 
ParvoMedics systems at sub-maximal workloads across the trials (Ametek: 
CV = 5.30% at 100 W and 3.25% at 150 W; r = 0.70; p < 0.01; ParvoMedics: CV 
= 5.60% at 100 W and 3.24% at 150 W; r = 0.77; p < 0.01). Between-system 
reliability was also confirmed for V̇CO2 with low CVs and strong correlations reported 
at both 100 W (CV = 3.87%; r = 0.92; p < 0.01) and 150 W (CV = 2.01%; r = 0.91; 
p < 0.01). Bland-Altman plots showed good agreement between systems for V̇CO2 
with low dispersion beyond the limits (± 1.96 SD) (Figure A.1.2 (c)).  
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Figure A.1.2. Agreement between Ametek SOV S-3A/1 and COV CD3A and 
ParvoMedics TrueOne 2400 Metabolic Systems for: (a) V̇O2; (b) V̇E; and (c) 
V̇CO2 whilst cycling at 150 W, using Bland-Altman plots. 
 
b. Maximal workloads 
Between-system reliability at maximal workloads was confirmed for V̇O2 
(CV = 4.56%; r = 0.89; p < 0.01) and V̇CO2 (7.42%; r = 0.81; p < 0.01). Furthermore, 
Bland-Altman plots showed good agreement between systems for V̇O2 and V̇CO2 
with low dispersion beyond the limits (± 1.96 SD) (Figure A.1.3 (a and c, 
respectively)). However, for V̇E, the reliability between systems was weaker 
(CV = 10.43%; r = 0.62; p < 0.05) but the agreement was good, as shown by the 
Bland-Altman plot with low dispersion beyond the limits (± 1.96 SD) (Figure A.1.3 
(b)).  
 
 
 
 
(a) 
(c) 
(b)
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Figure A.1.3. Agreement between Ametek SOV S-3A/1 and COV CD3A and 
ParvoMedics TrueOne 2400 Metabolic Systems for: (a) V̇O2; (b) V̇E; and (c) 
V̇CO2 at maximal exercise intensity, using Bland-Altman plots. 
 
iv. Discussion 
The purpose of this study was to assess the reliability of, and agreement between 
the Ametek SOV and ParvoMedics TrueOne 2400 metabolic systems. Both systems 
reported acceptable within-system reliability for V̇O2, V̇E and V̇CO2 during constant 
load, sub-maximal exercise with CVs all lower than the desirable criterion of ≤ 10.0% 
[371] (3.14-6.23%) and correlations were strong (r = 0.70-0.77).  
 
Additionally, between-system reliability was acceptable during constant load, sub-
maximal exercise for V̇O2 V̇E and V̇CO2 with low CVs (1.49-3.87%) and strong 
correlations (r = 0.76-0.97). However, at maximal exercise, although between-
system reliability was acceptable for V̇O2 and V̇CO2 with low CVs (4.56 and 7.42, 
respectively) and strong correlations (r = 0.89 and 0.81, respectively), the two 
systems did not reliably detect V̇E with a CV above the acceptable limit (10.43%) 
and a correlation of only moderate strength (r = 0.62). However, this result should be 
interpreted with caution, since alternative methods have been proposed to assess 
(c) 
(b)(a) 
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between-system reliability, or agreement. In contrast to a CV which expresses 
reliability as the variation between measurements in relation to the mean value of all 
measurements [372], agreement parameters (such as limits of agreement, as 
determined using a Bland-Altman plot) provide direct information about the absolute 
measurement error [372] and provide a more pure characteristic of the measurement 
instrument [373]. Since the Bland-Altman plot showed low dispersion beyond the limits 
(± 1.96 SD) for V̇E during sub-maximal and maximal exercise intensities, it can be 
concluded that the agreement between the Ametek and the ParvoMedics systems 
was acceptable. Additionally, Bland-Altman plots confirmed good agreement 
between systems for V̇O2 and V̇CO2 at sub-maximal and maximal exercise 
intensities and subsequently, it can be suggested that data collected from either 
system can be used interchangeably for measures of V̇O2, V̇CO2 and V̇E. 
 
In conclusion, the Ametek SOV and ParvoMedics TrueOne 2400 metabolic systems 
reported good within-system reliability to assess V̇O2, V̇CO2 and V̇E at sub-maximal 
exercise intensities. Furthermore, a good between-system agreement for the 
assessment of V̇O2, V̇CO2 and V̇E at both sub-maximal and maximal exercise 
intensities confirms that data collected from the Ametek SOV and ParvoMedics 
TrueOne 2400 metabolic systems can be directly compared and/or used 
interchangeably with confidence that the measurement error from each device is 
minimal. 
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Appendix two 
 
Agreement between and reliability of different 
methods of determining [La-] 
 
i. Purpose 
The purpose of this study was to assess the reliability of four methods of determining 
[La-]: (a) Cobas Integra clinical autoanalyser in the UQ School of Human Movement 
and Nutrition Sciences Biochemistry Laboratory, Brisbane (Cobas HMNS) (2) Cobas 
Integra clinical autoanalyser in the Sullivan Nicolaides Pathology Laboratory, 
Brisbane (Cobas SNP); (3) Unicam 5625 UV/VIS Spectrometer in the UQ School of 
Human Movement and Nutrition Sciences Biochemistry Laboratory, Brisbane (Spec); 
and (4) Lactate Pro Portable Analyser (Lactate Pro). The second purpose was to 
assess the agreement between the three methods assessing plasma [La-]: methods 
1-3 mentioned above. This study was undertaken because all four methods of [La-] 
determination were used in this thesis: methods 1 and 3 was used in study 1; 
method 2 was used in study 2; and method 4 was used in study 3. 
 
ii. Methods 
i. Experimental Overview 
The participant reported to the Human Performance Laboratory of the School of 
Human Movement and Nutrition Sciences at The University of Queensland on a 
single occasion after abstaining from caffeine for ≥ 6 h and high-intensity exercise for 
≥ 24 h. The trial was conducted on an air- and mechanically-braked cycle ergometer 
(Wattbike Ltd, Nottingham, UK).  
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ii. Participant 
One healthy, recreationally active male participated in this study. The participant was 
informed of the procedures and requirements and was free to withdraw at any time. 
The participant completed a self-selected warm-up immediately prior to the trial.  
 
iii. Exercise protocol 
The participant was requested to cycle multiple bouts so as to elicit as close as 
possible, three arbitrarily assigned [La-] zones. These were: (1) “low”: 0-4 mmol·L-1; 
(2) “moderate”: 4.1 - 8 mmol·L-1 and; (3) “high”: ≥ 8 mmol·L-1. Finger-tip capillary 
blood was sampled and analysed immediately after the exercise bout by a portable 
lactate analyser (Lactate Pro, Arkray KDK, Japan). This was used to ascertain 
whether the required [La-] had been reached. Once the required level was confirmed 
by the Lactate Pro, the participant was asked to dismount the bike in preparation for 
venous blood sampling. Venous blood (10 mL) was sampled into K2EDTA 
vacutainer (Becton Dickinson Plymouth UK) tubes directly from the antecubital veins. 
Samples were analysed using the Lactate Pro and then stored on ice for < 30 mins 
before centrifugation at 6500 x g at 4°C for 10 min. The plasma supernatant was 
removed and stored in 300 µL aliquots at -80°C until later analysis of plasma [La-] 
with the remaining three pieces of equipment. Each level of blood [La-] was analysed 
on each piece of equipment ten times. 
 
iv. Equipment and Analysis 
a. Cobas Integra clinical autoanalyser  
The method used for this analyser has been previously described in section 3.3.6 of 
the present thesis; samples were analysed both: (a) on site in the School of Human 
Movement and Nutrition Sciences Biochemistry Laboratory, Brisbane; and (b) at 
Sullivan Nicolaides Pathology Laboratory, Brisbane, as reported in section 4.3.7.1 of 
this thesis. 
 
b. Unicam 5625 UV/VIS Spectrometer 
The analysis method used for this analyser has been previously described in section 
3.3.6 of the present thesis. 
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c. Lactate Pro 
The Lactate Pro is a hand-held portable analyser measuring whole blood. Coded 
reagent strips fill by capillary action directly from the sample site or by pipetting 
whole blood samples onto the strip. Lactate in the sample reacts with potassium 
ferricyanide and lactate oxidase to form potassium ferrocyanide and pyruvate. Upon 
application of a given voltage, ferrocyanide is oxidised, releasing electrons and 
creating a current. This current is measured amperometrically and is directly 
proportional to the [La-] of the sample. A 5 µL blood sample is required for the 
analysis and the analysis duration is 60 s. The Lactate Pro was calibrated and 
operated in accordance with the manufacturer’s instructions. 
 
v. Statistical Analyses 
a. Reliability 
In addition to conventional descriptive statistics [mean ± standard deviation (SD)], 
the CV was calculated to determine relative variability within each method, for each 
lactate level.  
 
b. Agreement 
Between method agreement was examined by a two-way repeated-measures 
ANOVA.  
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iii. Results 
Table A.2.1. Results for four methods of [La-] determination, at three different [La-] 
zones.  
Data are mean ± SD. 
[La-] zone Cobas HMNS Cobas SNP Spec Lactate Pro 
Low  
(0-4 mmol·L-1) 
2.9 ± 0.0 3.1 ± 0.1 3.4 ± 0.1 2.6 ± 0.2 
Moderate  
(4.1-8 mmol·L-1) 
7.5 ± 0.1 8.9 ± 0.3 8.6 ± 0.2 6.2 ± 0.2 
High  
(≥ 8 mmol·L-1) 12.9 ± 1.4 25.5 ± 0.1 16.8 ± 0.4 12.5 ± 0.3 
[La-]: lactate concentration; HMNS: Human Movement and Nutrition Science; SNP: Sullivan 
Nicolaides Pathology; Spec: Spectrometer; mmol·L-1: millimoles per litre. 
 
Within-method reliability was confirmed for the Lactate Pro at low (CV = 6.2%), 
moderate (CV = 3.2%) and high (2.4%) [La-] zones, the Spec at low (CV = 3.0%), 
moderate (CV = 2.8 %) and high (2.6%) concentration zones and the Cobas SNP at 
low (CV = 4.8%), moderate (CV = 2.8%) and high (CV = 0.5%) [La-] zones. However, 
the Cobas HMNS was reliable at low (CV = 0.5%) and moderate (CV = 1.1%) but not 
high (CV = 10.7%) [La-] zones.  
 
Between-method agreement was assessed for the three plasma [La-] methods at 
each of the three [La-] zones (Figure A.2.1):  
 
a. Low [La-] zone:  
At the low [La-] zone, the Spec was significantly higher than the Cobas SNP 
(p = 0.03) and the Cobas HMNS (p < 0.01). Furthermore, the two Cobas methods 
were significantly different (p = 0.02). 
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b. Moderate [La-] zone:  
At the moderate [La-] zone, the Cobas HMNS was significantly lower than the Cobas 
SNP (p < 0.01) and the Spec (p < 0.01), but there was no significant difference 
between the Cobas SNP and the Spec (p = 0.10). 
 
c. High [La-] zone:  
At the high [La-] zone, the Cobas SNP was significantly higher than the Cobas 
HMNS (p < 0.01) and the Spec (p < 0.01). Furthermore, the Cobas HMNS was 
significantly lower than the Spec (p < 0.01). Additionally, there was a significant 
method x [La-] zone interaction (p < 0.01). 
 
 
Figure A.2.1. Results for three methods of plasma [La-] determination at the: 
(a) low [La-] zone; (b) moderate [La-] zone; and (c) high [La-] zone.  
Data are mean ± SD. *p < 0.05; **p < 0.01.  
 
iv. Discussion 
The purpose of this study was to assess the reliability of four methods of determining 
[La-]: (1) Lactate Pro Portable Analyser; (2) Unicam 5625 UV/VIS Spectrometer in 
the UQ HMNS Lab; (3) Cobas Integra clinical autoanalyser in the UQ HMNS Lab; 
and (4) Cobas Integra clinical autoanalyser in the Sullivan Nicolaides Pathology Lab. 
Reliability was confirmed for all four methods at the three [La-] zones assessed 
which reflected a range of low, moderate and high [La-], except for the Cobas HMNS 
which reported a CV slightly higher than the acceptable limit of ≤ 10% [371] (10.7%) at 
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the high [La-] zone. These findings suggest that all four methods are capable of 
detecting a consistent within-individual [La-] independent of the absolute 
concentration, with minimal influence of methodology. However, some caution 
should be expressed when using the Cobas HMNS method which was less reliable 
at detecting [La-] in the high zone. This has the potential to influence LT2 
determination which relies on the final [La-] elicited during an incremental trial. 
 
Furthermore, the agreement between the three methods assessing plasma [La-] 
(methods 2-4 above) was examined. The results show that there was poor 
agreement between methods and a significant interaction between the method and 
the [La-] zone, suggesting that differences between methods were dependent on the 
[La-]. These findings suggest that direct comparisons between [La-] when determined 
from any of the four methods assessed in this study should be avoided. 
 
These findings conclude that: (1) intra-individual reliability was good for each of the 
four methods independent to the level of [La-], although the Cobas HMNS method 
tended to be less reliable at high concentrations. The three methods of detecting 
plasma [La-] elicited poor agreement which was dependent on the [La-], suggesting 
that absolute values of [La-] should not be directly compared between methods. 
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Appendix three 
 
Menstrual cycle physiology and hormonal 
contraceptives 
 
i. Menstrual cycle physiology 
The menstrual cycle is broadly divided into two phases, separated by ovulation - the 
FP and the LP. In young (18-30 years), normally menstruating (eumenorrheic) 
women, the average length of the FP and LP has been reported as 16.9 ± 3.7 and 
12.9 ± 1.8, respectively, with an average total cycle length of 30.0 ± 3.6 days [374]. 
The system involved in the regulation of these phases and the corresponding 
ovarian hormones is the hypothalamic-pituitary ovarian axis. Briefly, the FP is 
characterised by low levels of oestradiol (150 < 370 pmol·L-1 [375]) and progesterone 
(1.2 < 4.4 nmol·L-1 [375]) and the LP is characterised by elevated levels of oestradiol 
(300 < 710 pmol·L-1 [375]) and progesterone (15 < 42 nmol·L-1 [375]). The period 
immediately before ovulation is known as the late FP and is characterised by 
oestradiol concentrations at their highest (690-2120 pmol·L-1 [375]), while the 
progesterone concentration remains low. During the FP, stimulation of gonadotropin 
releasing hormone (GnRH) secreted by the hypothalamus, results in the anterior 
pituitary gland releasing follicle stimulating hormone (FSH) and luteinising hormone 
(LH). These hormones are responsible for the initial development and maturation of 
ovarian follicles which in turn, produce oestradiol. Increased oestradiol in the late FP 
stimulates a surge in LH, resulting in ovulation and the beginning of the LP. The 
increased levels of oestradiol and progesterone during this phase inhibit the release 
of GnRH and result in decreased LH secretion, decreased levels of oestradiol and 
progesterone, and menstrual bleeding. Finally, via negative feedback the 
hypothalamic-pituitary ovarian axis initiates another menstrual cycle in response to 
the decreased oestradiol and progesterone concentrations. 
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ii. Hormonal contraceptive agents 
As discussed earlier in this thesis, hormonal contraceptive agents are typically 
‘combined’ in nature, containing one type of synthetic oestrogen; ethinyloestradiol 
and a progestogen component that can be present in up to eight different forms [184]. 
The oestrogenic and progestogenic content of combined OCs ranges from 0.01 to 
0.05 mg for oestradiol and 0.05 to 1.5 mg for progestin [25], with minimal differences 
in ethinyloestradiol content between monophasic (0.02 to 0.05 mg) and triphasic 
(0.03 to 0.04 mg) preparations [184]. Furthermore, there are also progestogen-only 
formulations, which together with biphasic combinations, are known to be used less 
than monophasic and triphasic preparations by female athletes [184]. Serum levels of 
ethinyloestradiol peak approximately 1 h after ingestion before falling rapidly for six h 
and declining slowly thereafter [184]. Ethinyloestradiol has been reported to be 
detectable for up to 2 days after cessation of active pills and some progestogens for 
up to 5 days [184]. This results in the continual suppression of endogenous oestradiol 
and progesterone early in the withdrawal phase, with the possibility of elevated 
levels of endogenous oestradiol later in the withdrawal phase while progesterone 
levels remain supressed [239]. 
 
iii. Mechanisms of action 
Mechanistically, hormonal contraceptives affect female neuroendocrine regulation by 
inhibiting ovulation. The suppression of ovulation is provided by the progestogenic 
component, while the estrogenic component maintains cycle control [229]. 
Gonadotropin-releasing hormone (GnRH) is secreted by the hypothalamus and 
stimulates the release of the gonadotropins; follicle-stimulating hormone (FSH) and 
luteinising hormone (LH) from the anterior pituitary gland [376]. LH and FSH are 
released every 60 to 90 min, but are open to modulation by oestrogen and 
progesterone via positive and negative feedback on GnRH secretion [377]. 
Contraceptive agents act by means of negative feedback on the hypothalamus and 
pituitary gland, resulting in the suppression of FSH, LH and GnRH [378]. Low levels of 
LH and FSH prevent follicular development and ovulation and result in the 
continuous down-regulation of endogenous oestrogen and progesterone. When 
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ovulation is inhibited, the cyclical variation in the uterus and ovaries of eumenorrheic 
females (seen as a surge in LH) is eliminated and pregnancy is avoided [25]. 
 
iv. Common hormonal contraceptive formulations 
Although the most widely used method of hormonal contraceptive is the OC pill [187], 
another method is the contraceptive vaginal ring, with NuvaRing® currently the only 
commercially available vaginal ring for combined hormonal contraception [187]. The 
hormones etonogestrel (a metabolite of progestogen; 11.7 mg) and ethinylestradiol 
(2.7 mg) are equally dispersed with 120 µg and 15 µg steadily released daily (for 
each hormone, respectively) and are continuously absorbed through the vaginal 
epithelium. Each ring remains in the vagina for 21 days before being removed for 
seven days to allow menstrual bleeding. A new ring is then inserted after the seven 
ring-free days [187]. It has been reported that sustained and more stable serum 
concentrations can be achieved with this contraceptive mode since the method of 
application is not subject to gastrointestinal fluctuations in absorption as is the case 
for OC’s taken by mouth [187]. In comparison with OCs, serum hormone 
concentrations are steadier, while oestrogenic exposure is lower [187]. In regards to 
absolute bioavailability and taking into account the differences in progestogen doses 
between OC and NuvaRing® (in this case 150 µg and 120 µg were used, 
respectively), it has been reported that the systemic exposure to progestogen is 
similar for both methods [230]. In the same report, the difference in daily dose of 
ethinylestradiol (30 µg vs. 15 µg for OC and NuvaRing®, respectively) meant the 
systemic exposure to ethinylestradiol was twice as high in the OC [230]. Additionally, 
the suppression of ovulation with the use of NuvaRing® has been reported as being 
comparable to that seen with OC administration, with complete suppression of LH 
and progesterone levels [379].  
 
The only other non-oral alternative to combined OCs that offers similar ease of use is 
the contraceptive transdermal patch (OrthoEvra®) [187]. The patch releases a daily 
dose of 150 mg of the progestin norelgestromin and 20 mg of the oestrogen 
ethinylestradiol into the systemic circulation [380]. Each patch lasts seven days; three 
patches are used consecutively, followed by a placebo patch or patch-free interval in 
week four, when withdrawal bleeding occurs [187]. In a trial where participants (n = 24) 
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were randomised to use either NuvaRing®, patch or a combined OC containing 
30 μg ethinylestradiol and 150 μg levonorgestrel, it was shown that there are 
differences in ethinylestradiol exposure between the mode of contraceptive delivery 
[229]. Area under the concentration-versus-time curve revealed that after 21 days of 
use, exposure to ethinylestradiol was lowest for the NuvaRing® users (3.4 times and 
2.1 times lower than the patch and OC groups, respectively; p < 0.05). Furthermore, 
the highest peak concentration of ethinylestradiol was seen in the OC group 
(4.5 times and 1.6 times higher than the NuvaRing® and patch groups, respectively; 
p < 0.05) and the mean peak concentration for the patch group was higher than the 
NuvaRing® group (2.8 times; p < 0.05). This can be explained by the daily dosing of 
the OC producing peaks and troughs in hormone concentrations [229], compared to 
the constant delivery of the patch and NuvaRing®, with interruptions only when they 
are changed (every seven and 21 days, respectively). Additionally, although the 
patch delivered only 33% more ethinylestradiol daily than the NuvaRing®, the 
exposure to ethinylestradiol was said to be ~250% greater in the patch versus the 
NuvaRing® group. Although the authors speculated that this seemed to indicate 
greater bioavailability of ethinylestradiol with the patch, the reason for this was stated 
as unclear [229]. To further differentiate between methods in their ethinylestradiol 
exposure, application site of the patch has shown to have a significant effect on the 
absorption with the abdomen (the site of choice in the study of van den Heuvel and 
others, above [229]) actually resulted in 20% less absorption compared with the arm, 
buttock or torso, which were all equivalent [381]. Therefore, the higher ethinylestradiol 
concentrations with the patch may be even more pronounced if different application 
sites are used. 
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Appendix four 
 
Men vs. women 
 
i. Physiological differences 
Numerous physiological differences exist between men and women, many of which 
have the potential to influence measures of athletic performance. Perhaps the most 
simple of these is the difference in body size and composition between sexes. In 
athletic populations, men are reported as being significantly taller and heavier with a 
lower percentage of body fat than women [313, 382, 383]. However, in relation to a 
number of physiological and performance measures, sex differences remain even 
when controlling for these size differences.  
 
ii. [La-] and LT2 
There is some evidence to suggest that there are differences between males and 
females in [La-] in response to exercise (Table A.4.1). Studies consistently show that 
at the same relative exercise intensity males produce significantly higher [La-] than 
females and this has been demonstrated in trained sprinters [384] and recreationally 
active individuals [385] during maximal 30 sec Wingate tests.  
 
Differences in [La-] have also been examined in exercise longer than 30 sec in 
duration. For example, untrained females produced a ~39% lower plasma [La-] at 
exhaustion, a ~16% lower peak [La-] post-exercise and lower [La-] at all relative 
intensities between 30 and 100% V̇O2peak than untrained males [386]. However in 
this study, both sexes completed the same incremental protocol, resulting in females 
performing less total work which likely contributed to the reduced [La-]. As these 
authors reported absolute total work rather than work relative to body mass, lean 
body mass or V̇O2max, meaningful comparisons cannot be made. Importantly, 
although testing was limited to the FP of the menstrual cycle, the high intra- and 
inter-individual variability in endogenous oestrogen and progesterone concentrations 
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even within a menstrual phase [21], indicates there is still (though minimised) a 
chance that hormonal concentrations influenced [La-]. Similar conclusions were 
made in a study involving graded exercise tests in national-level male and female 
wrestlers [382]. Although a significantly higher peak [La-] was seen in males than 
females, the authors have attributed this to the higher exercise intensity performed 
by males and therefore more energy being derived through anaerobic glycolysis 
leading to greater lactate formation. However, the authors only mentioned absolute 
(rather than relative) exercise intensities, which again, did not allow meaningful 
comparisons to be made. Furthermore, in well-trained runners heterogeneous in 
V̇O2max and running performance, peak [La-] was ~23% higher in males than 
females [88] (Table A.4.2). Since the incremental protocol utilised in this study was 
individualised and the mean time to fatigue was not noted it is unknown whether this 
may have affected peak [La-]. Additionally, no control of menstrual status or hormone 
concentrations were discussed. 
 
In addition to submaximal and maximal [La-], measures of LT2 have been compared 
between sexes. Scroop and Sargent [386] indicated a higher LT2 relative to V̇O2peak 
in females for LT2 methods utilising absolute [La-] but not when the log 
transformation method was used. From this lack of difference between sexes with 
the use of the log transformation method, together with research findings that LT2 
methods other than those using absolute [La-] are more highly correlated with 
endurance performance, one could infer that no meaningful sex differences exist in 
the LT2. The finding that females produced a higher relative LT2 when using methods 
of absolute [La-] supports the work of Maldonado-Martin [313] (Table A.4.2) who 
demonstrated a ~6% higher relative LT2 in females than males when using both 
OBLA and 1 mmol·L-1 methods in highly-trained distance runners. Whether these 
findings hold true with other methods of LT2 determination, namely those that utilise 
a [La-] curve rather than absolute values and which have shown to be more 
indicative of endurance performance such as the D-max and modified D-max 
methods, is yet to be examined. 
 
Conversely, others have shown that relative to V̇O2max, sex differences in [La-] and 
LT2 may be abolished. For example, Helgerud [383] has shown that in a group of elite 
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long distance runners, no sex differences were seen in [La-] when expressed as a 
function of V̇O2max despite females exhibiting a higher [La-] during identical 
submaximal running velocities. More recently, McLaughlin et al. [88] (Table A.4.2) 
showed that although absolute running speeds at LT2 were higher in well-trained 
male runners than females, a minimal relative difference of ~3% existed between 
sexes. Unfortunately not all studies have reported LT2 in relative terms which makes 
meaningful comparisons difficult [177, 387] (Table A.4.2). 
 
A link between males possessing greater percentage area [324, 325] and size of type II 
fibres [324] along with the high glycolytic capacity of type II fibres [388] may explain 
these differences in [La-] between males and females during sprint exercise. The [La-
] in response to maximal and submaximal exercise appears to be lower in females, 
although numerous issues exist in the literature in regards to controlling for total work 
completed, menstrual cycle status, ovarian hormone concentrations, V̇O2max and 
lean body mass. The LT2 has also been compared between sexes with the common 
consensus appearing to lie with females exhibiting LT2 at a lower absolute but similar 
or potentially higher relative exercise intensity (most commonly expressed as 
%V̇O2max or V̇O2peak) which has been suggested to accommodate for their 
relatively lower V̇O2max compared to males [382]. Numerous inconsistencies exist in 
the literature regarding the exercise protocols utilised and the methodology adopted 
to determine LT2. Additional research with tighter controls as discussed, appear 
warranted. 
 
In addition to these differences in [La-] and LT2, research has also focussed on sex 
differences in cardiac structure and function, substrate utilisation, gross efficiency, 
muscle fibre-type composition, respiration, V̇O2max and ability of physiological 
measures such as peak power output, V̇O2max and LT2 to correlate with endurance 
exercise performance. These will be focused on for the remainder of this appendix. 
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Table A.4.1. A summary of studies examining differences in [La-] and LT2 between men and women. 
Study Participants 
Training 
status 
Testing 
procedure/s 
Findings 
Ovarian 
hormone 
control 
Ovarian 
hormone 
analysis 
Scroop and 
Sargent [386] 
Men (n = 21) 
and women 
(n = 22) 
Untrained Maximal 
incremental cycle 
test; 
[La-] every min for 
10 min post-
exercise 
Women produced ~39% lower plasma [La-] at 
exhaustion than men (p = 0.01); 
Women elicited ~16% lower peak [La-] post-
exercise than men (p = 0.03); 
Women elicited lower [La-] than men at all relative 
intensities between 30 and 100% V̇O2peak (p < 
0.05); 
Women had higher LT2 relative to V̇O2peak (OBLA 
by ~20% and 2 mmol·L-1 LT2 by ~31%; both p ≤ 
0.01); than men 
No difference in LT2 (log transformation method) 
between sexes. 
Not taking an 
OC agent; 
Tested during 
FP. 
No 
Hubner-Wozniak, 
Kosmol and 
Gajewski [382] 
Male (n = 10) 
and female 
(n = 10) 
wrestlers 
National-
level 
Maximal 
incremental 
treadmill test; 
[La-] at 3, 5 and 7 
min post-exercise 
Higher (~34%) peak [La-] in men than women (p < 
0.01); 
No difference in V̇O2 at OBLA or IAT between 
sexes; 
No difference in [La-] at IAT between sexes; 
%V̇O2max at OBLA (~21%; p < 0.01) and IAT 
(~14%; p < 0.05) higher in women than men.  
No No 
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[La-]: lactate concentration; V̇O2peak: peak oxygen uptake; LT2: second lactate threshold; V̇O2: oxygen uptake; OBLA: onset of blood lactate accumulation; 
IAT: individual anaerobic threshold; D-max: maximum deviation method.  
 
Helgerud [383] Male (n = 6) 
and female 
(n = 6) long 
distance 
runners 
Elite Controlled treadmill 
running (mean 
marathon speed at 
1° and 3° gradients 
for 11 min); 
Marathon run 
No differences in [La-] as %V̇O2max between men 
and women; 
Women had higher [La-] (~57%) during identical 
submaximal running velocities than men (p < 0.01). 
No No 
Nicholson and 
Sleivert [177] 
Male (n = 19) 
and female 
(n = 11) 
runners  
Moderately-
trained 
2 x 10 km running 
time trials; 
Maximal 
incremental 
treadmill test 
Men produced higher absolute LT2 velocities 
(~22%) when calculated by three different LT2 
methods (D-max, OBLA and workload prior to an 
increase in [La-] of ≥ 1 mmol·L-1; p < 0.01); 
Only D-max LT2 correlated with 10 km performance 
in women (r = 0.84; p < 0.001); 
All three LT2 methods correlated with performance 
in men (r = 0.73-0.78; p < 0.01). 
No No 
327 
 
iii. Cardiac structure and function 
Differences in cardiac structure and function have been suggested to occur 
independent of body size [326-328] and are likely due to the influence of ovarian 
hormones [389, 390]. Left ventricular mass tends to be greater in men than women even 
after controlling for body surface area [326, 327], subscapular skinfold thickness, height, 
systolic and diastolic blood pressures, alcohol consumption, pulmonary function, 
smoking history, physical activity, total serum cholesterol and family history of 
hypertension [328]. However, a lack of consensus exists in the literature in relation to 
differences in resting stroke volume, heart rate and cardiac output between sexes. 
Some have shown lower resting heart rates in men [391] with others showing no sex 
difference [326, 389]. Selected findings on cardiac output [389] have shown this measure 
to be lower in women in the early-FP and during ovulation, whilst some maintain sex 
equality [326, 392]. A lack of control of training status in many studies has been reported 
[393] and may explain the equivocality of some findings to date. In studies reporting 
participants of an active status, men were shown to have lower resting heart rates 
than women [392] though a similar cardiac output when normalised to body size (m2; 
known as cardiac index) regardless of training status [392, 394]. Although these findings 
allude to a greater relative stroke volume in active men, research has been 
inconsistent. A possible reason for this is the use of different radiometric scaling 
approaches by which relative stroke volume has been determined, such as the use 
of fat-free mass [395] and body surface area [392], with fat-free mass suggested as the 
better method to control for body size [396, 397]. Nevertheless, consistent findings exist 
for a higher resting ejection fraction [326, 398] and a greater parasympathetic cardiac 
activation [399, 400] in women over men. Sympathetic activation however, has 
produced more variable findings with some studies demonstrating increased 
activation in women [401] while others have shown it to be lower in women [400]. 
Interestingly, after four weeks of endurance training in previously sedentary men (n = 
12) and women (n = 12), no difference in the change in nocturnal parasympathetic 
activation was exhibited between sexes, suggesting that differences at baseline may 
remain regardless of training status [402]. However, as discussed in section 2.3 of this 
thesis, endogenous concentrations and exogenous doses of ovarian hormones have 
the potential to influence measures of cardiac function and to the best of our 
knowledge, have not been adequately controlled for in studies comparing men and 
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women. As a measure of recovery from exercise, cardiac parasympathetic 
reactivation has been shown to be delayed in women following HIIT [403, 404]. 
Consequently, implications for training prescription exist whereby women may 
require a longer period of recovery between HIIT sessions than men [405]. 
Conversely, Laurent and others [350] examined differences in physiological and 
psychological recovery levels between men and women of a moderate fitness level 
during three treadmill HIIT sessions. They found that although men self-selected a 
higher (~5%) relative velocity than women (p < 0.01), females produced a higher 
relative heart rate (~5%; p < 0.01) and a trend towards a higher %V̇O2peak. 
Interestingly, no difference in [La-] or perceptual measures were seen. These results 
suggest that women may exhibit improved recovery to high-intensity exercise and 
self-select exercise intensities that induce greater cardiovascular strain. However, no 
control over menstrual cycle or hormonal status was adopted in this study which the 
authors note may have had some influence on the maintenance of higher levels of 
relative intensity with more rapid recovery in women [350]. Due to the findings 
surrounding positive effects of elevated oestrogen levels on exercise (discussed in 
section 2.3 of this thesis), this may indeed have confounded the results. The weight 
of evidence suggests that maximal heart rate is similar between sexes in untrained 
[395, 406, 407] and trained [382, 390, 395, 408] participants. Training status has been shown to 
influence peak cardiac output [395, 408] and stroke volume [395] whereby larger cardiac 
outputs (relative to fat-free mass [395] and total body mass [408]) and stroke volumes 
(relative to fat-free mass only [395]) were reported in men than women of a trained [395, 
408] but not an untrained [395] status. 
 
As discussed in section 2.3 of this thesis, some research has related ovarian 
hormones to the differences in cardiac structure and function between sexes, with 
oestrogen considered to be cardioprotective [390]. For this reason, it has been noted 
that cardiac data from a female athletic population may demonstrate larger variability 
if hormonal profiles are highly variable [393]. This suggests there is a need to control 
menstrual and/or hormonal contraceptive status and minimise hormonal variation as 
much as possible if testing cardiac function at rest or during exercise. Although there 
are weaknesses in some studies in relation to the control of training status and 
ovarian hormone concentrations, it appears likely that sex differences in cardiac 
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structure and function exist at rest and during exercise independent to body size. 
Additionally, differences in parasympathetic and sympathetic activation, abilities to 
tolerate cardiovascular strain and parasympathetic reactivation have also been 
shown between sexes. 
  
iv. Substrate utilisation 
Although research appears equivocal as to whether differences in substrate 
utilisation exist between different phases of the menstrual cycle in women, research 
surrounding sex differences in substrate utilisation appear more consistent. Women 
have been shown to oxidise proportionately more lipid compared with men during 
submaximal endurance exercise, regardless of training status [332-336] or exercise 
intensity [335, 337]. When exogenous carbohydrate was supplemented prior to and 
during a 90 min cycle at 60% V̇O2peak in endurance-trained athletes, it was shown 
that the percentage of exogenous carbohydrate oxidation relative to the total energy 
contribution over the final 60 min tended to be higher in women (14.3 ± 1.2%) than 
men (11.2 ± 1.2%; o = 0.09) [409]. Furthermore, a significantly greater reduction in 
endogenous carbohydrate oxidation was seen in women (12.9 ± 3.1%) compared to 
men (5.1 ± 2.0%; p < 0.05) when supplemented with the carbohydrate dose [409]. 
These findings suggest that compared to men, women may oxidise a greater relative 
proportion of supplemented carbohydrate during endurance exercise which may 
subsequently spare more endogenous stores, delay fatigue and improve endurance 
performance. 
 
It has been noted that these differences in lipid metabolism may be explained by 
greater mRNA levels of muscle lipoprotein lipase, membrane fatty acid transport 
protein-1, FAT/CD36 protein levels and citrate synthase in women, irrespective of 
training status and age [410, 411]. Intramyocellular lipid content describes the fat 
droplets accumulated in skeletal muscle. These have been shown to increase in 
response to endurance training [412, 413] and are accompanied by a greater oxidative 
capacity in athletes [414]. They also appear different between men and women [415, 416] 
and may help to further explain differences in lipid metabolism. Basal levels and 
utilisation during acute exercise have been shown to be higher in women than men 
irrespective of training status [415, 416] and this has been suggested to occur due to a 
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greater number of individual droplets [336]. Furthermore, as noted in section 2.3.3 of 
this thesis, lipid metabolism in skeletal muscle of women has been related to the 
presence of oestrogen [195, 321], whereby high levels of oestrogen appear to be 
effective at sparing muscle glycogen and delaying fatigue. Collectively, research 
suggests that differences in skeletal muscle metabolism between men and women 
may favour women during and in recovery from, moderate- and high-intensity 
exercise by minimising fatigue and enhancing recovery [318]. 
 
v. Gross efficiency 
In cycling, a variable related to substrate use is gross efficiency; defined as the ratio 
of work accomplished to energy expended [417]. According to Coyle [362] it is one of 
the most important functional abilities of a cyclist as it determines the amount of 
power that can be produced for a given O2 cost and level of energy expenditure. In 
addition, together with V̇O2 at LT2 it has been noted as being important to establish 
performance power output [418]. Using work rates that are representative of those 
commonly used during training and racing (absolute intensities of 150 and 180 W 
and relative intensities eliciting LT2 and 60% maximal aerobic power), Hopker et al. 
[331] questioned whether gross efficiency differed between trained male and female (n 
= 13 of each sex) cyclists. Menstrual cycle control was implemented for the female 
participants whereby testing was completed in the early-FP of the menstrual cycle. 
The results displayed higher gross efficiencies in women at absolute intensities of 
150 (~13%) and 180 (~9%) W (women: 22.5 ± 2.1% and 22.3 ± 1.8%; p < 0.05, men: 
19.9 ± 1.8% and 20.4 ± 1.5%; p < 0.05 for 150 and 180 W, respectively), while 
differences between sexes were insignificant for the relative intensities of LT2 (~6%; 
p = 0.30) and 60% maximal aerobic power (~8%; p = 0.07). When controlling for lean 
leg volume, differences between sexes were eliminated for absolute and remained 
insignificant for relative intensities. This study highlights lean tissue mass as an 
important physiological variable when comparing exercise performance between 
men and women, especially at intensities below LT2 and at 60% maximal aerobic 
power.  
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vi. Muscle fibre-type composition 
Muscle fibre-type composition is another physiological attribute shown to be different 
between men and women, therefore having the ability to impact exercise 
performance. Staron et al. [325] showed that although untrained men (n = 95) and 
women (n = 55) showed a similar overall distribution of fast (type IIA, IIB, IIAB) and 
slow (type I and IC) fibre-types in the vastus lateralis (41% I, 1% IC, 1% IIC, 31% IIA, 
6% IIAB, and 20% IIB), significant gender differences existed with regard to the total 
area occupied by each fibre type within the muscle. They revealed that type I fibres 
occupied ~8% greater area in women (44.0 ± 11.6 vs. 36.2 ± 11.6%; p ≤ 0.05), 
whereas the type IIA fibres occupied a ~7% greater area in men (41.2 ± 9.4 vs. 33.6 
± 8.7%; p ≤ 0.05). Additionally, it was suggested that these differences in percentage 
fibre type area may result in differences in performance. This finding of similar 
relative proportions of type I and II fibres but different percentages of total area 
between sexes has been supported by Carter et al. [324] who showed this consistently 
before and after a seven week endurance training period. Consistently, Staron et al. 
[325] showed significant differences in percentage area occupied by the different fibre 
types, whereby type I fibres exhibited a 10% greater area in women than men before 
(53% vs. 43%; p < 0.05) and an 18% greater area after (54% vs. 36%; p< 0.05) 
training. Consequently, type II fibres exhibited a 10% greater area in men than 
women before (57% vs. 47%; p < 0.05) and a 20% greater area after (64% vs. 44%; 
p < 0.05) training [324]. However, confounding evidence also exists with reports that 
proportions of type I and type II fibres are indeed different in males and females [365]. 
For example, Roepstorff et al. found that a lower proportion of type I fibres were 
present in recreationally trained men compared to women (~23%; p < 0.01) [365]. 
Nevertheless, the notion of type I fibres predominating in women (whether as a 
proportion of the total muscle or the absolute area) appears to hold true. Since type I 
fibres generate their energy from oxidative phosphorylation, there is accruing 
evidence to suggest that women are capable of maintaining continuous and 
intermittent muscle contractions at low to moderate intensities better than men [419-
421].  
 
Several mechanisms have been proposed to explain this phenomenon, including 
differences in (1) motivation and the sustainability of central drive, (2) blood supply to 
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the working muscles and (3) composition and fatigue characteristics of the muscle 
fibres. Wüst et al. [422] recruited a group of men (n = 29) and women (n = 35), 
matched for age and physical activity status, and investigated whether: (1) 
differences in susceptibility to peripheral fatigue existed between sexes and (2) 
whether differences in blood supply (assessed by exposing the muscle to hypoxic 
conditions) between men and women could be related to differences in fatigability. 
Over the course of 60 electrically evoked isometric contractions (protocol 1; 1:1 
work: relief ratio), quadriceps femoris torque declined ~8% more in men (by 37.7 
± 10.7%) than women (by 29.9 ± 10.0%; p < 0.01). Decreasing the recovery time 
between contractions (protocol 2; 1: 0.5 work: relief ratio) allowed differences 
between men and women to become apparent earlier (after 37.5 s versus 78 s for 
protocols 2 and 1, respectively). In protocol 2, the difference in torque reduction was 
~15% greater in men (55.7 ± 8.1%) compared to women (42.8 ± 13.4%; p < 0.01). 
Interestingly, when blood supply was occluded, the differences between men and 
women remained with the authors stating differences between male and female 
muscle must relate to the rate at which energy is used by the muscle fibres rather 
than the oxidative recovery rates [422]. Again however, findings to the contrary also 
exist. Russ and Kent-Braun [421] reported that sex differences in muscle fatigue were 
absent under ischaemic conditions and concluded that blood flow and/or substrate 
utilisation differs between men and women. However, this study did not consider the 
impact of motivation and central drive and asked participants to perform voluntary 
contractions, rather than using electrically evoked contractions as used in the study 
of Wüst et al. [422].  
 
Much less is known about the sex differences during dynamic contractions as they 
have been less studied than isometric contractions [318]. Based on limited studies, 
research appears to indicate that women exhibit less fatigue than men when 
assessed as either time to task failure [318] or as a loss of maximum torque [319]. 
However, it appears that the intensity of the dynamic contraction may affect the 
results. For example, as a regression in load from 90 to 50% of one repetition 
maximum was implemented, the difference between sexes in the number of 
completed elbow flexion repetitions was reduced (~91%; p < 0.01 at 50%, ~67%; 
p < 0.01 at 60%, ~42%; p < 0.05 at 70%, ~14%; p > 0.05 and 80% and ~6%; 
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p > 0.05 at 90%) [423]. Similarly, in a study examining repeated sprint ability in cycling 
it was shown that although men completed ~50% more absolute (74.5 ± 25.4 vs. 
49.7 ± 21.5 kJ; p < 0.01) and ~27% more relative (1030.6 ± 53.4 vs. 813.1 ± 
47.7 J·kg-1 body mass; p < 0.05) work, their work decrement from sprint 1-16 was 
also significantly greater than women by ~11% (-34.8 ± 8.9 vs. -23.6 ± 6.2%, 
respectively; p < 0.01) [424]. However, performance in the initial sprint appears 
influential and sex differences in total work accumulated (~0.7%; p = 0.83 [424] and 
~0.4%; p = 0.79 [425]) and work decrement (~2%; p = 0.72 [424] and ~10%; p = 0.79 
[425]) were eliminated when men and women were matched for initial mechanical 
work.  
 
Differences in muscle fibre-type composition between men and women appear 
independent to training status. For example, Carter et al. [324] showed no changes in 
muscle fibre area, muscle size or fibre-type distribution in men or women after a 
seven week endurance training program. A greater percentage of total area was 
occupied by type I fibres in women before (~10% difference) and after training 
(~18% difference; p < 0.05) and by type II fibres in men before (~10% difference) 
and after training (~20% difference; p < 0.05). Type II fibres remained larger in size 
in men pre- (~40%; p < 0.05) and post-training (~60%; P < 0.05) and no difference in 
the size of type I fibres existed between sexes before (~2%) or after (~11%) training. 
Finally, the 4% difference in distribution of type I (men: 43 ± 17% vs. women: 
47 ± 8%) and type II (men: 57 ± 17% vs. women: 53 ± 8%) fibres pre-training were 
not significantly different to the 13% difference in type I (men: 35 ± 9% vs. women: 
48 ± 14%) and 4% difference (men: 65 ± 9% vs. women: 53 ± 15%) in type II fibres 
post-training.  
 
Alternatively, others found differences in muscle fibre characteristics for men and 
women in response to training. After four weeks of cycle sprint training, Esbjorsson 
Liljedahl et al. [348] revealed a significant increase in type II fibre size in recreationally-
active women (17%; p < 0.05) without any change in men. This reduced the sex 
difference in type II fibre size from 39% to 11% (p < 0.05 for sex x training 
interaction). This improvement in women has been suggested to occur as a result of 
the absolute differences in type II fibre size; that is, women may be more responsive 
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to high intensity sprint exercise which is characterised by type II fibre recruitment, 
since they have smaller type II fibres than men [349]. More recently, a six week 
training intervention comparing a moderate intensity exercise program with a low 
volume HIIT program was conducted in recreationally-active men and women [426]. 
Although comparable changes occurred in fibre-type distribution (type I increased by 
~20 and ~25%, type IIA decreased by ~5 and ~5% and type IIAX/ IIX decreased by 
~120 and ~89% for the endurance and interval groups, respectively) and fibre-type 
specific oxidative and glycolytic capacity were seen between the endurance and HIIT 
groups, the authors failed to separate the findings of men and women to highlight the 
sex-specific adaptations to training. This was most likely due to the small sample 
size of women (n = 3) compared to men (n = 16). This failure to provide sex-specific 
findings, along with the predominance of male-only studies in the physiology, 
fatigability and exercise training literature [318] are part contributors to the lack of 
thorough understanding of sex differences in exercise capacity, the responses to 
training and the mechanisms responsible for the differences.  
 
vii.  Respiration 
In addition to fibre-type distribution, the fatigability of the diaphragm has been 
investigated and compared between endurance-trained men and women [320]. Due to 
previously reported pulmonary limitations in women (such as smaller lung volumes, a 
decreased capacity for lung diffusion even when corrected for age and height [427-429] 
and smaller diameter airways independent to lung volume [430]), it was originally 
hypothesised that men may actually have a more fatigue-resistant diaphragm than 
women [320]. However, the findings of Guenette et al. [320] suggest that the trained 
female diaphragm is more resistant to fatigue than the trained male diaphragm. 
Using a reduction in potentiated trans-diaphragmatic pressure twitches of ≥ 15% 
relative to the pre-exercise values at any time point after exercise as the criteria for 
fatigue of the diaphragm, their results showed fewer women (42%) than men (58%) 
developed diaphragmatic fatigue during a cycling time to exhaustion test at 90% 
peak power output until their cadence dropped below 60 rpm. Furthermore, in those 
that were classified as developing fatigue, the magnitude (calculated as the percent 
drop in potentiated trans-diaphragmatic pressure twitches 10, 30 and 60 min post-
exercise) was 10 (p < 0.01) and 9% (p < 0.05) greater in men compared to women at 
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10 and 30 min post-exercise, respectively. Interestingly, time to exhaustion was not 
different between those who did and did not reach diaphragmatic fatigue in men (8%; 
14.1 ± 1.0 vs. 13.0 ± 1.5 min; p > 0.05) or women (8%; 10.9 ± 1.2 vs. 11.8 ± 0.9 min; 
p > 0.05). 
 
viii. V̇O2max 
Research consistently shows that V̇O2max is lower in women than men and this has 
been reported in both absolute (L·min-1) and relative (mL·kg-1·min-1) terms [395, 431-433]. 
Differences in absolute and relative V̇O2max have been partially accounted for when 
normalising to fat-free mass and training status, whereby the ~15% difference 
between the sexes (men > women) is deemed a result of biological and physiological 
differences [432, 434, 435]. A recent study in participants of average fitness reported the 
difference between sexes when controlling for fat-free mass to be even lower at 4% 
[433]. However, this effect of fat-free mass doesn’t always hold true. For example, sex 
differences in V̇O2max have been shown to persist in wrestlers and middle-
distance/marathon runners independent to fat-free mass normalisation [313, 382]. 
These findings suggest that there may be discipline-specific differences between 
men and women in regards to V̇O2max. The mechanism(s) proposed to explain 
these differences relate to women having lower O2 delivery and/or O2 utilisation than 
men [433] which may be related to women having smaller hearts [436] and lower blood 
volume [433, 437], thus contributing to a lower stroke volume and cardiac output. 
However, as discussed earlier in this chapter, the scientific literature remains 
equivocal on these attributes. Furthermore, it has been shown that women have a 
lower arteriovenous O2 difference than men [432, 433] which has been associated to a 
degree with women possessing lower haemoglobin concentrations [433, 438] and 
haemoglobin mass [433] than men, leading to lower arterial O2 concentration [432]. 
Peltonen et al. [433] reported findings suggesting that women had a tendency towards 
an accelerated rate of cardiac output increase during incremental cycle exercise 
which may compensate for their lower blood O2 carrying capacity. 
 
In order to compare to previous findings in men, Hedman et al. [439] examined the 
relationship between cardiac dimensions and cardiac function to V̇O2max in a group 
of untrained women (n = 48) and a group of national and regional level female 
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athletes from a variety of endurance sports (n = 48). Results suggested that 
dimensional variables (one-dimensional and two-dimensional measurements of wall 
thickness and various dimensions, lengths and diameters of internal structures) 
correlated more strongly with V̇O2max (5 strongest correlations: r = 0.60 - 0.71; 
p < 0.01) than any systolic or diastolic functional measurement (including left 
ventricular ejection fraction, early and late diastolic filling velocities and their 
respective ratio, and blood flow velocity into the right pulmonary vein to name four of 
the nine reported measures (r = 0.22 - 0.59; p < 0.01-0.03). Furthermore, when 
indexed to body surface area (transferred to same dimension as the variable being 
scaled), significant relationships remained for the dimensional variables (r = 0.46 - 
0.56; p < 0.01). These findings are consistent with a previous study in female rowers 
[440] and young men [441]. The authors suggested that applying the approach of 
scaling cardiac dimensions by the appropriate power of body surface area may aid in 
future comparisons between male and female athletes, as this may prevent over- 
and underestimating the influence of differences in body composition between sexes 
[439]. 
 
ix. Measures of endurance performance 
Although numerous studies have investigated physiological correlates of endurance 
performance in trained male athletes [6, 9, 74, 86, 87, 99], very few have done so in trained 
female athletes [10, 298] and even fewer have directly compared this relationship 
between sexes in the same study. Furthermore, despite the numerous known 
physiological differences between men and women, some researchers have failed to 
distinguish the sex of their participants [329, 330]. Others, such as Schabort et al. [292] 
(Table A.4.2), have grouped the results of men and women together and therefore 
disregarded sex-specific findings. Additionally, studies such as that of Jacobs et al. 
[181] have recruited an unequal sample of men and women (n = 15 and 1, 
respectively). Table A.4.2 summarises the findings of studies comparing a number of 
different physiological variables and their respective correlations with endurance 
performance in male and female endurance athletes of trained to elite statuses. The 
only study to control for ovarian hormone status is the most recent study of Lamberts 
and Davidowitz [298]. However, despite limiting physiological and performance testing 
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to days 7 - 21 of the menstrual cycle, concomitant analysis of ovarian hormone 
concentrations, either via blood or urinary measures, was not implemented. 
Considering the high intra- and inter-individual variability in endogenous oestradiol 
and progesterone concentrations previously reported within a menstrual phase [21], it 
cannot be guaranteed with a high level of certainty that the influence of ovarian 
hormones was truly minimised in this study. Nonetheless, the conclusions of their 
related, though separately published findings in trained male [273] and female [298] 
cyclists are promising in regard to allometrically-scaled peak power output providing 
a strong relationship with 40 km cycling performance.  
 
LT2, while previously shown to correlate strongly with endurance performance when 
examined in men [6] and women [10] individually, tends to have a weaker relationship 
with endurance performance in studies in which men and women were tested using 
the same exercise protocols. Of the studies outlined in Table A.4.2, only three 
reported the LT2 [88, 313, 387]; all of which used LT2 methods based on measures of 
fixed [La-]. These included OBLA [313], a rise in [La-] of 1 mmol·L-1 above baseline 
values [313], the 2 and 3 mmol·L-1 LT2 [88] and the speed at which an increase in [La-] 
corresponding to 1 mmol·L-1 occurred between 3.5 and 5 mmol·L-1 [387]. 
Consequently, no method considered the entire [La-] curve over the duration of 
exercise until fatigue. Despite the LT2 determination method chosen, inconsistent 
findings were produced in these studies. The LT2 correlated with 16 km running 
performance when expressed as running velocity but not when expressed as 
%V̇O2max, however sex-specific results were not presented [88]. While OBLA was 
shown to be unrelated to endurance running performance in both men and women, 
the 1 mmol·L-1 method was correlated to performance, though only in men [313]. 
Finally, the study of Billat et al. [387] produced no relationship between LT2 and 10 km 
running performance for either sex. Methods utilising the entire [La-] curve such as 
the IAT, D-max and modified D-max have all been shown to produce stronger 
correlations with endurance performance as reported in earlier sections of this thesis 
and therefore comparisons of their versatility in men and women, are warranted. One 
study has utilised the D-max method along with two other LT2 methods in a group of 
runners of mixed training statuses to investigate the relationships with 10 km running 
velocity [177] (Table A.4.1). The only method producing a significant relationship with 
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running performance in women was the D-max method, whilst all three methods 
produced strong relationships with performance in mem (r = 0.73-0.78; p < 0.01) The 
authors didn’t discuss potential reasons for this, however since the other two LT2 
methods relied on fixed [La-] rather than the entire [La-]-workload curve as D-max 
utilises, one may speculate that sex differences in [La-] accumulation have impacted 
the LT2-performance relationship in this case. As no study has examined this in a 
more homogeneous group of trained endurance athletes, it is unknown whether the 
same results would persist. Furthermore, the more recent modified D-max method is 
currently used in Australia by the State Institutes and Academies of Sport for 
evaluation of their endurance athletes’ fitness and to examine the effectiveness of 
various training programs, and therefore needs to be investigated.  
 
Peak power output determined by maximal incremental tests or peak power output-
specific tests consistently appears as a strong correlate of endurance performance. 
For example, Jacobs and others [181] produced a strong correlation (r = 0.91; 
p < 0.01) between maximum power output and mean 26 km cycle time trial power 
output in 16 highly-trained endurance athletes. Additionally, McLaughlin et al. [88] 
reported a significant relationship (r = -0.89; p value not provided) between peak 
treadmill velocity and 16 km run time trial time in 17 well-trained distance runners. 
However, both of these studies combined the results of men and women so it is 
unknown whether the same relationships would hold true for men and women 
separately. More recently, two related studies by the same group of researchers 
have assessed male and female predictors of 40 km cycling performance [273, 298] 
separately. It was concluded that allometrically-scaled peak power output (W·kg0.32), 
provided the most accurate prediction of 40 km cycling time trial time in trained 
female and male cyclists. Interestingly, due to the known differences between men 
and women in lean body mass, the authors used this measure as a covariate in 
assessing the relationship. Despite this control, sex differences remained, indicating 
that body composition could not fully explain the phenomenon. However, the authors 
recommended building on their research by greater familiarisation of the female 
participants to the 40 km time trial distance, testing a female sample more 
heterogeneous in nature and using a DEXA scan or similar, for more accurate body 
composition analysis. 
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x. Training 
Training studies with a focus on improving endurance performance have been 
conducted for numerous years, with the recent shift in focus towards high intensity 
interval training. As with studies determining correlates of endurance performance, 
training studies involving female athletes are lacking. A recent study conducted by 
Astorino et al. [349] aimed to compare differences in adaptations to short-term high 
intensity interval training in active men (n = 11) and women (n = 9) matched for age, 
V̇O2max and physical activity. It was concluded that both sexes responded to six 
days of training with similar improvements in V̇O2max (~6% for men and ~7% for 
women), fat oxidation (max RER decreased by ~2% for men and ~3% for women), 
mean power output (~10% for men and ~11% for women) and peak power output 
(~11% for men and ~9% for women). Only one published study has implemented a 
training intervention in already well-trained male and female endurance athletes. 
This study has been discussed in section 2.4.2 of this thesis and was conducted in a 
group of junior elite cross-country skiers [41] and extended the findings of Astorino et 
al. [349] that there were no sex-specific adaptations in response to HIIT. However, 
although improvements in physiological measures (such as LT2) and endurance 
performance were exhibited, the relationship between them was not examined. 
Therefore, it is unknown which variable/s are responsible for the performance 
improvements and whether these are different between men and women. Further 
insight into sex-specific adaptations to training in those who are already well-trained 
will provide invaluable knowledge into the development of better training programs 
for this specific population where small improvements are of upmost importance. 
Furthermore, differences in the time-course and dose-response relationship to 
training in this population are unknown and a comparison between men and women 
will further enhance these findings. 
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Table A.4.2. A summary of studies correlating physiological measures to endurance performance in trained men and 
women. 
 
Study Participants Training status Testing procedure/s 
Physiological 
measure/s 
Performance 
measure/s Major findings 
Ovarian 
hormone 
control 
Ovarian 
hormone 
analysis 
Lamberts 
and 
Davidowitz 
[298] 
 
Female 
cyclists (n = 
20) 
Trained to well-
trained (V̇O2max 
50.5 ± 3.4 
mL·kg·min-1) 
LSCT:  
6 min at 60% 
HR max; 30 s 
rest; 6 min at 
80% HR max;  
3 min at 90% 
HR max. 
Peak PO test: 
Start at 2 W·kg-1 
(women), 2.5 
W·kg-1 (men), ↑ 
20 W·min-1 
LSCT: 
Predicted TT time; 
Peak PO test: 
Peak PO (mean 
PO during the last 
60 s); 
V̇O2max (highest 
over 30 s); 
Body fat % (7 
skinfolds) 
40 km cycle 
TT 
Peak PO relative to BW (W·kg0.32) 
correlated with 40 km TT time (r = -0.87; 
p < 0.01); 
Absolute peak PO (W) correlated with 
40 km TT time (r = -0.82; p < 0.01); 
LSCT-predicted TT time correlated with 
actual TT time (r = 0.98; no gender 
differences). 
Testing 
days 7-21 
of MC  
No 
Lamberts et 
al. [273] 
Male cyclists 
(n = 45) 
Trained to well-
trained (V̇O2max 
57.3 ± 6.2 
mL·kg·min-1) 
V̇O2max (mL·min-1·kg0.32) correlated with 
40 km TT time (r = -0.93; p < 0.01); 
Peak PO (W·kg0.32) correlated with 40 
km TT time (r = -0.96; p < 0.01); 
Peak PO (W) correlated with 40 km TT 
time (r = -0.90; p < 0.01); 
Peak PO (W·kg-1) correlated with 40 km 
TT time (r = -0.70; p < 0.01).  
N/A N/A 
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Study Participants Training status Testing procedure/s 
Physiological 
measure/s 
Performance 
measure/s Major findings 
Ovarian 
hormone 
control 
Ovarian 
hormone 
analysis 
Jacobs et al. 
[181] 
Male (n = 15) 
and female (n 
= 1) 
endurance 
athletes 
Highly trained 
(V̇O2max 70.53 
± 5.57 
mL·kg-1·min-1) 
 
Warm-up: 
Men: 5 min at 
150 W, 5 min at 
200 W 
Women: 5 min 
at 100 W, 5 min 
at 150 W 
Max test: 
↑ 25 W·min-1  
V̇O2max; 
RER; efficiency; 
[Hb] & Hb mass; 
O2 saturation; 
PaO2; [La-]; 
blood O2 content; 
tissue 
oxygenation; 
cerebral blood 
velocity; blood 
pressure; muscle 
function; 
mitochondrial 
respiration; 
muscle buffer 
capacity ([La-] 
peak-[La-] rest/ 
change in muscle 
pH); CS activity 
26.15 km 
cycle TT 
(software 
simulation) 
One parameter: Oxidative 
phosphorylation capacity of muscle (P) 
and mean TT PO (r2 = 0.47; p < 0.01); 
Two parameters:  P + submax [La-] 
(r2 = 0.68; p < 0.01); 
Three parameters: P + submax [La-] + 
leg oxygenation at exhaustion (r2 = 0.78; 
p < 0.01); 
Max PO correlated with mean TT PO 
(r = 0.91; p < 0.01); 
Overall aerobic performance (mean TT 
PO + max PO) correlated with V̇O2max, 
Hb mass, leg oxygenation, P and 
electron transport system capacity. 
Nil No 
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Study Participants Training status Testing procedure/s 
Physiological 
measure/s 
Performance 
measure/s Major findings 
Ovarian 
hormone 
control 
Ovarian 
hormone 
analysis 
McLaughlin 
et al. [88] 
Male (n = 10) 
and female (n 
= 7) distance 
runners 
Trained 
(V̇O2max men: 
60.2 ± 5.4  
mL·kg-1·min-1; 
women: 51.3 ± 
6.2 mL·kg-1·min-
1) 
Max test:  
Constant speed 
(10 km race 
pace) with ↑ in 
gradient by 
1%·min-1; 
LT test: 
150 m·min-1, ↑ 
by 10 m·min-1 
every 3 min until 
RPE 17.  
RE test: 
30 m·min-1 
below 10 km 
race pace, ↑ by 
15 m·min-1 x 4 
stages; 
PTV test: 
50 m·min-1 
below 10 km 
race pace, ↑ by 
1 km·h-1 every 
min 
Max test:  
V̇O2max; 
VV̇O2max; LT; 
RE test: 
RE; 
PTV test: 
PTV (highest 
velocity 
maintained for 60 
s) 
16 km run TT 
(track) 
VV̇O2max correlated with TT time 
(r = -0.97) and explained majority of total 
variance (r2 = 0.902); 
Velocity at LT correlated with TT time 
(r = -0.91); 
V̇O2max correlated with TT time 
(r = -0.90); 
PTV correlated with TT time (r = -0.89); 
Velocity at 2 and 3 mmol·L-1 LT 
correlated with TT time (r = -0.85 and 
-0.89, respectively); 
RE at 82% V̇O2max correlated with TT 
time (r = 0.81); 
%V̇O2max at LT not correlated with TT 
time (r = 0.14); 
Linear regression: V̇O2max, %V̇O2max 
at LT and RE; r2 = 0.95; 
Running speeds at LT were higher in 
men as determined by 2 (~22%) and 3 
(~21%) mmol·L-1 LTs;  
LT method defined as “highest velocity 
not associated with a rise in [La-] above 
baseline levels” higher (~25%) in men; 
Minimal difference in %V̇O2max at LT 
between sexes (~3%); 
*p ≤ 0.05 as default inclusion criteria. 
Nil No 
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Study Participants Training status Testing procedure/s 
Physiological 
measure/s 
Performance 
measure/s Major findings 
Ovarian 
hormone 
control 
Ovarian 
hormone 
analysis 
Maldonado-
Martin et al. 
[313] 
Male (n = 17) 
and female (n 
= 11) middle-
distance and 
marathon 
runners 
Highly trained 
(V̇O2max men: 
69.3 ± 3.5 
mL·kg-1·min-1; 
women: 60.7 ± 
4.7 
mL·kg-1·min-1) 
Max test: 
10 km·h-1, ↑ by 
1.5 km·h-1 every 
4 min (1 min 
rest between 
stages) 
V̇O2max; 
LT (OBLA and 1 
mmol·L-1 above 
baseline, between 
40-60% V̇O2max); 
Energy cost of 
running; 
Body fat (4 
skinfold sites); 
Va max (V̇O2max - 
0.083) x energy 
cost of running 
1500 m 
running TT 
OR 
Marathon 
(participants 
performed 
their preferred 
event) 
Va max correlated with performance in 
men (r = -0.58; p = 0.02) and women 
(r = -0.77; p < 0.01); 
1 mmol·L-1 LT correlated with 
performance in men (r = -0.59; p = 0.02) 
but not women (r = -0.23; p = 0.50);  
No other variables correlated with 
performance; 
Higher LT as %V̇O2max (~6%) in 
women than men for OBLA (p < 0.01) 
and1 mmol·L-1 LT (p < 0.01). 
Nil No 
Billat et al. 
[387] 
Male (n = 13; 
split into high 
speed 
training 
runners and 
low speed 
training 
runners) and 
female (n = 
7) distance 
runners 
Elite (V̇O2max 
men: 69.3 ± 3.5 
mL·kg-1·min-1; 
women: 60.7 ± 
4.7 
mL·kg-1·min-1) 
Max test: 
14 km·h-1 
(women) and 16 
km·h-1 (men), ↑ 
by 1 km·h-1 
every 3 min (30 
s rest between 
stages) 
V̇O2max; 
VV̇O2max; 
Velocity at LT (1 
mmol·L-1 ↑ in [La-] 
between 3.5 and 5 
mmol·L-1); 
Velocity between 
LT and V̇O2max;  
Energy cost of 
running (ratio 
between V̇O2 and 
running speed) 
10 km run TT Velocity at V̇O2max correlated with TT in 
men (ρ = -0.73; p < 0.01) and women 
(ρ = 0.954; p = 0.03); 
Velocity between LT and V̇O2max 
correlated with performance in men only 
(ρ = -0.77; p < 0.01); 
No other variables correlated with TT; 
Men: no correlates of TT in low speed 
group, velocity at V̇O2max correlated 
with TT in high speed group (ρ = -0.86; 
p = 0.05); 
Faster running speed at LT (~20%) in 
men than women (p < 0.01). 
Nil No 
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Study Participants Training status Testing procedure/s 
Physiological 
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Ovarian 
hormone 
control 
Ovarian 
hormone 
analysis 
Schabort et 
al. [292] 
 
 
 
 
 
 
 
 
Male (n = 5) 
and female (n 
= 5) 
triathletes 
 
 
 
 
 
 
 
 
Well trained 
(V̇O2peak men: 
69.9 ± 4.5 and 
74.4 ± 5.3 
mL·kg-1·min-1; 
women: 61.3 ± 
4.6 and 63.2 ± 
3.6 mL·kg-1·min-
1 for cycling and 
running, 
respectively) 
Swim tests: 
3 x 25m 
freestyle TT (3-5 
min rest); 
400m freestyle 
TT; 
Cycling tests: 
3.33 W·kg-1 for 
150 s, ↑ 50 W 
(men) and 25 W 
(women) for 150 
s, then ↑ 25 W 
every 150 s for 
all; 
10 min at 2 
W·kg-1, 10 min 
at 4 W·kg-1; 
Running tests: 
6 min stages, 5 
min rest, ↑ 1 
km·h-1 every 
min) 
Swimming: 
Max stroke 
distance; stroke 
velocity; 
stroke index 
(stroke distance x 
velocity); 
Cycling: 
V̇O2peak; 
Peak PO; 
efficiency; 
Running (max): 
V̇O2peak; 
Peak velocity 
Olympic 
distance 
triathlon total 
time, 
Split times 
(1500 m 
swim, 40 km 
cycle, 10 km 
run) 
 
 
 
 
 
 
 
Cycling split time correlated to overall 
time in men (r = 0.98; p < 0.01) and 
women (r = 0.84; p < 0.01) 
Running split time correlated to overall 
time in men (r = 0.93; p < 0.01) and 
women (r = 0.74; p < 0.01) 
Swim split time correlated to overall time 
in women only (r = 0.75; p < 0.01) 
No other results provided for men and 
women separately 
Best predictors of overall time (when 
men and women combined) were peak 
running velocity and [La-] at 4 W·kg-1 
during submax cycling (r2 value not 
presented)  
Strongest correlates of overall time 
(when men and women combined) were 
cycling peak PO (r = -0.86; p < 0.01), 
peak running speed (r = -0.85; p < 0.01) 
and % body fat (r = 0.85; p < 0.01) 
Nil 
 
 
 
 
 
 
 
 
 
 
 
o 
 
 
 
 
 
 
 
 
 
LSCT: Lamberts & Lambert Submax Cycling Test; V̇O2max : maximum oxygen uptake; VV̇O2max: velocity at maximum oxygen uptake; V̇O2peak : peak 
oxygen uptake; mL·kg·min-1: millilitres per kilogram per minute; BW: body weight; PO: power output; Hb: haemoglobin; RER: respiratory exchange ratio; 
kcal·min-1: kilocalories per minute; ↑: increase; HR: heart rate; W·kg-1: Watts per kilogram of body mass; LSCT: Lamberts submaximal cycling test; RPE: 
rating of perceived exertion; PTV: peak treadmill velocity; RE: running economy; m·min-1: metres per minute; Va max: maximal aerobic running velocity; TT: 
time trial; MC: menstrual cycle; CS: citrate synthase; PaO2: O2 tension. 
